Anhang 4-G: Ergänzende Daten zur Studie DeLLphi-304

Inhaltsverzeichnis

Seite

Anhang 4-G1: Angaben zu nachfolgenden Krebstherapien 2
Anhang 4-G2: Ergänzende Analysen zum Endpunkt „Symptomatik“ – RCT 11
Anhang 4-G2.1: Endpunkt „EORTC QLQ-C30/-LC13“ – RCT 11
Anhang 4-G2.1.1: Completion Rate 11
Anhang 4-G2.1.2: Veränderung zu Baseline 29
Anhang 4-G2.2: Endpunkt „EQ-5D VAS“ – RCT 65
Anhang 4-G2.2.1: Completion Rate 65
Anhang 4-G2.2.2: Veränderung zu Baseline 66
Anhang 4-G2.3: Endpunkt „PGI-C/PGI-S“ – RCT 68
Anhang 4-G2.3.1: Completion Rate 68
Anhang 4-G2.3.2: Veränderung zu Baseline 74
Anhang 4-G2.4: Endpunkt „BPI-SF“ – RCT 86
Anhang 4-G2.4.1: Completion Rate 86
Anhang 4-G2.4.2: Veränderung zu Baseline 99
Anhang 4-G2.5: Endpunkt „FACT-G GP5“ – RCT 125
Anhang 4-G2.5.1: Completion Rate 125
Anhang 4-G2.5.2: Veränderung zu Baseline 126
Anhang 4-G3: Ergänzende Analysen zum Endpunkt „Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ C30“ – RCT 128
Anhang 4-G3.1: Completion Rate 128
Anhang 4-G3.2: Veränderung zu Baseline 134
Anhang 4-G4: Ergänzende Analysen zum Endpunkt „Sicherheit“ – RCT 146
Anhang 4-G4.1: Unerwünschte Ereignisse nach SOC und PT 146
Anhang 4-G4.2: Auswertungen zum Endpunkt ”PRO-CTCAE”– RCT 476
Anhang 4-G5: Subgruppenanalysen 557
Anhang 4-G5.1: Endpunkt „Gesamtüberleben“ – RCT 557
Anhang 4-G5.2: Endpunkt „Progressionsfreies Überleben (PFS) – RCT 561
Anhang 4-G5.3: Endpunkt „Ansprechen“ – RCT 565
Anhang 4-G5.4: Endpunkt „Symptomatik“ – RCT 579
Anhang 4-G5.4.1: Endpunkt „EORTC QLQ-C30/-LC13“ – RCT 579
Anhang 4-G5.4.2: Endpunkt „EQ-5D VAS“ – RCT 615
Anhang 4-G5.4.3: Endpunkt „PGI-C/PGI-S“ – RCT 617
Anhang 4-G5.4.4: Endpunkt „BPI-SF“ – RCT 629
Anhang 4-G5.4.5: Endpunkt „FACT-G GP5“ – RCT 655
Anhang 4-G5.5: Endpunkt „Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ-C30“ – RCT 657
Anhang 4-G5.6: Endpunkt „Sicherheit“ – RCT 669
Anhang 4-G5.6.1: Unerwünschte Ereignisse – Gesamtraten 669
Anhang 4-G5.6.2: Unerwünschte Ereignisse nach SOC und PT 682

Anhang 4-G1: Angaben zu nachfolgenden Krebstherapien

Table 14-8.1.1. Subject Incidence of Subsequent Anti-cancer Therapy by Category and Preferred Term (Safety Analysis Set)

Category Preferred Term	Standard of Care (N = 244) n (%)	Tarlatamab (N = 252) n (%)
Number of subjects reporting subsequent anti-cancer therapy	125 (51.2)	112 (44.4)
No subsequent anti-cancer therapy	119 (48.8)	140 (55.6)
ADC	4 (1.6)	4 (1.6)
INVESTIGATIONAL ANTINEOPLASTIC DRUGS	3 (1.2)	1 (0.4)
ANTIBODY DRUG CONJUGATES (ADC)	0 (0.0)	1 (0.4)
HS 20093	0 (0.0)	1 (0.4)
INVESTIGATIONAL DRUG	0 (0.0)	1 (0.4)
ABBV 706	1 (0.4)	0 (0.0)
Anti DLL3 therapy	16 (6.6)	0 (0.0)
TARLATAMAB	15 (6.1)	0 (0.0)
INVESTIGATIONAL ANTINEOPLASTIC DRUGS	1 (0.4)	0 (0.0)

Page 1 of 5

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The subsequent anti-cancer therapy is based on pre-defined list of categories and preferred terms
Concomitant medications are coded using the WHO Drug Dictionary version GLOBALB3Mar24
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-cm-anti-catpt.sas
Output: t14-08-001-001-cm-anti-catpt.rtf (Date Generated: 31OCT25:07:22:10) Source: pa_adam.adsl, pa_adam.adcm

Table 14-8.1.1. Subject Incidence of Subsequent Anti-cancer Therapy by Category and Preferred Term (Safety Analysis Set)

Category Preferred Term	Standard of Care (N = 244) n (%)	Tarlatamab (N = 252) n (%)
Chemotherapy	2 (0.8)	4 (1.6)
CYCLOPHOSPHAMIDE;DOXORUBICIN;VINCRISTINE	1 (0.4)	2 (0.8)
CARBOPLATIN;PACLITAXEL	0 (0.0)	1 (0.4)
CISPLATIN;IRINOTECAN	0 (0.0)	1 (0.4)
CARBOPLATIN;ETOPOSIDE	1 (0.4)	0 (0.0)
CARBOPLATIN;IRINOTECAN	1 (0.4)	0 (0.0)
Other	8 (3.3)	6 (2.4)
BEVACIZUMAB	1 (0.4)	2 (0.8)
IPILIMUMAB	1 (0.4)	1 (0.4)
TRASTUZUMAB	0 (0.0)	1 (0.4)
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	0 (0.0)	1 (0.4)
Uncoded	0 (0.0)	1 (0.4)
HSTC 810	2 (0.8)	0 (0.0)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES	1 (0.4)	0 (0.0)
INTERLEUKIN-2	1 (0.4)	0 (0.0)
INVESTIGATIONAL ANTINEOPLASTIC DRUGS	1 (0.4)	0 (0.0)
RRX 001	1 (0.4)	0 (0.0)

Page 2 of 5

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The subsequent anti-cancer therapy is based on pre-defined list of categories and preferred terms
Concomitant medications are coded using the WHO Drug Dictionary version GLOBALB3Mar24
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-cm-anti-catpt.sas
Output: t14-08-001-001-cm-anti-catpt.rtf (Date Generated: 31OCT25:07:22:10) Source: pa_adam.adsl, pa_adam.adcm

Table 14-8.1.1. Subject Incidence of Subsequent Anti-cancer Therapy by Category and Preferred Term (Safety Analysis Set)

Category Preferred Term	Standard of Care (N = 244) n (%)	Tarlatamab (N = 252) n (%)
PD-(L)1 Checkpoint Inhibitor	21 (8.6)	19 (7.5)
DURVALUMAB	3 (1.2)	5 (2.0)
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS	1 (0.4)	4 (1.6)
ATEZOLIZUMAB	4 (1.6)	3 (1.2)
TISLELIZUMAB	4 (1.6)	2 (0.8)
TORIPALIMAB	4 (1.6)	2 (0.8)
SINTILIMAB	0 (0.0)	2 (0.8)
NIVOLUMAB	1 (0.4)	1 (0.4)
SERPLULIMAB	4 (1.6)	0 (0.0)
CAMRELIZUMAB	1 (0.4)	0 (0.0)
PEMBROLIZUMAB	1 (0.4)	0 (0.0)
Radiation	4 (1.6)	1 (0.4)
RADIOTHERAPY	4 (1.6)	1 (0.4)
Single agent chemotherapy	95 (38.9)	102 (40.5)
CARBOPLATIN	34 (13.9)	39 (15.5)
ETOPOSIDE	23 (9.4)	28 (11.1)
TOPOTECAN	6 (2.5)	21 (8.3)

Page 3 of 5

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The subsequent anti-cancer therapy is based on pre-defined list of categories and preferred terms
Concomitant medications are coded using the WHO Drug Dictionary version GLOBALB3Mar24
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-cm-anti-catpt.sas
Output: t14-08-001-001-cm-anti-catpt.rtf (Date Generated: 31OCT25:07:22:10) Source: pa_adam.adsl, pa_adam.adcm

Table 14-8.1.1. Subject Incidence of Subsequent Anti-cancer Therapy by Category and Preferred Term (Safety Analysis Set)

Category Preferred Term	Standard of Care (N = 244) n (%)	Tarlatamab (N = 252) n (%)
IRINOTECAN	23 (9.4)	20 (7.9)
LURBINECTEDIN	5 (2.0)	12 (4.8)
PACLITAXEL	23 (9.4)	9 (3.6)
CISPLATIN	16 (6.6)	9 (3.6)
CYCLOPHOSPHAMIDE	5 (2.0)	9 (3.6)
DOXORUBICIN	4 (1.6)	9 (3.6)
VINCRISTINE	2 (0.8)	7 (2.8)
IRINOTECAN HYDROCHLORIDE	7 (2.9)	5 (2.0)
PACLITAXEL NANOPARTICLE ALBUMIN-BOUND	8 (3.3)	4 (1.6)
AMRUBICIN	1 (0.4)	4 (1.6)
AMRUBICIN HYDROCHLORIDE	1 (0.4)	4 (1.6)
ETOPOSIDE PHOSPHATE	1 (0.4)	3 (1.2)
BELOTECAN	3 (1.2)	2 (0.8)
TEMOZOLOMIDE	3 (1.2)	2 (0.8)
LOBAPLATIN	0 (0.0)	2 (0.8)
DOCETAXEL	2 (0.8)	1 (0.4)
TOPOTECAN HYDROCHLORIDE	2 (0.8)	1 (0.4)
VINCRISTINE SULFATE	2 (0.8)	1 (0.4)
GEMCITABINE HYDROCHLORIDE	1 (0.4)	1 (0.4)
PACLITAXEL LIPOSOME	1 (0.4)	1 (0.4)

Page 4 of 5

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The subsequent anti-cancer therapy is based on pre-defined list of categories and preferred terms
Concomitant medications are coded using the WHO Drug Dictionary version GLOBALB3Mar24
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-cm-anti-catpt.sas
Output: t14-08-001-001-cm-anti-catpt.rtf (Date Generated: 31OCT25:07:22:10) Source: pa_adam.adsl, pa_adam.adcm

Table 14-8.1.1. Subject Incidence of Subsequent Anti-cancer Therapy by Category and Preferred Term (Safety Analysis Set)

Category Preferred Term	Standard of Care (N = 244) n (%)	Tarlatamab (N = 252) n (%)
DISODIUM CANTHARIDINATE;PYRIDOXINE HYDROCHLORIDE	0 (0.0)	1 (0.4)
GEMCITABINE	1 (0.4)	0 (0.0)
PLATINUM	1 (0.4)	0 (0.0)
VINORELBINE TARTRATE	1 (0.4)	0 (0.0)
Tyrosine Kinase Inhibitor	25 (10.2)	7 (2.8)
CATEQUENTINIB HYDROCHLORIDE	16 (6.6)	5 (2.0)
CATEQUENTINIB	8 (3.3)	2 (0.8)
INVESTIGATIONAL ANTINEOPLASTIC DRUGS	1 (0.4)	0 (0.0)
SURUFATINIB	1 (0.4)	0 (0.0)

Page 5 of 5

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The subsequent anti-cancer therapy is based on pre-defined list of categories and preferred terms
Concomitant medications are coded using the WHO Drug Dictionary version GLOBALB3Mar24
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-cm-anti-catpt.sas
Output: t14-08-001-001-cm-anti-catpt.rtf (Date Generated: 31OCT25:07:22:10) Source: pa_adam.adsl, pa_adam.adcm

Table 14-8.1.2. Subject Incidence of First Subsequent Anti-cancer Therapy by Category and Preferred Term (Safety Analysis Set)

Category Preferred Term	Standard of Care (N = 244) n (%)	Tarlatamab (N = 252) n (%)
Number of subjects reporting first subsequent anti-cancer therapy	125 (51.2)	112 (44.4)
No subsequent anti-cancer therapy	119 (48.8)	140 (55.6)
ADC	4 (1.6)	4 (1.6)
INVESTIGATIONAL ANTINEOPLASTIC DRUGS	3 (1.2)	1 (0.4)
ANTIBODY DRUG CONJUGATES (ADC)	0 (0.0)	1 (0.4)
HS 20093	0 (0.0)	1 (0.4)
INVESTIGATIONAL DRUG	0 (0.0)	1 (0.4)
ABBV 706	1 (0.4)	0 (0.0)
Anti DLL3 therapy	10 (4.1)	0 (0.0)
TARLATAMAB	9 (3.7)	0 (0.0)
INVESTIGATIONAL ANTINEOPLASTIC DRUGS	1 (0.4)	0 (0.0)
Chemotherapy	1 (0.4)	1 (0.4)
CISPLATIN;IRINOTECAN	0 (0.0)	1 (0.4)
CARBOPLATIN;IRINOTECAN	1 (0.4)	0 (0.0)

Page 1 of 4

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The subsequent anti-cancer therapy is based on pre-defined list of categories and preferred terms
Concomitant medications are coded using the WHO Drug Dictionary version GLOBALB3Mar24
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-cm-anti-catpt-first.sas
Output: t14-08-001-002-cm-anti-catpt-first.rtf (Date Generated: 31OCT25:07:22:04) Source: pa_adam.adsl, pa_adam.adcm

Table 14-8.1.2. Subject Incidence of First Subsequent Anti-cancer Therapy by Category and Preferred Term (Safety Analysis Set)

Category Preferred Term	Standard of Care (N = 244) n (%)	Tarlatamab (N = 252) n (%)
Other	4 (1.6)	4 (1.6)
BEVACIZUMAB	0 (0.0)	2 (0.8)
TRASTUZUMAB	0 (0.0)	1 (0.4)
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	0 (0.0)	1 (0.4)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES	1 (0.4)	0 (0.0)
INTERLEUKIN-2	1 (0.4)	0 (0.0)
INVESTIGATIONAL ANTINEOPLASTIC DRUGS	1 (0.4)	0 (0.0)
RRX 001	1 (0.4)	0 (0.0)
PD-(L)1 Checkpoint Inhibitor	13 (5.3)	12 (4.8)
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS	0 (0.0)	4 (1.6)
DURVALUMAB	3 (1.2)	3 (1.2)
ATEZOLIZUMAB	3 (1.2)	2 (0.8)
SINTILIMAB	0 (0.0)	2 (0.8)
TORIPALIMAB	3 (1.2)	1 (0.4)
SERPLULIMAB	3 (1.2)	0 (0.0)
TISLELIZUMAB	1 (0.4)	0 (0.0)

Page 2 of 4

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The subsequent anti-cancer therapy is based on pre-defined list of categories and preferred terms
Concomitant medications are coded using the WHO Drug Dictionary version GLOBALB3Mar24
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-cm-anti-catpt-first.sas
Output: t14-08-001-002-cm-anti-catpt-first.rtf (Date Generated: 31OCT25:07:22:04) Source: pa_adam.adsl, pa_adam.adcm

Table 14-8.1.2. Subject Incidence of First Subsequent Anti-cancer Therapy by Category and Preferred Term (Safety Analysis Set)

Category Preferred Term	Standard of Care (N = 244) n (%)	Tarlatamab (N = 252) n (%)
Radiation	3 (1.2)	1 (0.4)
RADIOTHERAPY	3 (1.2)	1 (0.4)
Single agent chemotherapy	89 (36.5)	102 (40.5)
CARBOPLATIN	28 (11.5)	36 (14.3)
ETOPOSIDE	18 (7.4)	25 (9.9)
TOPOTECAN	4 (1.6)	16 (6.3)
IRINOTECAN	21 (8.6)	14 (5.6)
LURBINECTEDIN	5 (2.0)	9 (3.6)
CISPLATIN	12 (4.9)	7 (2.8)
CYCLOPHOSPHAMIDE	5 (2.0)	7 (2.8)
DOXORUBICIN	4 (1.6)	7 (2.8)
PACLITAXEL	13 (5.3)	6 (2.4)
VINCRISTINE	1 (0.4)	6 (2.4)
AMRUBICIN	1 (0.4)	4 (1.6)
AMRUBICIN HYDROCHLORIDE	1 (0.4)	4 (1.6)
IRINOTECAN HYDROCHLORIDE	5 (2.0)	3 (1.2)
ETOPOSIDE PHOSPHATE	1 (0.4)	3 (1.2)
PACLITAXEL NANOPARTICLE ALBUMIN-BOUND	6 (2.5)	2 (0.8)
TEMOZOLOMIDE	0 (0.0)	2 (0.8)

Page 3 of 4

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The subsequent anti-cancer therapy is based on pre-defined list of categories and preferred terms
Concomitant medications are coded using the WHO Drug Dictionary version GLOBALB3Mar24
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-cm-anti-catpt-first.sas
Output: t14-08-001-002-cm-anti-catpt-first.rtf (Date Generated: 31OCT25:07:22:04) Source: pa_adam.adsl, pa_adam.adcm

Table 14-8.1.2. Subject Incidence of First Subsequent Anti-cancer Therapy by Category and Preferred Term (Safety Analysis Set)

Category Preferred Term	Standard of Care (N = 244) n (%)	Tarlatamab (N = 252) n (%)
DOCETAXEL	2 (0.8)	1 (0.4)
TOPOTECAN HYDROCHLORIDE	2 (0.8)	1 (0.4)
VINCRISTINE SULFATE	2 (0.8)	1 (0.4)
BELOTECAN	1 (0.4)	1 (0.4)
PACLITAXEL LIPOSOME	1 (0.4)	1 (0.4)
DISODIUM CANTHARIDINATE;PYRIDOXINE HYDROCHLORIDE	0 (0.0)	1 (0.4)
LOBAPLATIN	0 (0.0)	1 (0.4)
GEMCITABINE HYDROCHLORIDE	1 (0.4)	0 (0.0)
PLATINUM	1 (0.4)	0 (0.0)
Tyrosine Kinase Inhibitor	18 (7.4)	5 (2.0)
CATEQUENTINIB HYDROCHLORIDE	13 (5.3)	3 (1.2)
CATEQUENTINIB	4 (1.6)	2 (0.8)
INVESTIGATIONAL ANTINEOPLASTIC DRUGS	1 (0.4)	0 (0.0)

Page 4 of 4

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The subsequent anti-cancer therapy is based on pre-defined list of categories and preferred terms
Concomitant medications are coded using the WHO Drug Dictionary version GLOBALB3Mar24
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-cm-anti-catpt-first.sas
Output: t14-08-001-002-cm-anti-catpt-first.rtf (Date Generated: 31OCT25:07:22:04) Source: pa_adam.adsl, pa_adam.adcm

Anhang 4-G2: Ergänzende Analysen zum Endpunkt „Symptomatik“ – RCT

Anhang 4-G2.1: Endpunkt „EORTC QLQ-C30/-LC13“ – RCT

Anhang 4-G2.1.1: Completion Rate

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Appetite Loss
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)		Standard of Care (N=255)	
Timepoint	n/ N	Completion	n/ N	Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Constipation
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Diarrhoea
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Dyspnea
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Fatigue
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Nausea and Vomiting
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Pain
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Insomnia
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	155/ 221	70.14%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Alopecia
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Coughing
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Dysphagia
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Dyspnoea
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Haemoptysis
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Pain in arm or shoulder
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Pain in chest
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Peripheral neuropathy
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Pain in other parts
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of LC13 Sore mouth
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	156/ 221	70.59%	125/ 211	59.24%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Anhang 4-G2.1.2: Veränderung zu Baseline

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Appetite Loss
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	20.33 (29.86)	0	-	250	19.73 (27.73)	0	-
Week 2	225	26.52 (31.07)	221	7.69 (30.09)	170	23.14 (30.13)	169	5.13 (27.46)
Week 3	217	34.72 (30.98)	214	16.04 (32.41)	173	22.54 (29.63)	172	5.04 (29.29)
Week 4	175	28.95 (30.95)	172	12.60 (32.29)	190	24.91 (29.68)	189	8.64 (27.75)
Week 5	203	27.59 (29.76)	198	12.79 (32.63)	160	26.04 (30.98)	160	9.58 (28.57)
Week 6	159	21.59 (26.29)	158	6.96 (27.91)	160	22.92 (30.18)	159	8.18 (31.31)
Week 7	187	23.53 (29.00)	182	8.24 (32.29)	173	22.35 (26.44)	172	6.01 (28.55)
Week 8	144	19.21 (27.19)	141	6.86 (28.04)	139	21.34 (27.22)	138	7.25 (29.80)
Week 9	167	23.55 (29.34)	163	7.16 (29.57)	125	20.80 (27.97)	124	8.06 (29.56)
Week 10	142	19.25 (25.21)	139	6.47 (25.97)	134	16.42 (21.92)	133	2.76 (28.14)
Week 11	156	20.51 (27.94)	152	3.73 (27.27)	120	21.94 (27.84)	119	8.40 (32.83)
Week 12	130	20.77 (28.23)	126	7.14 (28.47)	116	21.26 (23.83)	116	7.76 (29.61)
Week 13	156	24.15 (30.19)	152	6.80 (30.29)	127	18.64 (21.68)	127	2.36 (28.85)
Week 19	118	18.36 (24.88)	115	4.35 (29.13)	89	20.22 (26.41)	89	5.99 (33.92)
Week 25	107	17.76 (23.04)	104	2.24 (29.84)	60	8.89 (17.21)	60	-4.44 (27.08)
Week 31	91	19.78 (23.30)	89	3.00 (30.42)	41	11.38 (17.65)	41	4.07 (16.99)
Week 37	75	14.67 (25.26)	73	-0.91 (31.90)	21	15.87 (24.99)	21	4.76 (28.45)
Week 43	46	11.59 (18.88)	45	-0.00 (28.43)	12	11.11 (16.41)	12	0.00 (24.62)
Week 49	32	9.37 (22.77)	30	-0.00 (32.75)	6	0.00 (0.00)	6	-5.56 (13.61)
Week 55	22	15.15 (22.37)	22	1.52 (24.07)	3	11.11 (19.25)	3	11.11 (19.25)
Week 61	17	1.96 (8.08)	17	-7.84 (22.14)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	11.11 (17.21)	6	-5.56 (25.09)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	-33.33 (47.14)	0	-	0	-
End of IP Administration	117	33.90 (31.86)	116	17.53 (40.16)	151	24.72 (32.08)	149	7.61 (33.81)
Safety Follow-Up	65	31.79 (30.29)	64	19.79 (34.99)	91	17.95 (25.97)	90	4.81 (32.21)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Constipation
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	12.87 (21.54)	0	-	250	12.40 (22.79)	0	-
Week 2	225	13.63 (23.19)	221	1.66 (24.04)	170	18.04 (26.43)	169	6.31 (26.22)
Week 3	217	20.89 (28.03)	214	8.72 (28.10)	173	15.61 (22.60)	172	3.68 (26.84)
Week 4	175	20.19 (28.57)	172	8.33 (26.52)	190	14.56 (23.35)	189	4.23 (23.69)
Week 5	203	19.54 (25.61)	198	7.58 (24.77)	160	19.79 (27.55)	160	9.79 (29.81)
Week 6	159	17.82 (24.81)	158	7.38 (23.08)	160	15.42 (25.05)	159	5.66 (28.12)
Week 7	187	20.14 (27.30)	182	8.97 (25.49)	173	13.29 (21.49)	172	4.46 (22.79)
Week 8	144	18.52 (27.81)	141	8.51 (26.55)	139	16.79 (23.87)	138	8.21 (23.76)
Week 9	167	19.16 (27.72)	163	8.38 (25.48)	125	14.40 (22.13)	124	5.65 (21.97)
Week 10	142	15.26 (23.02)	139	5.04 (21.95)	134	13.93 (20.96)	133	5.01 (21.90)
Week 11	156	16.88 (24.68)	152	5.92 (23.05)	120	18.33 (22.39)	119	9.52 (24.60)
Week 12	130	13.85 (22.27)	126	4.23 (21.49)	116	10.63 (17.91)	116	1.72 (23.20)
Week 13	156	16.88 (24.10)	152	4.82 (23.46)	127	14.17 (23.20)	127	4.72 (23.65)
Week 19	118	15.25 (23.73)	115	5.51 (22.04)	89	15.73 (23.62)	89	5.99 (25.90)
Week 25	107	19.94 (28.54)	104	10.26 (27.11)	60	9.44 (19.50)	60	1.11 (20.32)
Week 31	91	14.29 (21.74)	89	4.12 (21.80)	41	16.26 (23.71)	41	8.94 (21.11)
Week 37	75	18.67 (25.84)	73	9.59 (21.14)	21	22.22 (30.43)	21	12.70 (32.45)
Week 43	46	13.04 (20.46)	45	0.74 (19.45)	12	13.89 (26.43)	12	0.00 (14.21)
Week 49	32	12.50 (22.00)	30	-2.22 (24.66)	6	11.11 (17.21)	6	-5.56 (13.61)
Week 55	22	15.15 (26.68)	22	1.52 (29.95)	3	11.11 (19.25)	3	0.00 (0.00)
Week 61	17	15.69 (29.15)	17	1.96 (32.21)	2	16.67 (23.57)	2	0.00 (0.00)
Week 67	6	5.56 (13.61)	6	-11.11 (27.22)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	-16.67 (23.57)	0	-	0	-
End of IP Administration	117	23.93 (31.21)	116	11.49 (29.52)	151	18.10 (27.14)	149	6.26 (27.23)
Safety Follow-Up	65	22.05 (27.18)	64	13.02 (31.77)	91	14.29 (24.42)	90	4.44 (26.06)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Diarrhoea
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	3.79 (12.92)	0	-	250	5.60 (13.84)	0	-
Week 2	225	4.89 (14.11)	221	1.51 (16.14)	170	6.67 (16.05)	169	2.56 (15.85)
Week 3	217	3.69 (11.86)	214	0.00 (13.70)	173	5.78 (16.23)	172	1.94 (17.18)
Week 4	175	2.67 (10.98)	172	-0.58 (11.10)	190	6.49 (17.78)	189	0.88 (17.34)
Week 5	203	2.63 (9.60)	198	-0.84 (10.85)	160	6.25 (15.94)	160	1.67 (17.05)
Week 6	159	1.68 (8.22)	158	-1.27 (11.83)	160	4.38 (11.89)	159	0.21 (15.23)
Week 7	187	1.96 (8.59)	182	-1.47 (12.05)	173	3.28 (9.95)	172	-3.10 (14.53)
Week 8	144	3.24 (13.26)	141	-0.24 (15.17)	139	4.80 (14.78)	138	-0.24 (16.85)
Week 9	167	2.40 (11.32)	163	-1.64 (14.72)	125	4.00 (11.67)	124	-1.08 (16.97)
Week 10	142	2.58 (11.28)	139	-1.44 (15.99)	134	7.46 (16.68)	133	1.50 (18.29)
Week 11	156	2.56 (11.06)	152	-1.54 (16.43)	120	6.39 (15.76)	119	2.24 (15.48)
Week 12	130	1.79 (8.62)	126	-0.79 (11.52)	116	3.74 (10.56)	116	-1.15 (13.85)
Week 13	156	2.78 (10.68)	152	-1.97 (14.97)	127	4.72 (13.75)	127	-1.31 (14.79)
Week 19	118	2.82 (11.18)	115	-0.87 (14.28)	89	7.87 (15.09)	89	1.50 (16.60)
Week 25	107	2.18 (9.46)	104	-2.56 (15.88)	60	5.00 (12.00)	60	-1.11 (16.20)
Week 31	91	2.56 (8.93)	89	-1.50 (13.21)	41	7.32 (15.83)	41	1.63 (12.80)
Week 37	75	3.11 (11.19)	73	-1.37 (14.10)	21	4.76 (11.95)	21	0.00 (21.08)
Week 43	46	2.17 (8.32)	45	-0.74 (11.21)	12	2.78 (9.62)	12	0.00 (14.21)
Week 49	32	1.04 (5.89)	30	-1.11 (6.09)	6	0.00 (0.00)	6	0.00 (0.00)
Week 55	22	1.52 (7.11)	22	-1.52 (7.11)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.00 (0.00)	17	-1.96 (8.08)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.00 (0.00)	6	0.00 (0.00)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	117	2.56 (9.94)	116	-1.15 (16.41)	151	6.62 (15.88)	149	1.57 (17.90)
Safety Follow-Up	65	5.64 (13.91)	64	4.17 (17.32)	91	4.40 (12.38)	90	-1.85 (16.84)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Dyspnea
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	19.11 (23.73)	0	-	250	20.00 (23.90)	0	-
Week 2	225	18.52 (24.76)	221	1.21 (21.29)	170	18.43 (22.94)	169	1.78 (21.60)
Week 3	217	17.97 (23.78)	214	0.93 (22.36)	173	21.39 (25.39)	172	3.88 (28.58)
Week 4	175	16.00 (23.12)	172	-0.19 (24.32)	190	22.11 (23.81)	189	4.76 (26.31)
Week 5	203	14.29 (21.46)	198	-1.68 (21.44)	160	23.13 (23.64)	160	6.46 (22.27)
Week 6	159	11.95 (19.23)	158	-2.32 (21.65)	160	20.00 (24.57)	159	3.56 (27.20)
Week 7	187	14.80 (21.88)	182	0.00 (19.51)	173	20.62 (22.56)	172	2.91 (24.14)
Week 8	144	10.65 (18.34)	141	-2.13 (19.60)	139	20.38 (23.91)	138	5.07 (25.44)
Week 9	167	12.18 (20.49)	163	-1.84 (20.37)	125	18.67 (24.47)	124	3.23 (28.01)
Week 10	142	9.39 (17.92)	139	-3.60 (21.12)	134	21.64 (24.27)	133	4.76 (26.95)
Week 11	156	11.97 (18.53)	152	-2.63 (20.49)	120	20.00 (23.83)	119	3.64 (28.72)
Week 12	130	9.49 (18.67)	126	-2.12 (21.39)	116	16.95 (23.05)	116	1.72 (25.95)
Week 13	156	10.47 (18.86)	152	-3.95 (19.91)	127	17.59 (22.15)	127	-1.05 (27.52)
Week 19	118	11.02 (17.46)	115	-1.74 (20.16)	89	24.34 (25.51)	89	6.74 (25.22)
Week 25	107	8.41 (14.55)	104	-5.45 (18.64)	60	17.22 (24.16)	60	0.56 (20.80)
Week 31	91	10.26 (17.70)	89	-1.50 (21.27)	41	15.45 (19.86)	41	-1.63 (19.65)
Week 37	75	8.44 (15.59)	73	-3.20 (18.56)	21	22.22 (26.53)	21	-4.76 (30.34)
Week 43	46	10.87 (17.29)	45	-1.48 (21.27)	12	16.67 (22.47)	12	0.00 (14.21)
Week 49	32	7.29 (16.36)	30	-4.44 (19.04)	6	5.56 (13.61)	6	-11.11 (34.43)
Week 55	22	9.09 (15.19)	22	-3.03 (17.55)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	7.84 (14.57)	17	-5.88 (21.20)	2	16.67 (23.57)	2	16.67 (23.57)
Week 67	6	5.56 (13.61)	6	-11.11 (17.21)	1	0.00 (-)	1	0.00 (-)
Week 73	2	16.67 (23.57)	2	-16.67 (23.57)	0	-	0	-
End of IP Administration	117	21.37 (24.55)	116	3.16 (24.86)	151	27.81 (29.67)	149	10.07 (29.18)
Safety Follow-Up	65	18.97 (24.27)	64	1.04 (24.47)	91	19.78 (24.83)	90	3.70 (25.21)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Fatigue
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	27.55 (24.13)	0	-	250	28.62 (24.44)	0	-
Week 2	225	33.48 (25.71)	221	7.59 (20.13)	170	33.14 (22.66)	169	6.71 (21.08)
Week 3	217	39.22 (27.18)	214	13.81 (23.53)	173	34.62 (26.44)	172	9.24 (26.66)
Week 4	175	34.92 (26.12)	172	11.18 (21.98)	190	34.04 (23.44)	189	8.52 (23.73)
Week 5	203	30.49 (22.37)	198	7.24 (20.93)	160	33.61 (23.25)	160	9.58 (24.15)
Week 6	159	27.32 (23.45)	158	5.34 (20.05)	160	32.85 (25.49)	159	9.57 (27.80)
Week 7	187	27.81 (23.57)	182	4.27 (18.19)	173	33.01 (24.63)	172	8.07 (22.93)
Week 8	144	22.30 (21.69)	141	2.68 (20.14)	139	32.69 (23.99)	138	10.06 (25.15)
Week 9	167	26.48 (21.94)	163	3.95 (18.95)	125	34.49 (26.17)	124	12.46 (25.99)
Week 10	142	23.55 (21.80)	139	3.92 (20.28)	134	32.59 (24.53)	133	8.86 (23.24)
Week 11	156	25.36 (20.30)	152	2.92 (18.61)	120	32.50 (23.54)	119	10.64 (26.65)
Week 12	130	22.56 (20.70)	126	3.79 (19.58)	116	31.61 (25.57)	116	10.34 (25.24)
Week 13	156	25.07 (22.57)	152	2.19 (20.18)	127	33.86 (24.84)	127	9.01 (25.53)
Week 19	118	20.24 (18.81)	115	1.55 (20.12)	89	34.83 (25.08)	89	11.49 (22.06)
Week 25	107	21.91 (19.63)	104	1.92 (19.85)	60	23.33 (19.16)	60	2.41 (22.79)
Week 31	91	20.88 (19.38)	89	0.37 (20.68)	41	24.12 (21.07)	41	3.52 (23.63)
Week 37	75	20.74 (20.85)	73	0.46 (24.03)	21	37.57 (26.17)	21	7.94 (37.37)
Week 43	46	21.98 (19.39)	45	1.48 (25.03)	12	23.15 (15.32)	12	2.78 (22.29)
Week 49	32	20.83 (19.71)	30	-0.00 (22.03)	6	20.37 (34.01)	6	1.85 (49.40)
Week 55	22	18.69 (14.30)	22	-0.00 (19.40)	3	11.11 (11.11)	3	7.41 (12.83)
Week 61	17	9.80 (12.96)	17	-8.50 (19.85)	2	22.22 (0.00)	2	16.67 (7.86)
Week 67	6	14.81 (16.73)	6	-12.96 (14.77)	1	22.22 (-)	1	22.22 (-)
Week 73	2	27.78 (7.86)	2	-16.67 (23.57)	0	-	0	-
End of IP Administration	117	33.81 (25.33)	116	6.90 (21.57)	151	38.56 (29.78)	149	12.53 (30.90)
Safety Follow-Up	65	34.70 (25.72)	64	11.11 (24.08)	91	29.55 (24.13)	90	7.90 (26.03)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Nausea and Vomiting
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	5.15 (13.74)	0	-	250	7.20 (17.14)	0	-
Week 2	225	8.07 (17.61)	221	3.54 (16.40)	170	11.86 (21.71)	169	5.33 (19.02)
Week 3	217	9.60 (17.46)	214	4.98 (17.87)	173	7.51 (15.91)	172	1.55 (15.84)
Week 4	175	6.38 (13.80)	172	2.52 (15.51)	190	8.68 (16.60)	189	2.82 (16.96)
Week 5	203	5.42 (14.67)	198	1.94 (14.36)	160	9.90 (16.54)	160	3.75 (17.13)
Week 6	159	4.40 (13.96)	158	0.84 (14.67)	160	6.87 (12.87)	159	1.78 (13.20)
Week 7	187	3.83 (11.54)	182	0.27 (11.28)	173	7.03 (12.59)	172	1.55 (15.11)
Week 8	144	1.85 (6.57)	141	-0.71 (11.59)	139	7.91 (14.51)	138	2.78 (17.62)
Week 9	167	3.49 (11.83)	163	-0.31 (11.78)	125	6.67 (14.51)	124	1.61 (18.58)
Week 10	142	2.93 (10.74)	139	0.36 (9.08)	134	5.47 (10.77)	133	0.38 (13.83)
Week 11	156	3.85 (11.95)	152	0.00 (11.51)	120	8.33 (14.00)	119	3.78 (15.86)
Week 12	130	1.67 (6.17)	126	-0.40 (9.99)	116	5.46 (9.77)	116	1.72 (12.11)
Week 13	156	3.53 (10.71)	152	-0.22 (12.28)	127	3.67 (8.64)	127	-0.26 (12.94)
Week 19	118	1.98 (6.23)	115	-1.01 (8.63)	89	8.24 (15.72)	89	5.24 (16.01)
Week 25	107	2.65 (7.64)	104	-0.96 (11.10)	60	4.44 (11.43)	60	1.39 (13.82)
Week 31	91	2.75 (7.56)	89	-0.56 (7.72)	41	2.44 (7.96)	41	0.81 (10.51)
Week 37	75	2.44 (8.53)	73	-0.46 (10.75)	21	0.79 (3.64)	21	-2.38 (12.12)
Week 43	46	1.81 (6.31)	45	-0.74 (10.63)	12	2.78 (6.49)	12	1.39 (4.81)
Week 49	32	0.00 (0.00)	30	-2.22 (9.52)	6	5.56 (13.61)	6	2.78 (6.80)
Week 55	22	0.76 (3.55)	22	-3.79 (14.49)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.00 (0.00)	17	-0.98 (4.04)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	11.11 (27.22)	6	8.33 (20.41)	1	0.00 (-)	1	0.00 (-)
Week 73	2	8.33 (11.79)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	117	8.26 (18.39)	116	3.30 (21.22)	151	8.28 (16.09)	149	1.34 (22.13)
Safety Follow-Up	65	8.21 (14.77)	64	5.47 (17.83)	91	6.41 (14.22)	90	1.48 (15.33)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Pain
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	20.39 (23.78)	0	-	250	19.40 (24.73)	0	-
Week 2	225	20.74 (22.81)	221	2.49 (21.73)	170	17.94 (22.43)	169	0.69 (18.22)
Week 3	217	21.04 (23.46)	214	2.96 (23.21)	173	16.96 (24.14)	172	-0.10 (25.01)
Week 4	175	17.90 (22.03)	172	0.39 (21.55)	190	17.81 (20.93)	189	1.59 (21.48)
Week 5	203	14.29 (20.81)	198	-2.19 (21.33)	160	17.50 (21.62)	160	2.50 (21.25)
Week 6	159	14.05 (22.31)	158	-2.00 (20.81)	160	13.65 (19.77)	159	0.63 (21.62)
Week 7	187	14.97 (20.71)	182	-2.47 (21.35)	173	17.05 (20.25)	172	2.52 (20.47)
Week 8	144	11.92 (18.24)	141	-3.90 (21.79)	139	17.15 (22.52)	138	4.11 (21.76)
Week 9	167	14.87 (19.10)	163	-2.25 (20.58)	125	14.40 (22.23)	124	1.88 (19.15)
Week 10	142	13.50 (20.72)	139	-0.96 (20.24)	134	15.92 (22.19)	133	1.13 (18.49)
Week 11	156	15.06 (21.65)	152	-2.52 (19.25)	120	15.42 (19.47)	119	3.22 (20.04)
Week 12	130	12.56 (18.91)	126	-2.38 (17.48)	116	13.79 (18.94)	116	2.59 (17.94)
Week 13	156	13.78 (19.41)	152	-3.29 (19.56)	127	16.93 (22.42)	127	3.28 (20.14)
Week 19	118	12.29 (16.51)	115	-2.75 (20.34)	89	18.91 (22.92)	89	4.49 (19.91)
Week 25	107	14.49 (19.17)	104	-1.60 (21.10)	60	15.56 (21.23)	60	2.50 (15.29)
Week 31	91	12.45 (18.52)	89	-3.75 (20.37)	41	13.82 (20.38)	41	2.44 (17.70)
Week 37	75	11.56 (16.66)	73	-4.34 (18.22)	21	18.25 (25.22)	21	0.00 (28.87)
Week 43	46	12.32 (17.37)	45	-1.11 (13.48)	12	6.94 (13.22)	12	-8.33 (20.72)
Week 49	32	11.46 (16.09)	30	-2.22 (16.80)	6	0.00 (0.00)	6	-11.11 (17.21)
Week 55	22	12.12 (15.59)	22	-3.79 (17.77)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	8.82 (14.57)	17	-3.92 (15.06)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	13.89 (16.39)	6	-8.33 (22.97)	1	0.00 (-)	1	0.00 (-)
Week 73	2	16.67 (23.57)	2	-8.33 (11.79)	0	-	0	-
End of IP Administration	117	27.07 (25.68)	116	7.61 (22.56)	151	25.39 (27.94)	149	8.84 (27.37)
Safety Follow-Up	65	22.05 (22.46)	64	6.25 (22.32)	91	19.41 (21.84)	90	6.11 (20.97)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Insomnia
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	19.51 (27.41)	0	-	250	18.67 (24.42)	0	-
Week 2	225	19.85 (26.37)	221	2.11 (25.14)	170	17.06 (23.00)	169	0.59 (23.42)
Week 3	217	15.82 (21.53)	214	-1.71 (25.27)	173	19.08 (25.96)	172	1.74 (27.75)
Week 4	175	17.14 (26.23)	172	0.58 (26.61)	190	18.25 (23.64)	189	0.35 (25.95)
Week 5	203	16.58 (22.09)	198	-0.00 (24.22)	160	15.63 (23.02)	160	-0.63 (24.65)
Week 6	159	14.26 (23.26)	158	-1.05 (24.50)	160	13.96 (20.30)	159	-1.05 (25.00)
Week 7	187	14.08 (23.90)	182	-2.38 (23.77)	173	16.96 (23.47)	172	0.97 (25.60)
Week 8	144	11.81 (21.40)	141	-3.07 (21.42)	139	17.75 (25.16)	138	2.66 (26.73)
Week 9	167	13.57 (22.89)	163	-3.68 (22.83)	125	15.73 (24.53)	124	-0.54 (30.05)
Week 10	142	11.50 (19.47)	139	-2.88 (21.42)	134	15.42 (21.50)	133	-1.50 (23.52)
Week 11	156	14.32 (23.38)	152	-3.51 (24.01)	120	17.50 (23.26)	119	1.68 (27.05)
Week 12	130	12.56 (21.67)	126	-1.59 (22.65)	116	15.52 (23.44)	116	-1.15 (24.45)
Week 13	155	13.33 (25.65)	151	-4.19 (27.30)	127	14.96 (22.89)	127	-1.84 (26.66)
Week 19	118	11.02 (18.52)	115	-4.35 (20.48)	89	21.35 (26.23)	89	5.99 (22.23)
Week 25	107	12.15 (20.68)	104	-3.85 (19.87)	60	13.33 (22.30)	60	1.11 (20.32)
Week 31	91	12.82 (19.10)	89	-3.00 (25.45)	41	11.38 (17.65)	41	-1.63 (21.02)
Week 37	75	14.67 (22.08)	73	-3.65 (24.57)	21	22.22 (35.49)	21	7.94 (36.37)
Week 43	46	10.14 (18.42)	45	-5.19 (20.04)	12	11.11 (16.41)	12	-2.78 (22.29)
Week 49	32	14.58 (23.85)	30	-0.00 (19.57)	6	5.56 (13.61)	6	-5.56 (13.61)
Week 55	22	7.58 (14.30)	22	-3.03 (25.01)	3	11.11 (19.25)	3	0.00 (0.00)
Week 61	17	7.84 (14.57)	17	0.00 (16.67)	2	0.00 (0.00)	2	-16.67 (23.57)
Week 67	6	11.11 (17.21)	6	0.00 (21.08)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	-16.67 (23.57)	0	-	0	-
End of IP Administration	117	20.51 (28.31)	116	2.87 (24.70)	151	22.74 (29.91)	149	4.70 (31.00)
Safety Follow-Up	65	18.97 (28.24)	64	2.60 (29.88)	91	15.75 (23.49)	90	0.37 (28.92)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Alopecia
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	14.57 (29.81)	0	-	250	14.80 (29.10)	0	-
Week 7	186	5.56 (18.31)	182	-4.58 (20.96)	173	25.05 (33.36)	172	12.40 (38.34)
Week 13	156	6.41 (21.12)	153	-6.32 (27.24)	125	27.73 (36.35)	125	13.33 (44.60)
Week 19	118	4.52 (15.66)	116	-6.03 (25.48)	89	25.84 (35.09)	89	13.11 (40.71)
Week 25	107	4.05 (15.67)	105	-7.62 (29.33)	60	13.89 (26.96)	60	2.22 (37.77)
Week 31	91	5.13 (17.16)	89	-7.87 (27.53)	41	16.26 (25.95)	41	2.44 (39.71)
Week 37	75	4.44 (14.84)	73	-5.48 (23.58)	21	19.05 (32.61)	21	11.11 (37.02)
Week 43	46	2.90 (9.50)	45	-5.19 (17.34)	12	11.11 (16.41)	12	-2.78 (26.43)
Week 49	32	1.04 (5.89)	30	-5.56 (15.37)	6	16.67 (18.26)	6	11.11 (17.21)
Week 55	22	3.03 (9.81)	22	-7.58 (25.05)	3	33.33 (0.00)	3	22.22 (19.25)
Week 61	17	3.92 (11.07)	17	-3.92 (11.07)	2	33.33 (47.14)	2	33.33 (47.14)
Week 67	6	5.56 (13.61)	6	-5.56 (13.61)	1	33.33 (-)	1	33.33 (-)
Week 73	2	0.00 (0.00)	2	-16.67 (23.57)	0	-	0	-
End of IP Administration	116	8.91 (23.41)	116	-3.74 (25.55)	150	24.67 (34.20)	148	10.81 (43.16)
Safety Follow-Up	66	23.74 (31.90)	66	15.66 (43.45)	90	20.74 (29.80)	89	10.11 (40.33)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Coughing
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	28.61 (23.48)	0	-	250	27.73 (24.54)	0	-
Week 7	186	19.71 (20.64)	182	-6.59 (22.28)	173	22.54 (22.14)	172	-3.68 (24.57)
Week 13	156	14.96 (19.04)	153	-11.98 (24.37)	125	19.47 (22.07)	125	-7.20 (25.25)
Week 19	118	17.51 (19.83)	116	-9.77 (22.85)	89	22.47 (25.51)	89	-3.37 (22.50)
Week 25	107	19.00 (20.53)	105	-8.57 (23.58)	60	15.56 (19.86)	60	-5.56 (22.27)
Week 31	91	14.29 (17.32)	89	-12.36 (25.32)	41	13.82 (22.33)	41	-8.13 (17.92)
Week 37	75	15.56 (19.25)	73	-10.50 (22.82)	21	26.98 (20.05)	21	-4.76 (26.43)
Week 43	46	12.32 (19.06)	45	-11.11 (18.80)	12	8.33 (15.08)	12	-16.67 (22.47)
Week 49	32	14.58 (20.63)	30	-10.00 (23.41)	6	5.56 (13.61)	6	-22.22 (17.21)
Week 55	22	9.09 (15.19)	22	-15.15 (22.37)	3	11.11 (19.25)	3	-11.11 (38.49)
Week 61	17	13.73 (16.91)	17	-11.76 (20.21)	2	16.67 (23.57)	2	0.00 (47.14)
Week 67	6	22.22 (17.21)	6	-5.56 (25.09)	1	33.33 (-)	1	33.33 (-)
Week 73	2	16.67 (23.57)	2	-16.67 (23.57)	0	-	0	-
End of IP Administration	116	26.44 (23.88)	116	-0.29 (23.87)	150	26.00 (23.13)	148	-1.58 (22.11)
Safety Follow-Up	66	28.28 (26.95)	66	3.03 (26.62)	90	21.11 (22.60)	89	-5.24 (26.06)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Dysphagia
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	5.13 (14.44)	0	-	250	6.13 (14.25)	0	-
Week 7	186	5.02 (13.82)	182	0.92 (15.84)	173	5.39 (14.26)	172	0.97 (13.69)
Week 13	156	5.77 (13.74)	153	1.53 (16.82)	125	4.00 (12.41)	125	-0.53 (15.25)
Week 19	118	3.39 (11.02)	116	-0.29 (12.81)	89	4.12 (12.12)	89	-1.12 (15.45)
Week 25	107	3.43 (12.06)	105	-0.63 (12.21)	60	3.33 (11.81)	60	-1.11 (12.22)
Week 31	91	2.93 (10.71)	89	-0.37 (10.65)	41	7.32 (20.43)	41	4.07 (16.99)
Week 37	75	4.44 (14.84)	73	0.46 (14.16)	21	4.76 (11.95)	21	0.00 (18.26)
Week 43	46	1.45 (6.87)	45	-0.74 (11.21)	12	2.78 (9.62)	12	0.00 (14.21)
Week 49	32	3.13 (9.87)	30	0.00 (12.38)	6	0.00 (0.00)	6	0.00 (0.00)
Week 55	22	0.00 (0.00)	22	-6.06 (22.15)	3	11.11 (19.25)	3	11.11 (19.25)
Week 61	17	0.00 (0.00)	17	-1.96 (8.08)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.00 (0.00)	6	-5.56 (13.61)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	116	9.48 (20.53)	116	6.32 (20.10)	150	8.22 (17.67)	148	4.73 (19.83)
Safety Follow-Up	66	8.59 (19.66)	66	5.05 (20.46)	90	6.30 (14.04)	89	2.62 (14.41)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Dyspnoea
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	21.32 (20.09)	0	-	250	22.31 (19.92)	0	-
Week 7	186	17.03 (18.27)	182	-0.73 (15.91)	173	23.38 (20.19)	172	3.68 (19.04)
Week 13	156	14.53 (15.44)	153	-2.69 (14.81)	125	21.96 (20.23)	125	2.13 (20.04)
Week 19	118	14.03 (15.94)	116	-2.39 (16.95)	89	28.09 (22.67)	89	9.49 (17.21)
Week 25	107	14.02 (13.42)	105	-3.60 (15.37)	60	20.00 (20.64)	60	2.96 (16.09)
Week 31	91	12.82 (14.34)	89	-4.62 (16.90)	41	15.99 (19.57)	41	-2.44 (16.20)
Week 37	75	14.07 (15.21)	73	-2.59 (15.88)	21	30.69 (25.07)	21	4.76 (22.93)
Week 43	46	13.53 (13.64)	45	-3.21 (17.18)	12	16.67 (18.65)	12	-1.85 (12.38)
Week 49	32	12.85 (13.57)	30	-2.96 (14.86)	6	14.81 (16.73)	6	-3.70 (20.69)
Week 55	22	12.63 (12.02)	22	-5.05 (15.61)	3	14.81 (6.42)	3	11.11 (0.00)
Week 61	17	9.80 (8.68)	17	-11.11 (16.20)	2	16.67 (7.86)	2	16.67 (7.86)
Week 67	6	9.26 (8.36)	6	-7.41 (15.18)	1	22.22 (-)	1	22.22 (-)
Week 73	2	16.67 (7.86)	2	-5.56 (7.86)	0	-	0	-
End of IP Administration	116	25.96 (21.53)	116	4.60 (21.14)	150	28.59 (25.14)	148	9.01 (24.19)
Safety Follow-Up	66	25.42 (23.85)	66	6.73 (23.22)	90	21.98 (19.35)	89	4.49 (21.17)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Haemoptysis
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	0.94 (5.54)	0	-	250	2.40 (8.63)	0	-
Week 7	186	0.90 (5.41)	182	0.00 (6.07)	173	1.16 (6.12)	172	-0.78 (9.51)
Week 13	156	0.85 (5.29)	153	0.00 (6.62)	125	0.27 (2.98)	125	-2.13 (9.22)
Week 19	118	0.28 (3.07)	116	-0.57 (4.36)	89	0.75 (4.97)	89	-1.12 (9.33)
Week 25	107	0.62 (4.54)	105	-0.32 (5.65)	60	0.00 (0.00)	60	-1.67 (7.33)
Week 31	91	0.73 (4.91)	89	0.37 (6.14)	41	0.00 (0.00)	41	-1.63 (7.27)
Week 37	75	0.00 (0.00)	73	-0.46 (3.90)	21	1.59 (7.27)	21	0.00 (10.54)
Week 43	46	0.00 (0.00)	45	0.00 (0.00)	12	0.00 (0.00)	12	-2.78 (9.62)
Week 49	32	0.00 (0.00)	30	0.00 (0.00)	6	0.00 (0.00)	6	0.00 (0.00)
Week 55	22	0.00 (0.00)	22	0.00 (0.00)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.00 (0.00)	17	0.00 (0.00)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.00 (0.00)	6	0.00 (0.00)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	116	2.59 (9.98)	116	1.15 (10.71)	150	2.22 (9.19)	148	-0.00 (11.00)
Safety Follow-Up	66	3.03 (13.99)	66	0.51 (12.39)	90	1.48 (6.91)	89	-0.37 (9.39)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Pain in arm or shoulder
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	11.74 (21.50)	0	-	250	12.93 (19.97)	0	-
Week 7	186	6.99 (16.41)	182	-4.58 (19.75)	173	9.44 (17.81)	172	-2.52 (19.75)
Week 13	156	7.26 (16.63)	153	-4.14 (20.35)	125	8.27 (15.64)	125	-2.67 (18.26)
Week 19	118	8.47 (19.58)	116	-1.72 (21.01)	89	11.99 (20.26)	89	0.00 (22.47)
Week 25	107	10.90 (19.84)	105	-0.32 (22.41)	60	6.67 (16.00)	60	-3.89 (22.21)
Week 31	91	11.36 (20.01)	89	1.12 (22.72)	41	8.13 (17.92)	41	-2.44 (21.59)
Week 37	75	7.56 (16.05)	73	-2.74 (19.84)	21	6.35 (13.41)	21	-6.35 (20.05)
Week 43	46	5.07 (12.11)	45	-2.22 (16.51)	12	5.56 (12.97)	12	-8.33 (15.08)
Week 49	32	5.21 (12.30)	30	-2.22 (14.99)	6	0.00 (0.00)	6	-16.67 (18.26)
Week 55	22	7.58 (14.30)	22	1.52 (12.50)	3	0.00 (0.00)	3	-22.22 (19.25)
Week 61	17	7.84 (14.57)	17	1.96 (14.29)	2	0.00 (0.00)	2	-16.67 (23.57)
Week 67	6	5.56 (13.61)	6	5.56 (13.61)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	116	16.38 (24.67)	116	4.60 (21.49)	150	12.22 (20.95)	148	-0.45 (22.33)
Safety Follow-Up	66	11.11 (17.86)	66	0.00 (18.49)	90	11.11 (19.99)	89	-1.50 (21.27)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Pain in chest
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	11.07 (20.02)	0	-	250	12.27 (19.83)	0	-
Week 7	186	8.24 (19.70)	182	-1.28 (18.99)	173	9.63 (16.77)	172	-1.16 (21.90)
Week 13	156	7.05 (15.62)	153	-2.40 (17.14)	125	9.33 (16.18)	125	0.53 (20.30)
Week 19	118	5.37 (14.43)	116	-3.74 (16.89)	89	11.99 (20.26)	89	2.25 (21.20)
Week 25	107	8.10 (18.79)	105	-0.95 (19.86)	60	7.22 (15.15)	60	0.00 (18.41)
Week 31	91	7.69 (17.27)	89	-1.50 (20.04)	41	8.13 (14.49)	41	1.63 (21.02)
Week 37	75	8.89 (15.82)	73	-0.46 (18.00)	21	12.70 (19.65)	21	3.17 (17.97)
Week 43	46	6.52 (13.37)	45	-1.48 (17.34)	12	5.56 (12.97)	12	-2.78 (17.16)
Week 49	32	6.25 (13.22)	30	-1.11 (18.54)	6	0.00 (0.00)	6	0.00 (0.00)
Week 55	22	7.58 (17.61)	22	-1.52 (16.19)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	7.84 (14.57)	17	-1.96 (14.29)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	11.11 (17.21)	6	-5.56 (13.61)	1	0.00 (-)	1	0.00 (-)
Week 73	2	16.67 (23.57)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	116	16.95 (24.28)	116	6.03 (21.80)	150	12.67 (20.31)	148	2.03 (23.40)
Safety Follow-Up	66	11.62 (19.82)	66	0.51 (23.75)	90	7.78 (14.18)	89	-1.12 (17.00)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Peripheral neuropathy
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	8.77 (18.27)	0	-	250	9.07 (17.86)	0	-
Week 7	186	6.63 (16.56)	182	-0.18 (16.25)	173	9.25 (17.73)	172	1.16 (16.87)
Week 13	156	5.98 (14.41)	153	-0.44 (16.66)	125	6.93 (15.44)	125	-1.60 (20.24)
Week 19	118	6.21 (14.42)	116	-1.15 (18.09)	89	9.36 (18.11)	89	0.75 (18.79)
Week 25	107	6.85 (16.34)	105	-0.95 (20.91)	60	7.22 (16.34)	60	-1.11 (20.32)
Week 31	91	6.59 (15.09)	89	-0.37 (19.13)	41	9.76 (17.07)	41	2.44 (18.84)
Week 37	75	5.78 (16.78)	73	-0.46 (17.12)	21	7.94 (14.55)	21	-1.59 (19.65)
Week 43	46	2.17 (8.32)	45	-1.48 (12.22)	12	0.00 (0.00)	12	-8.33 (15.08)
Week 49	32	2.08 (8.20)	30	-2.22 (8.46)	6	5.56 (13.61)	6	0.00 (21.08)
Week 55	22	1.52 (7.11)	22	-3.03 (9.81)	3	11.11 (19.25)	3	0.00 (0.00)
Week 61	17	1.96 (8.08)	17	-1.96 (14.29)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.00 (0.00)	6	0.00 (0.00)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	116	8.05 (18.45)	116	0.29 (20.38)	150	10.89 (22.35)	148	2.03 (24.35)
Safety Follow-Up	66	11.62 (18.01)	66	3.54 (19.51)	90	9.26 (20.62)	89	-0.37 (22.75)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Pain in other parts
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	15.92 (23.82)	0	-	250	17.60 (25.90)	0	-
Week 7	186	11.47 (19.60)	182	-0.55 (22.01)	173	15.22 (20.16)	172	0.97 (24.03)
Week 13	156	13.25 (21.65)	153	1.53 (23.98)	125	16.00 (23.42)	125	1.60 (26.39)
Week 19	118	10.17 (18.75)	116	-1.15 (23.23)	89	16.85 (23.10)	89	1.12 (27.27)
Week 25	107	12.77 (20.29)	105	0.95 (19.86)	60	14.44 (21.58)	60	1.67 (24.10)
Week 31	91	9.52 (17.42)	89	-3.00 (21.70)	41	8.13 (16.30)	41	-2.44 (22.84)
Week 37	75	9.78 (17.99)	73	-1.83 (22.83)	21	22.22 (30.43)	21	6.35 (40.30)
Week 43	46	10.87 (18.66)	45	3.70 (19.10)	12	13.89 (22.29)	12	-2.78 (41.34)
Week 49	32	8.33 (18.93)	30	1.11 (10.66)	6	5.56 (13.61)	6	-16.67 (27.89)
Week 55	22	7.58 (17.61)	22	-0.00 (14.55)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	5.88 (13.10)	17	3.92 (16.17)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	11.11 (17.21)	6	11.11 (17.21)	1	0.00 (-)	1	0.00 (-)
Week 73	2	16.67 (23.57)	2	16.67 (23.57)	0	-	0	-
End of IP Administration	116	20.40 (25.16)	116	5.75 (27.20)	150	22.67 (29.99)	148	6.31 (34.20)
Safety Follow-Up	66	17.17 (22.07)	66	5.56 (24.52)	90	15.56 (22.46)	89	1.12 (23.27)


N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of LC13 Sore mouth
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	3.64 (14.11)	0	-	250	4.53 (13.26)	0	-
Week 7	186	2.69 (11.44)	182	-0.18 (13.34)	173	5.39 (13.80)	172	2.13 (15.77)
Week 13	156	2.78 (9.99)	153	-0.87 (15.74)	125	5.60 (15.11)	125	1.07 (13.34)
Week 19	118	2.54 (8.89)	116	-0.29 (12.04)	89	3.37 (11.29)	89	0.75 (15.06)
Week 25	107	1.87 (7.70)	105	-0.63 (11.30)	60	1.67 (7.33)	60	-1.11 (10.57)
Week 31	91	2.56 (10.22)	89	-0.75 (14.19)	41	4.88 (11.93)	41	-0.81 (18.99)
Week 37	75	0.89 (5.41)	73	-3.20 (12.63)	21	4.76 (11.95)	21	-3.17 (23.34)
Week 43	46	1.45 (6.87)	45	-2.96 (11.94)	12	11.11 (16.41)	12	5.56 (19.25)
Week 49	32	1.04 (5.89)	30	-4.44 (11.52)	6	0.00 (0.00)	6	-5.56 (13.61)
Week 55	22	1.52 (7.11)	22	-6.06 (24.42)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.00 (0.00)	17	-1.96 (8.08)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.00 (0.00)	6	-5.56 (13.61)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	116	5.75 (17.73)	116	4.31 (17.87)	150	7.11 (18.76)	148	3.38 (20.11)
Safety Follow-Up	66	4.04 (10.96)	66	2.53 (13.47)	90	2.59 (11.43)	89	-0.37 (15.48)


N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Appetite Loss
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Constipation
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Diarrhoea
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Dyspnea
Intention-to-Treat Analysis Set




Number of subjects:

Tarlatamab	182	152	115	104	89	73	45	30	22	17	6	116	64
SoC	172	127	89	60	41	21	12	6	3	2	1	149	90


Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Fatigue
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Nausea and Vomiting
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Pain
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Insomnia
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Alopecia
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Coughing
Intention-to-Treat Analysis Set




Number of subjects:

	Week 7	Week 13	Week 19	Week 25	Week 31	Week 37	Week 43	Week 49	Week 55	Week 61	Week 67	EOT	Safety FU
Tarlatamab	182	153	116	105	89	73	45	30	22	17	6	116	66
SoC	172	125	89	60	41	21	12	6	3	2	1	148	89


Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Dysphagia
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Dyspnoea
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Haemoptysis
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Pain in arm or shoulder
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Pain in chest
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Peripheral neuropathy
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Pain in other parts
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of LC13 Sore mouth
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Anhang 4-G2.2: Endpunkt „EQ-5D VAS“ – RCT

Anhang 4-G2.2.1: Completion Rate

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of Visual Analog Score
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)		Standard of Care (N=255)	
Timepoint	n/ N	Completion	n/ N	Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	154/ 221	69.68%	124/ 211	58.77%
Week 19	117/ 205	57.07%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	150/ 255	58.82%
Safety Follow-Up	66/ 254	25.98%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).


Anhang 4-G2.2.2: Veränderung zu Baseline

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of Visual Analog Score
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	73.94 (17.22)	0	-	250	73.75 (18.12)	0	-
Week 7	186	74.83 (16.06)	182	-1.36 (12.97)	173	72.65 (15.82)	172	-4.15 (15.56)
Week 13	154	75.96 (15.57)	151	-1.50 (16.05)	124	70.51 (19.10)	124	-5.54 (16.62)
Week 19	117	79.26 (13.77)	115	-0.79 (14.94)	89	73.30 (17.35)	89	-4.63 (15.79)
Week 25	107	79.23 (12.80)	105	0.49 (14.04)	60	76.65 (15.75)	60	-2.67 (13.89)
Week 31	91	80.63 (12.84)	89	1.38 (13.59)	41	76.80 (14.98)	41	-3.83 (14.50)
Week 37	75	79.88 (13.77)	73	0.81 (14.35)	21	69.95 (13.00)	21	-4.43 (21.12)
Week 43	46	81.20 (12.42)	45	0.64 (12.61)	12	75.08 (13.90)	12	-1.33 (18.39)
Week 49	32	82.41 (11.08)	30	2.00 (13.74)	6	80.17 (10.11)	6	-0.17 (16.47)
Week 55	22	79.95 (10.40)	22	3.32 (13.94)	3	79.33 (9.02)	3	-12.33 (13.32)
Week 61	17	82.18 (9.92)	17	3.88 (10.64)	2	81.50 (2.12)	2	-11.50 (7.78)
Week 67	6	80.67 (8.98)	6	5.33 (7.47)	1	80.00 (-)	1	-17.00 (-)
Week 73	2	80.00 (7.07)	2	5.00 (14.14)	0	-	0	-
End of IP Administration	117	64.59 (21.49)	117	-10.21 (20.37)	150	66.75 (20.57)	148	-9.56 (20.23)
Safety Follow-Up	66	68.24 (16.39)	66	-9.77 (14.13)	91	71.44 (16.47)	90	-7.29 (17.01)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of Visual Analog Score
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Anhang 4-G2.3: Endpunkt „PGI-C/PGI-S“ – RCT

Anhang 4-G2.3.1: Completion Rate

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of Cough Now
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)		Standard of Care (N=255)	
Timepoint	n/ N	Completion	n/ N	Completion
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	155/ 221	70.14%	124/ 211	58.77%
Week 19	116/ 205	56.59%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	114/ 254	44.88%	149/ 255	58.43%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of Chest Pain Now
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	155/ 221	70.14%	124/ 211	58.77%
Week 19	116/ 205	56.59%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	114/ 254	44.88%	149/ 255	58.43%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of Breath Shortness Now
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Week 7	186/ 232	80.17%	173/ 236	73.31%
Week 13	155/ 221	70.14%	124/ 211	58.77%
Week 19	116/ 205	56.59%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	114/ 254	44.88%	149/ 255	58.43%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of Cough
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 13	155/ 221	70.14%	123/ 211	58.29%
Week 19	116/ 205	56.59%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of Chest Pain
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 13	155/ 221	70.14%	123/ 211	58.29%
Week 19	116/ 205	56.59%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of Breath Shortness
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 13	155/ 221	70.14%	123/ 211	58.29%
Week 19	116/ 205	56.59%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Anhang 4-G2.3.2: Veränderung zu Baseline

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of Cough Now
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Week 7	186	-1.01 (0.94)	186	-1.01 (0.94)	173	-0.75 (0.95)	173	-0.75 (0.95)
Week 13	155	-1.04 (0.95)	155	-1.04 (0.95)	124	-0.65 (0.87)	124	-0.65 (0.87)
Week 19	116	-1.03 (0.93)	116	-1.03 (0.93)	89	-0.89 (0.99)	89	-0.89 (0.99)
Week 25	107	-1.12 (0.85)	107	-1.12 (0.85)	60	-0.87 (1.00)	60	-0.87 (1.00)
Week 31	90	-1.18 (0.84)	90	-1.18 (0.84)	41	-0.95 (0.97)	41	-0.95 (0.97)
Week 37	75	-1.11 (0.91)	75	-1.11 (0.91)	21	-0.86 (0.91)	21	-0.86 (0.91)
Week 43	46	-1.24 (0.87)	46	-1.24 (0.87)	12	-1.17 (0.94)	12	-1.17 (0.94)
Week 49	32	-1.25 (0.84)	32	-1.25 (0.84)	6	-1.00 (1.10)	6	-1.00 (1.10)
Week 55	22	-1.18 (0.85)	22	-1.18 (0.85)	3	-1.00 (1.00)	3	-1.00 (1.00)
Week 61	17	-1.24 (0.75)	17	-1.24 (0.75)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	-1.17 (0.75)	6	-1.17 (0.75)	1	0.00 (-)	1	0.00 (-)
Week 73	2	-1.50 (0.71)	2	-1.50 (0.71)	0	-	0	-
End of IP Administration	114	-0.57 (1.10)	114	-0.57 (1.10)	149	-0.63 (1.07)	149	-0.63 (1.07)
Safety Follow-Up	65	-0.51 (1.17)	65	-0.51 (1.17)	91	-0.84 (1.01)	91	-0.84 (1.01)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of Chest Pain Now
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Week 7	186	-0.89 (0.97)	186	-0.89 (0.97)	173	-0.68 (0.92)	173	-0.68 (0.92)
Week 13	155	-0.90 (0.99)	155	-0.90 (0.99)	124	-0.74 (0.90)	124	-0.74 (0.90)
Week 19	116	-0.95 (0.96)	116	-0.95 (0.96)	89	-0.79 (0.94)	89	-0.79 (0.94)
Week 25	107	-0.96 (0.96)	107	-0.96 (0.96)	60	-0.83 (0.98)	60	-0.83 (0.98)
Week 31	90	-1.09 (0.91)	90	-1.09 (0.91)	41	-0.98 (0.91)	41	-0.98 (0.91)
Week 37	75	-0.93 (0.91)	75	-0.93 (0.91)	21	-1.05 (0.92)	21	-1.05 (0.92)
Week 43	46	-1.04 (0.89)	46	-1.04 (0.89)	12	-1.00 (0.95)	12	-1.00 (0.95)
Week 49	32	-0.97 (0.90)	32	-0.97 (0.90)	6	-0.67 (1.03)	6	-0.67 (1.03)
Week 55	22	-1.05 (0.95)	22	-1.05 (0.95)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	-1.18 (0.88)	17	-1.18 (0.88)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	-1.17 (0.98)	6	-1.17 (0.98)	1	0.00 (-)	1	0.00 (-)
Week 73	2	-1.00 (1.41)	2	-1.00 (1.41)	0	-	0	-
End of IP Administration	114	-0.46 (1.05)	114	-0.46 (1.05)	149	-0.73 (1.00)	149	-0.73 (1.00)
Safety Follow-Up	65	-0.62 (0.93)	65	-0.62 (0.93)	91	-0.80 (0.92)	91	-0.80 (0.92)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of Breath Shortness Now
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Week 7	186	-0.79 (0.96)	186	-0.79 (0.96)	173	-0.49 (0.87)	173	-0.49 (0.87)
Week 13	155	-0.91 (0.94)	155	-0.91 (0.94)	124	-0.51 (0.95)	124	-0.51 (0.95)
Week 19	116	-0.90 (1.00)	116	-0.90 (1.00)	89	-0.53 (0.98)	89	-0.53 (0.98)
Week 25	107	-1.05 (0.89)	107	-1.05 (0.89)	60	-0.68 (0.97)	60	-0.68 (0.97)
Week 31	90	-1.09 (0.92)	90	-1.09 (0.92)	41	-0.76 (0.97)	41	-0.76 (0.97)
Week 37	75	-1.04 (0.94)	75	-1.04 (0.94)	21	-0.71 (0.90)	21	-0.71 (0.90)
Week 43	46	-1.07 (0.90)	46	-1.07 (0.90)	12	-0.83 (0.83)	12	-0.83 (0.83)
Week 49	32	-1.13 (0.87)	32	-1.13 (0.87)	6	-0.83 (0.98)	6	-0.83 (0.98)
Week 55	22	-1.14 (0.77)	22	-1.14 (0.77)	3	-0.67 (1.15)	3	-0.67 (1.15)
Week 61	17	-1.24 (0.90)	17	-1.24 (0.90)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	-1.17 (0.75)	6	-1.17 (0.75)	1	0.00 (-)	1	0.00 (-)
Week 73	2	-1.50 (0.71)	2	-1.50 (0.71)	0	-	0	-
End of IP Administration	114	-0.48 (1.10)	114	-0.48 (1.10)	149	-0.44 (1.09)	149	-0.44 (1.09)
Safety Follow-Up	65	-0.54 (1.11)	65	-0.54 (1.11)	91	-0.67 (0.98)	91	-0.67 (0.98)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of Cough
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.83 (0.77)	0	-	250	1.77 (0.75)	0	-
Week 7	187	1.57 (0.65)	183	-0.19 (0.69)	173	1.70 (0.77)	172	-0.01 (0.78)
Week 13	155	1.46 (0.58)	152	-0.28 (0.74)	123	1.54 (0.67)	123	-0.20 (0.73)
Week 19	116	1.49 (0.63)	114	-0.27 (0.73)	89	1.71 (0.73)	89	-0.07 (0.75)
Week 25	107	1.53 (0.59)	105	-0.27 (0.67)	60	1.47 (0.62)	60	-0.18 (0.77)
Week 31	90	1.40 (0.51)	88	-0.32 (0.75)	41	1.44 (0.71)	41	-0.17 (0.63)
Week 37	75	1.47 (0.58)	73	-0.23 (0.72)	21	1.81 (0.60)	21	0.00 (0.89)
Week 43	46	1.37 (0.57)	45	-0.29 (0.66)	12	1.17 (0.39)	12	-0.33 (0.78)
Week 49	32	1.38 (0.61)	30	-0.37 (0.76)	6	1.17 (0.41)	6	-0.17 (0.75)
Week 55	22	1.27 (0.55)	22	-0.50 (0.86)	3	1.33 (0.58)	3	0.00 (1.00)
Week 61	17	1.35 (0.49)	17	-0.41 (0.80)	2	1.50 (0.71)	2	0.50 (0.71)
Week 67	6	1.67 (0.52)	6	0.00 (0.89)	1	2.00 (-)	1	1.00 (-)
Week 73	2	1.50 (0.71)	2	-0.50 (0.71)	0	-	0	-
End of IP Administration	113	1.79 (0.74)	113	-0.01 (0.80)	149	1.77 (0.80)	147	0.02 (0.80)
Safety Follow-Up	65	1.88 (0.96)	65	0.14 (1.10)	91	1.65 (0.74)	90	-0.02 (0.81)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of Chest Pain
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.41 (0.75)	0	-	250	1.35 (0.63)	0	-
Week 7	187	1.27 (0.59)	183	-0.07 (0.64)	173	1.29 (0.55)	172	0.01 (0.62)
Week 13	155	1.23 (0.50)	152	-0.10 (0.62)	123	1.31 (0.50)	123	0.02 (0.62)
Week 19	116	1.19 (0.49)	114	-0.12 (0.65)	89	1.35 (0.59)	89	0.04 (0.66)
Week 25	107	1.26 (0.56)	105	-0.07 (0.68)	60	1.32 (0.60)	60	0.12 (0.72)
Week 31	90	1.22 (0.47)	88	-0.08 (0.71)	41	1.32 (0.57)	41	0.07 (0.85)
Week 37	75	1.23 (0.51)	73	-0.07 (0.56)	21	1.24 (0.44)	21	-0.10 (0.70)
Week 43	46	1.22 (0.42)	45	0.00 (0.56)	12	1.17 (0.39)	12	-0.08 (0.51)
Week 49	32	1.13 (0.34)	30	-0.13 (0.57)	6	1.00 (0.00)	6	0.00 (0.00)
Week 55	22	1.27 (0.55)	22	-0.09 (0.61)	3	1.00 (0.00)	3	0.00 (0.00)
Week 61	17	1.18 (0.39)	17	-0.24 (0.56)	2	1.00 (0.00)	2	0.00 (0.00)
Week 67	6	1.33 (0.52)	6	-0.33 (0.52)	1	1.00 (-)	1	0.00 (-)
Week 73	2	1.50 (0.71)	2	-0.50 (0.71)	0	-	0	-
End of IP Administration	113	1.61 (0.87)	113	0.19 (0.87)	149	1.37 (0.62)	147	0.08 (0.64)
Safety Follow-Up	65	1.42 (0.73)	65	-0.03 (0.75)	91	1.30 (0.53)	90	0.07 (0.60)


N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of Breath Shortness
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.62 (0.76)	0	-	250	1.65 (0.75)	0	-
Week 7	187	1.49 (0.68)	183	-0.02 (0.65)	173	1.62 (0.73)	172	0.05 (0.79)
Week 13	155	1.35 (0.56)	152	-0.13 (0.64)	123	1.59 (0.65)	123	-0.02 (0.83)
Week 19	116	1.34 (0.60)	114	-0.12 (0.60)	89	1.70 (0.79)	89	0.15 (0.67)
Week 25	107	1.36 (0.54)	105	-0.16 (0.65)	60	1.58 (0.72)	60	0.08 (0.59)
Week 31	90	1.22 (0.49)	88	-0.28 (0.66)	41	1.44 (0.59)	41	-0.12 (0.56)
Week 37	75	1.23 (0.51)	73	-0.25 (0.64)	21	1.71 (0.72)	21	-0.10 (0.70)
Week 43	46	1.35 (0.53)	45	-0.16 (0.64)	12	1.58 (0.67)	12	0.08 (0.51)
Week 49	32	1.16 (0.45)	30	-0.37 (0.61)	6	1.33 (0.82)	6	0.00 (0.00)
Week 55	22	1.23 (0.43)	22	-0.27 (0.55)	3	1.00 (0.00)	3	0.00 (0.00)
Week 61	17	1.12 (0.33)	17	-0.47 (0.51)	2	1.50 (0.71)	2	0.50 (0.71)
Week 67	6	1.17 (0.41)	6	-0.50 (0.55)	1	1.00 (-)	1	0.00 (-)
Week 73	2	1.50 (0.71)	2	-0.50 (0.71)	0	-	0	-
End of IP Administration	113	1.78 (0.82)	113	0.18 (0.83)	149	1.74 (0.79)	147	0.17 (0.78)
Safety Follow-Up	65	1.69 (0.73)	65	0.20 (0.75)	91	1.60 (0.76)	90	0.08 (0.78)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of Cough Now
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of Chest Pain Now
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of Breath Shortness Now
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of Cough
Intention-to-Treat Analysis Set




Number of subjects:

	Week 7	Week 13	Week 19	Week 25	Week 31	Week 37	Week 43	Week 49	Week 55	Week 61	Week 67	EOT	Safety FU
Tarlatamab	183	152	114	105	88	73	45	30	22	17	6	113	65
SoC	172	123	89	60	41	21	12	6	3	2	1	147	90

Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of Chest Pain
Intention-to-Treat Analysis Set




Number of subjects:

	Week 7	Week 13	Week 19	Week 25	Week 31	Week 37	Week 43	Week 49	Week 55	Week 61	Week 67	EOT	Safety FU
Tarlatamab	183	152	114	105	88	73	45	30	22	17	6	113	65
SoC	172	123	89	60	41	21	12	6	3	2	1	147	90

Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of Breath Shortness
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Anhang 4-G2.4: Endpunkt „BPI-SF“ – RCT

Anhang 4-G2.4.1: Completion Rate

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain at its Worst in Last 24 Hours
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)		Standard of Care (N=255)	
Timepoint	n/ N	Completion	n/ N	Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain at its Least in Last 24 Hours
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	249/ 255	97.65%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain on the Average
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	249/ 255	97.65%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Right Now
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	249/ 255	97.65%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Interfered General Activity
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	248/ 255	97.25%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Interfered with Mood
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	248/ 255	97.25%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Interfered Walking Ability
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	248/ 255	97.25%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Interfered with Normal Work
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	248/ 255	97.25%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Interfered with Relations
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	248/ 255	97.25%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Interfered with Sleep
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	248/ 255	97.25%
Week 7	185/ 232	79.74%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Interfered Enjoyment of Life
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	248/ 255	97.25%
Week 7	185/ 232	79.74%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Interference
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	248/ 255	97.25%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of BPI2-Pain Severity
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	249/ 255	97.65%
Week 7	186/ 232	80.17%	172/ 236	72.88%
Week 13	152/ 221	68.78%	120/ 211	56.87%
Week 19	115/ 205	56.10%	89/ 189	47.09%
Week 25	105/ 194	54.12%	60/ 164	36.59%
Week 31	90/ 184	48.91%	41/ 142	28.87%
Week 37	74/ 157	47.13%	20/ 114	17.54%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	31/ 76	40.79%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	113/ 254	44.49%	149/ 255	58.43%
Safety Follow-Up	64/ 254	25.20%	90/ 255	35.29%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Anhang 4-G2.4.2: Veränderung zu Baseline

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain at its Worst in Last 24 Hours
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	2.73 (2.91)	0	-	250	2.46 (2.78)	0	-
Week 7	186	1.89 (2.48)	182	-0.45 (3.07)	172	2.32 (2.57)	171	0.23 (2.70)
Week 13	152	2.05 (2.51)	149	-0.20 (2.78)	120	2.18 (2.47)	120	-0.16 (2.67)
Week 19	115	1.72 (2.27)	113	-0.53 (2.70)	89	2.25 (2.74)	89	0.07 (2.64)
Week 25	105	1.90 (2.42)	103	-0.37 (2.88)	60	1.90 (2.30)	60	0.02 (2.52)
Week 31	90	1.79 (2.53)	88	-0.33 (2.49)	41	1.83 (2.49)	41	0.10 (2.50)
Week 37	74	1.43 (1.87)	72	-0.65 (2.44)	20	2.15 (2.62)	20	-0.45 (3.52)
Week 43	46	1.48 (2.18)	45	-0.13 (2.04)	12	2.00 (1.86)	12	-0.83 (2.37)
Week 49	31	1.68 (2.81)	30	0.40 (2.53)	6	1.00 (2.45)	6	-0.67 (1.21)
Week 55	22	1.41 (2.40)	22	-0.59 (1.56)	3	0.00 (0.00)	3	-0.33 (0.58)
Week 61	17	0.88 (1.87)	17	-0.47 (1.77)	2	0.00 (0.00)	2	-0.50 (0.71)
Week 67	6	0.83 (1.33)	6	-1.00 (2.53)	1	0.00 (-)	1	0.00 (-)
Week 73	2	1.00 (1.41)	2	-1.00 (1.41)	0	-	0	-
End of IP Administration	113	3.35 (3.15)	113	0.81 (3.24)	149	2.85 (2.93)	147	0.71 (2.69)
Safety Follow-Up	64	2.48 (2.52)	64	0.05 (2.90)	90	2.24 (2.55)	89	0.20 (2.44)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain at its Least in Last 24 Hours
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.60 (2.21)	0	-	249	1.56 (2.10)	0	-
Week 7	186	1.26 (2.03)	182	-0.03 (2.47)	172	1.52 (2.06)	171	0.16 (2.21)
Week 13	152	1.38 (2.24)	149	0.04 (2.41)	120	1.30 (2.04)	120	-0.21 (2.32)
Week 19	115	1.10 (1.80)	113	-0.25 (2.47)	89	1.61 (2.43)	89	0.20 (2.34)
Week 25	105	1.14 (1.68)	103	-0.34 (2.42)	60	1.20 (1.79)	60	0.05 (2.08)
Week 31	90	1.08 (1.74)	88	-0.24 (2.35)	41	1.34 (2.12)	41	0.20 (2.34)
Week 37	74	0.80 (1.31)	72	-0.51 (2.39)	20	1.45 (2.67)	20	0.00 (3.57)
Week 43	46	1.00 (1.75)	45	0.29 (2.16)	12	1.33 (1.92)	12	-0.42 (2.71)
Week 49	31	1.13 (2.09)	30	0.37 (2.37)	6	0.67 (1.63)	6	-0.50 (0.55)
Week 55	22	0.82 (2.06)	22	-0.27 (1.12)	3	0.00 (0.00)	3	-0.33 (0.58)
Week 61	17	0.24 (0.75)	17	-0.35 (0.79)	2	0.00 (0.00)	2	-0.50 (0.71)
Week 67	6	0.00 (0.00)	6	-0.67 (1.21)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	113	1.95 (2.40)	113	0.46 (2.45)	149	1.83 (2.50)	147	0.41 (2.41)
Safety Follow-Up	64	1.34 (1.84)	64	0.02 (2.20)	90	1.37 (1.96)	89	0.01 (2.18)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain on the Average
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	2.26 (2.46)	0	-	249	2.02 (2.29)	0	-
Week 7	186	1.53 (2.05)	182	-0.40 (2.62)	172	1.86 (2.14)	171	0.13 (2.23)
Week 13	152	1.83 (2.29)	149	-0.05 (2.34)	120	1.80 (2.15)	120	-0.16 (2.05)
Week 19	115	1.41 (1.96)	113	-0.47 (2.41)	89	1.87 (2.31)	89	0.04 (2.05)
Week 25	105	1.63 (1.98)	103	-0.29 (2.39)	60	1.55 (2.00)	60	-0.05 (1.99)
Week 31	90	1.49 (2.03)	88	-0.34 (2.19)	41	1.37 (2.05)	41	-0.12 (2.19)
Week 37	74	1.16 (1.55)	72	-0.60 (2.10)	20	1.40 (1.96)	20	-1.20 (2.35)
Week 43	46	1.02 (1.57)	45	-0.20 (1.82)	12	1.83 (1.85)	12	-1.08 (2.68)
Week 49	31	1.13 (2.05)	30	0.00 (2.17)	6	0.67 (1.63)	6	-1.33 (2.34)
Week 55	22	1.00 (2.02)	22	-0.59 (1.33)	3	0.00 (0.00)	3	-0.33 (0.58)
Week 61	17	0.47 (1.07)	17	-0.71 (1.21)	2	0.00 (0.00)	2	-0.50 (0.71)
Week 67	6	0.50 (0.84)	6	-0.67 (1.63)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.50 (0.71)	2	-0.50 (0.71)	0	-	0	-
End of IP Administration	113	2.56 (2.60)	113	0.50 (2.66)	149	2.40 (2.58)	147	0.67 (2.46)
Safety Follow-Up	64	1.73 (1.81)	64	-0.13 (2.26)	90	1.90 (2.34)	89	0.18 (2.25)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Right Now
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.78 (2.36)	0	-	249	1.43 (2.08)	0	-
Week 7	186	1.09 (1.95)	182	-0.45 (2.75)	172	1.36 (1.94)	171	0.17 (2.09)
Week 13	152	1.29 (2.15)	149	-0.32 (2.54)	120	1.21 (1.89)	120	-0.09 (2.09)
Week 19	115	0.95 (1.72)	113	-0.58 (2.49)	89	1.43 (2.31)	89	0.24 (2.13)
Week 25	105	1.08 (1.81)	103	-0.55 (2.46)	60	1.22 (1.96)	60	0.38 (2.42)
Week 31	90	1.17 (2.07)	88	-0.35 (2.33)	41	1.37 (2.19)	41	0.56 (2.26)
Week 37	74	0.80 (1.48)	72	-0.68 (2.33)	20	1.00 (1.62)	20	-0.60 (1.96)
Week 43	46	0.96 (1.62)	45	-0.07 (2.13)	12	1.42 (1.73)	12	-0.33 (2.15)
Week 49	31	0.94 (1.86)	30	-0.07 (1.78)	6	0.67 (1.63)	6	0.50 (1.76)
Week 55	22	0.91 (1.90)	22	-0.50 (0.96)	3	0.00 (0.00)	3	-0.33 (0.58)
Week 61	17	0.47 (1.07)	17	-0.41 (1.00)	2	0.00 (0.00)	2	-0.50 (0.71)
Week 67	6	0.00 (0.00)	6	-0.67 (0.82)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	-0.50 (0.71)	0	-	0	-
End of IP Administration	113	2.27 (2.71)	113	0.57 (3.00)	149	2.14 (2.74)	147	0.91 (2.67)
Safety Follow-Up	64	1.33 (1.86)	64	-0.27 (2.53)	90	1.53 (2.21)	89	0.43 (1.88)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Interfered General Activity
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.85 (2.54)	0	-	248	1.79 (2.53)	0	-
Week 7	186	1.46 (2.35)	182	0.01 (2.57)	172	1.67 (2.32)	171	0.24 (2.15)
Week 13	152	1.30 (2.22)	149	-0.15 (2.17)	120	1.74 (2.35)	120	0.24 (2.38)
Week 19	115	1.03 (1.68)	113	-0.30 (2.14)	89	1.73 (2.34)	89	0.34 (2.20)
Week 25	105	1.23 (2.10)	103	-0.24 (2.52)	60	1.37 (2.11)	60	-0.02 (2.65)
Week 31	90	1.31 (2.34)	88	0.02 (2.15)	41	1.41 (2.27)	41	0.17 (2.42)
Week 37	74	0.97 (1.76)	72	-0.42 (2.37)	20	2.15 (2.68)	20	-0.35 (3.10)
Week 43	46	0.91 (1.74)	45	-0.13 (2.18)	12	1.83 (1.90)	12	-0.67 (2.57)
Week 49	31	1.16 (2.15)	30	0.13 (1.83)	6	0.83 (2.04)	6	-0.17 (0.41)
Week 55	22	0.77 (1.77)	22	-0.64 (1.59)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.53 (1.46)	17	-0.41 (1.54)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.50 (0.84)	6	-0.83 (1.33)	1	0.00 (-)	1	0.00 (-)
Week 73	2	1.00 (1.41)	2	-1.00 (1.41)	0	-	0	-
End of IP Administration	113	2.65 (2.98)	113	0.89 (2.83)	149	2.43 (2.91)	146	0.99 (2.66)
Safety Follow-Up	64	1.66 (2.16)	64	0.19 (2.31)	90	1.93 (2.47)	88	0.61 (2.22)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Interfered with Mood
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.78 (2.54)	0	-	248	1.87 (2.60)	0	-
Week 7	186	1.39 (2.24)	182	0.01 (2.47)	172	1.69 (2.35)	171	0.22 (2.44)
Week 13	152	1.26 (2.23)	149	-0.14 (2.37)	120	1.60 (2.14)	120	0.16 (2.20)
Week 19	115	1.09 (1.84)	113	-0.19 (2.01)	89	1.81 (2.46)	89	0.45 (2.55)
Week 25	105	1.29 (2.12)	103	-0.11 (2.47)	60	1.45 (2.20)	60	0.28 (2.52)
Week 31	90	1.27 (2.07)	88	-0.03 (1.90)	41	1.49 (2.39)	41	0.39 (2.45)
Week 37	74	1.03 (1.92)	72	-0.21 (2.43)	20	2.25 (2.73)	20	0.15 (2.80)
Week 43	46	1.00 (1.65)	45	0.07 (2.07)	12	1.83 (1.95)	12	-0.17 (2.08)
Week 49	31	1.10 (2.02)	30	0.37 (1.85)	6	0.83 (2.04)	6	-0.17 (0.41)
Week 55	22	0.82 (1.76)	22	-0.45 (1.53)	3	0.00 (0.00)	3	-0.33 (0.58)
Week 61	17	0.35 (1.22)	17	-0.53 (1.77)	2	0.00 (0.00)	2	-0.50 (0.71)
Week 67	6	0.17 (0.41)	6	-1.50 (2.07)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	-3.00 (4.24)	0	-	0	-
End of IP Administration	113	2.59 (3.04)	113	0.86 (2.78)	149	2.33 (2.97)	146	0.82 (2.98)
Safety Follow-Up	64	1.69 (2.21)	64	0.16 (2.28)	90	1.87 (2.60)	88	0.42 (2.31)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Interfered Walking Ability
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.65 (2.53)	0	-	248	1.70 (2.72)	0	-
Week 7	186	1.03 (2.05)	182	-0.20 (2.28)	172	1.55 (2.44)	171	0.37 (2.25)
Week 13	152	1.24 (2.13)	149	-0.11 (2.18)	120	1.35 (2.23)	120	0.19 (2.30)
Week 19	115	1.03 (1.83)	113	-0.03 (2.38)	89	1.74 (2.52)	89	0.76 (2.58)
Week 25	105	1.01 (2.00)	103	-0.18 (2.49)	60	1.37 (2.12)	60	0.28 (2.67)
Week 31	90	1.00 (2.05)	88	-0.09 (2.31)	41	1.34 (2.09)	41	0.32 (2.26)
Week 37	74	0.74 (1.67)	72	-0.39 (2.38)	20	2.25 (2.77)	20	0.05 (3.00)
Week 43	46	0.78 (1.65)	45	-0.04 (2.45)	12	1.75 (2.01)	12	-1.00 (3.05)
Week 49	31	1.00 (2.08)	30	0.17 (2.39)	6	0.83 (2.04)	6	-0.83 (2.04)
Week 55	22	0.86 (2.01)	22	-0.27 (1.45)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.35 (0.86)	17	-0.24 (1.35)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.33 (0.52)	6	-0.67 (1.03)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.50 (0.71)	2	-1.00 (1.41)	0	-	0	-
End of IP Administration	113	2.24 (2.93)	113	0.65 (2.93)	149	2.29 (3.04)	146	1.01 (2.65)
Safety Follow-Up	64	1.88 (2.68)	64	0.50 (3.06)	90	1.63 (2.47)	88	0.68 (2.33)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Interfered with Normal Work
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.68 (2.56)	0	-	248	1.75 (2.64)	0	-
Week 7	186	1.24 (2.23)	182	0.02 (2.35)	172	1.60 (2.38)	171	0.32 (2.30)
Week 13	152	1.24 (2.17)	149	-0.07 (2.40)	120	1.60 (2.37)	120	0.33 (2.52)
Week 19	115	1.22 (2.06)	113	0.13 (2.37)	89	1.91 (2.64)	89	0.79 (2.74)
Week 25	105	1.30 (2.23)	103	0.11 (2.66)	60	1.60 (2.51)	60	0.50 (2.68)
Week 31	90	1.12 (2.12)	88	-0.05 (2.33)	41	1.54 (2.52)	41	0.59 (2.53)
Week 37	74	1.08 (1.94)	72	-0.15 (2.49)	20	2.05 (2.63)	20	0.00 (2.79)
Week 43	46	0.96 (1.80)	45	0.09 (2.33)	12	1.83 (1.80)	12	-0.50 (2.58)
Week 49	31	0.97 (1.89)	30	0.07 (2.18)	6	0.83 (2.04)	6	0.00 (0.00)
Week 55	22	0.86 (1.91)	22	-0.27 (1.64)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.59 (1.50)	17	-0.12 (1.69)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.50 (0.84)	6	-0.83 (1.60)	1	0.00 (-)	1	0.00 (-)
Week 73	2	1.00 (1.41)	2	-0.50 (0.71)	0	-	0	-
End of IP Administration	113	2.63 (3.12)	113	1.12 (3.01)	149	2.40 (3.08)	146	0.98 (2.89)
Safety Follow-Up	64	1.83 (2.50)	64	0.56 (2.54)	90	1.63 (2.40)	88	0.44 (2.20)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Interfered with Relations
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.46 (2.46)	0	-	248	1.34 (2.28)	0	-
Week 7	186	0.89 (1.86)	182	-0.20 (2.23)	172	1.33 (2.17)	171	0.33 (1.83)
Week 13	152	0.86 (1.83)	149	-0.34 (2.19)	120	1.32 (2.10)	120	0.31 (2.07)
Week 19	115	0.77 (1.60)	113	-0.27 (2.18)	89	1.33 (2.28)	89	0.40 (2.11)
Week 25	105	1.01 (2.00)	103	-0.14 (2.78)	60	1.02 (1.87)	60	0.18 (2.08)
Week 31	90	0.89 (1.90)	88	-0.17 (2.35)	41	1.12 (1.99)	41	0.22 (1.86)
Week 37	74	0.76 (1.77)	72	-0.28 (2.44)	20	1.75 (2.61)	20	0.20 (2.48)
Week 43	46	0.72 (1.42)	45	-0.02 (2.18)	12	1.50 (1.83)	12	0.00 (1.35)
Week 49	31	0.81 (1.66)	30	0.10 (1.86)	6	1.00 (2.45)	6	0.33 (0.82)
Week 55	22	0.59 (1.50)	22	-0.73 (2.00)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.53 (1.74)	17	-0.47 (2.53)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.00 (0.00)	6	-2.17 (2.99)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.00 (0.00)	2	-3.00 (4.24)	0	-	0	-
End of IP Administration	113	2.06 (2.99)	113	0.73 (2.84)	149	1.92 (2.84)	146	0.84 (2.69)
Safety Follow-Up	64	1.33 (1.89)	64	0.27 (2.06)	90	1.39 (2.27)	88	0.57 (1.87)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Interfered with Sleep
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.96 (2.82)	0	-	248	1.62 (2.47)	0	-
Week 7	185	1.11 (2.10)	181	-0.48 (2.58)	172	1.53 (2.31)	171	0.29 (2.40)
Week 13	152	1.27 (2.32)	149	-0.36 (2.42)	120	1.44 (2.20)	120	0.10 (2.28)
Week 19	115	1.03 (1.91)	113	-0.50 (2.49)	89	1.58 (2.35)	89	0.37 (2.47)
Week 25	105	1.35 (2.33)	103	-0.26 (3.02)	60	1.33 (2.22)	60	0.35 (2.36)
Week 31	90	1.04 (1.98)	88	-0.55 (2.60)	41	1.41 (2.44)	41	0.56 (2.42)
Week 37	74	0.99 (1.74)	72	-0.71 (2.69)	20	1.75 (2.59)	20	-0.10 (2.75)
Week 43	46	1.02 (2.01)	45	-0.33 (2.98)	12	2.08 (2.97)	12	0.25 (2.26)
Week 49	31	0.87 (1.84)	30	-0.63 (3.00)	6	0.83 (2.04)	6	0.17 (0.41)
Week 55	22	0.82 (1.99)	22	-0.73 (1.64)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.47 (1.01)	17	-0.71 (1.86)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.50 (0.84)	6	-1.17 (2.40)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.50 (0.71)	2	-1.00 (1.41)	0	-	0	-
End of IP Administration	113	2.08 (2.98)	113	0.22 (3.19)	149	2.28 (3.02)	146	1.00 (2.91)
Safety Follow-Up	64	1.53 (2.42)	64	-0.03 (2.85)	90	1.52 (2.32)	88	0.47 (2.53)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Interfered Enjoyment of Life
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.83 (2.77)	0	-	248	1.83 (2.70)	0	-
Week 7	185	1.16 (2.22)	181	-0.22 (2.38)	172	1.74 (2.55)	171	0.37 (2.42)
Week 13	152	1.13 (1.99)	149	-0.30 (2.15)	120	1.68 (2.44)	120	0.35 (2.38)
Week 19	115	0.90 (1.68)	113	-0.47 (2.35)	89	1.75 (2.52)	89	0.52 (2.51)
Week 25	105	1.23 (2.06)	103	-0.22 (2.54)	60	1.30 (2.14)	60	0.20 (2.48)
Week 31	90	1.10 (2.10)	88	-0.20 (2.67)	41	1.41 (2.47)	41	0.37 (2.35)
Week 37	74	1.01 (2.00)	72	-0.42 (2.61)	20	1.90 (2.53)	20	0.10 (2.69)
Week 43	46	0.83 (1.76)	45	-0.31 (2.50)	12	1.67 (2.02)	12	0.00 (1.91)
Week 49	31	0.81 (1.56)	30	-0.33 (2.11)	6	0.83 (2.04)	6	-0.17 (0.98)
Week 55	22	0.91 (1.77)	22	-0.50 (1.47)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.47 (1.07)	17	-0.59 (1.37)	2	0.00 (0.00)	2	0.00 (0.00)
Week 67	6	0.33 (0.82)	6	-1.00 (1.55)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.50 (0.71)	2	-1.00 (1.41)	0	-	0	-
End of IP Administration	113	2.48 (3.10)	113	0.77 (3.24)	149	2.18 (2.91)	146	0.88 (2.95)
Safety Follow-Up	64	1.80 (2.55)	64	0.25 (2.53)	90	1.62 (2.39)	88	0.43 (2.22)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Interference
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	1.74 (2.40)	0	-	248	1.70 (2.38)	0	-
Week 7	186	1.18 (1.90)	182	-0.15 (2.04)	172	1.59 (2.14)	171	0.31 (1.92)
Week 13	152	1.19 (1.93)	149	-0.21 (1.91)	120	1.53 (2.10)	120	0.24 (2.04)
Week 19	115	1.01 (1.63)	113	-0.23 (1.97)	89	1.69 (2.26)	89	0.52 (2.17)
Week 25	105	1.20 (1.87)	103	-0.15 (2.27)	60	1.35 (2.00)	60	0.25 (2.21)
Week 31	90	1.10 (1.93)	88	-0.15 (2.03)	41	1.39 (2.24)	41	0.37 (2.19)
Week 37	74	0.94 (1.69)	72	-0.37 (2.27)	20	2.01 (2.58)	20	0.01 (2.57)
Week 43	46	0.89 (1.57)	45	-0.10 (2.17)	12	1.79 (1.89)	12	-0.30 (1.97)
Week 49	31	0.96 (1.77)	30	-0.02 (1.92)	6	0.86 (2.10)	6	-0.12 (0.47)
Week 55	22	0.81 (1.73)	22	-0.51 (1.38)	3	0.00 (0.00)	3	-0.05 (0.08)
Week 61	17	0.47 (1.23)	17	-0.44 (1.40)	2	0.00 (0.00)	2	-0.07 (0.10)
Week 67	6	0.33 (0.58)	6	-1.17 (1.71)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.50 (0.71)	2	-1.50 (2.12)	0	-	0	-
End of IP Administration	113	2.39 (2.79)	113	0.75 (2.64)	149	2.26 (2.76)	146	0.93 (2.54)
Safety Follow-Up	64	1.67 (2.04)	64	0.27 (2.11)	90	1.66 (2.16)	88	0.52 (1.97)


N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of BPI2-Pain Severity
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	2.09 (2.31)	0	-	249	1.86 (2.14)	0	-
Week 7	186	1.44 (1.97)	182	-0.33 (2.49)	172	1.77 (2.03)	171	0.17 (2.06)
Week 13	152	1.64 (2.16)	149	-0.13 (2.29)	120	1.62 (1.94)	120	-0.15 (1.94)
Week 19	115	1.29 (1.81)	113	-0.46 (2.31)	89	1.79 (2.32)	89	0.14 (1.98)
Week 25	105	1.44 (1.82)	103	-0.39 (2.34)	60	1.47 (1.87)	60	0.10 (1.82)
Week 31	90	1.38 (1.97)	88	-0.32 (2.11)	41	1.48 (2.08)	41	0.18 (1.86)
Week 37	74	1.05 (1.45)	72	-0.61 (2.17)	20	1.50 (1.72)	20	-0.56 (2.24)
Week 43	46	1.11 (1.67)	45	-0.03 (1.87)	12	1.65 (1.76)	12	-0.67 (2.21)
Week 49	31	1.22 (2.07)	30	0.18 (2.05)	6	0.75 (1.84)	6	-0.50 (1.10)
Week 55	22	1.03 (2.03)	22	-0.49 (0.94)	3	0.00 (0.00)	3	-0.33 (0.58)
Week 61	17	0.51 (1.11)	17	-0.49 (1.01)	2	0.00 (0.00)	2	-0.50 (0.71)
Week 67	6	0.33 (0.54)	6	-0.75 (1.48)	1	0.00 (-)	1	0.00 (-)
Week 73	2	0.38 (0.53)	2	-0.50 (0.71)	0	-	0	-
End of IP Administration	113	2.53 (2.52)	113	0.58 (2.56)	149	2.30 (2.56)	147	0.68 (2.30)
Safety Follow-Up	64	1.72 (1.78)	64	-0.08 (2.16)	90	1.76 (2.16)	89	0.21 (2.04)


N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain at its Worst in Last 24 Hours
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain at its Least in Last 24 Hours
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain on the Average
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Right Now
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Interfered General Activity
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Interfered with Mood
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Interfered Walking Ability
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Interfered with Normal Work
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Interfered with Relations
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Interfered with Sleep
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Interfered Enjoyment of Life
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Interference
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of BPI2-Pain Severity
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Anhang 4-G2.5: Endpunkt „FACT-G GP5“ – RCT

Anhang 4-G2.5.1: Completion Rate

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of Treatment Side Effects
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	215/ 247	87.04%	172/ 249	69.08%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	201/ 243	82.72%	159/ 242	65.70%
Week 6	157/ 236	66.53%	159/ 239	66.53%
Week 7	185/ 232	79.74%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	168/ 229	73.36%	125/ 230	54.35%
Week 10	141/ 226	62.39%	134/ 225	59.56%
Week 11	156/ 225	69.33%	119/ 217	54.84%
Week 12	130/ 225	57.78%	115/ 212	54.25%
Week 13	155/ 221	70.14%	127/ 211	60.19%
Week 19	116/ 205	56.59%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	89/ 184	48.37%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	114/ 254	44.88%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).


Anhang 4-G2.5.2: Veränderung zu Baseline

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of Treatment Side Effects
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	0.30 (0.66)	0	-	250	0.40 (0.75)	0	-
Week 2	225	0.70 (0.94)	221	0.43 (0.98)	170	0.90 (1.00)	169	0.55 (0.96)
Week 3	215	1.07 (1.13)	212	0.80 (1.09)	172	1.03 (1.11)	171	0.65 (1.14)
Week 4	175	0.93 (1.08)	172	0.66 (1.07)	190	0.98 (1.06)	189	0.65 (1.15)
Week 5	201	0.77 (0.95)	196	0.55 (0.97)	159	1.03 (1.08)	159	0.67 (1.13)
Week 6	157	0.60 (0.88)	156	0.37 (0.87)	159	1.01 (1.01)	158	0.67 (1.02)
Week 7	185	0.74 (0.96)	180	0.52 (0.98)	173	0.91 (0.99)	172	0.58 (0.94)
Week 8	144	0.65 (0.95)	141	0.45 (0.97)	139	0.97 (1.01)	138	0.64 (0.99)
Week 9	168	0.68 (0.91)	164	0.48 (0.95)	125	1.00 (1.14)	124	0.65 (1.08)
Week 10	141	0.60 (0.78)	139	0.40 (0.84)	134	1.02 (1.04)	133	0.65 (0.94)
Week 11	156	0.65 (0.87)	152	0.46 (0.86)	119	1.04 (0.98)	118	0.69 (0.95)
Week 12	130	0.68 (0.89)	127	0.50 (0.88)	115	0.87 (1.00)	115	0.50 (0.98)
Week 13	155	0.75 (0.96)	151	0.55 (0.91)	127	1.01 (1.04)	127	0.65 (1.00)
Week 19	116	0.48 (0.73)	114	0.27 (0.74)	89	1.04 (0.99)	89	0.70 (0.97)
Week 25	107	0.50 (0.68)	105	0.29 (0.77)	60	0.75 (0.82)	60	0.45 (0.89)
Week 31	89	0.55 (0.74)	87	0.29 (0.79)	41	0.59 (0.63)	41	0.37 (0.77)
Week 37	75	0.59 (0.90)	73	0.29 (0.99)	21	0.81 (0.75)	21	0.52 (0.81)
Week 43	46	0.50 (0.84)	45	0.20 (0.97)	12	0.75 (0.62)	12	0.42 (0.67)
Week 49	32	0.44 (0.56)	30	0.13 (0.57)	6	0.50 (0.84)	6	0.33 (1.03)
Week 55	22	0.32 (0.57)	22	0.00 (0.44)	3	0.00 (0.00)	3	0.00 (0.00)
Week 61	17	0.24 (0.56)	17	-0.06 (0.83)	2	1.00 (0.00)	2	1.00 (0.00)
Week 67	6	0.50 (0.84)	6	-0.17 (0.41)	1	0.00 (-)	1	0.00 (-)
Week 73	2	1.00 (1.41)	2	-0.50 (0.71)	0	-	0	-
End of IP Administration	114	0.81 (1.01)	114	0.49 (1.07)	151	1.21 (1.20)	149	0.79 (1.22)
Safety Follow-Up	65	1.00 (1.12)	65	0.71 (1.20)	91	0.86 (1.02)	90	0.53 (0.97)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of Treatment Side Effects
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Anhang 4-G3: Ergänzende Analysen zum Endpunkt „Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ C30“ – RCT

Anhang 4-G3.1: Completion Rate

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Cognitive Functioning
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)		Standard of Care (N=255)	
Timepoint	n/ N	Completion	n/ N	Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Emotional Functioning
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Physical Functioning
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	204/ 243	83.95%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Global Health Status/QOL
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	174/ 246	70.73%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	116/ 254	45.67%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Role Functioning
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	247/ 254	97.24%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Completion rates of C30 Social Functioning
Intention-to-Treat Analysis Set

Timepoint	Tarlatamab (N=254) n/ N	Tarlatamab (N=254) Completion	Standard of Care (N=255) n/ N	Standard of Care (N=255) Completion
Baseline	246/ 254	96.85%	250/ 255	98.04%
Week 2	225/ 251	89.64%	170/ 253	67.19%
Week 3	217/ 247	87.85%	173/ 249	69.48%
Week 4	175/ 246	71.14%	190/ 246	77.24%
Week 5	203/ 243	83.54%	160/ 242	66.12%
Week 6	159/ 236	67.37%	160/ 239	66.95%
Week 7	187/ 232	80.60%	173/ 236	73.31%
Week 8	144/ 231	62.34%	139/ 234	59.40%
Week 9	167/ 229	72.93%	125/ 230	54.35%
Week 10	142/ 226	62.83%	134/ 225	59.56%
Week 11	156/ 225	69.33%	120/ 217	55.30%
Week 12	130/ 225	57.78%	116/ 212	54.72%
Week 13	156/ 221	70.59%	127/ 211	60.19%
Week 19	118/ 205	57.56%	89/ 189	47.09%
Week 25	107/ 194	55.15%	60/ 164	36.59%
Week 31	91/ 184	49.46%	41/ 142	28.87%
Week 37	75/ 157	47.77%	21/ 114	18.42%
Week 43	46/ 114	40.35%	12/ 86	13.95%
Week 49	32/ 76	42.11%	6/ 54	11.11%
Week 55	22/ 50	44.00%	3/ 36	8.33%
Week 61	17/ 33	51.52%	2/ 21	9.52%
Week 67	6/ 16	37.50%	1/ 8	12.50%
Week 73	2/ 6	33.33%	0/ 3	0.00%
End of IP Administration	117/ 254	46.06%	151/ 255	59.22%
Safety Follow-Up	65/ 254	25.59%	91/ 255	35.69%

n describes number of patients with non-missing value at the respective timepoint.
N defines number of patients with minimum(death day, last contact day) >= planed day of respective visit (baseline=day 1, week 7=day 43, etc.).

Anhang 4-G3.2: Veränderung zu Baseline

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Cognitive Functioning
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	88.75 (16.50)	0	-	250	87.60 (17.28)	0	-
Week 2	225	87.70 (17.45)	221	-1.89 (15.74)	170	88.53 (16.04)	169	-0.69 (14.92)
Week 3	217	86.02 (18.12)	214	-3.74 (15.20)	173	85.36 (20.03)	172	-3.49 (18.58)
Week 4	175	88.29 (18.85)	172	-1.07 (16.34)	190	86.93 (18.31)	189	-2.20 (17.85)
Week 5	203	90.64 (14.92)	198	0.00 (14.15)	160	86.56 (16.67)	160	-2.40 (16.17)
Week 6	159	90.46 (16.40)	158	0.42 (15.84)	160	87.50 (18.88)	159	-2.94 (18.42)
Week 7	187	89.66 (17.11)	182	-0.64 (15.01)	173	86.90 (18.46)	172	-3.00 (17.73)
Week 8	144	89.93 (15.42)	141	-0.59 (14.96)	139	86.21 (18.81)	138	-2.78 (16.43)
Week 9	167	89.12 (17.73)	163	-1.12 (16.68)	125	84.27 (20.77)	124	-4.57 (18.93)
Week 10	142	89.67 (16.46)	139	-0.60 (16.10)	134	87.06 (18.35)	133	-2.88 (17.23)
Week 11	156	89.10 (16.79)	152	-0.88 (13.94)	120	84.17 (19.79)	119	-5.32 (18.78)
Week 12	130	90.00 (16.55)	126	-0.26 (17.76)	116	87.21 (18.44)	116	-2.44 (16.49)
Week 13	156	89.00 (16.67)	152	-0.88 (15.44)	127	87.40 (18.87)	127	-1.97 (18.14)
Week 19	118	90.25 (14.67)	115	-0.43 (15.84)	89	88.01 (17.22)	89	-2.25 (15.93)
Week 25	107	90.65 (14.87)	104	0.16 (14.60)	60	88.89 (16.14)	60	-1.67 (16.15)
Week 31	91	91.03 (13.90)	89	0.94 (18.18)	41	86.99 (18.07)	41	-2.44 (16.48)
Week 37	75	90.22 (17.35)	73	1.37 (19.20)	21	78.57 (25.90)	21	-7.94 (28.68)
Week 43	46	90.94 (17.46)	45	2.22 (21.20)	12	88.89 (12.97)	12	1.39 (11.14)
Week 49	32	91.15 (12.69)	30	-0.56 (16.66)	6	97.22 (6.80)	6	8.33 (17.48)
Week 55	22	92.42 (12.31)	22	3.03 (18.28)	3	94.44 (9.62)	3	0.00 (16.67)
Week 61	17	94.12 (10.11)	17	3.92 (15.06)	2	91.67 (11.79)	2	0.00 (23.57)
Week 67	6	91.67 (9.13)	6	2.78 (12.55)	1	83.33 (-)	1	-16.67 (-)
Week 73	2	100.00 (0.00)	2	8.33 (11.79)	0	-	0	-
End of IP Administration	117	84.62 (20.55)	116	-4.45 (18.95)	151	82.89 (23.57)	149	-6.38 (25.16)
Safety Follow-Up	65	84.36 (20.17)	64	-6.25 (16.13)	91	84.98 (22.51)	90	-5.19 (22.71)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Emotional Functioning
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	82.45 (19.71)	0	-	250	83.13 (19.35)	0	-
Week 2	225	82.78 (19.16)	221	-0.64 (15.61)	170	84.80 (17.61)	169	-0.54 (16.77)
Week 3	217	82.95 (20.41)	214	-0.27 (18.93)	173	82.80 (20.00)	172	-1.74 (19.79)
Week 4	175	84.90 (19.17)	172	0.29 (16.39)	190	83.86 (19.78)	189	-0.97 (19.89)
Week 5	203	86.00 (16.95)	198	1.68 (15.75)	160	83.75 (19.38)	160	-1.61 (17.55)
Week 6	159	86.06 (17.28)	158	1.48 (16.20)	160	84.27 (20.96)	159	-2.10 (20.02)
Week 7	187	85.87 (16.35)	182	1.65 (13.72)	173	83.48 (20.95)	172	-2.42 (17.79)
Week 8	144	86.86 (18.19)	141	1.83 (18.04)	139	83.69 (18.55)	138	-2.60 (17.66)
Week 9	167	86.48 (18.26)	163	2.66 (16.79)	125	82.40 (21.04)	124	-3.90 (21.34)
Week 10	142	87.79 (17.04)	139	1.80 (17.22)	134	82.96 (20.10)	133	-2.76 (17.67)
Week 11	156	87.07 (15.96)	152	2.96 (14.27)	120	83.40 (19.93)	119	-2.17 (19.30)
Week 12	130	87.63 (16.80)	126	1.06 (16.86)	116	83.98 (20.09)	116	-2.16 (18.20)
Week 13	156	86.16 (18.54)	152	2.52 (17.13)	127	85.04 (18.88)	127	0.52 (19.24)
Week 19	118	88.56 (15.82)	115	3.04 (15.78)	89	83.71 (18.59)	89	-2.43 (17.51)
Week 25	107	86.29 (16.52)	104	2.00 (14.80)	60	86.94 (16.05)	60	-4.31 (16.56)
Week 31	91	88.00 (15.77)	89	2.81 (15.79)	41	84.96 (18.37)	41	-6.50 (20.11)
Week 37	75	88.78 (16.58)	73	4.45 (17.90)	21	77.38 (26.37)	21	-11.51 (31.57)
Week 43	46	90.94 (15.09)	45	7.04 (18.88)	12	92.36 (10.33)	12	-0.69 (16.46)
Week 49	32	89.58 (12.34)	30	3.06 (16.45)	6	94.44 (6.80)	6	4.17 (17.28)
Week 55	22	92.05 (11.92)	22	4.92 (19.70)	3	94.44 (9.62)	3	0.00 (16.67)
Week 61	17	92.65 (12.11)	17	4.41 (16.70)	2	83.33 (11.79)	2	-8.33 (23.57)
Week 67	6	84.72 (15.29)	6	0.00 (20.41)	1	91.67 (-)	1	-8.33 (-)
Week 73	2	87.50 (5.89)	2	4.17 (17.68)	0	-	0	-
End of IP Administration	117	79.70 (22.00)	116	-4.09 (18.47)	151	80.35 (23.54)	149	-4.64 (23.16)
Safety Follow-Up	65	81.92 (23.32)	64	-1.69 (17.83)	91	83.24 (20.62)	90	-2.13 (17.87)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Physical Functioning
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	79.70 (20.38)	0	-	250	79.49 (19.70)	0	-
Week 2	225	78.76 (22.71)	221	-2.90 (16.01)	170	78.35 (21.20)	169	-3.16 (15.05)
Week 3	217	74.29 (23.24)	214	-7.94 (16.38)	173	76.11 (23.26)	172	-5.85 (21.50)
Week 4	175	78.21 (20.74)	172	-5.23 (15.89)	190	78.63 (20.23)	189	-3.95 (19.76)
Week 5	204	79.25 (19.63)	199	-4.12 (16.43)	160	78.00 (19.57)	160	-5.83 (18.39)
Week 6	159	81.22 (19.00)	158	-3.29 (14.49)	160	78.63 (20.87)	159	-5.87 (20.85)
Week 7	187	81.32 (18.66)	182	-1.94 (14.78)	173	78.11 (20.23)	172	-4.65 (17.06)
Week 8	144	85.14 (16.42)	141	-0.47 (13.72)	139	76.26 (21.24)	138	-8.79 (18.77)
Week 9	167	83.23 (17.77)	163	-0.70 (15.21)	125	74.83 (22.94)	124	-9.73 (22.30)
Week 10	142	84.55 (16.39)	140	-0.38 (15.06)	134	78.21 (19.71)	133	-5.11 (18.03)
Week 11	156	83.42 (16.60)	152	0.00 (13.79)	120	75.94 (20.60)	119	-8.80 (20.28)
Week 12	130	84.51 (17.30)	127	-0.47 (14.26)	116	77.82 (22.08)	116	-6.95 (20.27)
Week 13	156	83.42 (17.93)	152	0.31 (14.09)	127	77.80 (19.89)	127	-5.09 (19.33)
Week 19	118	86.95 (13.90)	116	0.69 (14.08)	89	77.15 (22.20)	89	-6.67 (19.87)
Week 25	107	85.42 (14.25)	105	0.63 (14.95)	60	80.89 (19.43)	60	-4.78 (16.97)
Week 31	91	86.23 (13.33)	89	0.30 (13.59)	41	76.75 (22.07)	41	-8.62 (22.02)
Week 37	75	85.78 (12.94)	73	-0.64 (13.29)	21	71.75 (28.98)	21	-6.03 (32.79)
Week 43	46	87.39 (11.94)	45	1.19 (15.06)	12	83.89 (14.06)	12	1.11 (20.66)
Week 49	32	86.46 (12.73)	30	-0.67 (14.99)	6	76.67 (37.89)	6	-3.33 (47.28)
Week 55	22	87.58 (10.75)	22	2.42 (11.37)	3	91.11 (3.85)	3	-8.89 (3.85)
Week 61	17	91.76 (7.65)	17	5.49 (11.36)	2	90.00 (4.71)	2	-10.00 (4.71)
Week 67	6	88.89 (6.89)	6	6.67 (14.61)	1	93.33 (-)	1	-6.67 (-)
Week 73	2	83.33 (4.71)	2	3.33 (14.14)	0	-	0	-
End of IP Administration	117	75.04 (23.72)	117	-5.47 (19.13)	151	71.43 (26.18)	149	-10.43 (24.84)
Safety Follow-Up	65	74.15 (26.21)	65	-9.64 (23.39)	91	77.88 (21.93)	90	-7.04 (21.47)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Global Health Status/QOL
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	68.12 (19.30)	0	-	250	65.83 (20.29)	0	-
Week 2	225	63.11 (21.11)	221	-6.45 (17.12)	170	60.25 (19.84)	169	-6.46 (18.20)
Week 3	217	58.87 (22.09)	214	-11.02 (20.99)	173	60.98 (22.66)	172	-5.67 (22.67)
Week 4	174	63.89 (19.27)	171	-7.55 (19.60)	190	61.67 (20.28)	189	-6.04 (21.07)
Week 5	203	65.72 (18.26)	198	-5.68 (19.47)	160	61.35 (19.32)	160	-7.34 (20.89)
Week 6	159	67.30 (18.83)	158	-4.38 (17.05)	160	61.41 (20.23)	159	-7.76 (22.07)
Week 7	187	67.34 (17.26)	182	-3.98 (17.09)	173	64.45 (17.99)	172	-4.31 (17.67)
Week 8	144	68.98 (18.13)	141	-3.31 (17.39)	139	61.09 (19.97)	138	-9.24 (20.85)
Week 9	167	68.81 (17.78)	163	-3.17 (16.85)	125	60.93 (19.58)	124	-10.22 (23.88)
Week 10	142	69.54 (16.73)	139	-4.08 (16.37)	134	61.19 (20.26)	133	-8.08 (21.47)
Week 11	156	67.47 (17.40)	152	-4.88 (18.71)	120	59.51 (19.12)	119	-10.15 (20.56)
Week 12	130	70.45 (18.18)	126	-3.64 (18.66)	116	61.42 (18.99)	116	-9.12 (19.69)
Week 13	156	69.98 (18.52)	152	-2.47 (20.41)	127	61.61 (19.79)	127	-6.17 (19.95)
Week 19	118	73.94 (14.10)	115	-0.14 (17.17)	89	62.92 (19.70)	89	-5.81 (18.74)
Week 25	107	74.22 (12.72)	104	0.80 (16.89)	60	65.83 (15.47)	60	-5.28 (16.31)
Week 31	91	73.81 (14.73)	89	0.84 (18.55)	41	64.43 (19.72)	41	-10.37 (24.78)
Week 37	75	72.11 (16.24)	73	-1.48 (19.01)	21	55.95 (22.38)	21	-15.08 (31.36)
Week 43	46	71.38 (15.97)	45	-2.04 (18.13)	12	61.11 (16.79)	12	-11.11 (26.43)
Week 49	32	72.66 (15.00)	30	-0.00 (21.99)	6	56.94 (28.10)	6	-22.22 (32.77)
Week 55	22	73.86 (12.93)	22	3.79 (24.90)	3	77.78 (9.62)	3	-11.11 (19.25)
Week 61	17	73.53 (9.43)	17	3.43 (14.75)	2	70.83 (5.89)	2	-20.83 (17.68)
Week 67	6	62.50 (18.07)	6	-6.94 (28.10)	1	75.00 (-)	1	-25.00 (-)
Week 73	2	66.67 (0.00)	2	-8.33 (11.79)	0	-	0	-
End of IP Administration	116	59.05 (22.80)	115	-10.94 (20.81)	151	56.57 (20.74)	149	-12.47 (23.30)
Safety Follow-Up	65	59.87 (20.46)	64	-12.50 (20.03)	91	63.37 (21.19)	90	-8.43 (23.42)

N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Role Functioning
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	247	81.71 (23.90)	0	-	250	82.73 (22.37)	0	-
Week 2	225	76.07 (28.20)	221	-7.32 (24.01)	170	79.22 (25.56)	169	-5.42 (22.61)
Week 3	217	70.20 (28.74)	214	-13.71 (25.41)	173	75.53 (27.23)	172	-9.98 (25.28)
Week 4	175	76.10 (26.17)	172	-9.11 (22.39)	190	78.60 (25.74)	189	-6.97 (23.57)
Week 5	203	76.68 (25.11)	198	-8.59 (24.03)	160	77.60 (24.66)	160	-10.00 (23.14)
Week 6	159	81.13 (25.24)	158	-4.43 (22.61)	160	77.71 (26.30)	159	-10.69 (26.34)
Week 7	187	81.19 (23.41)	182	-3.30 (21.70)	173	78.13 (22.77)	172	-7.07 (23.15)
Week 8	144	83.33 (21.41)	141	-3.66 (19.53)	139	77.58 (25.04)	138	-10.39 (27.03)
Week 9	167	81.34 (23.27)	163	-4.19 (21.14)	125	75.73 (27.07)	124	-12.10 (28.14)
Week 10	142	83.33 (21.47)	140	-4.64 (20.88)	134	76.74 (25.36)	133	-10.03 (24.09)
Week 11	156	81.73 (22.38)	152	-3.95 (20.81)	120	74.44 (25.19)	119	-13.73 (27.16)
Week 12	130	83.59 (19.69)	127	-3.81 (21.74)	116	77.30 (24.61)	116	-11.78 (24.18)
Week 13	156	83.44 (23.46)	152	-1.64 (22.68)	127	77.56 (25.75)	127	-8.53 (29.09)
Week 19	118	87.43 (18.61)	116	0.43 (20.67)	89	77.90 (26.68)	89	-9.18 (26.35)
Week 25	107	86.60 (19.48)	105	0.79 (20.85)	60	82.78 (23.36)	60	-5.28 (24.06)
Week 31	91	88.10 (15.17)	89	1.50 (18.74)	41	82.11 (20.88)	41	-6.10 (24.65)
Week 37	75	86.67 (18.58)	73	1.14 (22.45)	21	71.43 (32.55)	21	-7.14 (39.99)
Week 43	46	86.96 (19.22)	45	2.59 (27.05)	12	86.11 (15.62)	12	4.17 (27.64)
Week 49	32	85.42 (17.33)	30	2.22 (26.89)	6	83.33 (40.82)	6	5.56 (61.16)
Week 55	22	90.15 (15.14)	22	4.55 (20.69)	3	100.00 (0.00)	3	0.00 (0.00)
Week 61	17	93.14 (11.87)	17	7.84 (22.91)	2	100.00 (0.00)	2	0.00 (0.00)
Week 67	6	94.44 (13.61)	6	19.44 (26.70)	1	100.00 (-)	1	0.00 (-)
Week 73	2	83.33 (23.57)	2	0.00 (0.00)	0	-	0	-
End of IP Administration	117	75.93 (28.06)	117	-7.41 (24.71)	151	69.87 (30.29)	149	-15.10 (26.80)
Safety Follow-Up	65	76.92 (29.42)	65	-8.46 (25.71)	91	77.29 (28.49)	90	-10.74 (28.30)


N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary statistics and change from baseline of C30 Social Functioning
Intention-to-Treat Analysis Set

	Tarlatamab (N=254)				Standard of Care (N=255)			
	Value at Timepoint		Change from Baseline		Value at Timepoint		Change from Baseline	
Timepoint	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	246	82.18 (22.83)	0	-	250	84.13 (21.11)	0	-
Week 2	225	79.93 (23.74)	221	-3.85 (20.33)	170	80.29 (22.26)	169	-5.03 (22.11)
Week 3	217	74.65 (25.21)	214	-9.35 (23.20)	173	80.15 (22.97)	172	-5.14 (22.61)
Week 4	175	79.43 (22.44)	172	-5.14 (21.05)	190	80.35 (21.62)	189	-6.26 (22.95)
Week 5	203	81.53 (21.16)	198	-4.21 (22.07)	160	79.27 (23.18)	160	-8.13 (21.80)
Week 6	159	81.13 (23.43)	158	-4.01 (25.68)	160	79.06 (23.66)	159	-8.70 (23.93)
Week 7	187	81.91 (22.15)	182	-3.94 (21.84)	173	77.94 (23.97)	172	-9.50 (23.23)
Week 8	144	84.49 (20.64)	141	-1.54 (20.69)	139	78.78 (23.89)	138	-9.18 (21.97)
Week 9	167	84.13 (20.44)	163	-1.53 (22.13)	125	77.60 (24.60)	124	-10.35 (24.29)
Week 10	142	84.27 (20.61)	139	-2.76 (20.91)	134	79.23 (24.56)	133	-8.27 (23.54)
Week 11	156	83.33 (19.67)	152	-2.08 (19.68)	120	77.78 (24.57)	119	-9.38 (22.82)
Week 12	130	83.21 (20.49)	126	-3.17 (20.95)	116	80.89 (22.44)	116	-7.33 (20.65)
Week 13	156	83.97 (20.56)	152	-0.99 (19.49)	127	78.61 (25.19)	127	-8.40 (22.51)
Week 19	118	87.43 (17.01)	115	0.00 (18.99)	89	77.15 (26.16)	89	-10.11 (24.70)
Week 25	107	87.85 (17.07)	104	1.44 (22.77)	60	81.67 (21.41)	60	-6.94 (23.02)
Week 31	91	88.83 (15.53)	89	2.62 (20.86)	41	80.49 (24.97)	41	-7.72 (23.89)
Week 37	75	87.78 (15.58)	73	2.05 (20.59)	21	72.22 (27.05)	21	-8.73 (32.75)
Week 43	46	87.68 (17.37)	45	2.22 (22.64)	12	90.28 (15.01)	12	5.56 (22.84)
Week 49	32	85.42 (20.19)	30	-0.56 (20.75)	6	83.33 (40.82)	6	-0.00 (54.77)
Week 55	22	87.88 (13.78)	22	1.52 (19.86)	3	94.44 (9.62)	3	0.00 (0.00)
Week 61	17	86.27 (16.91)	17	0.00 (20.41)	2	100.00 (0.00)	2	0.00 (0.00)
Week 67	6	86.11 (16.39)	6	2.78 (6.80)	1	100.00 (-)	1	0.00 (-)
Week 73	2	91.67 (11.79)	2	8.33 (11.79)	0	-	0	-
End of IP Administration	117	77.49 (25.17)	116	-6.61 (24.07)	151	71.41 (28.50)	149	-16.00 (29.63)
Safety Follow-Up	65	81.03 (23.18)	64	-5.21 (20.55)	91	77.84 (27.34)	90	-10.93 (28.17)


N describes number of patients with non-missing value at the respective timepoint.
N=Number of subjects included in the analysis, SD: Standard Deviation.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Cognitive Functioning
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Emotional Functioning
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Physical Functioning
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Global Health Status/QOL
Intention-to-Treat Analysis Set




Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Role Functioning
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Graphical summary of change from baseline of C30 Social Functioning
Intention-to-Treat Analysis Set



Only visits with N>=5 patients in at least one treatment group are displayed.

Anhang 4-G4: Ergänzende Analysen zum Endpunkt „Sicherheit“ – RCT

Anhang 4-G4.1: Unerwünschte Ereignisse nach SOC und PT

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first blood and lymphatic system disorders TEAE							
Overall	180/244 (73.8)	0.7 (0.7, 1.2)	114/252 (45.2)	8.7 (4.6, NE)		0.384 (0.301, 0.490)	< 0.001
Age					0.511		
< 65 years	81/109 (74.3)	0.7 (0.7, 1.2)	53/128 (41.4)	NE (5.0, NE)			
≥ 65 years	99/135 (73.3)	0.8 (0.7, 1.4)	61/124 (49.2)	6.5 (3.7, 10.7)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.841		
Male	118/161 (73.3)	0.8 (0.7, 1.3)	79/180 (43.9)	8.7 (4.3, NE)			
Female	62/83 (74.7)	0.7 (0.7, 1.4)	35/72 (48.6)	6.6 (2.4, NE)			
Region					0.609		
North America and Europe	88/121 (72.7)	0.7 (0.7, 1.4)	61/139 (43.9)	8.9 (4.1, NE)			
Rest of world	92/123 (74.8)	0.7 (0.5, 1.2)	53/113 (46.9)	8.7 (3.7, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.874		
Yes	122/172 (70.9)	0.7 (0.7, 1.3)	81/179 (45.3)	8.9 (4.6, NE)			
No	58/72 (80.6)	0.7 (0.6, 1.3)	33/73 (45.2)	8.7 (2.4, NE)			
Chemotherapy-free interval					0.436		
< 90 days	70/109 (64.2)	0.7 (0.7, 1.4)	47/107 (43.9)	7.3 (3.8, NE)			
≥ 90 and < 180 days	56/73 (76.7)	0.7 (0.5, 1.4)	35/85 (41.2)	11.0 (3.7, NE)			
≥ 180 days	54/62 (87.1)	0.8 (0.7, 1.3)	32/60 (53.3)	6.5 (1.4, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.161		
Yes	79/108 (73.1)	0.7 (0.7, 1.2)	47/113 (41.6)	10.4 (5.0, NE)			
No	101/136 (74.3)	0.8 (0.7, 1.4)	67/139 (48.2)	6.5 (3.3, NE)			
Standard of care					0.095		
Topotecan/Amrubicin	161/199 (80.9)	0.7 (0.6, 0.7)	100/208 (48.1)	6.6 (3.6, NE)			
Lurbinectedin	19/45 (42.2)	8.3 (2.8, NE)	14/44 (31.8)	NE (5.5, NE)			

Page 4 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first anaemia TEAE							
Overall	156/244 (63.9)	1.5 (1.3, 2.1)	78/252 (31.0)	NE (10.7, NE)		0.303 (0.229, 0.403)	< 0.001
Age					0.792		
< 65 years	68/109 (62.4)	1.4 (0.8, 3.4)	37/128 (28.9)	NE (10.2, NE)			
≥ 65 years	88/135 (65.2)	1.6 (1.4, 2.1)	41/124 (33.1)	NE (8.7, NE)			

Page 5 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.524		
Male	104/161 (64.6)	1.6 (1.4, 2.2)	57/180 (31.7)	NE (10.2, NE)			
Female	52/83 (62.7)	1.4 (0.7, 3.5)	21/72 (29.2)	NE (10.1, NE)			
Region					0.457		
North America and Europe	80/121 (66.1)	1.4 (0.8, 2.1)	48/139 (34.5)	10.7 (8.6, NE)			
Rest of world	76/123 (61.8)	1.9 (1.3, 2.8)	30/113 (26.5)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.252		
Yes	103/172 (59.9)	1.8 (1.4, 2.6)	58/179 (32.4)	NE (10.2, NE)			
No	53/72 (73.6)	1.3 (0.8, 2.2)	20/73 (27.4)	NE (8.7, NE)			
Chemotherapy-free interval					0.381		
< 90 days	59/109 (54.1)	2.3 (1.3, 3.5)	32/107 (29.9)	NE (10.1, NE)			
≥ 90 and < 180 days	48/73 (65.8)	1.6 (0.7, 2.9)	26/85 (30.6)	NE (10.2, NE)			
≥ 180 days	49/62 (79.0)	1.3 (0.8, 1.7)	20/60 (33.3)	NE (8.7, NE)			

Page 7 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.848		
Yes	64/108 (59.3)	1.9 (1.0, 3.5)	35/113 (31.0)	NE (10.7, NE)			
No	92/136 (67.6)	1.4 (1.1, 2.1)	43/139 (30.9)	NE (10.1, NE)			
Standard of care					0.618		
Topotecan/Amrubicin	142/199 (71.4)	1.2 (0.8, 1.4)	72/208 (34.6)	10.7 (10.1, NE)			
Lurbinectedin	14/45 (31.1)	NE (6.5, NE)	6/44 (13.6)	NE (NE, NE)			

Page 8 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first neutropenia TEAE							
Overall	76/244 (31.1)	NE (10.2, NE)	27/252 (10.7)	NE (NE, NE)		0.263 (0.169, 0.410)	< 0.001
Age					0.208		
< 65 years	32/109 (29.4)	NE (8.3, NE)	16/128 (12.5)	NE (NE, NE)			
≥ 65 years	44/135 (32.6)	NE (7.6, NE)	11/124 (8.9)	NE (NE, NE)			

Page 9 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.405		
Male	45/161 (28.0)	NE (10.2, NE)	15/180 (8.3)	NE (NE, NE)			
Female	31/83 (37.3)	8.3 (5.1, NE)	12/72 (16.7)	NE (11.0, NE)			
Region					0.110		
North America and Europe	30/121 (24.8)	NE (NE, NE)	7/139 (5.0)	NE (NE, NE)			
Rest of world	46/123 (37.4)	10.2 (7.6, NE)	20/113 (17.7)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.726		
Yes	53/172 (30.8)	NE (8.3, NE)	20/179 (11.2)	NE (NE, NE)			
No	23/72 (31.9)	NE (5.1, NE)	7/73 (9.6)	NE (NE, NE)			
Chemotherapy-free interval					0.288		
< 90 days	30/109 (27.5)	NE (7.6, NE)	10/107 (9.3)	NE (NE, NE)			
≥ 90 and < 180 days	27/73 (37.0)	NE (6.0, NE)	7/85 (8.2)	NE (NE, NE)			
≥ 180 days	19/62 (30.6)	10.2 (6.8, NE)	10/60 (16.7)	NE (NE, NE)			

Page 11 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.093		
Yes	34/108 (31.5)	NE (8.3, NE)	8/113 (7.1)	NE (NE, NE)			
No	42/136 (30.9)	NE (10.2, NE)	19/139 (13.7)	NE (NE, NE)			
Standard of care					0.082		
Topotecan/Amrubicin	65/199 (32.7)	NE (NE, NE)	20/208 (9.6)	NE (NE, NE)			
Lurbinectedin	11/45 (24.4)	10.2 (8.3, NE)	7/44 (15.9)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first leukopenia TEAE							
Overall	54/244 (22.1)	NE (NE, NE)	24/252 (9.5)	NE (NE, NE)		0.369 (0.228, 0.597)	< 0.001
Age					0.976		
< 65 years	26/109 (23.9)	NE (NE, NE)	13/128 (10.2)	NE (NE, NE)			
≥ 65 years	28/135 (20.7)	NE (NE, NE)	11/124 (8.9)	NE (NE, NE)			

Page 13 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.047		
Male	40/161 (24.8)	NE (NE, NE)	14/180 (7.8)	NE (NE, NE)		0.258 (0.140, 0.476)	< 0.001
Female	14/83 (16.9)	NE (NE, NE)	10/72 (13.9)	NE (NE, NE)		0.761 (0.338, 1.715)	0.511
Region					0.762		
North America and Europe	21/121 (17.4)	NE (NE, NE)	11/139 (7.9)	NE (NE, NE)			
Rest of world	33/123 (26.8)	NE (NE, NE)	13/113 (11.5)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.677		
Yes	35/172 (20.3)	NE (NE, NE)	17/179 (9.5)	NE (NE, NE)			
No	19/72 (26.4)	NE (NE, NE)	7/73 (9.6)	NE (NE, NE)			
Chemotherapy-free interval					0.082		
< 90 days	27/109 (24.8)	NE (NE, NE)	12/107 (11.2)	NE (NE, NE)			
≥ 90 and < 180 days	16/73 (21.9)	NE (NE, NE)	3/85 (3.5)	NE (NE, NE)			
≥ 180 days	11/62 (17.7)	NE (NE, NE)	9/60 (15.0)	NE (NE, NE)			

Page 15 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.316		
Yes	25/108 (23.1)	NE (NE, NE)	9/113 (8.0)	NE (NE, NE)			
No	29/136 (21.3)	NE (NE, NE)	15/139 (10.8)	NE (NE, NE)			
Standard of care					0.445		
Topotecan/Amrubicin	53/199 (26.6)	NE (NE, NE)	23/208 (11.1)	NE (NE, NE)			
Lurbinectedin	1/45 (2.2)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first lymphopenia TEAE							
Overall	10/244 (4.1)	NE (NE, NE)	23/252 (9.1)	NE (NE, NE)		2.190 (1.041, 4.607)	0.034
Age					0.750		
< 65 years	4/109 (3.7)	NE (NE, NE)	12/128 (9.4)	NE (NE, NE)			
≥ 65 years	6/135 (4.4)	NE (NE, NE)	11/124 (8.9)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.778		
Male	7/161 (4.3)	NE (NE, NE)	18/180 (10.0)	NE (NE, NE)			
Female	3/83 (3.6)	NE (NE, NE)	5/72 (6.9)	NE (NE, NE)			
Region					0.980		
North America and Europe	8/121 (6.6)	NE (NE, NE)	19/139 (13.7)	NE (NE, NE)			
Rest of world	2/123 (1.6)	NE (NE, NE)	4/113 (3.5)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.437		
Yes	5/172 (2.9)	NE (NE, NE)	15/179 (8.4)	NE (NE, NE)			
No	5/72 (6.9)	NE (NE, NE)	8/73 (11.0)	NE (NE, NE)			
Chemotherapy-free interval					0.882		
< 90 days	4/109 (3.7)	NE (NE, NE)	10/107 (9.3)	NE (NE, NE)			
≥ 90 and < 180 days	4/73 (5.5)	NE (NE, NE)	8/85 (9.4)	NE (NE, NE)			
≥ 180 days	2/62 (3.2)	NE (NE, NE)	5/60 (8.3)	NE (NE, NE)			

Page 19 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.309		
Yes	6/108 (5.6)	NE (NE, NE)	10/113 (8.8)	NE (NE, NE)			
No	4/136 (2.9)	NE (NE, NE)	13/139 (9.4)	NE (NE, NE)			
Standard of care					1.000		
Topotecan/Amrubicin	10/199 (5.0)	NE (NE, NE)	23/208 (11.1)	NE (NE, NE)			
Lurbinectedin	0/45 (0.0)	NE (NE, NE)	0/44 (0.0)	NE (NE, NE)			

Page 20 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first thrombocytopenia TEAE							
Overall	62/244 (25.4)	NE (NE, NE)	14/252 (5.6)	NE (NE, NE)		0.177 (0.099, 0.318)	< 0.001
Age					0.604		
< 65 years	28/109 (25.7)	NE (NE, NE)	8/128 (6.3)	NE (NE, NE)			
≥ 65 years	34/135 (25.2)	NE (NE, NE)	6/124 (4.8)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.653		
Male	43/161 (26.7)	NE (7.9, NE)	11/180 (6.1)	NE (NE, NE)			
Female	19/83 (22.9)	NE (NE, NE)	3/72 (4.2)	NE (NE, NE)			
Region					0.294		
North America and Europe	32/121 (26.4)	NE (7.9, NE)	10/139 (7.2)	NE (NE, NE)			
Rest of world	30/123 (24.4)	NE (NE, NE)	4/113 (3.5)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.124		
Yes	38/172 (22.1)	NE (NE, NE)	12/179 (6.7)	NE (NE, NE)			
No	24/72 (33.3)	NE (5.4, NE)	2/73 (2.7)	NE (NE, NE)			
Chemotherapy-free interval					0.666		
< 90 days	25/109 (22.9)	NE (NE, NE)	7/107 (6.5)	NE (NE, NE)			
≥ 90 and < 180 days	19/73 (26.0)	NE (7.9, NE)	3/85 (3.5)	NE (NE, NE)			
≥ 180 days	18/62 (29.0)	NE (7.2, NE)	4/60 (6.7)	NE (NE, NE)			

Page 23 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.510		
Yes	28/108 (25.9)	NE (7.9, NE)	8/113 (7.1)	NE (NE, NE)			
No	34/136 (25.0)	NE (NE, NE)	6/139 (4.3)	NE (NE, NE)			
Standard of care					0.810		
Topotecan/Amrubicin	55/199 (27.6)	NE (NE, NE)	13/208 (6.3)	NE (NE, NE)			
Lurbinectedin	7/45 (15.6)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

Page 24 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first febrile neutropenia TEAE							
Overall	28/244 (11.5)	NE (NE, NE)	5/252 (2.0)	NE (NE, NE)		0.131 (0.050, 0.346)	< 0.001
Age					0.493		
< 65 years	9/109 (8.3)	NE (NE, NE)	1/128 (0.8)	NE (NE, NE)			
≥ 65 years	19/135 (14.1)	NE (NE, NE)	4/124 (3.2)	NE (NE, NE)			

Page 25 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.792		
Male	18/161 (11.2)	NE (NE, NE)	3/180 (1.7)	NE (NE, NE)			
Female	10/83 (12.0)	NE (NE, NE)	2/72 (2.8)	NE (NE, NE)			
Region					0.368		
North America and Europe	16/121 (13.2)	NE (NE, NE)	2/139 (1.4)	NE (NE, NE)			
Rest of world	12/123 (9.8)	NE (NE, NE)	3/113 (2.7)	NE (NE, NE)			

Page 26 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.787		
Yes	20/172 (11.6)	NE (NE, NE)	4/179 (2.2)	NE (NE, NE)			
No	8/72 (11.1)	NE (NE, NE)	1/73 (1.4)	NE (NE, NE)			
Chemotherapy-free interval					0.643		
< 90 days	11/109 (10.1)	NE (NE, NE)	3/107 (2.8)	NE (NE, NE)			
≥ 90 and < 180 days	10/73 (13.7)	NE (NE, NE)	1/85 (1.2)	NE (NE, NE)			
≥ 180 days	7/62 (11.3)	NE (NE, NE)	1/60 (1.7)	NE (NE, NE)			

Page 27 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.804		
Yes	12/108 (11.1)	NE (NE, NE)	2/113 (1.8)	NE (NE, NE)			
No	16/136 (11.8)	NE (NE, NE)	3/139 (2.2)	NE (NE, NE)			
Standard of care					0.686		
Topotecan/Amrubicin	24/199 (12.1)	NE (NE, NE)	4/208 (1.9)	NE (NE, NE)			
Lurbinectedin	4/45 (8.9)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

Page 28 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first cardiac disorders TEAE							
Overall	32/244 (13.1)	NE (NE, NE)	32/252 (12.7)	NE (NE, NE)		0.850 (0.519, 1.393)	0.518
Time to first endocrine disorders TEAE							
Overall	9/244 (3.7)	NE (NE, NE)	21/252 (8.3)	NE (NE, NE)		2.068 (0.944, 4.534)	0.064
Time to first eye disorders TEAE							
Overall	15/244 (6.1)	NE (NE, NE)	5/252 (2.0)	NE (NE, NE)		0.248 (0.089, 0.691)	0.004

Page 29 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.500		
< 65 years	5/109 (4.6)	NE (NE, NE)	1/128 (0.8)	NE (NE, NE)			
≥ 65 years	10/135 (7.4)	NE (NE, NE)	4/124 (3.2)	NE (NE, NE)			
Sex					0.343		
Male	8/161 (5.0)	NE (NE, NE)	4/180 (2.2)	NE (NE, NE)			
Female	7/83 (8.4)	NE (NE, NE)	1/72 (1.4)	NE (NE, NE)			

Page 30 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.203		
North America and Europe	10/121 (8.3)	NE (NE, NE)	2/139 (1.4)	NE (NE, NE)			
Rest of world	5/123 (4.1)	NE (NE, NE)	3/113 (2.7)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					0.463		
Yes	9/172 (5.2)	NE (NE, NE)	4/179 (2.2)	NE (NE, NE)			
No	6/72 (8.3)	NE (NE, NE)	1/73 (1.4)	NE (NE, NE)			

Page 31 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					0.244		
< 90 days	6/109 (5.5)	NE (NE, NE)	1/107 (0.9)	NE (NE, NE)			
≥ 90 and < 180 days	6/73 (8.2)	NE (NE, NE)	1/85 (1.2)	NE (NE, NE)			
≥ 180 days	3/62 (4.8)	NE (NE, NE)	3/60 (5.0)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.174		
Yes	8/108 (7.4)	NE (NE, NE)	1/113 (0.9)	NE (NE, NE)			
No	7/136 (5.1)	NE (NE, NE)	4/139 (2.9)	NE (NE, NE)			

Page 32 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.489		
Topotecan/Amrubicin	11/199 (5.5)	NE (NE, NE)	3/208 (1.4)	NE (NE, NE)			
Lurbinectedin	4/45 (8.9)	NE (NE, NE)	2/44 (4.5)	NE (NE, NE)			
Time to first gastrointestinal disorders TEAE							
Overall	155/244 (63.5)	1.6 (0.9, 2.5)	142/252 (56.3)	3.3 (1.5, 6.6)		0.772 (0.613, 0.973)	0.025

Page 33 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.395		
< 65 years	63/109 (57.8)	2.6 (0.7, 5.3)	71/128 (55.5)	3.9 (1.7, 7.7)			
≥ 65 years	92/135 (68.1)	1.3 (0.8, 2.1)	71/124 (57.3)	2.1 (0.9, 10.2)			
Sex					0.006		
Male	101/161 (62.7)	1.8 (0.9, 3.2)	87/180 (48.3)	8.2 (3.8, 10.6)		0.628 (0.470, 0.841)	0.001
Female	54/83 (65.1)	1.4 (0.6, 3.1)	55/72 (76.4)	0.5 (0.3, 1.4)		1.235 (0.844, 1.807)	0.291

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.015		
North America and Europe	63/121 (52.1)	4.5 (2.1, 5.8)	75/139 (54.0)	3.9 (1.2, 8.9)		1.032 (0.737, 1.446)	0.874
Rest of world	92/123 (74.8)	0.8 (0.3, 1.1)	67/113 (59.3)	3.1 (0.6, 8.2)		0.603 (0.436, 0.832)	0.002
Prior anti-PD-(L)1 exposure					0.602		
Yes	105/172 (61.0)	1.5 (0.8, 3.4)	97/179 (54.2)	4.4 (2.1, 8.9)			
No	50/72 (69.4)	1.6 (0.7, 2.6)	45/73 (61.6)	0.7 (0.5, 5.5)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					0.501		
< 90 days	69/109 (63.3)	1.0 (0.5, 2.1)	57/107 (53.3)	2.7 (1.4, 10.2)			
≥ 90 and < 180 days	48/73 (65.8)	1.8 (0.8, 3.1)	51/85 (60.0)	2.6 (0.5, 6.6)			
≥ 180 days	38/62 (61.3)	3.4 (0.8, 5.8)	34/60 (56.7)	4.4 (0.5, 12.3)			
Presence (previous or current) of brain metastases					0.293		
Yes	70/108 (64.8)	1.4 (0.7, 3.1)	63/113 (55.8)	5.4 (1.8, 10.6)			
No	85/136 (62.5)	1.8 (0.9, 3.1)	79/139 (56.8)	1.7 (0.7, 7.7)			

Page 36 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.563		
Topotecan/Amrubicin	121/199 (60.8)	1.6 (0.9, 3.1)	115/208 (55.3)	3.8 (1.4, 7.7)			
Lurbinectedin	34/45 (75.6)	1.6 (0.4, 2.4)	27/44 (61.4)	2.7 (0.6, 10.2)			
Time to first constipation TEAE							
Overall	54/244 (22.1)	NE (10.8, NE)	72/252 (28.6)	NE (NE, NE)		1.186 (0.830, 1.693)	0.346
Time to first nausea TEAE							
Overall	78/244 (32.0)	NE (NE, NE)	61/252 (24.2)	NE (NE, NE)		0.702 (0.501, 0.983)	0.037

Page 37 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.543		
< 65 years	34/109 (31.2)	NE (NE, NE)	33/128 (25.8)	NE (NE, NE)			
≥ 65 years	44/135 (32.6)	NE (NE, NE)	28/124 (22.6)	NE (14.1, NE)			
Sex					0.003		
Male	52/161 (32.3)	NE (NE, NE)	31/180 (17.2)	NE (NE, NE)		0.477 (0.305, 0.744)	< 0.001
Female	26/83 (31.3)	NE (NE, NE)	30/72 (41.7)	14.1 (2.2, NE)		1.354 (0.797, 2.301)	0.270

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.039		
North America and Europe	26/121 (21.5)	NE (NE, NE)	32/139 (23.0)	NE (NE, NE)		1.070 (0.637, 1.797)	0.804
Rest of world	52/123 (42.3)	NE (3.3, NE)	29/113 (25.7)	NE (14.1, NE)		0.522 (0.330, 0.827)	0.005
Prior anti-PD-(L)1 exposure					0.723		
Yes	51/172 (29.7)	NE (NE, NE)	43/179 (24.0)	NE (14.1, NE)			
No	27/72 (37.5)	NE (3.2, NE)	18/73 (24.7)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					0.501		
< 90 days	38/109 (34.9)	NE (5.0, NE)	25/107 (23.4)	NE (NE, NE)			
≥ 90 and < 180 days	20/73 (27.4)	NE (NE, NE)	21/85 (24.7)	NE (14.1, NE)			
≥ 180 days	20/62 (32.3)	NE (4.9, NE)	15/60 (25.0)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.465		
Yes	35/108 (32.4)	NE (7.1, NE)	25/113 (22.1)	NE (NE, NE)			
No	43/136 (31.6)	NE (NE, NE)	36/139 (25.9)	NE (14.1, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.039		
Topotecan/Amrubicin	56/199 (28.1)	NE (NE, NE)	52/208 (25.0)	NE (NE, NE)		0.847 (0.580, 1.237)	0.383
Lurbinectedin	22/45 (48.9)	7.1 (0.9, NE)	9/44 (20.5)	NE (14.1, NE)		0.329 (0.146, 0.741)	0.005
Time to first vomiting TEAE							
Overall	28/244 (11.5)	NE (NE, NE)	35/252 (13.9)	NE (NE, NE)		1.185 (0.719, 1.953)	0.510
Time to first diarrhoea TEAE							
Overall	37/244 (15.2)	NE (NE, NE)	28/252 (11.1)	NE (NE, NE)		0.659 (0.402, 1.079)	0.095

Page 41 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first abdominal pain TEAE							
Overall	10/244 (4.1)	NE (NE, NE)	19/252 (7.5)	NE (NE, NE)		1.660 (0.768, 3.587)	0.193
Time to first dyspepsia TEAE							
Overall	2/244 (0.8)	NE (NE, NE)	13/252 (5.2)	NE (NE, NE)		5.963 (1.339, 26.542)	0.008
Age					0.990		
< 65 years	0/109 (0.0)	NE (NE, NE)	6/128 (4.7)	NE (NE, NE)			
≥ 65 years	2/135 (1.5)	NE (NE, NE)	7/124 (5.6)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.991		
Male	2/161 (1.2)	NE (NE, NE)	9/180 (5.0)	NE (NE, NE)			
Female	0/83 (0.0)	NE (NE, NE)	4/72 (5.6)	NE (NE, NE)			
Region					0.993		
North America and Europe	0/121 (0.0)	NE (NE, NE)	2/139 (1.4)	NE (NE, NE)			
Rest of world	2/123 (1.6)	NE (NE, NE)	11/113 (9.7)	NE (NE, NE)			

Page 43 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.989		
Yes	2/172 (1.2)	NE (NE, NE)	6/179 (3.4)	NE (NE, NE)			
No	0/72 (0.0)	NE (NE, NE)	7/73 (9.6)	NE (12.3, NE)			
Chemotherapy-free interval					0.787		
< 90 days	1/109 (0.9)	NE (NE, NE)	2/107 (1.9)	NE (NE, NE)			
≥ 90 and < 180 days	1/73 (1.4)	NE (NE, NE)	7/85 (8.2)	NE (NE, NE)			
≥ 180 days	0/62 (0.0)	NE (NE, NE)	4/60 (6.7)	NE (12.3, NE)			

Page 44 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.993		
Yes	2/108 (1.9)	NE (NE, NE)	4/113 (3.5)	NE (NE, NE)			
No	0/136 (0.0)	NE (NE, NE)	9/139 (6.5)	NE (NE, NE)			
Standard of care					0.281		
Topotecan/Amrubicin	1/199 (0.5)	NE (NE, NE)	11/208 (5.3)	NE (NE, NE)			
Lurbinectedin	1/45 (2.2)	NE (NE, NE)	2/44 (4.5)	NE (NE, NE)			

Page 45 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first stomatitis TEAE							
Overall	11/244 (4.5)	NE (NE, NE)	8/252 (3.2)	NE (NE, NE)		0.632 (0.253, 1.581)	0.322
Time to first general disorders and administration site conditions TEAE							
Overall	154/244 (63.1)	2.1 (1.4, 2.9)	161/252 (63.9)	1.2 (0.5, 2.0)		1.065 (0.852, 1.332)	0.620
Time to first fatigue TEAE							
Overall	74/244 (30.3)	NE (NE, NE)	72/252 (28.6)	NE (NE, NE)		0.873 (0.630, 1.210)	0.413

Page 46 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first pyrexia TEAE							
Overall	27/244 (11.1)	NE (NE, NE)	69/252 (27.4)	NE (NE, NE)		2.737 (1.752, 4.277)	< 0.001
Age					0.219		
< 65 years	11/109 (10.1)	NE (NE, NE)	40/128 (31.3)	NE (NE, NE)			
≥ 65 years	16/135 (11.9)	NE (NE, NE)	29/124 (23.4)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.939		
Male	17/161 (10.6)	NE (NE, NE)	48/180 (26.7)	NE (NE, NE)			
Female	10/83 (12.0)	NE (NE, NE)	21/72 (29.2)	NE (NE, NE)			
Region					0.747		
North America and Europe	11/121 (9.1)	NE (NE, NE)	35/139 (25.2)	NE (NE, NE)			
Rest of world	16/123 (13.0)	NE (NE, NE)	34/113 (30.1)	NE (NE, NE)			

Page 48 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.139		
Yes	22/172 (12.8)	NE (NE, NE)	47/179 (26.3)	NE (NE, NE)			
No	5/72 (6.9)	NE (NE, NE)	22/73 (30.1)	NE (NE, NE)			
Chemotherapy-free interval					0.348		
< 90 days	13/109 (11.9)	NE (NE, NE)	24/107 (22.4)	NE (NE, NE)			
≥ 90 and < 180 days	6/73 (8.2)	NE (NE, NE)	27/85 (31.8)	NE (10.0, NE)			
≥ 180 days	8/62 (12.9)	NE (NE, NE)	18/60 (30.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.866		
Yes	12/108 (11.1)	NE (NE, NE)	31/113 (27.4)	NE (NE, NE)			
No	15/136 (11.0)	NE (NE, NE)	38/139 (27.3)	NE (NE, NE)			
Standard of care					0.025		
Topotecan/Amrubicin	17/199 (8.5)	NE (NE, NE)	58/208 (27.9)	NE (NE, NE)		3.697 (2.152, 6.354)	< 0.001
Lurbinectedin	10/45 (22.2)	NE (7.1, NE)	11/44 (25.0)	NE (NE, NE)		1.091 (0.457, 2.606)	0.853

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first asthenia TEAE							
Overall	36/244 (14.8)	NE (NE, NE)	28/252 (11.1)	NE (NE, NE)		0.684 (0.416, 1.126)	0.133
Time to first chest pain TEAE							
Overall	12/244 (4.9)	NE (NE, NE)	15/252 (6.0)	NE (NE, NE)		1.141 (0.534, 2.442)	0.732
Time to first oedema peripheral TEAE							
Overall	11/244 (4.5)	NE (NE, NE)	5/252 (2.0)	NE (NE, NE)		0.400 (0.138, 1.163)	0.082

Page 51 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first hepatobiliary disorders TEAE							
Overall	11/244 (4.5)	NE (NE, NE)	10/252 (4.0)	NE (NE, NE)		0.681 (0.284, 1.629)	0.385
Time to first immune system disorders TEAE							
Overall	4/244 (1.6)	NE (NE, NE)	142/252 (56.3)	0.3 (0.3, 0.5)		50.676 (18.746, 136.991)	< 0.001
Age					0.222		
< 65 years	3/109 (2.8)	NE (NE, NE)	68/128 (53.1)	0.3 (0.3, NE)			
≥ 65 years	1/135 (0.7)	NE (NE, NE)	74/124 (59.7)	0.3 (0.1, 0.5)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.189		
Male	1/161 (0.6)	NE (NE, NE)	96/180 (53.3)	0.3 (0.3, NE)			
Female	3/83 (3.6)	NE (NE, NE)	46/72 (63.9)	0.3 (0.1, 0.3)			
Region					0.982		
North America and Europe	4/121 (3.3)	NE (NE, NE)	75/139 (54.0)	0.3 (0.3, NE)			
Rest of world	0/123 (0.0)	NE (NE, NE)	67/113 (59.3)	0.3 (0.3, 0.5)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.990		
Yes	3/172 (1.7)	NE (NE, NE)	105/179 (58.7)	0.3 (0.3, 0.3)			
No	1/72 (1.4)	NE (NE, NE)	37/73 (50.7)	1.2 (0.3, NE)			
Chemotherapy-free interval					0.632		
< 90 days	1/109 (0.9)	NE (NE, NE)	63/107 (58.9)	0.3 (0.1, 0.5)			
≥ 90 and < 180 days	2/73 (2.7)	NE (NE, NE)	50/85 (58.8)	0.3 (0.1, NE)			
≥ 180 days	1/62 (1.6)	NE (NE, NE)	29/60 (48.3)	NE (0.3, NE)			

Page 54 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.443		
Yes	1/108 (0.9)	NE (NE, NE)	64/113 (56.6)	0.3 (0.1, NE)			
No	3/136 (2.2)	NE (NE, NE)	78/139 (56.1)	0.3 (0.3, NE)			
Standard of care					0.038		
Topotecan/Amrubicin	1/199 (0.5)	NE (NE, NE)	115/208 (55.3)	0.3 (0.3, NE)		159.975 (22.342, > 999.999)	< 0.001
Lurbinectedin	3/45 (6.7)	NE (NE, NE)	27/44 (61.4)	0.3 (0.1, NE)		14.871 (4.483, 49.330)	< 0.001

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first cytokine release syndrome TEAE							
Overall	3/244 (1.2)	NE (NE, NE)	142/252 (56.3)	0.3 (0.3, 0.5)		67.718 (21.576, 212.542)	< 0.001
Age					0.409		
< 65 years	2/109 (1.8)	NE (NE, NE)	68/128 (53.1)	0.3 (0.3, NE)			
≥ 65 years	1/135 (0.7)	NE (NE, NE)	74/124 (59.7)	0.3 (0.1, 0.5)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.361		
Male	1/161 (0.6)	NE (NE, NE)	96/180 (53.3)	0.3 (0.3, NE)			
Female	2/83 (2.4)	NE (NE, NE)	46/72 (63.9)	0.3 (0.1, 0.3)			
Region					0.982		
North America and Europe	3/121 (2.5)	NE (NE, NE)	75/139 (54.0)	0.3 (0.3, NE)			
Rest of world	0/123 (0.0)	NE (NE, NE)	67/113 (59.3)	0.3 (0.3, 0.5)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.734		
Yes	2/172 (1.2)	NE (NE, NE)	105/179 (58.7)	0.3 (0.3, 0.3)			
No	1/72 (1.4)	NE (NE, NE)	37/73 (50.7)	1.2 (0.3, NE)			
Chemotherapy-free interval					0.641		
< 90 days	1/109 (0.9)	NE (NE, NE)	63/107 (58.9)	0.3 (0.1, 0.5)			
≥ 90 and < 180 days	2/73 (2.7)	NE (NE, NE)	50/85 (58.8)	0.3 (0.1, NE)			
≥ 180 days	0/62 (0.0)	NE (NE, NE)	29/60 (48.3)	NE (0.3, NE)			

Page 58 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.691		
Yes	1/108 (0.9)	NE (NE, NE)	64/113 (56.6)	0.3 (0.1, NE)			
No	2/136 (1.5)	NE (NE, NE)	78/139 (56.1)	0.3 (0.3, NE)			
Standard of care					0.976		
Topotecan/Amrubicin	0/199 (0.0)	NE (NE, NE)	115/208 (55.3)	0.3 (0.3, NE)			
Lurbinectedin	3/45 (6.7)	NE (NE, NE)	27/44 (61.4)	0.3 (0.1, NE)			

Page 59 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first infections and infestations TEAE							
Overall	95/244 (38.9)	7.0 (5.2, NE)	91/252 (36.1)	NE (9.3, NE)		0.821 (0.614, 1.098)	0.182
Time to first pneumonia TEAE							
Overall	32/244 (13.1)	NE (NE, NE)	23/252 (9.1)	NE (NE, NE)		0.570 (0.331, 0.980)	0.040
Age					0.260		
< 65 years	13/109 (11.9)	NE (NE, NE)	7/128 (5.5)	NE (NE, NE)			
≥ 65 years	19/135 (14.1)	NE (NE, NE)	16/124 (12.9)	NE (NE, NE)			

Page 60 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.925		
Male	21/161 (13.0)	NE (NE, NE)	16/180 (8.9)	NE (NE, NE)			
Female	11/83 (13.3)	NE (NE, NE)	7/72 (9.7)	NE (NE, NE)			
Region					0.464		
North America and Europe	17/121 (14.0)	NE (NE, NE)	11/139 (7.9)	NE (NE, NE)			
Rest of world	15/123 (12.2)	NE (NE, NE)	12/113 (10.6)	NE (NE, NE)			

Page 61 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.137		
Yes	17/172 (9.9)	NE (NE, NE)	17/179 (9.5)	NE (NE, NE)			
No	15/72 (20.8)	NE (NE, NE)	6/73 (8.2)	NE (NE, NE)			
Chemotherapy-free interval					0.076		
< 90 days	13/109 (11.9)	NE (NE, NE)	10/107 (9.3)	NE (NE, NE)			
≥ 90 and < 180 days	9/73 (12.3)	NE (NE, NE)	12/85 (14.1)	NE (11.5, NE)			
≥ 180 days	10/62 (16.1)	NE (NE, NE)	1/60 (1.7)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.967		
Yes	13/108 (12.0)	NE (NE, NE)	10/113 (8.8)	NE (NE, NE)			
No	19/136 (14.0)	NE (NE, NE)	13/139 (9.4)	NE (NE, NE)			
Standard of care					0.042		
Topotecan/Amrubicin	29/199 (14.6)	NE (NE, NE)	16/208 (7.7)	NE (NE, NE)		0.432 (0.233, 0.798)	0.006
Lurbinectedin	3/45 (6.7)	NE (NE, NE)	7/44 (15.9)	NE (NE, NE)		1.850 (0.457, 7.493)	0.382

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first urinary tract infection TEAE							
Overall	8/244 (3.3)	NE (12.2, NE)	16/252 (6.3)	NE (NE, NE)		1.606 (0.679, 3.795)	0.276
Time to first upper respiratory tract infection TEAE							
Overall	9/244 (3.7)	NE (11.4, NE)	11/252 (4.4)	NE (NE, NE)		0.875 (0.355, 2.158)	0.772
Time to first injury, poisoning and procedural complications TEAE							
Overall	17/244 (7.0)	NE (NE, NE)	14/252 (5.6)	NE (NE, NE)		0.649 (0.318, 1.326)	0.232

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first investigations TEAE							
Overall	100/244 (41.0)	7.6 (4.7, NE)	112/252 (44.4)	10.2 (5.4, NE)		1.023 (0.780, 1.342)	0.881
Time to first weight decreased TEAE							
Overall	16/244 (6.6)	NE (NE, NE)	31/252 (12.3)	NE (NE, NE)		1.840 (1.004, 3.370)	0.045
Age					0.368		
< 65 years	9/109 (8.3)	NE (NE, NE)	15/128 (11.7)	NE (NE, NE)			
≥ 65 years	7/135 (5.2)	NE (NE, NE)	16/124 (12.9)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.980		
Male	10/161 (6.2)	NE (NE, NE)	21/180 (11.7)	NE (NE, NE)			
Female	6/83 (7.2)	NE (NE, NE)	10/72 (13.9)	NE (NE, NE)			
Region					0.449		
North America and Europe	6/121 (5.0)	NE (NE, NE)	17/139 (12.2)	NE (NE, NE)			
Rest of world	10/123 (8.1)	NE (NE, NE)	14/113 (12.4)	NE (NE, NE)			

Page 66 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.659		
Yes	11/172 (6.4)	NE (NE, NE)	20/179 (11.2)	NE (NE, NE)			
No	5/72 (6.9)	NE (NE, NE)	11/73 (15.1)	NE (NE, NE)			
Chemotherapy-free interval					0.794		
< 90 days	9/109 (8.3)	NE (NE, NE)	14/107 (13.1)	NE (NE, NE)			
≥ 90 and < 180 days	4/73 (5.5)	NE (NE, NE)	9/85 (10.6)	NE (NE, NE)			
≥ 180 days	3/62 (4.8)	NE (NE, NE)	8/60 (13.3)	NE (NE, NE)			

Page 67 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.858		
Yes	10/108 (9.3)	NE (NE, NE)	19/113 (16.8)	NE (NE, NE)			
No	6/136 (4.4)	NE (NE, NE)	12/139 (8.6)	NE (NE, NE)			
Standard of care					0.449		
Topotecan/Amrubicin	13/199 (6.5)	NE (NE, NE)	28/208 (13.5)	NE (NE, NE)			
Lurbinectedin	3/45 (6.7)	NE (NE, NE)	3/44 (6.8)	NE (NE, NE)			

Page 68 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first white blood cell count decreased TEAE							
Overall	32/244 (13.1)	NE (NE, NE)	24/252 (9.5)	NE (NE, NE)		0.608 (0.356, 1.039)	0.066
Time to first neutrophil count decreased TEAE							
Overall	42/244 (17.2)	NE (NE, NE)	20/252 (7.9)	NE (NE, NE)		0.365 (0.212, 0.628)	< 0.001
Age					0.792		
< 65 years	21/109 (19.3)	NE (NE, NE)	12/128 (9.4)	NE (NE, NE)			
≥ 65 years	21/135 (15.6)	NE (NE, NE)	8/124 (6.5)	NE (NE, NE)			

Page 69 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.649		
Male	34/161 (21.1)	NE (NE, NE)	16/180 (8.9)	NE (NE, NE)			
Female	8/83 (9.6)	NE (NE, NE)	4/72 (5.6)	NE (13.7, NE)			
Region					0.227		
North America and Europe	7/121 (5.8)	NE (NE, NE)	1/139 (0.7)	NE (NE, NE)			
Rest of world	35/123 (28.5)	NE (9.5, NE)	19/113 (16.8)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.872		
Yes	24/172 (14.0)	NE (NE, NE)	12/179 (6.7)	NE (NE, NE)			
No	18/72 (25.0)	NE (NE, NE)	8/73 (11.0)	NE (13.7, NE)			
Chemotherapy-free interval					0.039		
< 90 days	12/109 (11.0)	NE (NE, NE)	12/107 (11.2)	NE (13.7, NE)		0.817 (0.360, 1.854)	0.630
≥ 90 and < 180 days	13/73 (17.8)	NE (NE, NE)	4/85 (4.7)	NE (NE, NE)		0.239 (0.078, 0.735)	0.007
≥ 180 days	17/62 (27.4)	NE (9.5, NE)	4/60 (6.7)	NE (NE, NE)		0.178 (0.059, 0.532)	< 0.001

Page 71 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.642		
Yes	15/108 (13.9)	NE (9.5, NE)	9/113 (8.0)	NE (NE, NE)			
No	27/136 (19.9)	NE (NE, NE)	11/139 (7.9)	NE (NE, NE)			
Standard of care					0.744		
Topotecan/Amrubicin	39/199 (19.6)	NE (NE, NE)	19/208 (9.1)	NE (13.7, NE)			
Lurbinectedin	3/45 (6.7)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first alanine aminotransferase increased TEAE							
Overall	14/244 (5.7)	NE (NE, NE)	19/252 (7.5)	NE (NE, NE)		1.235 (0.617, 2.471)	0.554
Time to first aspartate aminotransferase increased TEAE							
Overall	8/244 (3.3)	NE (NE, NE)	19/252 (7.5)	NE (NE, NE)		2.121 (0.924, 4.869)	0.070
Time to first lymphocyte count decreased TEAE							
Overall	12/244 (4.9)	NE (NE, NE)	15/252 (6.0)	NE (NE, NE)		1.144 (0.534, 2.447)	0.730

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first platelet count decreased TEAE							
Overall	44/244 (18.0)	NE (NE, NE)	10/252 (4.0)	NE (NE, NE)		0.178 (0.089, 0.356)	< 0.001
Age					0.590		
< 65 years	20/109 (18.3)	NE (NE, NE)	6/128 (4.7)	NE (NE, NE)			
≥ 65 years	24/135 (17.8)	NE (NE, NE)	4/124 (3.2)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.911		
Male	33/161 (20.5)	NE (NE, NE)	8/180 (4.4)	NE (NE, NE)			
Female	11/83 (13.3)	NE (NE, NE)	2/72 (2.8)	NE (NE, NE)			
Region					0.591		
North America and Europe	9/121 (7.4)	NE (NE, NE)	3/139 (2.2)	NE (NE, NE)			
Rest of world	35/123 (28.5)	NE (NE, NE)	7/113 (6.2)	NE (NE, NE)			

Page 75 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.929		
Yes	27/172 (15.7)	NE (NE, NE)	6/179 (3.4)	NE (NE, NE)			
No	17/72 (23.6)	NE (NE, NE)	4/73 (5.5)	NE (NE, NE)			
Chemotherapy-free interval					0.606		
< 90 days	16/109 (14.7)	NE (NE, NE)	5/107 (4.7)	NE (NE, NE)			
≥ 90 and < 180 days	14/73 (19.2)	NE (NE, NE)	2/85 (2.4)	NE (NE, NE)			
≥ 180 days	14/62 (22.6)	NE (NE, NE)	3/60 (5.0)	NE (NE, NE)			

Page 76 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.266		
Yes	17/108 (15.7)	NE (NE, NE)	6/113 (5.3)	NE (NE, NE)			
No	27/136 (19.9)	NE (NE, NE)	4/139 (2.9)	NE (NE, NE)			
Standard of care					0.392		
Topotecan/Amrubicin	42/199 (21.1)	NE (NE, NE)	9/208 (4.3)	NE (NE, NE)			
Lurbinectedin	2/45 (4.4)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

Page 77 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first metabolism and nutrition disorders TEAE							
Overall	112/244 (45.9)	5.1 (3.6, NE)	146/252 (57.9)	2.8 (1.4, 4.6)		1.395 (1.089, 1.787)	0.008
Age					0.039		
< 65 years	55/109 (50.5)	4.9 (2.1, NE)	67/128 (52.3)	5.7 (1.4, NE)		1.067 (0.745, 1.527)	0.726
≥ 65 years	57/135 (42.2)	5.2 (2.9, NE)	79/124 (63.7)	1.9 (0.7, 3.7)		1.792 (1.273, 2.523)	< 0.001

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.393		
Male	76/161 (47.2)	5.1 (2.8, NE)	102/180 (56.7)	3.3 (1.8, 5.8)			
Female	36/83 (43.4)	5.1 (3.6, NE)	44/72 (61.1)	1.2 (0.5, 5.1)			
Region					0.594		
North America and Europe	58/121 (47.9)	4.5 (2.8, NE)	78/139 (56.1)	2.2 (1.1, 7.4)			
Rest of world	54/123 (43.9)	6.5 (2.9, NE)	68/113 (60.2)	2.8 (1.2, 4.6)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.739		
Yes	73/172 (42.4)	5.2 (4.1, NE)	102/179 (57.0)	3.5 (1.9, 5.8)			
No	39/72 (54.2)	4.9 (1.4, 6.5)	44/73 (60.3)	1.0 (0.4, 5.7)			
Chemotherapy-free interval					0.155		
< 90 days	48/109 (44.0)	4.5 (2.8, NE)	71/107 (66.4)	1.2 (0.5, 3.3)			
≥ 90 and < 180 days	35/73 (47.9)	6.2 (2.3, NE)	40/85 (47.1)	8.3 (2.7, NE)			
≥ 180 days	29/62 (46.8)	5.1 (2.8, NE)	35/60 (58.3)	3.0 (0.9, NE)			

Page 80 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.251		
Yes	53/108 (49.1)	4.3 (2.2, NE)	66/113 (58.4)	3.3 (1.2, 6.9)			
No	59/136 (43.4)	6.5 (3.6, NE)	80/139 (57.6)	2.2 (1.2, 5.1)			
Standard of care					0.778		
Topotecan/Amrubicin	94/199 (47.2)	4.5 (2.9, 7.4)	123/208 (59.1)	2.2 (1.2, 4.4)			
Lurbinectedin	18/45 (40.0)	NE (2.6, NE)	23/44 (52.3)	5.8 (1.2, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first decreased appetite TEAE							
Overall	54/244 (22.1)	NE (NE, NE)	89/252 (35.3)	NE (13.4, NE)		1.620 (1.154, 2.274)	0.005
Age					0.471		
< 65 years	23/109 (21.1)	NE (NE, NE)	39/128 (30.5)	NE (NE, NE)			
≥ 65 years	31/135 (23.0)	NE (NE, NE)	50/124 (40.3)	13.4 (4.4, NE)			

Page 82 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.123		
Male	41/161 (25.5)	NE (NE, NE)	62/180 (34.4)	NE (8.3, NE)			
Female	13/83 (15.7)	NE (NE, NE)	27/72 (37.5)	NE (3.7, NE)			
Region					0.485		
North America and Europe	21/121 (17.4)	NE (NE, NE)	44/139 (31.7)	13.4 (NE, NE)			
Rest of world	33/123 (26.8)	NE (NE, NE)	45/113 (39.8)	NE (5.7, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.740		
Yes	36/172 (20.9)	NE (NE, NE)	63/179 (35.2)	NE (13.4, NE)			
No	18/72 (25.0)	NE (NE, NE)	26/73 (35.6)	NE (5.7, NE)			
Chemotherapy-free interval					0.929		
< 90 days	24/109 (22.0)	NE (NE, NE)	38/107 (35.5)	NE (5.8, NE)			
≥ 90 and < 180 days	15/73 (20.5)	NE (NE, NE)	26/85 (30.6)	NE (13.4, NE)			
≥ 180 days	15/62 (24.2)	NE (NE, NE)	25/60 (41.7)	NE (3.3, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.820		
Yes	25/108 (23.1)	NE (NE, NE)	42/113 (37.2)	13.4 (6.7, NE)			
No	29/136 (21.3)	NE (NE, NE)	47/139 (33.8)	NE (NE, NE)			
Standard of care					0.254		
Topotecan/Amrubicin	42/199 (21.1)	NE (NE, NE)	75/208 (36.1)	13.4 (13.4, NE)			
Lurbinectedin	12/45 (26.7)	NE (NE, NE)	14/44 (31.8)	NE (5.8, NE)			

Page 85 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first hyponatraemia TEAE							
Overall	24/244 (9.8)	NE (NE, NE)	43/252 (17.1)	NE (NE, NE)		1.686 (1.021, 2.783)	0.039
Age					0.912		
< 65 years	12/109 (11.0)	NE (NE, NE)	23/128 (18.0)	NE (NE, NE)			
≥ 65 years	12/135 (8.9)	NE (NE, NE)	20/124 (16.1)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.610		
Male	17/161 (10.6)	NE (NE, NE)	34/180 (18.9)	NE (NE, NE)			
Female	7/83 (8.4)	NE (NE, NE)	9/72 (12.5)	NE (NE, NE)			
Region					0.121		
North America and Europe	16/121 (13.2)	NE (NE, NE)	23/139 (16.5)	NE (NE, NE)			
Rest of world	8/123 (6.5)	NE (NE, NE)	20/113 (17.7)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.707		
Yes	18/172 (10.5)	NE (NE, NE)	31/179 (17.3)	NE (NE, NE)			
No	6/72 (8.3)	NE (NE, NE)	12/73 (16.4)	NE (NE, NE)			
Chemotherapy-free interval					0.185		
< 90 days	10/109 (9.2)	NE (NE, NE)	26/107 (24.3)	NE (NE, NE)			
≥ 90 and < 180 days	7/73 (9.6)	NE (NE, NE)	7/85 (8.2)	NE (NE, NE)			
≥ 180 days	7/62 (11.3)	NE (NE, NE)	10/60 (16.7)	NE (NE, NE)			

Page 88 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.873		
Yes	12/108 (11.1)	NE (NE, NE)	23/113 (20.4)	NE (NE, NE)			
No	12/136 (8.8)	NE (NE, NE)	20/139 (14.4)	NE (NE, NE)			
Standard of care					0.984		
Topotecan/Amrubicin	24/199 (12.1)	NE (NE, NE)	36/208 (17.3)	NE (NE, NE)			
Lurbinectedin	0/45 (0.0)	NE (NE, NE)	7/44 (15.9)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first hypokalaemia TEAE							
Overall	19/244 (7.8)	NE (NE, NE)	24/252 (9.5)	NE (NE, NE)		1.173 (0.641, 2.146)	0.605
Time to first hypoalbuminaemia TEAE							
Overall	14/244 (5.7)	NE (NE, NE)	22/252 (8.7)	NE (NE, NE)		1.457 (0.743, 2.857)	0.270
Time to first hypomagnesaemia TEAE							
Overall	8/244 (3.3)	NE (NE, NE)	17/252 (6.7)	NE (NE, NE)		1.895 (0.814, 4.413)	0.132

Page 90 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first hyperglycaemia TEAE							
Overall	4/244 (1.6)	NE (NE, NE)	12/252 (4.8)	NE (NE, NE)		2.556 (0.819, 7.980)	0.095
Time to first musculoskeletal and connective tissue disorders TEAE							
Overall	61/244 (25.0)	NE (9.0, NE)	74/252 (29.4)	14.6 (14.1, NE)		1.045 (0.741, 1.475)	0.807
Time to first back pain TEAE							
Overall	17/244 (7.0)	NE (NE, NE)	22/252 (8.7)	NE (NE, NE)		1.111 (0.588, 2.102)	0.746

Page 91 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first arthralgia TEAE							
Overall	17/244 (7.0)	NE (NE, NE)	19/252 (7.5)	NE (NE, NE)		0.856 (0.440, 1.665)	0.648
Time to first myalgia TEAE							
Overall	6/244 (2.5)	NE (NE, NE)	16/252 (6.3)	NE (NE, NE)		2.547 (0.994, 6.523)	0.043
Age					0.173		
< 65 years	1/109 (0.9)	NE (NE, NE)	9/128 (7.0)	NE (NE, NE)			
≥ 65 years	5/135 (3.7)	NE (NE, NE)	7/124 (5.6)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.605		
Male	4/161 (2.5)	NE (NE, NE)	13/180 (7.2)	NE (NE, NE)			
Female	2/83 (2.4)	NE (NE, NE)	3/72 (4.2)	NE (NE, NE)			
Region					0.613		
North America and Europe	3/121 (2.5)	NE (NE, NE)	7/139 (5.0)	NE (NE, NE)			
Rest of world	3/123 (2.4)	NE (NE, NE)	9/113 (8.0)	NE (NE, NE)			

Page 93 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.325		
Yes	5/172 (2.9)	NE (NE, NE)	10/179 (5.6)	NE (NE, NE)			
No	1/72 (1.4)	NE (NE, NE)	6/73 (8.2)	NE (NE, NE)			
Chemotherapy-free interval					0.945		
< 90 days	2/109 (1.8)	NE (NE, NE)	6/107 (5.6)	NE (NE, NE)			
≥ 90 and < 180 days	2/73 (2.7)	NE (NE, NE)	6/85 (7.1)	NE (NE, NE)			
≥ 180 days	2/62 (3.2)	NE (NE, NE)	4/60 (6.7)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.296		
Yes	1/108 (0.9)	NE (NE, NE)	7/113 (6.2)	NE (NE, NE)			
No	5/136 (3.7)	NE (NE, NE)	9/139 (6.5)	NE (NE, NE)			
Standard of care					0.934		
Topotecan/Amrubicin	3/199 (1.5)	NE (NE, NE)	8/208 (3.8)	NE (NE, NE)			
Lurbinectedin	3/45 (6.7)	NE (NE, NE)	8/44 (18.2)	NE (NE, NE)			

Page 95 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first pain in extremity TEAE							
Overall	10/244 (4.1)	NE (NE, NE)	11/252 (4.4)	NE (15.7, NE)		0.852 (0.353, 2.060)	0.723
Time to first muscular weakness TEAE							
Overall	10/244 (4.1)	NE (NE, NE)	2/252 (0.8)	NE (NE, NE)		0.145 (0.032, 0.669)	0.004
Age					0.646		
< 65 years	3/109 (2.8)	NE (NE, NE)	1/128 (0.8)	NE (NE, NE)			
≥ 65 years	7/135 (5.2)	NE (NE, NE)	1/124 (0.8)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.764		
Male	6/161 (3.7)	NE (NE, NE)	1/180 (0.6)	NE (NE, NE)			
Female	4/83 (4.8)	NE (NE, NE)	1/72 (1.4)	NE (NE, NE)			
Region					0.324		
North America and Europe	8/121 (6.6)	NE (NE, NE)	1/139 (0.7)	NE (NE, NE)			
Rest of world	2/123 (1.6)	NE (NE, NE)	1/113 (0.9)	NE (NE, NE)			

Page 97 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.354		
Yes	8/172 (4.7)	NE (NE, NE)	1/179 (0.6)	NE (NE, NE)			
No	2/72 (2.8)	NE (NE, NE)	1/73 (1.4)	NE (NE, NE)			
Chemotherapy-free interval					1.000		
< 90 days	3/109 (2.8)	NE (8.7, NE)	0/107 (0.0)	NE (NE, NE)			
≥ 90 and < 180 days	4/73 (5.5)	NE (NE, NE)	2/85 (2.4)	NE (NE, NE)			
≥ 180 days	3/62 (4.8)	NE (NE, NE)	0/60 (0.0)	NE (NE, NE)			

Page 98 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.742		
Yes	6/108 (5.6)	NE (NE, NE)	1/113 (0.9)	NE (NE, NE)			
No	4/136 (2.9)	NE (NE, NE)	1/139 (0.7)	NE (NE, NE)			
Standard of care					0.917		
Topotecan/Amrubicin	5/199 (2.5)	NE (NE, NE)	1/208 (0.5)	NE (NE, NE)			
Lurbinectedin	5/45 (11.1)	NE (8.7, NE)	1/44 (2.3)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first nervous system disorders TEAE							
Overall	73/244 (29.9)	NE (7.4, NE)	134/252 (53.2)	3.3 (1.4, 5.9)		2.214 (1.664, 2.946)	< 0.001
Age					0.379		
< 65 years	35/109 (32.1)	8.5 (6.0, NE)	63/128 (49.2)	5.1 (1.5, NE)			
≥ 65 years	38/135 (28.1)	NE (7.4, NE)	71/124 (57.3)	2.0 (1.0, 4.9)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.197		
Male	44/161 (27.3)	NE (7.4, NE)	84/180 (46.7)	5.4 (2.7, NE)			
Female	29/83 (34.9)	8.5 (5.5, NE)	50/72 (69.4)	0.6 (0.3, 1.4)			
Region					0.902		
North America and Europe	43/121 (35.5)	7.4 (4.9, NE)	82/139 (59.0)	1.8 (1.0, 3.8)			
Rest of world	30/123 (24.4)	NE (NE, NE)	52/113 (46.0)	6.4 (1.7, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.636		
Yes	54/172 (31.4)	8.5 (6.2, NE)	101/179 (56.4)	1.7 (1.0, 5.4)			
No	19/72 (26.4)	NE (NE, NE)	33/73 (45.2)	5.1 (3.3, NE)			
Chemotherapy-free interval					0.225		
< 90 days	30/109 (27.5)	6.8 (6.0, NE)	53/107 (49.5)	2.8 (1.4, NE)			
≥ 90 and < 180 days	21/73 (28.8)	NE (7.4, NE)	50/85 (58.8)	2.0 (0.6, 5.9)			
≥ 180 days	22/62 (35.5)	NE (4.9, NE)	31/60 (51.7)	5.1 (1.4, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.136		
Yes	39/108 (36.1)	6.3 (4.9, NE)	61/113 (54.0)	3.6 (1.4, NE)			
No	34/136 (25.0)	NE (8.5, NE)	73/139 (52.5)	2.3 (1.0, NE)			
Standard of care					0.543		
Topotecan/Amrubicin	57/199 (28.6)	NE (6.8, NE)	112/208 (53.8)	3.3 (1.4, 5.9)			
Lurbinectedin	16/45 (35.6)	NE (4.3, NE)	22/44 (50.0)	2.5 (0.4, NE)			

Page 103 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first dysgeusia TEAE							
Overall	4/244 (1.6)	NE (NE, NE)	61/252 (24.2)	NE (NE, NE)		16.195 (5.888, 44.549)	< 0.001
Age					0.460		
< 65 years	1/109 (0.9)	NE (NE, NE)	30/128 (23.4)	NE (NE, NE)			
≥ 65 years	3/135 (2.2)	NE (NE, NE)	31/124 (25.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.425		
Male	1/161 (0.6)	NE (NE, NE)	34/180 (18.9)	NE (NE, NE)			
Female	3/83 (3.6)	NE (NE, NE)	27/72 (37.5)	NE (6.2, NE)			
Region					0.739		
North America and Europe	2/121 (1.7)	NE (NE, NE)	38/139 (27.3)	NE (NE, NE)			
Rest of world	2/123 (1.6)	NE (NE, NE)	23/113 (20.4)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.849		
Yes	3/172 (1.7)	NE (NE, NE)	48/179 (26.8)	NE (NE, NE)			
No	1/72 (1.4)	NE (NE, NE)	13/73 (17.8)	NE (NE, NE)			
Chemotherapy-free interval					0.974		
< 90 days	2/109 (1.8)	NE (NE, NE)	24/107 (22.4)	NE (NE, NE)			
≥ 90 and < 180 days	2/73 (2.7)	NE (NE, NE)	22/85 (25.9)	NE (NE, NE)			
≥ 180 days	0/62 (0.0)	NE (NE, NE)	15/60 (25.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.196		
Yes	3/108 (2.8)	NE (NE, NE)	26/113 (23.0)	NE (NE, NE)			
No	1/136 (0.7)	NE (NE, NE)	35/139 (25.2)	NE (NE, NE)			
Standard of care					0.045		
Topotecan/Amrubicin	2/199 (1.0)	NE (NE, NE)	55/208 (26.4)	NE (NE, NE)		29.242 (7.131, 119.910)	< 0.001
Lurbinectedin	2/45 (4.4)	NE (NE, NE)	6/44 (13.6)	NE (NE, NE)		3.030 (0.606, 15.165)	0.156

Page 107 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first headache TEAE							
Overall	21/244 (8.6)	NE (NE, NE)	38/252 (15.1)	NE (NE, NE)		1.724 (1.010, 2.944)	0.044
Age					0.633		
< 65 years	9/109 (8.3)	NE (10.0, NE)	16/128 (12.5)	NE (NE, NE)			
≥ 65 years	12/135 (8.9)	NE (NE, NE)	22/124 (17.7)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.311		
Male	12/161 (7.5)	NE (NE, NE)	19/180 (10.6)	NE (NE, NE)			
Female	9/83 (10.8)	NE (NE, NE)	19/72 (26.4)	NE (NE, NE)			
Region					0.182		
North America and Europe	13/121 (10.7)	NE (10.0, NE)	19/139 (13.7)	NE (NE, NE)			
Rest of world	8/123 (6.5)	NE (NE, NE)	19/113 (16.8)	NE (NE, NE)			

Page 109 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.186		
Yes	17/172 (9.9)	NE (NE, NE)	25/179 (14.0)	NE (NE, NE)			
No	4/72 (5.6)	NE (NE, NE)	13/73 (17.8)	NE (NE, NE)			
Chemotherapy-free interval					0.194		
< 90 days	10/109 (9.2)	10.0 (8.3, NE)	10/107 (9.3)	NE (NE, NE)			
≥ 90 and < 180 days	5/73 (6.8)	NE (NE, NE)	17/85 (20.0)	NE (NE, NE)			
≥ 180 days	6/62 (9.7)	NE (NE, NE)	11/60 (18.3)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.619		
Yes	9/108 (8.3)	NE (10.0, NE)	15/113 (13.3)	NE (NE, NE)			
No	12/136 (8.8)	NE (NE, NE)	23/139 (16.5)	NE (NE, NE)			
Standard of care					0.986		
Topotecan/Amrubicin	16/199 (8.0)	NE (NE, NE)	30/208 (14.4)	NE (NE, NE)			
Lurbinectedin	5/45 (11.1)	NE (8.3, NE)	8/44 (18.2)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first dizziness TEAE							
Overall	25/244 (10.2)	NE (NE, NE)	24/252 (9.5)	NE (NE, NE)		0.872 (0.497, 1.530)	0.635
Time to first immune effector cell-associated neurotoxicity syndrome TEAE							
Overall	2/244 (0.8)	NE (NE, NE)	15/252 (6.0)	NE (NE, NE)		7.029 (1.603, 30.816)	0.003
Age					0.991		
< 65 years	0/109 (0.0)	NE (NE, NE)	4/128 (3.1)	NE (NE, NE)			
≥ 65 years	2/135 (1.5)	NE (NE, NE)	11/124 (8.9)	NE (NE, NE)			

Page 112 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.937		
Male	1/161 (0.6)	NE (NE, NE)	8/180 (4.4)	NE (NE, NE)			
Female	1/83 (1.2)	NE (NE, NE)	7/72 (9.7)	NE (NE, NE)			
Region					0.991		
North America and Europe	2/121 (1.7)	NE (NE, NE)	12/139 (8.6)	NE (NE, NE)			
Rest of world	0/123 (0.0)	NE (NE, NE)	3/113 (2.7)	NE (NE, NE)			

Page 113 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.992		
Yes	2/172 (1.2)	NE (NE, NE)	13/179 (7.3)	NE (NE, NE)			
No	0/72 (0.0)	NE (NE, NE)	2/73 (2.7)	NE (NE, NE)			
Chemotherapy-free interval					1.000		
< 90 days	1/109 (0.9)	NE (8.8, NE)	7/107 (6.5)	NE (NE, NE)			
≥ 90 and < 180 days	1/73 (1.4)	NE (NE, NE)	8/85 (9.4)	NE (NE, NE)			
≥ 180 days	0/62 (0.0)	NE (NE, NE)	0/60 (0.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.993		
Yes	2/108 (1.9)	NE (NE, NE)	9/113 (8.0)	NE (NE, NE)			
No	0/136 (0.0)	NE (NE, NE)	6/139 (4.3)	NE (NE, NE)			
Standard of care					0.991		
Topotecan/Amrubicin	0/199 (0.0)	NE (NE, NE)	11/208 (5.3)	NE (NE, NE)			
Lurbinectedin	2/45 (4.4)	NE (8.8, NE)	4/44 (9.1)	NE (NE, NE)			

Page 115 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first psychiatric disorders TEAE							
Overall	32/244 (13.1)	NE (NE, NE)	30/252 (11.9)	NE (NE, NE)		0.826 (0.501, 1.361)	0.452
Time to first insomnia TEAE							
Overall	21/244 (8.6)	NE (NE, NE)	18/252 (7.1)	NE (NE, NE)		0.756 (0.403, 1.421)	0.385
Time to first renal and urinary disorders TEAE							
Overall	13/244 (5.3)	NE (NE, NE)	31/252 (12.3)	NE (NE, NE)		2.143 (1.118, 4.105)	0.019

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.724		
< 65 years	4/109 (3.7)	NE (NE, NE)	13/128 (10.2)	NE (NE, NE)			
≥ 65 years	9/135 (6.7)	NE (NE, NE)	18/124 (14.5)	NE (NE, NE)			
Sex					0.557		
Male	6/161 (3.7)	NE (NE, NE)	19/180 (10.6)	NE (NE, NE)			
Female	7/83 (8.4)	NE (NE, NE)	12/72 (16.7)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.717		
North America and Europe	9/121 (7.4)	NE (NE, NE)	21/139 (15.1)	NE (NE, NE)			
Rest of world	4/123 (3.3)	NE (NE, NE)	10/113 (8.8)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					0.324		
Yes	7/172 (4.1)	NE (NE, NE)	22/179 (12.3)	NE (NE, NE)			
No	6/72 (8.3)	NE (NE, NE)	9/73 (12.3)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					0.665		
< 90 days	6/109 (5.5)	NE (8.3, NE)	14/107 (13.1)	NE (NE, NE)			
≥ 90 and < 180 days	3/73 (4.1)	NE (NE, NE)	11/85 (12.9)	NE (NE, NE)			
≥ 180 days	4/62 (6.5)	NE (NE, NE)	6/60 (10.0)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.612		
Yes	5/108 (4.6)	NE (NE, NE)	15/113 (13.3)	NE (NE, NE)			
No	8/136 (5.9)	NE (NE, NE)	16/139 (11.5)	NE (NE, NE)			

Page 119 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.913		
Topotecan/Amrubicin	8/199 (4.0)	NE (NE, NE)	20/208 (9.6)	NE (NE, NE)			
Lurbinectedin	5/45 (11.1)	NE (8.3, NE)	11/44 (25.0)	NE (NE, NE)			
Time to first respiratory, thoracic and mediastinal disorders TEAE							
Overall	87/244 (35.7)	NE (7.5, NE)	91/252 (36.1)	12.9 (11.1, NE)		0.877 (0.651, 1.181)	0.380
Time to first cough TEAE							
Overall	34/244 (13.9)	NE (NE, NE)	31/252 (12.3)	NE (NE, NE)		0.752 (0.460, 1.231)	0.255

Page 120 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first dyspnoea TEAE							
Overall	28/244 (11.5)	NE (NE, NE)	18/252 (7.1)	NE (NE, NE)		0.574 (0.317, 1.041)	0.064
Time to first productive cough TEAE							
Overall	15/244 (6.1)	NE (NE, NE)	11/252 (4.4)	NE (NE, NE)		0.524 (0.236, 1.161)	0.106
Time to first skin and subcutaneous tissue disorders TEAE							
Overall	52/244 (21.3)	NE (NE, NE)	56/252 (22.2)	NE (NE, NE)		0.914 (0.624, 1.338)	0.638

Page 121 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first pruritus TEAE							
Overall	9/244 (3.7)	NE (NE, NE)	22/252 (8.7)	NE (NE, NE)		2.138 (0.980, 4.667)	0.051
Time to first rash TEAE							
Overall	12/244 (4.9)	NE (NE, NE)	21/252 (8.3)	NE (NE, NE)		1.553 (0.761, 3.169)	0.224
Time to first alopecia TEAE							
Overall	19/244 (7.8)	NE (NE, NE)	8/252 (3.2)	NE (NE, NE)		0.336 (0.146, 0.774)	0.007

Page 122 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.069		
< 65 years	4/109 (3.7)	NE (NE, NE)	5/128 (3.9)	NE (NE, NE)			
≥ 65 years	15/135 (11.1)	NE (NE, NE)	3/124 (2.4)	NE (NE, NE)			
Sex					0.055		
Male	14/161 (8.7)	NE (NE, NE)	3/180 (1.7)	NE (NE, NE)			
Female	5/83 (6.0)	NE (NE, NE)	5/72 (6.9)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.923		
North America and Europe	9/121 (7.4)	NE (NE, NE)	4/139 (2.9)	NE (NE, NE)			
Rest of world	10/123 (8.1)	NE (NE, NE)	4/113 (3.5)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					0.311		
Yes	15/172 (8.7)	NE (NE, NE)	5/179 (2.8)	NE (NE, NE)			
No	4/72 (5.6)	NE (NE, NE)	3/73 (4.1)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					0.419		
< 90 days	5/109 (4.6)	NE (NE, NE)	4/107 (3.7)	NE (NE, NE)			
≥ 90 and < 180 days	8/73 (11.0)	NE (NE, NE)	2/85 (2.4)	NE (NE, NE)			
≥ 180 days	6/62 (9.7)	NE (NE, NE)	2/60 (3.3)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.403		
Yes	8/108 (7.4)	NE (NE, NE)	5/113 (4.4)	NE (NE, NE)			
No	11/136 (8.1)	NE (NE, NE)	3/139 (2.2)	NE (NE, NE)			

Page 125 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					1.000		
Topotecan/Amrubicin	19/199 (9.5)	NE (NE, NE)	8/208 (3.8)	NE (NE, NE)			
Lurbinectedin	0/45 (0.0)	NE (NE, NE)	0/44 (0.0)	NE (NE, NE)			
Time to first vascular disorders TEAE							
Overall	27/244 (11.1)	NE (NE, NE)	34/252 (13.5)	NE (NE, NE)		1.165 (0.700, 1.938)	0.567
Time to first hypertension TEAE							
Overall	4/244 (1.6)	NE (NE, NE)	14/252 (5.6)	NE (NE, NE)		3.262 (1.070, 9.946)	0.029

Page 126 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.422		
< 65 years	3/109 (2.8)	NE (NE, NE)	8/128 (6.3)	NE (NE, NE)			
≥ 65 years	1/135 (0.7)	NE (NE, NE)	6/124 (4.8)	NE (NE, NE)			
Sex					0.948		
Male	2/161 (1.2)	NE (NE, NE)	8/180 (4.4)	NE (NE, NE)			
Female	2/83 (2.4)	NE (NE, NE)	6/72 (8.3)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.769		
North America and Europe	3/121 (2.5)	NE (NE, NE)	10/139 (7.2)	NE (NE, NE)			
Rest of world	1/123 (0.8)	NE (NE, NE)	4/113 (3.5)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					0.657		
Yes	2/172 (1.2)	NE (NE, NE)	9/179 (5.0)	NE (NE, NE)			
No	2/72 (2.8)	NE (NE, NE)	5/73 (6.8)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Chemotherapy-free interval					0.893		
< 90 days	3/109 (2.8)	NE (NE, NE)	7/107 (6.5)	NE (NE, NE)			
≥ 90 and < 180 days	1/73 (1.4)	NE (NE, NE)	5/85 (5.9)	NE (NE, NE)			
≥ 180 days	0/62 (0.0)	NE (NE, NE)	2/60 (3.3)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.357		
Yes	3/108 (2.8)	NE (NE, NE)	7/113 (6.2)	NE (NE, NE)			
No	1/136 (0.7)	NE (NE, NE)	7/139 (5.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.2. Summary of Time to First Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.644		
Topotecan/Amrubicin	3/199 (1.5)	NE (NE, NE)	12/208 (5.8)	NE (NE, NE)			
Lurbinectedin	1/45 (2.2)	NE (NE, NE)	2/44 (4.5)	NE (NE, NE)			
Time to first hypotension TEAE							
Overall	6/244 (2.5)	NE (NE, NE)	11/252 (4.4)	NE (NE, NE)		1.621 (0.594, 4.422)	0.341

Page 130 of 130

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-001-002-ae-teae-socpt.rtf (Date Generated: 21DEC25:20:37:52) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 blood and lymphatic system disorders TEAE							
Overall	117/244 (48.0)	4.8 (2.9, 8.3)	40/252 (15.9)	NE (NE, NE)		0.223 (0.154, 0.322)	< 0.001
Age					0.151		
< 65 years	45/109 (41.3)	8.3 (3.6, NE)	21/128 (16.4)	NE (NE, NE)			
≥ 65 years	72/135 (53.3)	3.2 (1.9, 6.5)	19/124 (15.3)	NE (NE, NE)			

Page 1 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.232		
Male	77/161 (47.8)	4.2 (2.8, NE)	24/180 (13.3)	NE (NE, NE)			
Female	40/83 (48.2)	4.8 (1.8, NE)	16/72 (22.2)	NE (NE, NE)			
Region					0.299		
North America and Europe	53/121 (43.8)	6.8 (3.2, NE)	16/139 (11.5)	NE (NE, NE)			
Rest of world	64/123 (52.0)	3.5 (1.9, 10.2)	24/113 (21.2)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.846		
Yes	80/172 (46.5)	4.8 (2.8, NE)	29/179 (16.2)	NE (NE, NE)			
No	37/72 (51.4)	4.1 (1.9, NE)	11/73 (15.1)	NE (NE, NE)			
Chemotherapy-free interval					0.195		
< 90 days	47/109 (43.1)	4.8 (2.1, NE)	21/107 (19.6)	NE (10.4, NE)			
≥ 90 and < 180 days	37/73 (50.7)	4.1 (2.0, NE)	9/85 (10.6)	NE (NE, NE)			
≥ 180 days	33/62 (53.2)	4.2 (1.7, NE)	10/60 (16.7)	NE (NE, NE)			

Page 3 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.319		
Yes	52/108 (48.1)	4.8 (1.8, NE)	16/113 (14.2)	NE (NE, NE)			
No	65/136 (47.8)	4.2 (2.8, NE)	24/139 (17.3)	NE (NE, NE)			
Standard of care					0.007		
Topotecan/Amrubicin	101/199 (50.8)	3.5 (2.0, 7.9)	29/208 (13.9)	NE (NE, NE)		0.186 (0.123, 0.283)	< 0.001
Lurbinectedin	16/45 (35.6)	8.3 (4.8, NE)	11/44 (25.0)	NE (6.8, NE)		0.490 (0.216, 1.112)	0.082

Page 4 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 neutropenia TEAE							
Overall	57/244 (23.4)	NE (10.2, NE)	15/252 (6.0)	NE (NE, NE)		0.206 (0.116, 0.365)	< 0.001
Age					0.202		
< 65 years	22/109 (20.2)	NE (NE, NE)	9/128 (7.0)	NE (NE, NE)			
≥ 65 years	35/135 (25.9)	NE (10.2, NE)	6/124 (4.8)	NE (NE, NE)			

Page 5 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.303		
Male	36/161 (22.4)	NE (10.2, NE)	8/180 (4.4)	NE (NE, NE)			
Female	21/83 (25.3)	NE (8.3, NE)	7/72 (9.7)	NE (NE, NE)			
Region					0.039		
North America and Europe	20/121 (16.5)	NE (NE, NE)	1/139 (0.7)	NE (NE, NE)		0.035 (0.005, 0.261)	< 0.001
Rest of world	37/123 (30.1)	NE (8.3, NE)	14/113 (12.4)	NE (NE, NE)		0.330 (0.177, 0.613)	< 0.001

Page 6 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.710		
Yes	42/172 (24.4)	NE (10.2, NE)	12/179 (6.7)	NE (NE, NE)			
No	15/72 (20.8)	NE (NE, NE)	3/73 (4.1)	NE (NE, NE)			
Chemotherapy-free interval					0.225		
< 90 days	22/109 (20.2)	NE (NE, NE)	6/107 (5.6)	NE (NE, NE)			
≥ 90 and < 180 days	18/73 (24.7)	NE (8.3, NE)	2/85 (2.4)	NE (NE, NE)			
≥ 180 days	17/62 (27.4)	10.2 (6.8, NE)	7/60 (11.7)	NE (NE, NE)			

Page 7 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.227		
Yes	27/108 (25.0)	NE (8.3, NE)	5/113 (4.4)	NE (NE, NE)			
No	30/136 (22.1)	NE (10.2, NE)	10/139 (7.2)	NE (NE, NE)			
Standard of care					0.045		
Topotecan/Amrubicin	46/199 (23.1)	NE (NE, NE)	9/208 (4.3)	NE (NE, NE)		0.153 (0.075, 0.313)	< 0.001
Lurbinectedin	11/45 (24.4)	10.2 (8.3, NE)	6/44 (13.6)	NE (NE, NE)		0.471 (0.169, 1.314)	0.140

Page 8 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 anaemia TEAE							
Overall	70/244 (28.7)	NE (NE, NE)	11/252 (4.4)	NE (NE, NE)		0.113 (0.060, 0.214)	< 0.001
Age					0.111		
< 65 years	25/109 (22.9)	NE (NE, NE)	7/128 (5.5)	NE (NE, NE)			
≥ 65 years	45/135 (33.3)	NE (4.6, NE)	4/124 (3.2)	NE (NE, NE)			

Page 9 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.730		
Male	46/161 (28.6)	NE (7.9, NE)	7/180 (3.9)	NE (NE, NE)			
Female	24/83 (28.9)	NE (6.5, NE)	4/72 (5.6)	NE (NE, NE)			
Region					0.097		
North America and Europe	39/121 (32.2)	NE (6.5, NE)	4/139 (2.9)	NE (NE, NE)			
Rest of world	31/123 (25.2)	NE (NE, NE)	7/113 (6.2)	NE (NE, NE)			

Page 10 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.996		
Yes	44/172 (25.6)	NE (NE, NE)	7/179 (3.9)	NE (NE, NE)			
No	26/72 (36.1)	NE (4.2, NE)	4/73 (5.5)	NE (NE, NE)			
Chemotherapy-free interval					0.256		
< 90 days	27/109 (24.8)	NE (NE, NE)	7/107 (6.5)	NE (NE, NE)			
≥ 90 and < 180 days	22/73 (30.1)	NE (7.9, NE)	3/85 (3.5)	NE (NE, NE)			
≥ 180 days	21/62 (33.9)	NE (4.6, NE)	1/60 (1.7)	NE (NE, NE)			

Page 11 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.735		
Yes	27/108 (25.0)	NE (7.9, NE)	4/113 (3.5)	NE (NE, NE)			
No	43/136 (31.6)	NE (6.5, NE)	7/139 (5.0)	NE (NE, NE)			
Standard of care					0.014		
Topotecan/Amrubicin	62/199 (31.2)	NE (7.9, NE)	7/208 (3.4)	NE (NE, NE)		0.078 (0.036, 0.171)	< 0.001
Lurbinectedin	8/45 (17.8)	NE (NE, NE)	4/44 (9.1)	NE (NE, NE)		0.441 (0.131, 1.481)	0.175

Page 12 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 lymphopenia TEAE							
Overall	3/244 (1.2)	NE (NE, NE)	10/252 (4.0)	NE (NE, NE)		3.110 (0.854, 11.318)	0.070
Time to first grade ≥ 3 febrile neutropenia TEAE							
Overall	28/244 (11.5)	NE (NE, NE)	5/252 (2.0)	NE (NE, NE)		0.131 (0.050, 0.346)	< 0.001
Age					0.493		
< 65 years	9/109 (8.3)	NE (NE, NE)	1/128 (0.8)	NE (NE, NE)			
≥ 65 years	19/135 (14.1)	NE (NE, NE)	4/124 (3.2)	NE (NE, NE)			

Page 13 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.792		
Male	18/161 (11.2)	NE (NE, NE)	3/180 (1.7)	NE (NE, NE)			
Female	10/83 (12.0)	NE (NE, NE)	2/72 (2.8)	NE (NE, NE)			
Region					0.368		
North America and Europe	16/121 (13.2)	NE (NE, NE)	2/139 (1.4)	NE (NE, NE)			
Rest of world	12/123 (9.8)	NE (NE, NE)	3/113 (2.7)	NE (NE, NE)			

Page 14 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.787		
Yes	20/172 (11.6)	NE (NE, NE)	4/179 (2.2)	NE (NE, NE)			
No	8/72 (11.1)	NE (NE, NE)	1/73 (1.4)	NE (NE, NE)			
Chemotherapy-free interval					0.643		
< 90 days	11/109 (10.1)	NE (NE, NE)	3/107 (2.8)	NE (NE, NE)			
≥ 90 and < 180 days	10/73 (13.7)	NE (NE, NE)	1/85 (1.2)	NE (NE, NE)			
≥ 180 days	7/62 (11.3)	NE (NE, NE)	1/60 (1.7)	NE (NE, NE)			

Page 15 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.804		
Yes	12/108 (11.1)	NE (NE, NE)	2/113 (1.8)	NE (NE, NE)			
No	16/136 (11.8)	NE (NE, NE)	3/139 (2.2)	NE (NE, NE)			
Standard of care					0.686		
Topotecan/Amrubicin	24/199 (12.1)	NE (NE, NE)	4/208 (1.9)	NE (NE, NE)			
Lurbinectedin	4/45 (8.9)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

Page 16 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 leukopenia TEAE							
Overall	34/244 (13.9)	NE (NE, NE)	4/252 (1.6)	NE (NE, NE)		0.103 (0.036, 0.289)	< 0.001
Age					0.883		
< 65 years	14/109 (12.8)	NE (NE, NE)	2/128 (1.6)	NE (NE, NE)			
≥ 65 years	20/135 (14.8)	NE (NE, NE)	2/124 (1.6)	NE (NE, NE)			

Page 17 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.805		
Male	22/161 (13.7)	NE (NE, NE)	3/180 (1.7)	NE (NE, NE)			
Female	12/83 (14.5)	NE (NE, NE)	1/72 (1.4)	NE (NE, NE)			
Region					0.984		
North America and Europe	12/121 (9.9)	NE (NE, NE)	0/139 (0.0)	NE (NE, NE)			
Rest of world	22/123 (17.9)	NE (NE, NE)	4/113 (3.5)	NE (NE, NE)			

Page 18 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.898		
Yes	24/172 (14.0)	NE (NE, NE)	3/179 (1.7)	NE (NE, NE)			
No	10/72 (13.9)	NE (NE, NE)	1/73 (1.4)	NE (NE, NE)			
Chemotherapy-free interval					0.881		
< 90 days	14/109 (12.8)	NE (NE, NE)	3/107 (2.8)	NE (NE, NE)			
≥ 90 and < 180 days	11/73 (15.1)	NE (NE, NE)	0/85 (0.0)	NE (NE, NE)			
≥ 180 days	9/62 (14.5)	NE (NE, NE)	1/60 (1.7)	NE (NE, NE)			

Page 19 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.984		
Yes	14/108 (13.0)	NE (NE, NE)	0/113 (0.0)	NE (NE, NE)			
No	20/136 (14.7)	NE (NE, NE)	4/139 (2.9)	NE (NE, NE)			
Standard of care					0.984		
Topotecan/Amrubicin	34/199 (17.1)	NE (NE, NE)	3/208 (1.4)	NE (NE, NE)			
Lurbinectedin	0/45 (0.0)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

Page 20 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 thrombocytopenia TEAE							
Overall	28/244 (11.5)	NE (NE, NE)	2/252 (0.8)	NE (NE, NE)		0.058 (0.014, 0.245)	< 0.001
Age					0.987		
< 65 years	9/109 (8.3)	NE (NE, NE)	0/128 (0.0)	NE (NE, NE)			
≥ 65 years	19/135 (14.1)	NE (NE, NE)	2/124 (1.6)	NE (NE, NE)			

Page 21 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.990		
Male	16/161 (9.9)	NE (NE, NE)	2/180 (1.1)	NE (NE, NE)			
Female	12/83 (14.5)	NE (NE, NE)	0/72 (0.0)	NE (NE, NE)			
Region					0.964		
North America and Europe	13/121 (10.7)	NE (NE, NE)	1/139 (0.7)	NE (NE, NE)			
Rest of world	15/123 (12.2)	NE (NE, NE)	1/113 (0.9)	NE (NE, NE)			

Page 22 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.633		
Yes	18/172 (10.5)	NE (NE, NE)	1/179 (0.6)	NE (NE, NE)			
No	10/72 (13.9)	NE (NE, NE)	1/73 (1.4)	NE (NE, NE)			
Chemotherapy-free interval					0.903		
< 90 days	12/109 (11.0)	NE (NE, NE)	1/107 (0.9)	NE (NE, NE)			
≥ 90 and < 180 days	10/73 (13.7)	NE (NE, NE)	0/85 (0.0)	NE (NE, NE)			
≥ 180 days	6/62 (9.7)	NE (NE, NE)	1/60 (1.7)	NE (NE, NE)			

Page 23 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.987		
Yes	14/108 (13.0)	NE (NE, NE)	0/113 (0.0)	NE (NE, NE)			
No	14/136 (10.3)	NE (NE, NE)	2/139 (1.4)	NE (NE, NE)			
Standard of care					0.277		
Topotecan/Amrubicin	23/199 (11.6)	NE (NE, NE)	1/208 (0.5)	NE (NE, NE)			
Lurbinectedin	5/45 (11.1)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

Page 24 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 cardiac disorders TEAE							
Overall	8/244 (3.3)	NE (NE, NE)	11/252 (4.4)	NE (NE, NE)		1.196 (0.479, 2.984)	0.701
Time to first grade ≥ 3 general disorders and administration site conditions TEAE							
Overall	31/244 (12.7)	NE (NE, NE)	25/252 (9.9)	NE (NE, NE)		0.667 (0.391, 1.136)	0.133
Time to first grade ≥ 3 fatigue TEAE							
Overall	17/244 (7.0)	NE (NE, NE)	9/252 (3.6)	NE (NE, NE)		0.467 (0.208, 1.050)	0.059

Page 25 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 infections and infestations TEAE							
Overall	42/244 (17.2)	NE (NE, NE)	32/252 (12.7)	NE (NE, NE)		0.619 (0.388, 0.987)	0.042
Age					0.838		
< 65 years	13/109 (11.9)	NE (NE, NE)	12/128 (9.4)	NE (NE, NE)			
≥ 65 years	29/135 (21.5)	NE (NE, NE)	20/124 (16.1)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.636		
Male	28/161 (17.4)	NE (NE, NE)	21/180 (11.7)	NE (NE, NE)			
Female	14/83 (16.9)	NE (NE, NE)	11/72 (15.3)	NE (NE, NE)			
Region					0.526		
North America and Europe	20/121 (16.5)	NE (NE, NE)	19/139 (13.7)	NE (NE, NE)			
Rest of world	22/123 (17.9)	NE (NE, NE)	13/113 (11.5)	NE (NE, NE)			

Page 27 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.459		
Yes	26/172 (15.1)	NE (NE, NE)	23/179 (12.8)	NE (NE, NE)			
No	16/72 (22.2)	NE (NE, NE)	9/73 (12.3)	NE (NE, NE)			
Chemotherapy-free interval					0.405		
< 90 days	19/109 (17.4)	NE (NE, NE)	16/107 (15.0)	NE (11.1, NE)			
≥ 90 and < 180 days	14/73 (19.2)	NE (NE, NE)	13/85 (15.3)	NE (NE, NE)			
≥ 180 days	9/62 (14.5)	NE (NE, NE)	3/60 (5.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.327		
Yes	19/108 (17.6)	NE (NE, NE)	19/113 (16.8)	NE (NE, NE)			
No	23/136 (16.9)	NE (NE, NE)	13/139 (9.4)	NE (NE, NE)			
Standard of care					0.389		
Topotecan/Amrubicin	32/199 (16.1)	NE (NE, NE)	22/208 (10.6)	NE (NE, NE)			
Lurbinectedin	10/45 (22.2)	NE (NE, NE)	10/44 (22.7)	NE (11.1, NE)			

Page 29 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 pneumonia TEAE							
Overall	20/244 (8.2)	NE (NE, NE)	14/252 (5.6)	NE (NE, NE)		0.557 (0.279, 1.113)	0.093
Time to first grade ≥ 3 investigations TEAE							
Overall	54/244 (22.1)	NE (NE, NE)	33/252 (13.1)	NE (NE, NE)		0.477 (0.308, 0.740)	< 0.001
Age					0.866		
< 65 years	27/109 (24.8)	NE (NE, NE)	19/128 (14.8)	NE (NE, NE)			
≥ 65 years	27/135 (20.0)	NE (9.5, NE)	14/124 (11.3)	NE (NE, NE)			

Page 30 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.597		
Male	40/161 (24.8)	NE (9.5, NE)	27/180 (15.0)	NE (NE, NE)			
Female	14/83 (16.9)	NE (NE, NE)	6/72 (8.3)	NE (NE, NE)			
Region					0.690		
North America and Europe	21/121 (17.4)	NE (NE, NE)	15/139 (10.8)	NE (NE, NE)			
Rest of world	33/123 (26.8)	NE (9.5, NE)	18/113 (15.9)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.972		
Yes	34/172 (19.8)	NE (NE, NE)	21/179 (11.7)	NE (NE, NE)			
No	20/72 (27.8)	NE (6.2, NE)	12/73 (16.4)	NE (NE, NE)			
Chemotherapy-free interval					0.137		
< 90 days	18/109 (16.5)	NE (NE, NE)	17/107 (15.9)	NE (NE, NE)			
≥ 90 and < 180 days	20/73 (27.4)	NE (6.2, NE)	11/85 (12.9)	NE (NE, NE)			
≥ 180 days	16/62 (25.8)	NE (9.5, NE)	5/60 (8.3)	NE (NE, NE)			

Page 32 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.303		
Yes	26/108 (24.1)	NE (9.5, NE)	13/113 (11.5)	NE (NE, NE)			
No	28/136 (20.6)	NE (NE, NE)	20/139 (14.4)	NE (NE, NE)			
Standard of care					0.037		
Topotecan/Amrubicin	51/199 (25.6)	NE (9.5, NE)	27/208 (13.0)	NE (NE, NE)		0.399 (0.249, 0.639)	< 0.001
Lurbinectedin	3/45 (6.7)	NE (NE, NE)	6/44 (13.6)	NE (NE, NE)		1.714 (0.412, 7.126)	0.453

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Time to first grade ≥ 3 neutrophil count decreased TEAE							
Overall	28/244 (11.5)	NE (NE, NE)	10/252 (4.0)	NE (NE, NE)		0.279 (0.134, 0.580)	< 0.001
Age					0.347		
< 65 years	13/109 (11.9)	NE (NE, NE)	7/128 (5.5)	NE (NE, NE)			
≥ 65 years	15/135 (11.1)	NE (NE, NE)	3/124 (2.4)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.914		
Male	25/161 (15.5)	NE (NE, NE)	9/180 (5.0)	NE (NE, NE)			
Female	3/83 (3.6)	NE (NE, NE)	1/72 (1.4)	NE (NE, NE)			
Region					0.938		
North America and Europe	3/121 (2.5)	NE (NE, NE)	1/139 (0.7)	NE (NE, NE)			
Rest of world	25/123 (20.3)	NE (9.5, NE)	9/113 (8.0)	NE (NE, NE)			

Page 35 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.828		
Yes	18/172 (10.5)	NE (NE, NE)	7/179 (3.9)	NE (NE, NE)			
No	10/72 (13.9)	NE (NE, NE)	3/73 (4.1)	NE (NE, NE)			
Chemotherapy-free interval					0.398		
< 90 days	8/109 (7.3)	NE (NE, NE)	5/107 (4.7)	NE (NE, NE)			
≥ 90 and < 180 days	10/73 (13.7)	NE (NE, NE)	3/85 (3.5)	NE (NE, NE)			
≥ 180 days	10/62 (16.1)	NE (9.5, NE)	2/60 (3.3)	NE (NE, NE)			

Page 36 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.707		
Yes	12/108 (11.1)	NE (9.5, NE)	4/113 (3.5)	NE (NE, NE)			
No	16/136 (11.8)	NE (NE, NE)	6/139 (4.3)	NE (NE, NE)			
Standard of care					0.423		
Topotecan/Amrubicin	27/199 (13.6)	NE (NE, NE)	9/208 (4.3)	NE (NE, NE)			
Lurbinectedin	1/45 (2.2)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

Page 37 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 white blood cell count decreased TEAE							
Overall	11/244 (4.5)	NE (NE, NE)	5/252 (2.0)	NE (NE, NE)		0.356 (0.122, 1.039)	0.049
Age					0.992		
< 65 years	4/109 (3.7)	NE (NE, NE)	5/128 (3.9)	NE (NE, NE)			
≥ 65 years	7/135 (5.2)	NE (NE, NE)	0/124 (0.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.992		
Male	10/161 (6.2)	NE (NE, NE)	5/180 (2.8)	NE (NE, NE)			
Female	1/83 (1.2)	NE (NE, NE)	0/72 (0.0)	NE (NE, NE)			
Region					0.989		
North America and Europe	2/121 (1.7)	NE (NE, NE)	0/139 (0.0)	NE (NE, NE)			
Rest of world	9/123 (7.3)	NE (9.5, NE)	5/113 (4.4)	NE (NE, NE)			

Page 39 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.625		
Yes	5/172 (2.9)	NE (NE, NE)	3/179 (1.7)	NE (NE, NE)			
No	6/72 (8.3)	NE (NE, NE)	2/73 (2.7)	NE (NE, NE)			
Chemotherapy-free interval					0.461		
< 90 days	2/109 (1.8)	NE (NE, NE)	2/107 (1.9)	NE (NE, NE)			
≥ 90 and < 180 days	3/73 (4.1)	NE (NE, NE)	2/85 (2.4)	NE (NE, NE)			
≥ 180 days	6/62 (9.7)	NE (NE, NE)	1/60 (1.7)	NE (NE, NE)			

Page 40 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.687		
Yes	3/108 (2.8)	NE (9.5, NE)	1/113 (0.9)	NE (NE, NE)			
No	8/136 (5.9)	NE (NE, NE)	4/139 (2.9)	NE (NE, NE)			
Standard of care					0.993		
Topotecan/Amrubicin	10/199 (5.0)	NE (NE, NE)	5/208 (2.4)	NE (NE, NE)			
Lurbinectedin	1/45 (2.2)	NE (NE, NE)	0/44 (0.0)	NE (NE, NE)			

Page 41 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 platelet count decreased TEAE							
Overall	20/244 (8.2)	NE (NE, NE)	1/252 (0.4)	NE (NE, NE)		0.044 (0.006, 0.326)	< 0.001
Age					0.989		
< 65 years	7/109 (6.4)	NE (NE, NE)	0/128 (0.0)	NE (NE, NE)			
≥ 65 years	13/135 (9.6)	NE (NE, NE)	1/124 (0.8)	NE (NE, NE)			

Page 42 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Sex					0.991		
Male	15/161 (9.3)	NE (NE, NE)	0/180 (0.0)	NE (NE, NE)			
Female	5/83 (6.0)	NE (NE, NE)	1/72 (1.4)	NE (NE, NE)			
Region					0.990		
North America and Europe	6/121 (5.0)	NE (NE, NE)	1/139 (0.7)	NE (NE, NE)			
Rest of world	14/123 (11.4)	NE (NE, NE)	0/113 (0.0)	NE (NE, NE)			

Page 43 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.991		
Yes	13/172 (7.6)	NE (NE, NE)	0/179 (0.0)	NE (NE, NE)			
No	7/72 (9.7)	NE (NE, NE)	1/73 (1.4)	NE (NE, NE)			
Chemotherapy-free interval					1.000		
< 90 days	7/109 (6.4)	NE (NE, NE)	1/107 (0.9)	NE (NE, NE)			
≥ 90 and < 180 days	8/73 (11.0)	NE (NE, NE)	0/85 (0.0)	NE (NE, NE)			
≥ 180 days	5/62 (8.1)	NE (NE, NE)	0/60 (0.0)	NE (NE, NE)			

Page 44 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.989		
Yes	11/108 (10.2)	NE (NE, NE)	1/113 (0.9)	NE (NE, NE)			
No	9/136 (6.6)	NE (NE, NE)	0/139 (0.0)	NE (NE, NE)			
Standard of care					0.999		
Topotecan/Amrubicin	20/199 (10.1)	NE (NE, NE)	1/208 (0.5)	NE (NE, NE)			
Lurbinectedin	0/45 (0.0)	NE (NE, NE)	0/44 (0.0)	NE (NE, NE)			

Page 45 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 metabolism and nutrition disorders TEAE							
Overall	33/244 (13.5)	NE (NE, NE)	27/252 (10.7)	NE (NE, NE)		0.690 (0.413, 1.151)	0.153
Time to first grade ≥ 3 hyponatraemia TEAE							
Overall	13/244 (5.3)	NE (NE, NE)	12/252 (4.8)	NE (NE, NE)		0.779 (0.354, 1.717)	0.535
Time to first grade ≥ 3 nervous system disorders TEAE							
Overall	14/244 (5.7)	NE (NE, NE)	8/252 (3.2)	NE (NE, NE)		0.476 (0.199, 1.140)	0.088

Page 46 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.2. Summary of Time to first grade ≥ 3 Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 respiratory, thoracic and mediastinal disorders TEAE							
Overall	16/244 (6.6)	NE (NE, NE)	20/252 (7.9)	NE (NE, NE)		1.056 (0.543, 2.054)	0.871
Time to first grade ≥ 3 vascular disorders TEAE							
Overall	10/244 (4.1)	NE (NE, NE)	11/252 (4.4)	NE (NE, NE)		1.022 (0.432, 2.415)	0.966

Page 47 of 47

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1. The adverse events graded using CTCAE version 5.0.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-002-002-ae-teae-grd3-socpt.rtf (Date Generated: 21DEC25:20:38:06) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first serious blood and lymphatic system disorders TEAE							
Overall	45/244 (18.4)	NE (NE, NE)	6/252 (2.4)	NE (NE, NE)		0.102 (0.043, 0.242)	< 0.001
Age					0.990		
< 65 years	14/109 (12.8)	NE (NE, NE)	2/128 (1.6)	NE (NE, NE)			
≥ 65 years	31/135 (23.0)	NE (NE, NE)	4/124 (3.2)	NE (NE, NE)			

Page 1 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.856		
Male	27/161 (16.8)	NE (NE, NE)	4/180 (2.2)	NE (NE, NE)			
Female	18/83 (21.7)	NE (NE, NE)	2/72 (2.8)	NE (NE, NE)			
Region					0.174		
North America and Europe	26/121 (21.5)	NE (NE, NE)	2/139 (1.4)	NE (NE, NE)			
Rest of world	19/123 (15.4)	NE (NE, NE)	4/113 (3.5)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.469		
Yes	30/172 (17.4)	NE (NE, NE)	5/179 (2.8)	NE (NE, NE)			
No	15/72 (20.8)	NE (NE, NE)	1/73 (1.4)	NE (NE, NE)			
Chemotherapy-free interval					0.503		
< 90 days	19/109 (17.4)	NE (NE, NE)	4/107 (3.7)	NE (NE, NE)			
≥ 90 and < 180 days	15/73 (20.5)	NE (NE, NE)	1/85 (1.2)	NE (NE, NE)			
≥ 180 days	11/62 (17.7)	NE (NE, NE)	1/60 (1.7)	NE (NE, NE)			

Page 3 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.334		
Yes	23/108 (21.3)	NE (NE, NE)	2/113 (1.8)	NE (NE, NE)			
No	22/136 (16.2)	NE (NE, NE)	4/139 (2.9)	NE (NE, NE)			
Standard of care					0.862		
Topotecan/Amrubicin	38/199 (19.1)	NE (NE, NE)	5/208 (2.4)	NE (NE, NE)			
Lurbinectedin	7/45 (15.6)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first serious febrile neutropenia TEAE							
Overall	24/244 (9.8)	NE (NE, NE)	5/252 (2.0)	NE (NE, NE)		0.156 (0.059, 0.417)	< 0.001
Age					0.711		
< 65 years	6/109 (5.5)	NE (NE, NE)	1/128 (0.8)	NE (NE, NE)			
≥ 65 years	18/135 (13.3)	NE (NE, NE)	4/124 (3.2)	NE (NE, NE)			

Page 5 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.682		
Male	16/161 (9.9)	NE (NE, NE)	3/180 (1.7)	NE (NE, NE)			
Female	8/83 (9.6)	NE (NE, NE)	2/72 (2.8)	NE (NE, NE)			
Region					0.345		
North America and Europe	14/121 (11.6)	NE (NE, NE)	2/139 (1.4)	NE (NE, NE)			
Rest of world	10/123 (8.1)	NE (NE, NE)	3/113 (2.7)	NE (NE, NE)			

Page 6 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	Hazard Ratio p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.906		
Yes	18/172 (10.5)	NE (NE, NE)	4/179 (2.2)	NE (NE, NE)			
No	6/72 (8.3)	NE (NE, NE)	1/73 (1.4)	NE (NE, NE)			
Chemotherapy-free interval					0.729		
< 90 days	10/109 (9.2)	NE (NE, NE)	3/107 (2.8)	NE (NE, NE)			
≥ 90 and < 180 days	8/73 (11.0)	NE (NE, NE)	1/85 (1.2)	NE (NE, NE)			
≥ 180 days	6/62 (9.7)	NE (NE, NE)	1/60 (1.7)	NE (NE, NE)			

Page 7 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.856		
Yes	10/108 (9.3)	NE (NE, NE)	2/113 (1.8)	NE (NE, NE)			
No	14/136 (10.3)	NE (NE, NE)	3/139 (2.2)	NE (NE, NE)			
Standard of care					0.800		
Topotecan/Amrubicin	20/199 (10.1)	NE (NE, NE)	4/208 (1.9)	NE (NE, NE)			
Lurbinectedin	4/45 (8.9)	NE (NE, NE)	1/44 (2.3)	NE (NE, NE)			

Page 8 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first serious anaemia TEAE							
Overall	10/244 (4.1)	NE (NE, NE)	1/252 (0.4)	NE (NE, NE)		0.089 (0.011, 0.698)	0.004
Age					0.992		
< 65 years	3/109 (2.8)	NE (NE, NE)	1/128 (0.8)	NE (NE, NE)			
≥ 65 years	7/135 (5.2)	NE (NE, NE)	0/124 (0.0)	NE (NE, NE)			

Page 9 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					0.994		
Male	5/161 (3.1)	NE (NE, NE)	1/180 (0.6)	NE (NE, NE)			
Female	5/83 (6.0)	NE (NE, NE)	0/72 (0.0)	NE (NE, NE)			
Region					0.992		
North America and Europe	8/121 (6.6)	NE (NE, NE)	0/139 (0.0)	NE (NE, NE)			
Rest of world	2/123 (1.6)	NE (NE, NE)	1/113 (0.9)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.993		
Yes	7/172 (4.1)	NE (NE, NE)	1/179 (0.6)	NE (NE, NE)			
No	3/72 (4.2)	NE (NE, NE)	0/73 (0.0)	NE (NE, NE)			
Chemotherapy-free interval					1.000		
< 90 days	5/109 (4.6)	NE (NE, NE)	1/107 (0.9)	NE (NE, NE)			
≥ 90 and < 180 days	3/73 (4.1)	NE (NE, NE)	0/85 (0.0)	NE (NE, NE)			
≥ 180 days	2/62 (3.2)	NE (NE, NE)	0/60 (0.0)	NE (NE, NE)			

Page 11 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.992		
Yes	3/108 (2.8)	NE (NE, NE)	0/113 (0.0)	NE (NE, NE)			
No	7/136 (5.1)	NE (NE, NE)	1/139 (0.7)	NE (NE, NE)			
Standard of care					0.999		
Topotecan/Amrubicin	10/199 (5.0)	NE (NE, NE)	1/208 (0.5)	NE (NE, NE)			
Lurbinectedin	0/45 (0.0)	NE (NE, NE)	0/44 (0.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first serious thrombocytopenia TEAE							
Overall	11/244 (4.5)	NE (NE, NE)	0/252 (0.0)	NE (NE, NE)		NE (NE, NE)	< 0.001
Age					1.000		
< 65 years	4/109 (3.7)	NE (NE, NE)	0/128 (0.0)	NE (NE, NE)			
≥ 65 years	7/135 (5.2)	NE (NE, NE)	0/124 (0.0)	NE (NE, NE)			

Page 13 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Sex					1.000		
Male	7/161 (4.3)	NE (NE, NE)	0/180 (0.0)	NE (NE, NE)			
Female	4/83 (4.8)	NE (NE, NE)	0/72 (0.0)	NE (NE, NE)			
Region					1.000		
North America and Europe	6/121 (5.0)	NE (NE, NE)	0/139 (0.0)	NE (NE, NE)			
Rest of world	5/123 (4.1)	NE (NE, NE)	0/113 (0.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					1.000		
Yes	6/172 (3.5)	NE (NE, NE)	0/179 (0.0)	NE (NE, NE)			
No	5/72 (6.9)	NE (NE, NE)	0/73 (0.0)	NE (NE, NE)			
Chemotherapy-free interval					1.000		
< 90 days	5/109 (4.6)	NE (NE, NE)	0/107 (0.0)	NE (NE, NE)			
≥ 90 and < 180 days	2/73 (2.7)	NE (NE, NE)	0/85 (0.0)	NE (NE, NE)			
≥ 180 days	4/62 (6.5)	NE (NE, NE)	0/60 (0.0)	NE (NE, NE)			

Page 15 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					1.000		
Yes	6/108 (5.6)	NE (NE, NE)	0/113 (0.0)	NE (NE, NE)			
No	5/136 (3.7)	NE (NE, NE)	0/139 (0.0)	NE (NE, NE)			
Standard of care					1.000		
Topotecan/Amrubicin	10/199 (5.0)	NE (NE, NE)	0/208 (0.0)	NE (NE, NE)			
Lurbinectedin	1/45 (2.2)	NE (NE, NE)	0/44 (0.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first serious cardiac disorders TEAE							
Overall	7/244 (2.9)	NE (NE, NE)	12/252 (4.8)	NE (NE, NE)		1.465 (0.575, 3.735)	0.420
Time to first serious gastrointestinal disorders TEAE							
Overall	5/244 (2.0)	NE (NE, NE)	13/252 (5.2)	NE (NE, NE)		2.320 (0.824, 6.527)	0.101
Time to first serious general disorders and administration site conditions TEAE							
Overall	6/244 (2.5)	NE (NE, NE)	25/252 (9.9)	NE (NE, NE)		3.865 (1.580, 9.458)	0.001

Page 17 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.488		
< 65 years	4/109 (3.7)	NE (NE, NE)	14/128 (10.9)	NE (NE, NE)			
≥ 65 years	2/135 (1.5)	NE (NE, NE)	11/124 (8.9)	NE (NE, NE)			
Sex					0.424		
Male	3/161 (1.9)	NE (NE, NE)	18/180 (10.0)	NE (NE, NE)			
Female	3/83 (3.6)	NE (NE, NE)	7/72 (9.7)	NE (NE, NE)			

Page 18 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.154		
North America and Europe	1/121 (0.8)	NE (NE, NE)	14/139 (10.1)	NE (NE, NE)			
Rest of world	5/123 (4.1)	NE (NE, NE)	11/113 (9.7)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					0.694		
Yes	4/172 (2.3)	NE (NE, NE)	19/179 (10.6)	NE (NE, NE)			
No	2/72 (2.8)	NE (NE, NE)	6/73 (8.2)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					0.657		
< 90 days	2/109 (1.8)	NE (NE, NE)	10/107 (9.3)	NE (NE, NE)			
≥ 90 and < 180 days	2/73 (2.7)	NE (NE, NE)	11/85 (12.9)	NE (NE, NE)			
≥ 180 days	2/62 (3.2)	NE (NE, NE)	4/60 (6.7)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.578		
Yes	4/108 (3.7)	NE (NE, NE)	14/113 (12.4)	NE (NE, NE)			
No	2/136 (1.5)	NE (NE, NE)	11/139 (7.9)	NE (NE, NE)			

Page 20 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.022		
Topotecan/Amrubicin	2/199 (1.0)	NE (NE, NE)	21/208 (10.1)	NE (NE, NE)		10.275 (2.409, 43.829)	< 0.001
Lurbinectedin	4/45 (8.9)	NE (NE, NE)	4/44 (9.1)	NE (NE, NE)		0.631 (0.135, 2.949)	0.556
Time to first serious pyrexia TEAE							
Overall	0/244 (0.0)	NE (NE, NE)	14/252 (5.6)	NE (NE, NE)		NE (NE, NE)	< 0.001

Page 21 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					1.000		
< 65 years	0/109 (0.0)	NE (NE, NE)	10/128 (7.8)	NE (NE, NE)			
≥ 65 years	0/135 (0.0)	NE (NE, NE)	4/124 (3.2)	NE (NE, NE)			
Sex					1.000		
Male	0/161 (0.0)	NE (NE, NE)	10/180 (5.6)	NE (NE, NE)			
Female	0/83 (0.0)	NE (NE, NE)	4/72 (5.6)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					1.000		
North America and Europe	0/121 (0.0)	NE (NE, NE)	7/139 (5.0)	NE (NE, NE)			
Rest of world	0/123 (0.0)	NE (NE, NE)	7/113 (6.2)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					1.000		
Yes	0/172 (0.0)	NE (NE, NE)	11/179 (6.1)	NE (NE, NE)			
No	0/72 (0.0)	NE (NE, NE)	3/73 (4.1)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					1.000		
< 90 days	0/109 (0.0)	NE (NE, NE)	5/107 (4.7)	NE (NE, NE)			
≥ 90 and < 180 days	0/73 (0.0)	NE (NE, NE)	7/85 (8.2)	NE (NE, NE)			
≥ 180 days	0/62 (0.0)	NE (NE, NE)	2/60 (3.3)	NE (NE, NE)			
Presence (previous or current) of brain metastases					1.000		
Yes	0/108 (0.0)	NE (NE, NE)	8/113 (7.1)	NE (NE, NE)			
No	0/136 (0.0)	NE (NE, NE)	6/139 (4.3)	NE (NE, NE)			

Page 24 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					1.000		
Topotecan/Amrubicin	0/199 (0.0)	NE (NE, NE)	12/208 (5.8)	NE (NE, NE)			
Lurbinectedin	0/45 (0.0)	NE (NE, NE)	2/44 (4.5)	NE (NE, NE)			
Time to first serious immune system disorders TEAE							
Overall	1/244 (0.4)	NE (NE, NE)	43/252 (17.1)	NE (NE, NE)		45.686 (6.294, 331.589)	< 0.001

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.990		
< 65 years	1/109 (0.9)	NE (NE, NE)	23/128 (18.0)	NE (NE, NE)			
≥ 65 years	0/135 (0.0)	NE (NE, NE)	20/124 (16.1)	NE (NE, NE)			
Sex					0.989		
Male	0/161 (0.0)	NE (NE, NE)	28/180 (15.6)	NE (NE, NE)			
Female	1/83 (1.2)	NE (NE, NE)	15/72 (20.8)	NE (NE, NE)			

Page 26 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.987		
North America and Europe	1/121 (0.8)	NE (NE, NE)	30/139 (21.6)	NE (NE, NE)			
Rest of world	0/123 (0.0)	NE (NE, NE)	13/113 (11.5)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					0.988		
Yes	0/172 (0.0)	NE (NE, NE)	30/179 (16.8)	NE (NE, NE)			
No	1/72 (1.4)	NE (NE, NE)	13/73 (17.8)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					1.000		
< 90 days	0/109 (0.0)	NE (NE, NE)	22/107 (20.6)	NE (NE, NE)			
≥ 90 and < 180 days	1/73 (1.4)	NE (NE, NE)	17/85 (20.0)	NE (NE, NE)			
≥ 180 days	0/62 (0.0)	NE (NE, NE)	4/60 (6.7)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.986		
Yes	0/108 (0.0)	NE (NE, NE)	21/113 (18.6)	NE (NE, NE)			
No	1/136 (0.7)	NE (NE, NE)	22/139 (15.8)	NE (NE, NE)			

Page 28 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.986		
Topotecan/Amrubicin	0/199 (0.0)	NE (NE, NE)	37/208 (17.8)	NE (NE, NE)			
Lurbinectedin	1/45 (2.2)	NE (NE, NE)	6/44 (13.6)	NE (NE, NE)			
Time to first serious cytokine release syndrome TEAE							
Overall	1/244 (0.4)	NE (NE, NE)	43/252 (17.1)	NE (NE, NE)		45.686 (6.294, 331.589)	< 0.001

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.990		
< 65 years	1/109 (0.9)	NE (NE, NE)	23/128 (18.0)	NE (NE, NE)			
≥ 65 years	0/135 (0.0)	NE (NE, NE)	20/124 (16.1)	NE (NE, NE)			
Sex					0.989		
Male	0/161 (0.0)	NE (NE, NE)	28/180 (15.6)	NE (NE, NE)			
Female	1/83 (1.2)	NE (NE, NE)	15/72 (20.8)	NE (NE, NE)			

Page 30 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.987		
North America and Europe	1/121 (0.8)	NE (NE, NE)	30/139 (21.6)	NE (NE, NE)			
Rest of world	0/123 (0.0)	NE (NE, NE)	13/113 (11.5)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					0.988		
Yes	0/172 (0.0)	NE (NE, NE)	30/179 (16.8)	NE (NE, NE)			
No	1/72 (1.4)	NE (NE, NE)	13/73 (17.8)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					1.000		
< 90 days	0/109 (0.0)	NE (NE, NE)	22/107 (20.6)	NE (NE, NE)			
≥ 90 and < 180 days	1/73 (1.4)	NE (NE, NE)	17/85 (20.0)	NE (NE, NE)			
≥ 180 days	0/62 (0.0)	NE (NE, NE)	4/60 (6.7)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.986		
Yes	0/108 (0.0)	NE (NE, NE)	21/113 (18.6)	NE (NE, NE)			
No	1/136 (0.7)	NE (NE, NE)	22/139 (15.8)	NE (NE, NE)			

Page 32 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.986		
Topotecan/Amrubicin	0/199 (0.0)	NE (NE, NE)	37/208 (17.8)	NE (NE, NE)			
Lurbinectedin	1/45 (2.2)	NE (NE, NE)	6/44 (13.6)	NE (NE, NE)			
Time to first serious infections and infestations TEAE							
Overall	43/244 (17.6)	NE (NE, NE)	28/252 (11.1)	NE (NE, NE)		0.525 (0.324, 0.851)	0.008

Page 33 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.872		
< 65 years	14/109 (12.8)	NE (NE, NE)	11/128 (8.6)	NE (NE, NE)			
≥ 65 years	29/135 (21.5)	NE (NE, NE)	17/124 (13.7)	NE (NE, NE)			
Sex					0.894		
Male	28/161 (17.4)	NE (NE, NE)	19/180 (10.6)	NE (NE, NE)			
Female	15/83 (18.1)	NE (NE, NE)	9/72 (12.5)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.417		
North America and Europe	20/121 (16.5)	NE (NE, NE)	17/139 (12.2)	NE (NE, NE)			
Rest of world	23/123 (18.7)	NE (NE, NE)	11/113 (9.7)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					0.219		
Yes	24/172 (14.0)	NE (NE, NE)	20/179 (11.2)	NE (NE, NE)			
No	19/72 (26.4)	NE (NE, NE)	8/73 (11.0)	NE (NE, NE)			

Page 35 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					0.331		
< 90 days	20/109 (18.3)	NE (NE, NE)	14/107 (13.1)	NE (11.1, NE)			
≥ 90 and < 180 days	12/73 (16.4)	NE (NE, NE)	11/85 (12.9)	NE (NE, NE)			
≥ 180 days	11/62 (17.7)	NE (NE, NE)	3/60 (5.0)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.211		
Yes	20/108 (18.5)	NE (NE, NE)	18/113 (15.9)	NE (NE, NE)			
No	23/136 (16.9)	NE (NE, NE)	10/139 (7.2)	NE (NE, NE)			

Page 36 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.579		
Topotecan/Amrubicin	33/199 (16.6)	NE (NE, NE)	20/208 (9.6)	NE (NE, NE)			
Lurbinectedin	10/45 (22.2)	NE (NE, NE)	8/44 (18.2)	NE (11.1, NE)			
Time to first serious pneumonia TEAE							
Overall	21/244 (8.6)	NE (NE, NE)	10/252 (4.0)	NE (NE, NE)		0.382 (0.178, 0.820)	0.010

Page 37 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Age					0.859		
< 65 years	6/109 (5.5)	NE (NE, NE)	3/128 (2.3)	NE (NE, NE)			
≥ 65 years	15/135 (11.1)	NE (NE, NE)	7/124 (5.6)	NE (NE, NE)			
Sex					0.992		
Male	14/161 (8.7)	NE (NE, NE)	7/180 (3.9)	NE (NE, NE)			
Female	7/83 (8.4)	NE (NE, NE)	3/72 (4.2)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.869		
North America and Europe	9/121 (7.4)	NE (NE, NE)	5/139 (3.6)	NE (NE, NE)			
Rest of world	12/123 (9.8)	NE (NE, NE)	5/113 (4.4)	NE (NE, NE)			
Prior anti-PD-(L)1 exposure					0.271		
Yes	10/172 (5.8)	NE (NE, NE)	7/179 (3.9)	NE (NE, NE)			
No	11/72 (15.3)	NE (NE, NE)	3/73 (4.1)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Chemotherapy-free interval					0.485		
< 90 days	10/109 (9.2)	NE (NE, NE)	4/107 (3.7)	NE (NE, NE)			
≥ 90 and < 180 days	5/73 (6.8)	NE (NE, NE)	6/85 (7.1)	NE (NE, NE)			
≥ 180 days	6/62 (9.7)	NE (NE, NE)	0/60 (0.0)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.529		
Yes	8/108 (7.4)	NE (NE, NE)	3/113 (2.7)	NE (NE, NE)			
No	13/136 (9.6)	NE (NE, NE)	7/139 (5.0)	NE (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.157		
Topotecan/Amrubicin	19/199 (9.5)	NE (NE, NE)	7/208 (3.4)	NE (NE, NE)			
Lurbinectedin	2/45 (4.4)	NE (NE, NE)	3/44 (6.8)	NE (NE, NE)			
Time to first serious metabolism and nutrition disorders TEAE							
Overall	8/244 (3.3)	NE (NE, NE)	10/252 (4.0)	NE (NE, NE)		1.117 (0.440, 2.838)	0.815

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.2. Summary of Time to First Serious Treatment Emergent Adverse Event by SOC and PT (Safety Analysis Set)


Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first serious nervous system disorders TEAE							
Overall	10/244 (4.1)	NE (NE, NE)	16/252 (6.3)	NE (NE, NE)		1.461 (0.662, 3.227)	0.347
Time to first serious respiratory, thoracic and mediastinal disorders TEAE							
Overall	11/244 (4.5)	NE (NE, NE)	18/252 (7.1)	NE (NE, NE)		1.392 (0.653, 2.967)	0.389

Page 42 of 42

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Adverse events are coded using MedDRA version 27.1.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-002-ae-teae-ser-socpt.rtf (Date Generated: 21DEC25:20:38:14) Source: pa_adam.adsl, pa_adam.adae


Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)



Page 1 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)



Page 3 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 7 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 9 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)



Footnotes defined on last page of this output


Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)



Page 12 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 14 of 73

Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 15 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 17 of 73

Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 18 of 73

Footnotes defined on last page of this output


Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)



Page 19 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 22 of 73

Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 23 of 73

Footnotes defined on last page of this output


Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)



Page 24 of 73

Footnotes defined on last page of this output


Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)



Page 25 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 27 of 73

Footnotes defined on last page of this output


Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)



Page 28 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 32 of 73


Footnotes defined on last page of this output

Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 35 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 37 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 39 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)



Page 41 of 73

Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 42 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 47 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 53 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 55 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 57 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 59 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 67 of 73


Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 71 of 73

Footnotes defined on last page of this output

**Figure 14-6.1.2. Kaplan-Meier Plot of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

Censor indicated by vertical bar |.
N = Number of subjects in the analysis set, CI = Confidence Interval, NE = Not Estimable.
The SOC/PTs of Time to first TEAE are displayed where at least 10% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/figures/f-ae-teae-km-scpt.sas
Output: f14-06-001-002-ae-teae-km-scpt.rtf (Date Generated: 21DEC25 20:42) Source Data: pa_adam.adsl, pa_adam.adae


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 1 of 22


Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 4 of 22

Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 5 of 22


Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 9 of 22

Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 10 of 22

Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 11 of 22

Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 12 of 22

Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 13 of 22


Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 15 of 22


Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 17 of 22


Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Footnotes defined on last page of this output


**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 20 of 22

Footnotes defined on last page of this output

**Figure 14-6.2.2. Kaplan-Meier Plot of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

Censor indicated by vertical bar |.
N = Number of subjects in the analysis set, CI = Confidence Interval, NE = Not Estimable.
The SOC/PTs of Time to first TEAE grade ≥ 3 are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/figures/f-ae-teae-km-scpt.sas
Output: f14-06-002-002-ae-teae-km-grd3-scpt.rtf (Date Generated: 21DEC25 20:42) Source Data: pa_adam.adsl, pa_adam.adae


**Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 1 of 16

Footnotes defined on last page of this output


Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) (Safety Analysis Set)



Page 2 of 16

Footnotes defined on last page of this output


Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) (Safety Analysis Set)



Page 3 of 16


Footnotes defined on last page of this output

Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) (Safety Analysis Set)




Footnotes defined on last page of this output

Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) (Safety Analysis Set)



Footnotes defined on last page of this output


**Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 6 of 16

Footnotes defined on last page of this output


**Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 7 of 16


Footnotes defined on last page of this output

Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) (Safety Analysis Set)




Footnotes defined on last page of this output

**Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**




Footnotes defined on last page of this output

Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) (Safety Analysis Set)




Footnotes defined on last page of this output

Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) (Safety Analysis Set)




Footnotes defined on last page of this output

Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) (Safety Analysis Set)



Footnotes defined on last page of this output


**Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 13 of 16

Footnotes defined on last page of this output


**Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT)
(Safety Analysis Set)**



Page 14 of 16

Footnotes defined on last page of this output

Figure 14-6.3.2. Kaplan-Meier Plot of Time to First Serious Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) (Safety Analysis Set)



Footnotes defined on last page of this output

Censor indicated by vertical bar |.
N = Number of subjects in the analysis set, CI = Confidence Interval, NE = Not Estimable.
The SOC/PTs of Time to first Serious TEAE are displayed where at least 5% of subjects in a study arm, or at least 10 subjects and at least 1% of subjects in a study arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/figures/f-ae-teae-km-scpt.sas
Output: f14-06-003-002-ae-teae-km-ser-scpt.rtf (Date Generated: 21DEC25 20:42) Source Data: pa_adam.adsl, pa_adam.adae

Anhang 4-G4.2: Auswertungen zum Endpunkt ”PRO-CTCAE”– RCT

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Nausea Frequency	Baseline	n	247	250
		Never	199 (80.57)	194 (77.60)
		Rarely	24 (9.72)	26 (10.40)
		Occasionally	17 (6.88)	19 (7.60)
		Frequently	4 (1.62)	9 (3.60)
		Almost constantly	3 (1.21)	2 (0.80)
	Week 2	n	225	170
		Never	169 (75.11)	106 (62.35)
		Rarely	28 (12.44)	35 (20.59)
		Occasionally	17 (7.56)	13 (7.65)
		Frequently	9 (4.00)	15 (8.82)
		Almost constantly	2 (0.89)	1 (0.59)
	Week 3	n	215	172
		Never	139 (64.65)	120 (69.77)
		Rarely	45 (20.93)	29 (16.86)
		Occasionally	19 (8.84)	17 (9.88)
		Frequently	9 (4.19)	5 (2.91)
		Almost constantly	3 (1.40)	1 (0.58)
	Week 4	n	175	190
		Never	132 (75.43)	126 (66.32)
		Rarely	25 (14.29)	36 (18.95)
		Occasionally	12 (6.86)	22 (11.58)
		Frequently	4 (2.29)	4 (2.11)
		Almost constantly	2 (1.14)	2 (1.05)
	Week 5	n	201	159
		Never	160 (79.60)	97 (61.01)
		Rarely	22 (10.95)	35 (22.01)
		Occasionally	14 (6.97)	14 (8.81)
		Frequently	3 (1.49)	13 (8.18)
		Almost constantly	2 (1.00)	0 (0.00)
	Week 6	n	157	159
		Never	128 (81.53)	110 (69.18)
		Rarely	20 (12.74)	28 (17.61)
		Occasionally	4 (2.55)	15 (9.43)
		Frequently	1 (0.64)	6 (3.77)
		Almost constantly	4 (2.55)	0 (0.00)
	Week 7	n	186	173
		Never	154 (82.80)	118 (68.21)
		Rarely	24 (12.90)	41 (23.70)
		Occasionally	6 (3.23)	10 (5.78)
		Frequently	1 (0.54)	4 (2.31)
		Almost constantly	1 (0.54)	0 (0.00)
	Week 8	n	145	139
		Never	131 (90.34)	96 (69.06)
		Rarely	11 (7.59)	22 (15.83)
		Occasionally	2 (1.38)	14 (10.07)
		Frequently	1 (0.69)	7 (5.04)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 9	n	168	125
		Never	142 (84.52)	90 (72.00)
		Rarely	14 (8.33)	16 (12.80)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Nausea Frequency	Week 9	Occasionally	9 (5.36)	12 (9.60)
		Frequently	2 (1.19)	5 (4.00)
		Almost constantly	1 (0.60)	2 (1.60)
	Week 10	n	141	134
		Never	119 (84.40)	95 (70.90)
		Rarely	13 (9.22)	29 (21.64)
		Occasionally	8 (5.67)	9 (6.72)
		Frequently	0 (0.00)	1 (0.75)
		Almost constantly	1 (0.71)	0 (0.00)
	Week 11	n	156	119
		Never	133 (85.26)	80 (67.23)
		Rarely	12 (7.69)	27 (22.69)
		Occasionally	6 (3.85)	7 (5.88)
		Frequently	4 (2.56)	4 (3.36)
		Almost constantly	1 (0.64)	1 (0.84)
	Week 12	n	130	116
		Never	114 (87.69)	81 (69.83)
		Rarely	11 (8.46)	31 (26.72)
		Occasionally	3 (2.31)	3 (2.59)
		Frequently	2 (1.54)	1 (0.86)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 13	n	155	126
		Never	131 (84.52)	94 (74.60)
		Rarely	14 (9.03)	24 (19.05)
		Occasionally	8 (5.16)	8 (6.35)
		Frequently	2 (1.29)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 19	n	117	89
		Never	103 (88.03)	62 (69.66)
		Rarely	9 (7.69)	18 (20.22)
		Occasionally	4 (3.42)	6 (6.74)
		Frequently	1 (0.85)	3 (3.37)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 25	n	107	60
		Never	93 (86.92)	48 (80.00)
		Rarely	8 (7.48)	9 (15.00)
		Occasionally	6 (5.61)	2 (3.33)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	1 (1.67)
	Week 31	n	90	41
		Never	79 (87.78)	34 (82.93)
		Rarely	6 (6.67)	5 (12.20)
		Occasionally	5 (5.56)	2 (4.88)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 37	n	75	21
		Never	64 (85.33)	18 (85.71)
		Rarely	8 (10.67)	2 (9.52)
		Occasionally	1 (1.33)	0 (0.00)
		Frequently	2 (2.67)	0 (0.00)
		Almost constantly	0 (0.00)	1 (4.76)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Nausea Frequency	Week 43	n	46	12
		Never	41 (89.13)	9 (75.00)
		Rarely	3 (6.52)	3 (25.00)
		Occasionally	2 (4.35)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 49	n	32	6
		Never	32 (100.0)	5 (83.33)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	1 (16.67)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		Never	21 (95.45)	3 (100.0)
		Rarely	1 (4.55)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		Never	17 (100.0)	2 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		Never	5 (83.33)	1 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	1 (16.67)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		Never	1 (50.00)	0 (0.00)
		Rarely	1 (50.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		Never	89 (78.07)	104 (68.87)
		Rarely	14 (12.28)	30 (19.87)
		Occasionally	3 (2.63)	12 (7.95)
		Frequently	8 (7.02)	2 (1.32)
		Almost constantly	0 (0.00)	3 (1.99)
	Safety Follow-Up	n	65	91
		Never	46 (70.77)	66 (72.53)
		Rarely	9 (13.85)	19 (20.88)
		Occasionally	7 (10.77)	3 (3.30)
		Frequently	3 (4.62)	3 (3.30)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Vomiting Frequency	Baseline	n	2	1
		Never	2 (100.0)	1 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 2	n	11	3
		Never	11 (100.0)	3 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 3	n	20	5
		Never	16 (80.00)	5 (100.0)
		Rarely	1 (5.00)	0 (0.00)
		Occasionally	2 (10.00)	0 (0.00)
		Frequently	1 (5.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 4	n	16	11
		Never	15 (93.75)	10 (90.91)
		Rarely	1 (6.25)	1 (9.09)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 5	n	27	10
		Never	26 (96.30)	10 (100.0)
		Rarely	1 (3.70)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 6	n	20	15
		Never	20 (100.0)	15 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 7	n	34	19
		Never	33 (97.06)	18 (94.74)
		Rarely	0 (0.00)	1 (5.26)
		Occasionally	1 (2.94)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 8	n	20	13
		Never	19 (95.00)	13 (100.0)
		Rarely	1 (5.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 9	n	33	13
		Never	31 (93.94)	13 (100.0)
		Rarely	1 (3.03)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Vomiting Frequency	Week 9	Occasionally	1 (3.03)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 10	n	25	20
		Never	24 (96.00)	18 (90.00)
		Rarely	1 (4.00)	2 (10.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 11	n	34	20
		Never	31 (91.18)	20 (100.0)
		Rarely	1 (2.94)	0 (0.00)
		Occasionally	1 (2.94)	0 (0.00)
		Frequently	1 (2.94)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 12	n	29	17
		Never	29 (100.0)	17 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 13	n	34	26
		Never	33 (97.06)	26 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	1 (2.94)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 19	n	31	20
		Never	29 (93.55)	17 (85.00)
		Rarely	1 (3.23)	3 (15.00)
		Occasionally	1 (3.23)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 25	n	36	23
		Never	35 (97.22)	23 (100.0)
		Rarely	1 (2.78)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 31	n	37	17
		Never	36 (97.30)	17 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	1 (2.70)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 37	n	42	15
		Never	41 (97.62)	15 (100.0)
		Rarely	1 (2.38)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Vomiting Frequency	Week 43	n	29	8
		Never	29 (100.0)	8 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 49	n	19	4
		Never	19 (100.0)	4 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 55	n	13	1
		Never	13 (100.0)	1 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 61	n	12	1
		Never	12 (100.0)	1 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 67	n	5	0
		Never	4 (80.00)	0 (0.00)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	1 (20.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		Never	2 (100.0)	0 (0.00)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	End of IP Administration	n	33	46
		Never	29 (87.88)	43 (93.48)
		Rarely	2 (6.06)	3 (6.52)
		Occasionally	1 (3.03)	0 (0.00)
		Frequently	1 (3.03)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Safety Follow-Up	n	18	27
		Never	13 (72.22)	27 (100.0)
		Rarely	5 (27.78)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Swelling Frequency	Baseline	n	247	250
		Never	218 (88.26)	221 (88.40)
		Rarely	16 (6.48)	16 (6.40)
		Occasionally	7 (2.83)	9 (3.60)
		Frequently	2 (0.81)	2 (0.80)
		Almost constantly	4 (1.62)	2 (0.80)
	Week 2	n	225	170
		Never	201 (89.33)	151 (88.82)
		Rarely	15 (6.67)	14 (8.24)
		Occasionally	5 (2.22)	5 (2.94)
		Frequently	3 (1.33)	0 (0.00)
		Almost constantly	1 (0.44)	0 (0.00)
	Week 3	n	215	172
		Never	191 (88.84)	148 (86.05)
		Rarely	11 (5.12)	19 (11.05)
		Occasionally	6 (2.79)	3 (1.74)
		Frequently	6 (2.79)	0 (0.00)
		Almost constantly	1 (0.47)	2 (1.16)
	Week 4	n	175	190
		Never	164 (93.71)	157 (82.63)
		Rarely	5 (2.86)	22 (11.58)
		Occasionally	3 (1.71)	5 (2.63)
		Frequently	2 (1.14)	1 (0.53)
		Almost constantly	1 (0.57)	5 (2.63)
	Week 5	n	201	159
		Never	189 (94.03)	142 (89.31)
		Rarely	10 (4.98)	9 (5.66)
		Occasionally	0 (0.00)	4 (2.52)
		Frequently	2 (1.00)	2 (1.26)
		Almost constantly	0 (0.00)	2 (1.26)
	Week 6	n	157	159
		Never	147 (93.63)	139 (87.42)
		Rarely	4 (2.55)	14 (8.81)
		Occasionally	5 (3.18)	6 (3.77)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	1 (0.64)	0 (0.00)
	Week 7	n	186	173
		Never	174 (93.55)	140 (80.92)
		Rarely	8 (4.30)	24 (13.87)
		Occasionally	3 (1.61)	4 (2.31)
		Frequently	1 (0.54)	4 (2.31)
		Almost constantly	0 (0.00)	1 (0.58)
	Week 8	n	145	139
		Never	140 (96.55)	119 (85.61)
		Rarely	3 (2.07)	15 (10.79)
		Occasionally	2 (1.38)	3 (2.16)
		Frequently	0 (0.00)	1 (0.72)
		Almost constantly	0 (0.00)	1 (0.72)
	Week 9	n	168	125
		Never	159 (94.64)	103 (82.40)
		Rarely	8 (4.76)	16 (12.80)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Swelling Frequency	Week 9	Occasionally	1 (0.60)	4 (3.20)
		Frequently	0 (0.00)	1 (0.80)
		Almost constantly	0 (0.00)	1 (0.80)
	Week 10	n	141	134
		Never	134 (95.04)	107 (79.85)
		Rarely	4 (2.84)	21 (15.67)
		Occasionally	3 (2.13)	3 (2.24)
		Frequently	0 (0.00)	2 (1.49)
		Almost constantly	0 (0.00)	1 (0.75)
	Week 11	n	156	119
		Never	145 (92.95)	100 (84.03)
		Rarely	8 (5.13)	12 (10.08)
		Occasionally	3 (1.92)	2 (1.68)
		Frequently	0 (0.00)	1 (0.84)
		Almost constantly	0 (0.00)	4 (3.36)
	Week 12	n	130	116
		Never	123 (94.62)	98 (84.48)
		Rarely	5 (3.85)	13 (11.21)
		Occasionally	1 (0.77)	3 (2.59)
		Frequently	1 (0.77)	1 (0.86)
		Almost constantly	0 (0.00)	1 (0.86)
	Week 13	n	155	126
		Never	144 (92.90)	103 (81.75)
		Rarely	8 (5.16)	13 (10.32)
		Occasionally	2 (1.29)	5 (3.97)
		Frequently	1 (0.65)	2 (1.59)
		Almost constantly	0 (0.00)	3 (2.38)
	Week 19	n	117	89
		Never	111 (94.87)	67 (75.28)
		Rarely	4 (3.42)	14 (15.73)
		Occasionally	2 (1.71)	6 (6.74)
		Frequently	0 (0.00)	2 (2.25)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 25	n	107	60
		Never	96 (89.72)	50 (83.33)
		Rarely	9 (8.41)	5 (8.33)
		Occasionally	2 (1.87)	4 (6.67)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	1 (1.67)
	Week 31	n	90	41
		Never	83 (92.22)	32 (78.05)
		Rarely	5 (5.56)	5 (12.20)
		Occasionally	2 (2.22)	4 (9.76)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 37	n	75	21
		Never	69 (92.00)	13 (61.90)
		Rarely	6 (8.00)	6 (28.57)
		Occasionally	0 (0.00)	2 (9.52)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Swelling Frequency	Week 43	n	46	12
		Never	43 (93.48)	9 (75.00)
		Rarely	2 (4.35)	3 (25.00)
		Occasionally	1 (2.17)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 49	n	32	6
		Never	31 (96.88)	6 (100.0)
		Rarely	1 (3.13)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		Never	21 (95.45)	3 (100.0)
		Rarely	1 (4.55)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		Never	17 (100.0)	2 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		Never	6 (100.0)	1 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		Never	1 (50.00)	0 (0.00)
		Rarely	1 (50.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		Never	103 (90.35)	118 (78.15)
		Rarely	7 (6.14)	17 (11.26)
		Occasionally	3 (2.63)	9 (5.96)
		Frequently	1 (0.88)	5 (3.31)
		Almost constantly	0 (0.00)	2 (1.32)
	Safety Follow-Up	n	65	91
		Never	55 (84.62)	80 (87.91)
		Rarely	6 (9.23)	4 (4.40)
		Occasionally	3 (4.62)	7 (7.69)
		Frequently	1 (1.54)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Heart Palpitations Frequency	Baseline	n	247	250
		Never	201 (81.38)	187 (74.80)
		Rarely	30 (12.15)	45 (18.00)
		Occasionally	11 (4.45)	13 (5.20)
		Frequently	3 (1.21)	5 (2.00)
		Almost constantly	2 (0.81)	0 (0.00)
	Week 2	n	225	170
		Never	173 (76.89)	124 (72.94)
		Rarely	35 (15.56)	28 (16.47)
		Occasionally	15 (6.67)	16 (9.41)
		Frequently	1 (0.44)	2 (1.18)
		Almost constantly	1 (0.44)	0 (0.00)
	Week 3	n	215	172
		Never	170 (79.07)	126 (73.26)
		Rarely	33 (15.35)	28 (16.28)
		Occasionally	10 (4.65)	13 (7.56)
		Frequently	2 (0.93)	2 (1.16)
		Almost constantly	0 (0.00)	3 (1.74)
	Week 4	n	175	190
		Never	146 (83.43)	140 (73.68)
		Rarely	20 (11.43)	35 (18.42)
		Occasionally	7 (4.00)	12 (6.32)
		Frequently	2 (1.14)	2 (1.05)
		Almost constantly	0 (0.00)	1 (0.53)
	Week 5	n	201	159
		Never	165 (82.09)	111 (69.81)
		Rarely	28 (13.93)	25 (15.72)
		Occasionally	4 (1.99)	15 (9.43)
		Frequently	4 (1.99)	8 (5.03)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 6	n	157	159
		Never	136 (86.62)	125 (78.62)
		Rarely	15 (9.55)	21 (13.21)
		Occasionally	4 (2.55)	11 (6.92)
		Frequently	1 (0.64)	2 (1.26)
		Almost constantly	1 (0.64)	0 (0.00)
	Week 7	n	186	173
		Never	160 (86.02)	134 (77.46)
		Rarely	18 (9.68)	24 (13.87)
		Occasionally	8 (4.30)	12 (6.94)
		Frequently	0 (0.00)	3 (1.73)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 8	n	145	139
		Never	132 (91.03)	108 (77.70)
		Rarely	12 (8.28)	19 (13.67)
		Occasionally	0 (0.00)	8 (5.76)
		Frequently	0 (0.00)	4 (2.88)
		Almost constantly	1 (0.69)	0 (0.00)
	Week 9	n	168	125
		Never	144 (85.71)	90 (72.00)
		Rarely	18 (10.71)	20 (16.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Heart Palpitations Frequency	Week 9	Occasionally	5 (2.98)	13 (10.40)
		Frequently	1 (0.60)	2 (1.60)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 10	n	141	134
		Never	127 (90.07)	98 (73.13)
		Rarely	13 (9.22)	24 (17.91)
		Occasionally	1 (0.71)	11 (8.21)
		Frequently	0 (0.00)	1 (0.75)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 11	n	156	119
		Never	132 (84.62)	87 (73.11)
		Rarely	20 (12.82)	22 (18.49)
		Occasionally	3 (1.92)	7 (5.88)
		Frequently	1 (0.64)	3 (2.52)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 12	n	130	116
		Never	114 (87.69)	83 (71.55)
		Rarely	16 (12.31)	22 (18.97)
		Occasionally	0 (0.00)	8 (6.90)
		Frequently	0 (0.00)	3 (2.59)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 13	n	155	126
		Never	138 (89.03)	96 (76.19)
		Rarely	13 (8.39)	19 (15.08)
		Occasionally	2 (1.29)	9 (7.14)
		Frequently	2 (1.29)	2 (1.59)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 19	n	117	89
		Never	100 (85.47)	60 (67.42)
		Rarely	14 (11.97)	20 (22.47)
		Occasionally	3 (2.56)	8 (8.99)
		Frequently	0 (0.00)	1 (1.12)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 25	n	107	60
		Never	99 (92.52)	51 (85.00)
		Rarely	5 (4.67)	7 (11.67)
		Occasionally	2 (1.87)	2 (3.33)
		Frequently	1 (0.93)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 31	n	90	41
		Never	82 (91.11)	32 (78.05)
		Rarely	6 (6.67)	9 (21.95)
		Occasionally	2 (2.22)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 37	n	75	21
		Never	68 (90.67)	15 (71.43)
		Rarely	2 (2.67)	4 (19.05)
		Occasionally	5 (6.67)	2 (9.52)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Heart Palpitations Frequency	Week 43	n	46	12
		Never	43 (93.48)	9 (75.00)
		Rarely	2 (4.35)	3 (25.00)
		Occasionally	1 (2.17)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 49	n	32	6
		Never	31 (96.88)	6 (100.0)
		Rarely	1 (3.13)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		Never	22 (100.0)	3 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		Never	17 (100.0)	1 (50.00)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	1 (50.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		Never	6 (100.0)	1 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		Never	2 (100.0)	0 (0.00)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		Never	83 (72.81)	103 (68.21)
		Rarely	21 (18.42)	30 (19.87)
		Occasionally	10 (8.77)	10 (6.62)
		Frequently	0 (0.00)	7 (4.64)
		Almost constantly	0 (0.00)	1 (0.66)
	Safety Follow-Up	n	65	91
		Never	51 (78.46)	69 (75.82)
		Rarely	11 (16.92)	17 (18.68)
		Occasionally	3 (4.62)	4 (4.40)
		Frequently	0 (0.00)	1 (1.10)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Headache Frequency	Baseline	n	247	250
		Never	187 (75.71)	187 (74.80)
		Rarely	40 (16.19)	41 (16.40)
		Occasionally	18 (7.29)	15 (6.00)
		Frequently	2 (0.81)	4 (1.60)
		Almost constantly	0 (0.00)	3 (1.20)
	Week 2	n	225	170
		Never	152 (67.56)	123 (72.35)
		Rarely	48 (21.33)	33 (19.41)
		Occasionally	19 (8.44)	13 (7.65)
		Frequently	6 (2.67)	1 (0.59)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 3	n	215	172
		Never	133 (61.86)	133 (77.33)
		Rarely	42 (19.53)	25 (14.53)
		Occasionally	24 (11.16)	10 (5.81)
		Frequently	15 (6.98)	4 (2.33)
		Almost constantly	1 (0.47)	0 (0.00)
	Week 4	n	175	190
		Never	128 (73.14)	129 (67.89)
		Rarely	28 (16.00)	39 (20.53)
		Occasionally	15 (8.57)	18 (9.47)
		Frequently	4 (2.29)	2 (1.05)
		Almost constantly	0 (0.00)	2 (1.05)
	Week 5	n	201	159
		Never	155 (77.11)	107 (67.30)
		Rarely	33 (16.42)	36 (22.64)
		Occasionally	11 (5.47)	12 (7.55)
		Frequently	2 (1.00)	2 (1.26)
		Almost constantly	0 (0.00)	2 (1.26)
	Week 6	n	157	159
		Never	120 (76.43)	116 (72.96)
		Rarely	21 (13.38)	31 (19.50)
		Occasionally	13 (8.28)	11 (6.92)
		Frequently	3 (1.91)	0 (0.00)
		Almost constantly	0 (0.00)	1 (0.63)
	Week 7	n	186	173
		Never	143 (76.88)	134 (77.46)
		Rarely	32 (17.20)	22 (12.72)
		Occasionally	9 (4.84)	15 (8.67)
		Frequently	1 (0.54)	2 (1.16)
		Almost constantly	1 (0.54)	0 (0.00)
	Week 8	n	145	139
		Never	116 (80.00)	104 (74.82)
		Rarely	24 (16.55)	23 (16.55)
		Occasionally	5 (3.45)	11 (7.91)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	1 (0.72)
	Week 9	n	168	125
		Never	130 (77.38)	88 (70.40)
		Rarely	29 (17.26)	26 (20.80)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Headache Frequency	Week 9	Occasionally	8 (4.76)	8 (6.40)
		Frequently	1 (0.60)	0 (0.00)
		Almost constantly	0 (0.00)	3 (2.40)
	Week 10	n	141	134
		Never	113 (80.14)	89 (66.42)
		Rarely	19 (13.48)	29 (21.64)
		Occasionally	7 (4.96)	13 (9.70)
		Frequently	1 (0.71)	3 (2.24)
		Almost constantly	1 (0.71)	0 (0.00)
	Week 11	n	156	119
		Never	123 (78.85)	79 (66.39)
		Rarely	24 (15.38)	30 (25.21)
		Occasionally	7 (4.49)	9 (7.56)
		Frequently	2 (1.28)	0 (0.00)
		Almost constantly	0 (0.00)	1 (0.84)
	Week 12	n	130	116
		Never	98 (75.38)	76 (65.52)
		Rarely	23 (17.69)	32 (27.59)
		Occasionally	7 (5.38)	7 (6.03)
		Frequently	2 (1.54)	1 (0.86)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 13	n	155	126
		Never	126 (81.29)	96 (76.19)
		Rarely	18 (11.61)	19 (15.08)
		Occasionally	11 (7.10)	9 (7.14)
		Frequently	0 (0.00)	2 (1.59)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 19	n	117	89
		Never	92 (78.63)	65 (73.03)
		Rarely	17 (14.53)	15 (16.85)
		Occasionally	5 (4.27)	8 (8.99)
		Frequently	3 (2.56)	0 (0.00)
		Almost constantly	0 (0.00)	1 (1.12)
	Week 25	n	107	60
		Never	79 (73.83)	44 (73.33)
		Rarely	17 (15.89)	12 (20.00)
		Occasionally	11 (10.28)	3 (5.00)
		Frequently	0 (0.00)	1 (1.67)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 31	n	90	41
		Never	63 (70.00)	30 (73.17)
		Rarely	18 (20.00)	9 (21.95)
		Occasionally	9 (10.00)	1 (2.44)
		Frequently	0 (0.00)	1 (2.44)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 37	n	75	21
		Never	52 (69.33)	11 (52.38)
		Rarely	15 (20.00)	7 (33.33)
		Occasionally	5 (6.67)	3 (14.29)
		Frequently	3 (4.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Headache Frequency	Week 43	n	46	12
		Never	37 (80.43)	9 (75.00)
		Rarely	7 (15.22)	2 (16.67)
		Occasionally	2 (4.35)	1 (8.33)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 49	n	32	6
		Never	26 (81.25)	6 (100.0)
		Rarely	4 (12.50)	0 (0.00)
		Occasionally	2 (6.25)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		Never	20 (90.91)	3 (100.0)
		Rarely	2 (9.09)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		Never	15 (88.24)	2 (100.0)
		Rarely	1 (5.88)	0 (0.00)
		Occasionally	1 (5.88)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		Never	6 (100.0)	1 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		Never	2 (100.0)	0 (0.00)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		Never	83 (72.81)	97 (64.24)
		Rarely	19 (16.67)	39 (25.83)
		Occasionally	8 (7.02)	10 (6.62)
		Frequently	4 (3.51)	2 (1.32)
		Almost constantly	0 (0.00)	3 (1.99)
	Safety Follow-Up	n	65	91
		Never	45 (69.23)	63 (69.23)
		Rarely	17 (26.15)	24 (26.37)
		Occasionally	2 (3.08)	3 (3.30)
		Frequently	1 (1.54)	1 (1.10)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Anxious Frequency	Baseline	n	247	250
		Never	135 (54.66)	133 (53.20)
		Rarely	68 (27.53)	61 (24.40)
		Occasionally	30 (12.15)	41 (16.40)
		Frequently	9 (3.64)	12 (4.80)
		Almost constantly	5 (2.02)	3 (1.20)
	Week 2	n	225	170
		Never	128 (56.89)	93 (54.71)
		Rarely	42 (18.67)	49 (28.82)
		Occasionally	45 (20.00)	21 (12.35)
		Frequently	8 (3.56)	5 (2.94)
		Almost constantly	2 (0.89)	2 (1.18)
	Week 3	n	215	172
		Never	130 (60.47)	93 (54.07)
		Rarely	44 (20.47)	41 (23.84)
		Occasionally	25 (11.63)	25 (14.53)
		Frequently	16 (7.44)	10 (5.81)
		Almost constantly	0 (0.00)	3 (1.74)
	Week 4	n	175	190
		Never	109 (62.29)	119 (62.63)
		Rarely	39 (22.29)	42 (22.11)
		Occasionally	21 (12.00)	21 (11.05)
		Frequently	5 (2.86)	5 (2.63)
		Almost constantly	1 (0.57)	3 (1.58)
	Week 5	n	201	159
		Never	126 (62.69)	84 (52.83)
		Rarely	43 (21.39)	44 (27.67)
		Occasionally	24 (11.94)	23 (14.47)
		Frequently	7 (3.48)	6 (3.77)
		Almost constantly	1 (0.50)	2 (1.26)
	Week 6	n	157	159
		Never	90 (57.32)	90 (56.60)
		Rarely	45 (28.66)	38 (23.90)
		Occasionally	15 (9.55)	26 (16.35)
		Frequently	5 (3.18)	5 (3.14)
		Almost constantly	2 (1.27)	0 (0.00)
	Week 7	n	186	173
		Never	118 (63.44)	97 (56.07)
		Rarely	46 (24.73)	40 (23.12)
		Occasionally	20 (10.75)	28 (16.18)
		Frequently	2 (1.08)	5 (2.89)
		Almost constantly	0 (0.00)	3 (1.73)
	Week 8	n	145	139
		Never	95 (65.52)	79 (56.83)
		Rarely	33 (22.76)	31 (22.30)
		Occasionally	14 (9.66)	21 (15.11)
		Frequently	3 (2.07)	6 (4.32)
		Almost constantly	0 (0.00)	2 (1.44)
	Week 9	n	168	125
		Never	113 (67.26)	70 (56.00)
		Rarely	31 (18.45)	30 (24.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Anxious Frequency	Week 9	Occasionally	19 (11.31)	19 (15.20)
		Frequently	3 (1.79)	3 (2.40)
		Almost constantly	2 (1.19)	3 (2.40)
	Week 10	n	141	134
		Never	95 (67.38)	76 (56.72)
		Rarely	28 (19.86)	29 (21.64)
		Occasionally	16 (11.35)	24 (17.91)
		Frequently	1 (0.71)	4 (2.99)
		Almost constantly	1 (0.71)	1 (0.75)
	Week 11	n	156	119
		Never	101 (64.74)	65 (54.62)
		Rarely	38 (24.36)	31 (26.05)
		Occasionally	15 (9.62)	16 (13.45)
		Frequently	2 (1.28)	6 (5.04)
		Almost constantly	0 (0.00)	1 (0.84)
	Week 12	n	130	116
		Never	85 (65.38)	67 (57.76)
		Rarely	27 (20.77)	32 (27.59)
		Occasionally	17 (13.08)	9 (7.76)
		Frequently	1 (0.77)	7 (6.03)
		Almost constantly	0 (0.00)	1 (0.86)
	Week 13	n	155	126
		Never	102 (65.81)	75 (59.52)
		Rarely	36 (23.23)	30 (23.81)
		Occasionally	13 (8.39)	15 (11.90)
		Frequently	4 (2.58)	5 (3.97)
		Almost constantly	0 (0.00)	1 (0.79)
	Week 19	n	117	89
		Never	75 (64.10)	48 (53.93)
		Rarely	31 (26.50)	23 (25.84)
		Occasionally	9 (7.69)	15 (16.85)
		Frequently	2 (1.71)	3 (3.37)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 25	n	107	60
		Never	63 (58.88)	35 (58.33)
		Rarely	22 (20.56)	16 (26.67)
		Occasionally	20 (18.69)	8 (13.33)
		Frequently	2 (1.87)	1 (1.67)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 31	n	90	41
		Never	58 (64.44)	24 (58.54)
		Rarely	18 (20.00)	8 (19.51)
		Occasionally	11 (12.22)	9 (21.95)
		Frequently	3 (3.33)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 37	n	75	21
		Never	48 (64.00)	9 (42.86)
		Rarely	15 (20.00)	7 (33.33)
		Occasionally	9 (12.00)	5 (23.81)
		Frequently	3 (4.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Anxious Frequency	Week 43	n	46	12
		Never	33 (71.74)	9 (75.00)
		Rarely	8 (17.39)	2 (16.67)
		Occasionally	4 (8.70)	1 (8.33)
		Frequently	1 (2.17)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 49	n	32	6
		Never	21 (65.63)	5 (83.33)
		Rarely	7 (21.88)	1 (16.67)
		Occasionally	4 (12.50)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		Never	16 (72.73)	3 (100.0)
		Rarely	5 (22.73)	0 (0.00)
		Occasionally	1 (4.55)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		Never	12 (70.59)	0 (0.00)
		Rarely	3 (17.65)	1 (50.00)
		Occasionally	1 (5.88)	1 (50.00)
		Frequently	1 (5.88)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		Never	5 (83.33)	1 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	1 (16.67)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		Never	1 (50.00)	0 (0.00)
		Rarely	1 (50.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		Never	55 (48.25)	71 (47.02)
		Rarely	30 (26.32)	44 (29.14)
		Occasionally	21 (18.42)	25 (16.56)
		Frequently	8 (7.02)	5 (3.31)
		Almost constantly	0 (0.00)	6 (3.97)
	Safety Follow-Up	n	65	91
		Never	40 (61.54)	52 (57.14)
		Rarely	12 (18.46)	17 (18.68)
		Occasionally	7 (10.77)	18 (19.78)
		Frequently	5 (7.69)	2 (2.20)
		Almost constantly	1 (1.54)	2 (2.20)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Chills Frequency	Baseline	n	247	250
		Never	219 (88.66)	199 (79.60)
		Rarely	21 (8.50)	35 (14.00)
		Occasionally	5 (2.02)	11 (4.40)
		Frequently	1 (0.40)	5 (2.00)
		Almost constantly	1 (0.40)	0 (0.00)
	Week 2	n	225	170
		Never	160 (71.11)	141 (82.94)
		Rarely	46 (20.44)	21 (12.35)
		Occasionally	14 (6.22)	7 (4.12)
		Frequently	5 (2.22)	1 (0.59)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 3	n	215	172
		Never	133 (61.86)	133 (77.33)
		Rarely	38 (17.67)	20 (11.63)
		Occasionally	39 (18.14)	10 (5.81)
		Frequently	4 (1.86)	6 (3.49)
		Almost constantly	1 (0.47)	3 (1.74)
	Week 4	n	175	190
		Never	141 (80.57)	154 (81.05)
		Rarely	19 (10.86)	25 (13.16)
		Occasionally	11 (6.29)	7 (3.68)
		Frequently	4 (2.29)	4 (2.11)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 5	n	201	159
		Never	170 (84.58)	126 (79.25)
		Rarely	22 (10.95)	27 (16.98)
		Occasionally	7 (3.48)	4 (2.52)
		Frequently	2 (1.00)	2 (1.26)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 6	n	157	159
		Never	131 (83.44)	128 (80.50)
		Rarely	17 (10.83)	20 (12.58)
		Occasionally	5 (3.18)	9 (5.66)
		Frequently	3 (1.91)	2 (1.26)
		Almost constantly	1 (0.64)	0 (0.00)
	Week 7	n	186	173
		Never	160 (86.02)	137 (79.19)
		Rarely	14 (7.53)	20 (11.56)
		Occasionally	9 (4.84)	14 (8.09)
		Frequently	3 (1.61)	2 (1.16)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 8	n	145	139
		Never	127 (87.59)	113 (81.29)
		Rarely	14 (9.66)	19 (13.67)
		Occasionally	3 (2.07)	4 (2.88)
		Frequently	1 (0.69)	3 (2.16)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 9	n	168	125
		Never	144 (85.71)	95 (76.00)
		Rarely	19 (11.31)	22 (17.60)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Chills Frequency	Week 9	Occasionally	1 (0.60)	5 (4.00)
		Frequently	4 (2.38)	3 (2.40)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 10	n	141	134
		Never	125 (88.65)	108 (80.60)
		Rarely	10 (7.09)	16 (11.94)
		Occasionally	3 (2.13)	6 (4.48)
		Frequently	3 (2.13)	4 (2.99)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 11	n	156	119
		Never	139 (89.10)	96 (80.67)
		Rarely	10 (6.41)	13 (10.92)
		Occasionally	6 (3.85)	8 (6.72)
		Frequently	1 (0.64)	2 (1.68)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 12	n	130	116
		Never	115 (88.46)	89 (76.72)
		Rarely	12 (9.23)	20 (17.24)
		Occasionally	3 (2.31)	5 (4.31)
		Frequently	0 (0.00)	2 (1.72)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 13	n	155	126
		Never	135 (87.10)	104 (82.54)
		Rarely	16 (10.32)	16 (12.70)
		Occasionally	3 (1.94)	4 (3.17)
		Frequently	1 (0.65)	2 (1.59)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 19	n	117	89
		Never	102 (87.18)	68 (76.40)
		Rarely	12 (10.26)	15 (16.85)
		Occasionally	3 (2.56)	5 (5.62)
		Frequently	0 (0.00)	1 (1.12)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 25	n	107	60
		Never	94 (87.85)	47 (78.33)
		Rarely	10 (9.35)	10 (16.67)
		Occasionally	2 (1.87)	3 (5.00)
		Frequently	1 (0.93)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 31	n	90	41
		Never	78 (86.67)	32 (78.05)
		Rarely	8 (8.89)	8 (19.51)
		Occasionally	4 (4.44)	1 (2.44)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 37	n	75	21
		Never	68 (90.67)	18 (85.71)
		Rarely	3 (4.00)	3 (14.29)
		Occasionally	1 (1.33)	0 (0.00)
		Frequently	3 (4.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Frequency Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Chills Frequency	Week 43	n	46	12
		Never	44 (95.65)	9 (75.00)
		Rarely	0 (0.00)	3 (25.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	2 (4.35)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 49	n	32	6
		Never	30 (93.75)	6 (100.0)
		Rarely	1 (3.13)	0 (0.00)
		Occasionally	1 (3.13)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		Never	22 (100.0)	3 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		Never	16 (94.12)	2 (100.0)
		Rarely	1 (5.88)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		Never	6 (100.0)	1 (100.0)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		Never	2 (100.0)	0 (0.00)
		Rarely	0 (0.00)	0 (0.00)
		Occasionally	0 (0.00)	0 (0.00)
		Frequently	0 (0.00)	0 (0.00)
		Almost constantly	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		Never	94 (82.46)	112 (74.17)
		Rarely	15 (13.16)	30 (19.87)
		Occasionally	4 (3.51)	6 (3.97)
		Frequently	1 (0.88)	2 (1.32)
		Almost constantly	0 (0.00)	1 (0.66)
	Safety Follow-Up	n	65	91
		Never	52 (80.00)	74 (81.32)
		Rarely	8 (12.31)	12 (13.19)
		Occasionally	4 (6.15)	4 (4.40)
		Frequently	1 (1.54)	1 (1.10)
		Almost constantly	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Taste Changes Severity	Baseline	n	14	9
		None	12 (85.71)	6 (66.67)
		Mild	1 (7.14)	2 (22.22)
		Moderate	0 (0.00)	0 (0.00)
		Severe	1 (7.14)	0 (0.00)
		Very severe	0 (0.00)	1 (11.11)
	Week 2	n	20	5
		None	12 (60.00)	4 (80.00)
		Mild	4 (20.00)	0 (0.00)
		Moderate	2 (10.00)	1 (20.00)
		Severe	1 (5.00)	0 (0.00)
		Very severe	1 (5.00)	0 (0.00)
	Week 3	n	29	10
		None	15 (51.72)	5 (50.00)
		Mild	5 (17.24)	3 (30.00)
		Moderate	2 (6.90)	0 (0.00)
		Severe	5 (17.24)	1 (10.00)
		Very severe	2 (6.90)	1 (10.00)
	Week 4	n	24	19
		None	9 (37.50)	12 (63.16)
		Mild	6 (25.00)	3 (15.79)
		Moderate	6 (25.00)	2 (10.53)
		Severe	1 (4.17)	1 (5.26)
		Very severe	2 (8.33)	1 (5.26)
	Week 5	n	37	15
		None	13 (35.14)	6 (40.00)
		Mild	8 (21.62)	4 (26.67)
		Moderate	6 (16.22)	4 (26.67)
		Severe	4 (10.81)	0 (0.00)
		Very severe	6 (16.22)	1 (6.67)
	Week 6	n	28	21
		None	9 (32.14)	11 (52.38)
		Mild	9 (32.14)	6 (28.57)
		Moderate	6 (21.43)	3 (14.29)
		Severe	3 (10.71)	0 (0.00)
		Very severe	1 (3.57)	1 (4.76)
	Week 7	n	48	27
		None	12 (25.00)	17 (62.96)
		Mild	17 (35.42)	7 (25.93)
		Moderate	9 (18.75)	2 (7.41)
		Severe	6 (12.50)	1 (3.70)
		Very severe	4 (8.33)	0 (0.00)
	Week 8	n	31	18
		None	7 (22.58)	11 (61.11)
		Mild	10 (32.26)	6 (33.33)
		Moderate	8 (25.81)	0 (0.00)
		Severe	4 (12.90)	0 (0.00)
		Very severe	2 (6.45)	1 (5.56)
	Week 9	n	48	17
		None	12 (25.00)	10 (58.82)
		Mild	9 (18.75)	3 (17.65)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Taste Changes Severity	Week 9	Moderate	12 (25.00)	2 (11.76)
		Severe	10 (20.83)	0 (0.00)
		Very severe	5 (10.42)	2 (11.76)
	Week 10	n	39	31
		None	9 (23.08)	19 (61.29)
		Mild	11 (28.21)	9 (29.03)
		Moderate	10 (25.64)	2 (6.45)
		Severe	8 (20.51)	1 (3.23)
		Very severe	1 (2.56)	0 (0.00)
	Week 11	n	50	29
		None	15 (30.00)	16 (55.17)
		Mild	10 (20.00)	8 (27.59)
		Moderate	12 (24.00)	3 (10.34)
		Severe	10 (20.00)	1 (3.45)
		Very severe	3 (6.00)	1 (3.45)
	Week 12	n	38	26
		None	9 (23.68)	16 (61.54)
		Mild	8 (21.05)	8 (30.77)
		Moderate	4 (10.53)	1 (3.85)
		Severe	13 (34.21)	1 (3.85)
		Very severe	4 (10.53)	0 (0.00)
	Week 13	n	56	43
		None	12 (21.43)	26 (60.47)
		Mild	15 (26.79)	14 (32.56)
		Moderate	11 (19.64)	2 (4.65)
		Severe	15 (26.79)	1 (2.33)
		Very severe	3 (5.36)	0 (0.00)
	Week 19	n	50	36
		None	11 (22.00)	21 (58.33)
		Mild	11 (22.00)	12 (33.33)
		Moderate	11 (22.00)	2 (5.56)
		Severe	14 (28.00)	1 (2.78)
		Very severe	3 (6.00)	0 (0.00)
	Week 25	n	58	34
		None	20 (34.48)	28 (82.35)
		Mild	14 (24.14)	5 (14.71)
		Moderate	12 (20.69)	1 (2.94)
		Severe	9 (15.52)	0 (0.00)
		Very severe	3 (5.17)	0 (0.00)
	Week 31	n	55	24
		None	21 (38.18)	16 (66.67)
		Mild	16 (29.09)	7 (29.17)
		Moderate	8 (14.55)	1 (4.17)
		Severe	5 (9.09)	0 (0.00)
		Very severe	5 (9.09)	0 (0.00)
	Week 37	n	55	18
		None	20 (36.36)	9 (50.00)
		Mild	19 (34.55)	6 (33.33)
		Moderate	9 (16.36)	1 (5.56)
		Severe	4 (7.27)	0 (0.00)
		Very severe	3 (5.45)	2 (11.11)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Taste Changes Severity	Week 43	n	34	10
		None	19 (55.88)	6 (60.00)
		Mild	8 (23.53)	4 (40.00)
		Moderate	2 (5.88)	0 (0.00)
		Severe	3 (8.82)	0 (0.00)
		Very severe	2 (5.88)	0 (0.00)
	Week 49	n	24	4
		None	13 (54.17)	3 (75.00)
		Mild	3 (12.50)	1 (25.00)
		Moderate	5 (20.83)	0 (0.00)
		Severe	2 (8.33)	0 (0.00)
		Very severe	1 (4.17)	0 (0.00)
	Week 55	n	15	1
		None	11 (73.33)	0 (0.00)
		Mild	2 (13.33)	1 (100.0)
		Moderate	1 (6.67)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	1 (6.67)	0 (0.00)
	Week 61	n	12	1
		None	9 (75.00)	0 (0.00)
		Mild	3 (25.00)	0 (0.00)
		Moderate	0 (0.00)	1 (100.0)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	5	0
		None	3 (60.00)	0 (0.00)
		Mild	2 (40.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		None	1 (50.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	1 (50.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	41	57
		None	13 (31.71)	37 (64.91)
		Mild	12 (29.27)	12 (21.05)
		Moderate	7 (17.07)	3 (5.26)
		Severe	6 (14.63)	2 (3.51)
		Very severe	3 (7.32)	3 (5.26)
	Safety Follow-Up	n	25	35
		None	6 (24.00)	26 (74.29)
		Mild	8 (32.00)	6 (17.14)
		Moderate	5 (20.00)	0 (0.00)
		Severe	4 (16.00)	1 (2.86)
		Very severe	2 (8.00)	2 (5.71)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Decreased Appetite Severity	Baseline	n	247	250
		None	151 (61.13)	144 (57.60)
		Mild	44 (17.81)	54 (21.60)
		Moderate	28 (11.34)	35 (14.00)
		Severe	19 (7.69)	13 (5.20)
		Very severe	5 (2.02)	4 (1.60)
	Week 2	n	225	170
		None	110 (48.89)	84 (49.41)
		Mild	49 (21.78)	44 (25.88)
		Moderate	35 (15.56)	20 (11.76)
		Severe	21 (9.33)	17 (10.00)
		Very severe	10 (4.44)	5 (2.94)
	Week 3	n	215	172
		None	67 (31.16)	91 (52.91)
		Mild	62 (28.84)	39 (22.67)
		Moderate	43 (20.00)	19 (11.05)
		Severe	30 (13.95)	19 (11.05)
		Very severe	13 (6.05)	4 (2.33)
	Week 4	n	175	190
		None	65 (37.14)	89 (46.84)
		Mild	60 (34.29)	54 (28.42)
		Moderate	25 (14.29)	24 (12.63)
		Severe	19 (10.86)	17 (8.95)
		Very severe	6 (3.43)	6 (3.16)
	Week 5	n	201	159
		None	82 (40.80)	67 (42.14)
		Mild	65 (32.34)	52 (32.70)
		Moderate	32 (15.92)	19 (11.95)
		Severe	16 (7.96)	15 (9.43)
		Very severe	6 (2.99)	6 (3.77)
	Week 6	n	157	159
		None	75 (47.77)	82 (51.57)
		Mild	51 (32.48)	43 (27.04)
		Moderate	18 (11.46)	20 (12.58)
		Severe	10 (6.37)	9 (5.66)
		Very severe	3 (1.91)	5 (3.14)
	Week 7	n	186	173
		None	81 (43.55)	85 (49.13)
		Mild	66 (35.48)	53 (30.64)
		Moderate	21 (11.29)	22 (12.72)
		Severe	14 (7.53)	11 (6.36)
		Very severe	4 (2.15)	2 (1.16)
	Week 8	n	145	139
		None	72 (49.66)	70 (50.36)
		Mild	48 (33.10)	43 (30.94)
		Moderate	16 (11.03)	18 (12.95)
		Severe	8 (5.52)	6 (4.32)
		Very severe	1 (0.69)	2 (1.44)
	Week 9	n	168	125
		None	84 (50.00)	66 (52.80)
		Mild	42 (25.00)	30 (24.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Decreased Appetite Severity	Week 9	Moderate	26 (15.48)	21 (16.80)
		Severe	13 (7.74)	7 (5.60)
		Very severe	3 (1.79)	1 (0.80)
	Week 10	n	141	134
		None	71 (50.35)	71 (52.99)
		Mild	41 (29.08)	42 (31.34)
		Moderate	20 (14.18)	18 (13.43)
		Severe	8 (5.67)	3 (2.24)
		Very severe	1 (0.71)	0 (0.00)
	Week 11	n	156	119
		None	86 (55.13)	62 (52.10)
		Mild	35 (22.44)	36 (30.25)
		Moderate	19 (12.18)	10 (8.40)
		Severe	13 (8.33)	7 (5.88)
		Very severe	3 (1.92)	4 (3.36)
	Week 12	n	130	116
		None	72 (55.38)	53 (45.69)
		Mild	30 (23.08)	40 (34.48)
		Moderate	14 (10.77)	16 (13.79)
		Severe	11 (8.46)	6 (5.17)
		Very severe	3 (2.31)	1 (0.86)
	Week 13	n	155	126
		None	76 (49.03)	62 (49.21)
		Mild	42 (27.10)	41 (32.54)
		Moderate	20 (12.90)	19 (15.08)
		Severe	13 (8.39)	2 (1.59)
		Very severe	4 (2.58)	2 (1.59)
	Week 19	n	117	89
		None	59 (50.43)	48 (53.93)
		Mild	38 (32.48)	25 (28.09)
		Moderate	14 (11.97)	7 (7.87)
		Severe	6 (5.13)	9 (10.11)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	107	60
		None	57 (53.27)	44 (73.33)
		Mild	29 (27.10)	10 (16.67)
		Moderate	19 (17.76)	6 (10.00)
		Severe	2 (1.87)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	90	41
		None	46 (51.11)	26 (63.41)
		Mild	24 (26.67)	10 (24.39)
		Moderate	14 (15.56)	3 (7.32)
		Severe	5 (5.56)	2 (4.88)
		Very severe	1 (1.11)	0 (0.00)
	Week 37	n	75	21
		None	35 (46.67)	12 (57.14)
		Mild	28 (37.33)	7 (33.33)
		Moderate	7 (9.33)	1 (4.76)
		Severe	3 (4.00)	0 (0.00)
		Very severe	2 (2.67)	1 (4.76)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Decreased Appetite Severity	Week 43	n	46	12
		None	29 (63.04)	7 (58.33)
		Mild	13 (28.26)	5 (41.67)
		Moderate	2 (4.35)	0 (0.00)
		Severe	2 (4.35)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	32	6
		None	20 (62.50)	6 (100.0)
		Mild	7 (21.88)	0 (0.00)
		Moderate	4 (12.50)	0 (0.00)
		Severe	1 (3.13)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		None	15 (68.18)	3 (100.0)
		Mild	5 (22.73)	0 (0.00)
		Moderate	2 (9.09)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		None	14 (82.35)	2 (100.0)
		Mild	3 (17.65)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		None	4 (66.67)	1 (100.0)
		Mild	1 (16.67)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	1 (16.67)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		None	2 (100.0)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		None	39 (34.21)	76 (50.33)
		Mild	36 (31.58)	33 (21.85)
		Moderate	24 (21.05)	21 (13.91)
		Severe	7 (6.14)	14 (9.27)
		Very severe	8 (7.02)	7 (4.64)
	Safety Follow-Up	n	65	91
		None	21 (32.31)	55 (60.44)
		Mild	25 (38.46)	23 (25.27)
		Moderate	11 (16.92)	9 (9.89)
		Severe	3 (4.62)	1 (1.10)
		Very severe	5 (7.69)	3 (3.30)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Nausea Severity	Baseline	n	48	56
		None	8 (16.67)	5 (8.93)
		Mild	23 (47.92)	28 (50.00)
		Moderate	13 (27.08)	15 (26.79)
		Severe	3 (6.25)	7 (12.50)
		Very severe	1 (2.08)	1 (1.79)
	Week 2	n	56	64
		None	2 (3.57)	7 (10.94)
		Mild	26 (46.43)	27 (42.19)
		Moderate	18 (32.14)	17 (26.56)
		Severe	7 (12.50)	9 (14.06)
		Very severe	3 (5.36)	4 (6.25)
	Week 3	n	76	52
		None	8 (10.53)	7 (13.46)
		Mild	40 (52.63)	29 (55.77)
		Moderate	17 (22.37)	10 (19.23)
		Severe	11 (14.47)	5 (9.62)
		Very severe	0 (0.00)	1 (1.92)
	Week 4	n	43	64
		None	0 (0.00)	2 (3.13)
		Mild	30 (69.77)	41 (64.06)
		Moderate	9 (20.93)	17 (26.56)
		Severe	4 (9.30)	3 (4.69)
		Very severe	0 (0.00)	1 (1.56)
	Week 5	n	41	62
		None	2 (4.88)	6 (9.68)
		Mild	22 (53.66)	32 (51.61)
		Moderate	15 (36.59)	15 (24.19)
		Severe	2 (4.88)	9 (14.52)
		Very severe	0 (0.00)	0 (0.00)
	Week 6	n	29	49
		None	3 (10.34)	6 (12.24)
		Mild	19 (65.52)	27 (55.10)
		Moderate	3 (10.34)	11 (22.45)
		Severe	1 (3.45)	4 (8.16)
		Very severe	3 (10.34)	1 (2.04)
	Week 7	n	32	55
		None	1 (3.13)	8 (14.55)
		Mild	24 (75.00)	33 (60.00)
		Moderate	4 (12.50)	13 (23.64)
		Severe	2 (6.25)	1 (1.82)
		Very severe	1 (3.13)	0 (0.00)
	Week 8	n	14	43
		None	2 (14.29)	6 (13.95)
		Mild	9 (64.29)	21 (48.84)
		Moderate	3 (21.43)	10 (23.26)
		Severe	0 (0.00)	6 (13.95)
		Very severe	0 (0.00)	0 (0.00)
	Week 9	n	26	35
		None	1 (3.85)	1 (2.86)
		Mild	17 (65.38)	19 (54.29)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Nausea Severity	Week 9	Moderate	6 (23.08)	10 (28.57)
		Severe	1 (3.85)	2 (5.71)
		Very severe	1 (3.85)	3 (8.57)
	Week 10	n	22	39
		None	5 (22.73)	5 (12.82)
		Mild	11 (50.00)	25 (64.10)
		Moderate	4 (18.18)	8 (20.51)
		Severe	1 (4.55)	1 (2.56)
		Very severe	1 (4.55)	0 (0.00)
	Week 11	n	23	39
		None	0 (0.00)	4 (10.26)
		Mild	15 (65.22)	20 (51.28)
		Moderate	6 (26.09)	12 (30.77)
		Severe	1 (4.35)	2 (5.13)
		Very severe	1 (4.35)	1 (2.56)
	Week 12	n	16	35
		None	1 (6.25)	6 (17.14)
		Mild	10 (62.50)	26 (74.29)
		Moderate	4 (25.00)	3 (8.57)
		Severe	1 (6.25)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 13	n	24	32
		None	2 (8.33)	5 (15.63)
		Mild	13 (54.17)	21 (65.63)
		Moderate	7 (29.17)	6 (18.75)
		Severe	2 (8.33)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 19	n	14	27
		None	2 (14.29)	1 (3.70)
		Mild	8 (57.14)	15 (55.56)
		Moderate	1 (7.14)	10 (37.04)
		Severe	3 (21.43)	1 (3.70)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	14	12
		None	0 (0.00)	0 (0.00)
		Mild	12 (85.71)	9 (75.00)
		Moderate	2 (14.29)	2 (16.67)
		Severe	0 (0.00)	1 (8.33)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	11	7
		None	0 (0.00)	1 (14.29)
		Mild	7 (63.64)	5 (71.43)
		Moderate	4 (36.36)	1 (14.29)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	11	3
		None	1 (9.09)	1 (33.33)
		Mild	7 (63.64)	1 (33.33)
		Moderate	1 (9.09)	0 (0.00)
		Severe	1 (9.09)	0 (0.00)
		Very severe	1 (9.09)	1 (33.33)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Nausea Severity	Week 43	n	5	3
		None	0 (0.00)	1 (33.33)
		Mild	3 (60.00)	2 (66.67)
		Moderate	2 (40.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	0	1
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	1 (100.0)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	1 (100.0)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	25	47
		None	1 (4.00)	9 (19.15)
		Mild	15 (60.00)	22 (46.81)
		Moderate	3 (12.00)	9 (19.15)
		Severe	5 (20.00)	4 (8.51)
		Very severe	1 (4.00)	3 (6.38)
	Safety Follow-Up	n	19	25
		None	1 (5.26)	4 (16.00)
		Mild	9 (47.37)	16 (64.00)
		Moderate	4 (21.05)	5 (20.00)
		Severe	3 (15.79)	0 (0.00)
		Very severe	2 (10.53)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Vomiting Severity	Baseline	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 2	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 3	n	4	0
		None	1 (25.00)	0 (0.00)
		Mild	2 (50.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	1 (25.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 4	n	1	1
		None	0 (0.00)	1 (100.0)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 5	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 6	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 7	n	1	1
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	1 (100.0)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 8	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 9	n	2	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (50.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Vomiting Severity	Week 9	Moderate	1 (50.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 10	n	1	2
		None	0 (0.00)	2 (100.0)
		Mild	0 (0.00)	0 (0.00)
		Moderate	1 (100.0)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 11	n	3	0
		None	0 (0.00)	0 (0.00)
		Mild	2 (66.67)	0 (0.00)
		Moderate	1 (33.33)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 12	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 13	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	1 (100.0)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 19	n	2	3
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	3 (100.0)
		Moderate	2 (100.0)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	1 (100.0)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	1 (100.0)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Vomiting Severity	Week 43	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	1 (100.0)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	4	3
		None	0 (0.00)	0 (0.00)
		Mild	2 (50.00)	3 (100.0)
		Moderate	1 (25.00)	0 (0.00)
		Severe	1 (25.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Safety Follow-Up	n	5	0
		None	0 (0.00)	0 (0.00)
		Mild	5 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Constipation Severity	Baseline	n	2	1
		None	2 (100.0)	1 (100.0)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 2	n	11	3
		None	8 (72.73)	3 (100.0)
		Mild	3 (27.27)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 3	n	20	5
		None	11 (55.00)	5 (100.0)
		Mild	5 (25.00)	0 (0.00)
		Moderate	3 (15.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	1 (5.00)	0 (0.00)
	Week 4	n	16	11
		None	11 (68.75)	8 (72.73)
		Mild	3 (18.75)	3 (27.27)
		Moderate	0 (0.00)	0 (0.00)
		Severe	2 (12.50)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 5	n	27	10
		None	18 (66.67)	7 (70.00)
		Mild	5 (18.52)	1 (10.00)
		Moderate	1 (3.70)	2 (20.00)
		Severe	2 (7.41)	0 (0.00)
		Very severe	1 (3.70)	0 (0.00)
	Week 6	n	20	15
		None	16 (80.00)	11 (73.33)
		Mild	3 (15.00)	2 (13.33)
		Moderate	1 (5.00)	1 (6.67)
		Severe	0 (0.00)	1 (6.67)
		Very severe	0 (0.00)	0 (0.00)
	Week 7	n	34	19
		None	19 (55.88)	15 (78.95)
		Mild	8 (23.53)	2 (10.53)
		Moderate	4 (11.76)	1 (5.26)
		Severe	0 (0.00)	1 (5.26)
		Very severe	3 (8.82)	0 (0.00)
	Week 8	n	20	13
		None	16 (80.00)	11 (84.62)
		Mild	2 (10.00)	1 (7.69)
		Moderate	1 (5.00)	1 (7.69)
		Severe	1 (5.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 9	n	33	13
		None	19 (57.58)	11 (84.62)
		Mild	7 (21.21)	1 (7.69)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Constipation Severity	Week 9	Moderate	4 (12.12)	0 (0.00)
		Severe	2 (6.06)	1 (7.69)
		Very severe	1 (3.03)	0 (0.00)
	Week 10	n	25	20
		None	17 (68.00)	11 (55.00)
		Mild	4 (16.00)	7 (35.00)
		Moderate	3 (12.00)	2 (10.00)
		Severe	1 (4.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 11	n	34	20
		None	21 (61.76)	14 (70.00)
		Mild	7 (20.59)	4 (20.00)
		Moderate	5 (14.71)	2 (10.00)
		Severe	1 (2.94)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 12	n	29	17
		None	20 (68.97)	13 (76.47)
		Mild	5 (17.24)	3 (17.65)
		Moderate	2 (6.90)	1 (5.88)
		Severe	2 (6.90)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 13	n	34	26
		None	19 (55.88)	18 (69.23)
		Mild	8 (23.53)	6 (23.08)
		Moderate	5 (14.71)	2 (7.69)
		Severe	2 (5.88)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 19	n	31	20
		None	16 (51.61)	14 (70.00)
		Mild	5 (16.13)	3 (15.00)
		Moderate	7 (22.58)	2 (10.00)
		Severe	3 (9.68)	1 (5.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	36	23
		None	20 (55.56)	17 (73.91)
		Mild	5 (13.89)	3 (13.04)
		Moderate	8 (22.22)	2 (8.70)
		Severe	3 (8.33)	1 (4.35)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	37	17
		None	22 (59.46)	12 (70.59)
		Mild	8 (21.62)	3 (17.65)
		Moderate	5 (13.51)	0 (0.00)
		Severe	2 (5.41)	2 (11.76)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	42	15
		None	26 (61.90)	6 (40.00)
		Mild	9 (21.43)	4 (26.67)
		Moderate	3 (7.14)	5 (33.33)
		Severe	2 (4.76)	0 (0.00)
		Very severe	2 (4.76)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Constipation Severity	Week 43	n	29	8
		None	19 (65.52)	5 (62.50)
		Mild	6 (20.69)	2 (25.00)
		Moderate	3 (10.34)	1 (12.50)
		Severe	1 (3.45)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	19	4
		None	14 (73.68)	3 (75.00)
		Mild	3 (15.79)	1 (25.00)
		Moderate	2 (10.53)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	13	1
		None	10 (76.92)	1 (100.0)
		Mild	3 (23.08)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	12	1
		None	9 (75.00)	0 (0.00)
		Mild	2 (16.67)	1 (100.0)
		Moderate	0 (0.00)	0 (0.00)
		Severe	1 (8.33)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	5	0
		None	4 (80.00)	0 (0.00)
		Mild	1 (20.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		None	2 (100.0)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	33	46
		None	17 (51.52)	27 (58.70)
		Mild	8 (24.24)	12 (26.09)
		Moderate	6 (18.18)	6 (13.04)
		Severe	2 (6.06)	1 (2.17)
		Very severe	0 (0.00)	0 (0.00)
	Safety Follow-Up	n	18	27
		None	12 (66.67)	20 (74.07)
		Mild	4 (22.22)	4 (14.81)
		Moderate	1 (5.56)	0 (0.00)
		Severe	0 (0.00)	2 (7.41)
		Very severe	1 (5.56)	1 (3.70)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Swelling Severity	Baseline	n	29	29
		None	5 (17.24)	2 (6.90)
		Mild	15 (51.72)	20 (68.97)
		Moderate	7 (24.14)	5 (17.24)
		Severe	0 (0.00)	1 (3.45)
		Very severe	2 (6.90)	1 (3.45)
	Week 2	n	24	19
		None	4 (16.67)	6 (31.58)
		Mild	14 (58.33)	10 (52.63)
		Moderate	4 (16.67)	3 (15.79)
		Severe	2 (8.33)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 3	n	24	24
		None	4 (16.67)	6 (25.00)
		Mild	14 (58.33)	16 (66.67)
		Moderate	3 (12.50)	0 (0.00)
		Severe	3 (12.50)	0 (0.00)
		Very severe	0 (0.00)	2 (8.33)
	Week 4	n	11	33
		None	3 (27.27)	7 (21.21)
		Mild	3 (27.27)	18 (54.55)
		Moderate	4 (36.36)	2 (6.06)
		Severe	1 (9.09)	4 (12.12)
		Very severe	0 (0.00)	2 (6.06)
	Week 5	n	12	17
		None	2 (16.67)	3 (17.65)
		Mild	8 (66.67)	8 (47.06)
		Moderate	1 (8.33)	4 (23.53)
		Severe	1 (8.33)	2 (11.76)
		Very severe	0 (0.00)	0 (0.00)
	Week 6	n	10	20
		None	2 (20.00)	5 (25.00)
		Mild	7 (70.00)	10 (50.00)
		Moderate	1 (10.00)	4 (20.00)
		Severe	0 (0.00)	1 (5.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 7	n	12	33
		None	1 (8.33)	10 (30.30)
		Mild	9 (75.00)	15 (45.45)
		Moderate	2 (16.67)	3 (9.09)
		Severe	0 (0.00)	4 (12.12)
		Very severe	0 (0.00)	1 (3.03)
	Week 8	n	5	20
		None	1 (20.00)	4 (20.00)
		Mild	3 (60.00)	13 (65.00)
		Moderate	1 (20.00)	1 (5.00)
		Severe	0 (0.00)	1 (5.00)
		Very severe	0 (0.00)	1 (5.00)
	Week 9	n	9	22
		None	0 (0.00)	4 (18.18)
		Mild	9 (100.0)	13 (59.09)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Swelling Severity	Week 9	Moderate	0 (0.00)	4 (18.18)
		Severe	0 (0.00)	1 (4.55)
		Very severe	0 (0.00)	0 (0.00)
	Week 10	n	7	27
		None	0 (0.00)	4 (14.81)
		Mild	6 (85.71)	18 (66.67)
		Moderate	1 (14.29)	3 (11.11)
		Severe	0 (0.00)	2 (7.41)
		Very severe	0 (0.00)	0 (0.00)
	Week 11	n	11	19
		None	3 (27.27)	3 (15.79)
		Mild	7 (63.64)	10 (52.63)
		Moderate	1 (9.09)	2 (10.53)
		Severe	0 (0.00)	4 (21.05)
		Very severe	0 (0.00)	0 (0.00)
	Week 12	n	7	18
		None	1 (14.29)	3 (16.67)
		Mild	6 (85.71)	11 (61.11)
		Moderate	0 (0.00)	2 (11.11)
		Severe	0 (0.00)	2 (11.11)
		Very severe	0 (0.00)	0 (0.00)
	Week 13	n	11	23
		None	1 (9.09)	2 (8.70)
		Mild	10 (90.91)	15 (65.22)
		Moderate	0 (0.00)	5 (21.74)
		Severe	0 (0.00)	1 (4.35)
		Very severe	0 (0.00)	0 (0.00)
	Week 19	n	6	22
		None	1 (16.67)	3 (13.64)
		Mild	5 (83.33)	14 (63.64)
		Moderate	0 (0.00)	4 (18.18)
		Severe	0 (0.00)	1 (4.55)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	11	10
		None	3 (27.27)	0 (0.00)
		Mild	8 (72.73)	9 (90.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	1 (10.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	7	9
		None	1 (14.29)	1 (11.11)
		Mild	6 (85.71)	8 (88.89)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	6	8
		None	3 (50.00)	0 (0.00)
		Mild	3 (50.00)	7 (87.50)
		Moderate	0 (0.00)	1 (12.50)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Swelling Severity	Week 43	n	3	3
		None	1 (33.33)	0 (0.00)
		Mild	2 (66.67)	3 (100.0)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	11	33
		None	2 (18.18)	3 (9.09)
		Mild	5 (45.45)	21 (63.64)
		Moderate	3 (27.27)	7 (21.21)
		Severe	1 (9.09)	1 (3.03)
		Very severe	0 (0.00)	1 (3.03)
	Safety Follow-Up	n	10	11
		None	2 (20.00)	0 (0.00)
		Mild	5 (50.00)	6 (54.55)
		Moderate	3 (30.00)	5 (45.45)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Heart Palpitations Severity	Baseline	n	46	63
		None	3 (6.52)	11 (17.46)
		Mild	35 (76.09)	35 (55.56)
		Moderate	4 (8.70)	15 (23.81)
		Severe	3 (6.52)	2 (3.17)
		Very severe	1 (2.17)	0 (0.00)
	Week 2	n	52	46
		None	5 (9.62)	7 (15.22)
		Mild	41 (78.85)	27 (58.70)
		Moderate	5 (9.62)	11 (23.91)
		Severe	1 (1.92)	1 (2.17)
		Very severe	0 (0.00)	0 (0.00)
	Week 3	n	45	46
		None	7 (15.56)	4 (8.70)
		Mild	29 (64.44)	28 (60.87)
		Moderate	8 (17.78)	11 (23.91)
		Severe	0 (0.00)	1 (2.17)
		Very severe	1 (2.22)	2 (4.35)
	Week 4	n	29	50
		None	6 (20.69)	6 (12.00)
		Mild	17 (58.62)	35 (70.00)
		Moderate	6 (20.69)	6 (12.00)
		Severe	0 (0.00)	2 (4.00)
		Very severe	0 (0.00)	1 (2.00)
	Week 5	n	36	48
		None	6 (16.67)	0 (0.00)
		Mild	21 (58.33)	34 (70.83)
		Moderate	8 (22.22)	11 (22.92)
		Severe	1 (2.78)	3 (6.25)
		Very severe	0 (0.00)	0 (0.00)
	Week 6	n	21	34
		None	4 (19.05)	3 (8.82)
		Mild	13 (61.90)	24 (70.59)
		Moderate	2 (9.52)	6 (17.65)
		Severe	2 (9.52)	1 (2.94)
		Very severe	0 (0.00)	0 (0.00)
	Week 7	n	26	39
		None	2 (7.69)	4 (10.26)
		Mild	20 (76.92)	25 (64.10)
		Moderate	4 (15.38)	9 (23.08)
		Severe	0 (0.00)	1 (2.56)
		Very severe	0 (0.00)	0 (0.00)
	Week 8	n	13	31
		None	0 (0.00)	3 (9.68)
		Mild	11 (84.62)	21 (67.74)
		Moderate	1 (7.69)	4 (12.90)
		Severe	0 (0.00)	3 (9.68)
		Very severe	1 (7.69)	0 (0.00)
	Week 9	n	24	35
		None	5 (20.83)	3 (8.57)
		Mild	15 (62.50)	24 (68.57)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Heart Palpitations Severity	Week 9	Moderate	3 (12.50)	6 (17.14)
		Severe	1 (4.17)	2 (5.71)
		Very severe	0 (0.00)	0 (0.00)
	Week 10	n	14	36
		None	3 (21.43)	3 (8.33)
		Mild	9 (64.29)	25 (69.44)
		Moderate	2 (14.29)	7 (19.44)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	1 (2.78)
	Week 11	n	24	32
		None	2 (8.33)	4 (12.50)
		Mild	19 (79.17)	20 (62.50)
		Moderate	3 (12.50)	7 (21.88)
		Severe	0 (0.00)	1 (3.13)
		Very severe	0 (0.00)	0 (0.00)
	Week 12	n	16	33
		None	3 (18.75)	4 (12.12)
		Mild	12 (75.00)	18 (54.55)
		Moderate	1 (6.25)	9 (27.27)
		Severe	0 (0.00)	1 (3.03)
		Very severe	0 (0.00)	1 (3.03)
	Week 13	n	17	30
		None	4 (23.53)	2 (6.67)
		Mild	10 (58.82)	20 (66.67)
		Moderate	3 (17.65)	7 (23.33)
		Severe	0 (0.00)	1 (3.33)
		Very severe	0 (0.00)	0 (0.00)
	Week 19	n	17	29
		None	3 (17.65)	3 (10.34)
		Mild	13 (76.47)	19 (65.52)
		Moderate	1 (5.88)	5 (17.24)
		Severe	0 (0.00)	2 (6.90)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	8	9
		None	2 (25.00)	2 (22.22)
		Mild	4 (50.00)	6 (66.67)
		Moderate	2 (25.00)	1 (11.11)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	8	9
		None	1 (12.50)	1 (11.11)
		Mild	4 (50.00)	8 (88.89)
		Moderate	3 (37.50)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	7	6
		None	1 (14.29)	0 (0.00)
		Mild	3 (42.86)	6 (100.0)
		Moderate	3 (42.86)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Heart Palpitations Severity	Week 43	n	3	3
		None	2 (66.67)	0 (0.00)
		Mild	1 (33.33)	3 (100.0)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	1	0
		None	1 (100.0)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	0	1
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	1 (100.0)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	31	48
		None	3 (9.68)	6 (12.50)
		Mild	23 (74.19)	27 (56.25)
		Moderate	5 (16.13)	11 (22.92)
		Severe	0 (0.00)	2 (4.17)
		Very severe	0 (0.00)	2 (4.17)
	Safety Follow-Up	n	14	22
		None	1 (7.14)	4 (18.18)
		Mild	12 (85.71)	15 (68.18)
		Moderate	1 (7.14)	2 (9.09)
		Severe	0 (0.00)	1 (4.55)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Dizziness Severity	Baseline	n	247	250
		None	197 (79.76)	183 (73.20)
		Mild	39 (15.79)	48 (19.20)
		Moderate	8 (3.24)	17 (6.80)
		Severe	2 (0.81)	2 (0.80)
		Very severe	1 (0.40)	0 (0.00)
	Week 2	n	225	170
		None	160 (71.11)	120 (70.59)
		Mild	51 (22.67)	37 (21.76)
		Moderate	12 (5.33)	8 (4.71)
		Severe	2 (0.89)	5 (2.94)
		Very severe	0 (0.00)	0 (0.00)
	Week 3	n	215	172
		None	141 (65.58)	126 (73.26)
		Mild	54 (25.12)	29 (16.86)
		Moderate	13 (6.05)	12 (6.98)
		Severe	5 (2.33)	3 (1.74)
		Very severe	2 (0.93)	2 (1.16)
	Week 4	n	175	190
		None	125 (71.43)	133 (70.00)
		Mild	37 (21.14)	37 (19.47)
		Moderate	8 (4.57)	18 (9.47)
		Severe	5 (2.86)	1 (0.53)
		Very severe	0 (0.00)	1 (0.53)
	Week 5	n	201	159
		None	145 (72.14)	94 (59.12)
		Mild	47 (23.38)	51 (32.08)
		Moderate	7 (3.48)	8 (5.03)
		Severe	1 (0.50)	6 (3.77)
		Very severe	1 (0.50)	0 (0.00)
	Week 6	n	157	159
		None	125 (79.62)	108 (67.92)
		Mild	28 (17.83)	44 (27.67)
		Moderate	2 (1.27)	6 (3.77)
		Severe	2 (1.27)	1 (0.63)
		Very severe	0 (0.00)	0 (0.00)
	Week 7	n	186	173
		None	145 (77.96)	114 (65.90)
		Mild	36 (19.35)	47 (27.17)
		Moderate	3 (1.61)	9 (5.20)
		Severe	2 (1.08)	2 (1.16)
		Very severe	0 (0.00)	1 (0.58)
	Week 8	n	145	139
		None	120 (82.76)	90 (64.75)
		Mild	22 (15.17)	34 (24.46)
		Moderate	2 (1.38)	14 (10.07)
		Severe	1 (0.69)	1 (0.72)
		Very severe	0 (0.00)	0 (0.00)
	Week 9	n	168	125
		None	136 (80.95)	87 (69.60)
		Mild	25 (14.88)	24 (19.20)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Dizziness Severity	Week 9	Moderate	5 (2.98)	10 (8.00)
		Severe	2 (1.19)	2 (1.60)
		Very severe	0 (0.00)	2 (1.60)
	Week 10	n	141	134
		None	118 (83.69)	86 (64.18)
		Mild	20 (14.18)	36 (26.87)
		Moderate	3 (2.13)	10 (7.46)
		Severe	0 (0.00)	2 (1.49)
		Very severe	0 (0.00)	0 (0.00)
	Week 11	n	156	119
		None	128 (82.05)	73 (61.34)
		Mild	22 (14.10)	33 (27.73)
		Moderate	5 (3.21)	10 (8.40)
		Severe	1 (0.64)	3 (2.52)
		Very severe	0 (0.00)	0 (0.00)
	Week 12	n	130	116
		None	105 (80.77)	77 (66.38)
		Mild	19 (14.62)	27 (23.28)
		Moderate	6 (4.62)	7 (6.03)
		Severe	0 (0.00)	4 (3.45)
		Very severe	0 (0.00)	1 (0.86)
	Week 13	n	155	126
		None	124 (80.00)	80 (63.49)
		Mild	27 (17.42)	33 (26.19)
		Moderate	4 (2.58)	10 (7.94)
		Severe	0 (0.00)	3 (2.38)
		Very severe	0 (0.00)	0 (0.00)
	Week 19	n	117	89
		None	96 (82.05)	58 (65.17)
		Mild	19 (16.24)	21 (23.60)
		Moderate	2 (1.71)	6 (6.74)
		Severe	0 (0.00)	4 (4.49)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	107	60
		None	82 (76.64)	42 (70.00)
		Mild	22 (20.56)	14 (23.33)
		Moderate	3 (2.80)	4 (6.67)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	90	41
		None	73 (81.11)	31 (75.61)
		Mild	14 (15.56)	6 (14.63)
		Moderate	2 (2.22)	4 (9.76)
		Severe	1 (1.11)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	75	21
		None	62 (82.67)	10 (47.62)
		Mild	13 (17.33)	10 (47.62)
		Moderate	0 (0.00)	1 (4.76)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Dizziness Severity	Week 43	n	46	12
		None	37 (80.43)	7 (58.33)
		Mild	9 (19.57)	5 (41.67)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	32	6
		None	29 (90.63)	4 (66.67)
		Mild	3 (9.38)	2 (33.33)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		None	21 (95.45)	2 (66.67)
		Mild	1 (4.55)	1 (33.33)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		None	15 (88.24)	1 (50.00)
		Mild	2 (11.76)	0 (0.00)
		Moderate	0 (0.00)	1 (50.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		None	5 (83.33)	1 (100.0)
		Mild	1 (16.67)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		None	2 (100.0)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		None	81 (71.05)	96 (63.58)
		Mild	23 (20.18)	37 (24.50)
		Moderate	7 (6.14)	13 (8.61)
		Severe	3 (2.63)	3 (1.99)
		Very severe	0 (0.00)	2 (1.32)
	Safety Follow-Up	n	65	91
		None	44 (67.69)	63 (69.23)
		Mild	16 (24.62)	27 (29.67)
		Moderate	3 (4.62)	0 (0.00)
		Severe	2 (3.08)	1 (1.10)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Concentration Problems Severity	Baseline	n	247	250
		None	185 (74.90)	177 (70.80)
		Mild	48 (19.43)	54 (21.60)
		Moderate	12 (4.86)	15 (6.00)
		Severe	2 (0.81)	4 (1.60)
		Very severe	0 (0.00)	0 (0.00)
	Week 2	n	225	170
		None	157 (69.78)	120 (70.59)
		Mild	53 (23.56)	34 (20.00)
		Moderate	11 (4.89)	15 (8.82)
		Severe	3 (1.33)	1 (0.59)
		Very severe	1 (0.44)	0 (0.00)
	Week 3	n	215	172
		None	143 (66.51)	112 (65.12)
		Mild	52 (24.19)	40 (23.26)
		Moderate	15 (6.98)	16 (9.30)
		Severe	4 (1.86)	2 (1.16)
		Very severe	1 (0.47)	2 (1.16)
	Week 4	n	175	190
		None	124 (70.86)	127 (66.84)
		Mild	40 (22.86)	47 (24.74)
		Moderate	8 (4.57)	12 (6.32)
		Severe	2 (1.14)	3 (1.58)
		Very severe	1 (0.57)	1 (0.53)
	Week 5	n	201	159
		None	147 (73.13)	99 (62.26)
		Mild	42 (20.90)	44 (27.67)
		Moderate	8 (3.98)	13 (8.18)
		Severe	4 (1.99)	3 (1.89)
		Very severe	0 (0.00)	0 (0.00)
	Week 6	n	157	159
		None	117 (74.52)	109 (68.55)
		Mild	31 (19.75)	39 (24.53)
		Moderate	6 (3.82)	10 (6.29)
		Severe	3 (1.91)	1 (0.63)
		Very severe	0 (0.00)	0 (0.00)
	Week 7	n	186	173
		None	143 (76.88)	115 (66.47)
		Mild	33 (17.74)	45 (26.01)
		Moderate	10 (5.38)	11 (6.36)
		Severe	0 (0.00)	1 (0.58)
		Very severe	0 (0.00)	1 (0.58)
	Week 8	n	145	139
		None	117 (80.69)	89 (64.03)
		Mild	21 (14.48)	37 (26.62)
		Moderate	6 (4.14)	13 (9.35)
		Severe	1 (0.69)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 9	n	168	125
		None	125 (74.40)	83 (66.40)
		Mild	34 (20.24)	28 (22.40)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Concentration Problems Severity	Week 9	Moderate	4 (2.38)	10 (8.00)
		Severe	5 (2.98)	2 (1.60)
		Very severe	0 (0.00)	2 (1.60)
	Week 10	n	141	134
		None	111 (78.72)	88 (65.67)
		Mild	21 (14.89)	34 (25.37)
		Moderate	6 (4.26)	10 (7.46)
		Severe	3 (2.13)	2 (1.49)
		Very severe	0 (0.00)	0 (0.00)
	Week 11	n	156	119
		None	109 (69.87)	73 (61.34)
		Mild	39 (25.00)	33 (27.73)
		Moderate	7 (4.49)	8 (6.72)
		Severe	1 (0.64)	5 (4.20)
		Very severe	0 (0.00)	0 (0.00)
	Week 12	n	130	116
		None	91 (70.00)	79 (68.10)
		Mild	33 (25.38)	25 (21.55)
		Moderate	5 (3.85)	10 (8.62)
		Severe	1 (0.77)	1 (0.86)
		Very severe	0 (0.00)	1 (0.86)
	Week 13	n	155	126
		None	112 (72.26)	86 (68.25)
		Mild	36 (23.23)	22 (17.46)
		Moderate	6 (3.87)	17 (13.49)
		Severe	1 (0.65)	1 (0.79)
		Very severe	0 (0.00)	0 (0.00)
	Week 19	n	117	89
		None	90 (76.92)	62 (69.66)
		Mild	25 (21.37)	20 (22.47)
		Moderate	1 (0.85)	4 (4.49)
		Severe	1 (0.85)	3 (3.37)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	107	60
		None	74 (69.16)	47 (78.33)
		Mild	28 (26.17)	10 (16.67)
		Moderate	4 (3.74)	3 (5.00)
		Severe	1 (0.93)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	90	41
		None	69 (76.67)	25 (60.98)
		Mild	16 (17.78)	12 (29.27)
		Moderate	5 (5.56)	4 (9.76)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	75	21
		None	58 (77.33)	12 (57.14)
		Mild	11 (14.67)	8 (38.10)
		Moderate	5 (6.67)	0 (0.00)
		Severe	1 (1.33)	0 (0.00)
		Very severe	0 (0.00)	1 (4.76)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Concentration Problems Severity	Week 43	n	46	12
		None	36 (78.26)	8 (66.67)
		Mild	8 (17.39)	4 (33.33)
		Moderate	2 (4.35)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	32	6
		None	25 (78.13)	6 (100.0)
		Mild	5 (15.63)	0 (0.00)
		Moderate	2 (6.25)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		None	21 (95.45)	3 (100.0)
		Mild	1 (4.55)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		None	15 (88.24)	1 (50.00)
		Mild	2 (11.76)	1 (50.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		None	5 (83.33)	1 (100.0)
		Mild	1 (16.67)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		None	2 (100.0)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		None	76 (66.67)	91 (60.26)
		Mild	28 (24.56)	44 (29.14)
		Moderate	6 (5.26)	11 (7.28)
		Severe	3 (2.63)	2 (1.32)
		Very severe	1 (0.88)	3 (1.99)
	Safety Follow-Up	n	65	91
		None	42 (64.62)	61 (67.03)
		Mild	20 (30.77)	24 (26.37)
		Moderate	1 (1.54)	4 (4.40)
		Severe	1 (1.54)	0 (0.00)
		Very severe	1 (1.54)	2 (2.20)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Headache Severity	Baseline	n	60	63
		None	5 (8.33)	7 (11.11)
		Mild	40 (66.67)	39 (61.90)
		Moderate	13 (21.67)	12 (19.05)
		Severe	2 (3.33)	1 (1.59)
		Very severe	0 (0.00)	4 (6.35)
	Week 2	n	73	47
		None	6 (8.22)	3 (6.38)
		Mild	44 (60.27)	33 (70.21)
		Moderate	19 (26.03)	11 (23.40)
		Severe	4 (5.48)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 3	n	82	39
		None	4 (4.88)	2 (5.13)
		Mild	48 (58.54)	23 (58.97)
		Moderate	18 (21.95)	9 (23.08)
		Severe	9 (10.98)	5 (12.82)
		Very severe	3 (3.66)	0 (0.00)
	Week 4	n	47	61
		None	3 (6.38)	1 (1.64)
		Mild	30 (63.83)	44 (72.13)
		Moderate	10 (21.28)	15 (24.59)
		Severe	2 (4.26)	0 (0.00)
		Very severe	2 (4.26)	1 (1.64)
	Week 5	n	46	52
		None	5 (10.87)	6 (11.54)
		Mild	31 (67.39)	37 (71.15)
		Moderate	9 (19.57)	6 (11.54)
		Severe	1 (2.17)	3 (5.77)
		Very severe	0 (0.00)	0 (0.00)
	Week 6	n	37	43
		None	3 (8.11)	4 (9.30)
		Mild	24 (64.86)	32 (74.42)
		Moderate	9 (24.32)	7 (16.28)
		Severe	1 (2.70)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 7	n	43	39
		None	3 (6.98)	1 (2.56)
		Mild	31 (72.09)	28 (71.79)
		Moderate	8 (18.60)	9 (23.08)
		Severe	1 (2.33)	1 (2.56)
		Very severe	0 (0.00)	0 (0.00)
	Week 8	n	29	35
		None	3 (10.34)	3 (8.57)
		Mild	21 (72.41)	24 (68.57)
		Moderate	5 (17.24)	7 (20.00)
		Severe	0 (0.00)	1 (2.86)
		Very severe	0 (0.00)	0 (0.00)
	Week 9	n	38	37
		None	4 (10.53)	7 (18.92)
		Mild	26 (68.42)	22 (59.46)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Headache Severity	Week 9	Moderate	7 (18.42)	6 (16.22)
		Severe	1 (2.63)	1 (2.70)
		Very severe	0 (0.00)	1 (2.70)
	Week 10	n	28	45
		None	4 (14.29)	5 (11.11)
		Mild	15 (53.57)	30 (66.67)
		Moderate	8 (28.57)	10 (22.22)
		Severe	0 (0.00)	0 (0.00)
		Very severe	1 (3.57)	0 (0.00)
	Week 11	n	33	40
		None	5 (15.15)	6 (15.00)
		Mild	21 (63.64)	29 (72.50)
		Moderate	6 (18.18)	5 (12.50)
		Severe	1 (3.03)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 12	n	32	40
		None	4 (12.50)	6 (15.00)
		Mild	21 (65.63)	30 (75.00)
		Moderate	7 (21.88)	4 (10.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 13	n	29	30
		None	6 (20.69)	1 (3.33)
		Mild	18 (62.07)	22 (73.33)
		Moderate	4 (13.79)	6 (20.00)
		Severe	1 (3.45)	1 (3.33)
		Very severe	0 (0.00)	0 (0.00)
	Week 19	n	25	24
		None	0 (0.00)	1 (4.17)
		Mild	19 (76.00)	18 (75.00)
		Moderate	4 (16.00)	4 (16.67)
		Severe	1 (4.00)	0 (0.00)
		Very severe	1 (4.00)	1 (4.17)
	Week 25	n	28	16
		None	0 (0.00)	1 (6.25)
		Mild	24 (85.71)	14 (87.50)
		Moderate	3 (10.71)	1 (6.25)
		Severe	1 (3.57)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	27	11
		None	3 (11.11)	3 (27.27)
		Mild	16 (59.26)	7 (63.64)
		Moderate	5 (18.52)	1 (9.09)
		Severe	3 (11.11)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	23	10
		None	2 (8.70)	0 (0.00)
		Mild	13 (56.52)	7 (70.00)
		Moderate	6 (26.09)	3 (30.00)
		Severe	1 (4.35)	0 (0.00)
		Very severe	1 (4.35)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Headache Severity	Week 43	n	9	3
		None	0 (0.00)	0 (0.00)
		Mild	6 (66.67)	2 (66.67)
		Moderate	2 (22.22)	1 (33.33)
		Severe	1 (11.11)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	6	0
		None	1 (16.67)	0 (0.00)
		Mild	3 (50.00)	0 (0.00)
		Moderate	2 (33.33)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	2	0
		None	0 (0.00)	0 (0.00)
		Mild	2 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	2	0
		None	0 (0.00)	0 (0.00)
		Mild	2 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	31	54
		None	1 (3.23)	5 (9.26)
		Mild	18 (58.06)	37 (68.52)
		Moderate	10 (32.26)	8 (14.81)
		Severe	0 (0.00)	2 (3.70)
		Very severe	2 (6.45)	2 (3.70)
	Safety Follow-Up	n	20	28
		None	2 (10.00)	3 (10.71)
		Mild	13 (65.00)	22 (78.57)
		Moderate	4 (20.00)	2 (7.14)
		Severe	1 (5.00)	1 (3.57)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Fatigue Severity	Baseline	n	247	250
		None	94 (38.06)	91 (36.40)
		Mild	93 (37.65)	93 (37.20)
		Moderate	41 (16.60)	43 (17.20)
		Severe	13 (5.26)	19 (7.60)
		Very severe	6 (2.43)	4 (1.60)
	Week 2	n	225	170
		None	60 (26.67)	53 (31.18)
		Mild	101 (44.89)	69 (40.59)
		Moderate	38 (16.89)	31 (18.24)
		Severe	16 (7.11)	12 (7.06)
		Very severe	10 (4.44)	5 (2.94)
	Week 3	n	215	172
		None	50 (23.26)	53 (30.81)
		Mild	75 (34.88)	70 (40.70)
		Moderate	52 (24.19)	29 (16.86)
		Severe	27 (12.56)	14 (8.14)
		Very severe	11 (5.12)	6 (3.49)
	Week 4	n	175	190
		None	37 (21.14)	53 (27.89)
		Mild	79 (45.14)	76 (40.00)
		Moderate	33 (18.86)	44 (23.16)
		Severe	18 (10.29)	12 (6.32)
		Very severe	8 (4.57)	5 (2.63)
	Week 5	n	201	159
		None	59 (29.35)	43 (27.04)
		Mild	88 (43.78)	61 (38.36)
		Moderate	36 (17.91)	37 (23.27)
		Severe	14 (6.97)	12 (7.55)
		Very severe	4 (1.99)	6 (3.77)
	Week 6	n	157	159
		None	58 (36.94)	42 (26.42)
		Mild	66 (42.04)	71 (44.65)
		Moderate	21 (13.38)	32 (20.13)
		Severe	7 (4.46)	8 (5.03)
		Very severe	5 (3.18)	6 (3.77)
	Week 7	n	186	173
		None	71 (38.17)	56 (32.37)
		Mild	64 (34.41)	68 (39.31)
		Moderate	37 (19.89)	29 (16.76)
		Severe	9 (4.84)	17 (9.83)
		Very severe	5 (2.69)	3 (1.73)
	Week 8	n	145	139
		None	59 (40.69)	42 (30.22)
		Mild	60 (41.38)	56 (40.29)
		Moderate	16 (11.03)	28 (20.14)
		Severe	7 (4.83)	8 (5.76)
		Very severe	3 (2.07)	5 (3.60)
	Week 9	n	168	125
		None	68 (40.48)	44 (35.20)
		Mild	65 (38.69)	46 (36.80)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Fatigue Severity	Week 9	Moderate	25 (14.88)	18 (14.40)
		Severe	6 (3.57)	9 (7.20)
		Very severe	4 (2.38)	8 (6.40)
	Week 10	n	141	134
		None	62 (43.97)	42 (31.34)
		Mild	47 (33.33)	52 (38.81)
		Moderate	22 (15.60)	27 (20.15)
		Severe	8 (5.67)	10 (7.46)
		Very severe	2 (1.42)	3 (2.24)
	Week 11	n	156	119
		None	56 (35.90)	32 (26.89)
		Mild	67 (42.95)	51 (42.86)
		Moderate	24 (15.38)	20 (16.81)
		Severe	8 (5.13)	14 (11.76)
		Very severe	1 (0.64)	2 (1.68)
	Week 12	n	130	116
		None	48 (36.92)	40 (34.48)
		Mild	57 (43.85)	44 (37.93)
		Moderate	18 (13.85)	19 (16.38)
		Severe	6 (4.62)	5 (4.31)
		Very severe	1 (0.77)	8 (6.90)
	Week 13	n	155	126
		None	63 (40.65)	40 (31.75)
		Mild	52 (33.55)	46 (36.51)
		Moderate	32 (20.65)	21 (16.67)
		Severe	6 (3.87)	11 (8.73)
		Very severe	2 (1.29)	8 (6.35)
	Week 19	n	117	89
		None	52 (44.44)	20 (22.47)
		Mild	51 (43.59)	41 (46.07)
		Moderate	11 (9.40)	19 (21.35)
		Severe	3 (2.56)	7 (7.87)
		Very severe	0 (0.00)	2 (2.25)
	Week 25	n	107	60
		None	50 (46.73)	24 (40.00)
		Mild	37 (34.58)	22 (36.67)
		Moderate	17 (15.89)	13 (21.67)
		Severe	3 (2.80)	1 (1.67)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	90	41
		None	40 (44.44)	16 (39.02)
		Mild	35 (38.89)	14 (34.15)
		Moderate	9 (10.00)	8 (19.51)
		Severe	5 (5.56)	3 (7.32)
		Very severe	1 (1.11)	0 (0.00)
	Week 37	n	75	21
		None	35 (46.67)	5 (23.81)
		Mild	28 (37.33)	8 (38.10)
		Moderate	9 (12.00)	6 (28.57)
		Severe	1 (1.33)	0 (0.00)
		Very severe	2 (2.67)	2 (9.52)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Fatigue Severity	Week 43	n	46	12
		None	22 (47.83)	4 (33.33)
		Mild	17 (36.96)	5 (41.67)
		Moderate	6 (13.04)	1 (8.33)
		Severe	0 (0.00)	2 (16.67)
		Very severe	1 (2.17)	0 (0.00)
	Week 49	n	32	6
		None	15 (46.88)	4 (66.67)
		Mild	13 (40.63)	1 (16.67)
		Moderate	4 (12.50)	1 (16.67)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	22	3
		None	12 (54.55)	1 (33.33)
		Mild	7 (31.82)	1 (33.33)
		Moderate	3 (13.64)	1 (33.33)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	17	2
		None	12 (70.59)	0 (0.00)
		Mild	4 (23.53)	1 (50.00)
		Moderate	1 (5.88)	1 (50.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	6	1
		None	4 (66.67)	0 (0.00)
		Mild	1 (16.67)	1 (100.0)
		Moderate	0 (0.00)	0 (0.00)
		Severe	1 (16.67)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (50.00)	0 (0.00)
		Moderate	1 (50.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	114	151
		None	32 (28.07)	40 (26.49)
		Mild	45 (39.47)	56 (37.09)
		Moderate	23 (20.18)	30 (19.87)
		Severe	8 (7.02)	15 (9.93)
		Very severe	6 (5.26)	10 (6.62)
	Safety Follow-Up	n	65	91
		None	19 (29.23)	29 (31.87)
		Mild	25 (38.46)	42 (46.15)
		Moderate	14 (21.54)	12 (13.19)
		Severe	4 (6.15)	5 (5.49)
		Very severe	3 (4.62)	3 (3.30)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Anxious Severity	Baseline	n	112	117
		None	11 (9.82)	11 (9.40)
		Mild	67 (59.82)	70 (59.83)
		Moderate	26 (23.21)	27 (23.08)
		Severe	6 (5.36)	7 (5.98)
		Very severe	2 (1.79)	2 (1.71)
	Week 2	n	97	77
		None	5 (5.15)	9 (11.69)
		Mild	52 (53.61)	44 (57.14)
		Moderate	37 (38.14)	18 (23.38)
		Severe	3 (3.09)	5 (6.49)
		Very severe	0 (0.00)	1 (1.30)
	Week 3	n	85	79
		None	4 (4.71)	9 (11.39)
		Mild	47 (55.29)	44 (55.70)
		Moderate	28 (32.94)	15 (18.99)
		Severe	6 (7.06)	9 (11.39)
		Very severe	0 (0.00)	2 (2.53)
	Week 4	n	66	71
		None	9 (13.64)	3 (4.23)
		Mild	45 (68.18)	56 (78.87)
		Moderate	7 (10.61)	5 (7.04)
		Severe	5 (7.58)	5 (7.04)
		Very severe	0 (0.00)	2 (2.82)
	Week 5	n	75	75
		None	3 (4.00)	7 (9.33)
		Mild	51 (68.00)	44 (58.67)
		Moderate	15 (20.00)	17 (22.67)
		Severe	5 (6.67)	7 (9.33)
		Very severe	1 (1.33)	0 (0.00)
	Week 6	n	67	69
		None	6 (8.96)	5 (7.25)
		Mild	47 (70.15)	47 (68.12)
		Moderate	8 (11.94)	12 (17.39)
		Severe	4 (5.97)	3 (4.35)
		Very severe	2 (2.99)	2 (2.90)
	Week 7	n	68	76
		None	7 (10.29)	3 (3.95)
		Mild	44 (64.71)	47 (61.84)
		Moderate	14 (20.59)	20 (26.32)
		Severe	3 (4.41)	4 (5.26)
		Very severe	0 (0.00)	2 (2.63)
	Week 8	n	50	60
		None	8 (16.00)	4 (6.67)
		Mild	28 (56.00)	36 (60.00)
		Moderate	11 (22.00)	16 (26.67)
		Severe	3 (6.00)	3 (5.00)
		Very severe	0 (0.00)	1 (1.67)
	Week 9	n	55	55
		None	5 (9.09)	4 (7.27)
		Mild	33 (60.00)	30 (54.55)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Anxious Severity	Week 9	Moderate	13 (23.64)	15 (27.27)
		Severe	4 (7.27)	4 (7.27)
		Very severe	0 (0.00)	2 (3.64)
	Week 10	n	46	58
		None	10 (21.74)	6 (10.34)
		Mild	23 (50.00)	34 (58.62)
		Moderate	12 (26.09)	16 (27.59)
		Severe	1 (2.17)	1 (1.72)
		Very severe	0 (0.00)	1 (1.72)
	Week 11	n	55	54
		None	9 (16.36)	2 (3.70)
		Mild	35 (63.64)	37 (68.52)
		Moderate	11 (20.00)	8 (14.81)
		Severe	0 (0.00)	6 (11.11)
		Very severe	0 (0.00)	1 (1.85)
	Week 12	n	45	49
		None	4 (8.89)	1 (2.04)
		Mild	31 (68.89)	30 (61.22)
		Moderate	10 (22.22)	14 (28.57)
		Severe	0 (0.00)	3 (6.12)
		Very severe	0 (0.00)	1 (2.04)
	Week 13	n	53	51
		None	4 (7.55)	6 (11.76)
		Mild	35 (66.04)	25 (49.02)
		Moderate	13 (24.53)	17 (33.33)
		Severe	1 (1.89)	2 (3.92)
		Very severe	0 (0.00)	1 (1.96)
	Week 19	n	42	41
		None	6 (14.29)	4 (9.76)
		Mild	31 (73.81)	22 (53.66)
		Moderate	4 (9.52)	13 (31.71)
		Severe	1 (2.38)	2 (4.88)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	44	25
		None	3 (6.82)	1 (4.00)
		Mild	28 (63.64)	19 (76.00)
		Moderate	11 (25.00)	5 (20.00)
		Severe	2 (4.55)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	32	17
		None	2 (6.25)	1 (5.88)
		Mild	21 (65.63)	9 (52.94)
		Moderate	6 (18.75)	7 (41.18)
		Severe	3 (9.38)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	27	12
		None	2 (7.41)	2 (16.67)
		Mild	19 (70.37)	6 (50.00)
		Moderate	3 (11.11)	3 (25.00)
		Severe	2 (7.41)	0 (0.00)
		Very severe	1 (3.70)	1 (8.33)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Anxious Severity	Week 43	n	13	3
		None	0 (0.00)	0 (0.00)
		Mild	9 (69.23)	2 (66.67)
		Moderate	4 (30.77)	1 (33.33)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	11	1
		None	2 (18.18)	0 (0.00)
		Mild	9 (81.82)	1 (100.0)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	6	0
		None	0 (0.00)	0 (0.00)
		Mild	5 (83.33)	0 (0.00)
		Moderate	1 (16.67)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	5	2
		None	2 (40.00)	0 (0.00)
		Mild	2 (40.00)	2 (100.0)
		Moderate	1 (20.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	1 (100.0)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	59	80
		None	4 (6.78)	7 (8.75)
		Mild	33 (55.93)	47 (58.75)
		Moderate	17 (28.81)	14 (17.50)
		Severe	4 (6.78)	6 (7.50)
		Very severe	1 (1.69)	6 (7.50)
	Safety Follow-Up	n	25	39
		None	1 (4.00)	1 (2.56)
		Mild	13 (52.00)	22 (56.41)
		Moderate	7 (28.00)	13 (33.33)
		Severe	4 (16.00)	2 (5.13)
		Very severe	0 (0.00)	1 (2.56)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Chills Severity	Baseline	n	28	51
		None	4 (14.29)	13 (25.49)
		Mild	18 (64.29)	29 (56.86)
		Moderate	5 (17.86)	8 (15.69)
		Severe	1 (3.57)	1 (1.96)
		Very severe	0 (0.00)	0 (0.00)
	Week 2	n	65	29
		None	7 (10.77)	4 (13.79)
		Mild	42 (64.62)	18 (62.07)
		Moderate	12 (18.46)	6 (20.69)
		Severe	4 (6.15)	1 (3.45)
		Very severe	0 (0.00)	0 (0.00)
	Week 3	n	82	39
		None	5 (6.10)	3 (7.69)
		Mild	43 (52.44)	21 (53.85)
		Moderate	25 (30.49)	7 (17.95)
		Severe	5 (6.10)	7 (17.95)
		Very severe	4 (4.88)	1 (2.56)
	Week 4	n	34	36
		None	3 (8.82)	4 (11.11)
		Mild	23 (67.65)	24 (66.67)
		Moderate	5 (14.71)	5 (13.89)
		Severe	3 (8.82)	3 (8.33)
		Very severe	0 (0.00)	0 (0.00)
	Week 5	n	31	33
		None	3 (9.68)	6 (18.18)
		Mild	21 (67.74)	24 (72.73)
		Moderate	5 (16.13)	3 (9.09)
		Severe	2 (6.45)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 6	n	26	31
		None	2 (7.69)	2 (6.45)
		Mild	17 (65.38)	22 (70.97)
		Moderate	4 (15.38)	6 (19.35)
		Severe	3 (11.54)	1 (3.23)
		Very severe	0 (0.00)	0 (0.00)
	Week 7	n	26	36
		None	5 (19.23)	5 (13.89)
		Mild	12 (46.15)	19 (52.78)
		Moderate	8 (30.77)	12 (33.33)
		Severe	1 (3.85)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 8	n	18	26
		None	5 (27.78)	5 (19.23)
		Mild	10 (55.56)	16 (61.54)
		Moderate	3 (16.67)	3 (11.54)
		Severe	0 (0.00)	2 (7.69)
		Very severe	0 (0.00)	0 (0.00)
	Week 9	n	24	30
		None	5 (20.83)	6 (20.00)
		Mild	14 (58.33)	15 (50.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Chills Severity	Week 9	Moderate	5 (20.83)	5 (16.67)
		Severe	0 (0.00)	2 (6.67)
		Very severe	0 (0.00)	2 (6.67)
	Week 10	n	16	26
		None	5 (31.25)	4 (15.38)
		Mild	6 (37.50)	15 (57.69)
		Moderate	5 (31.25)	4 (15.38)
		Severe	0 (0.00)	3 (11.54)
		Very severe	0 (0.00)	0 (0.00)
	Week 11	n	17	23
		None	2 (11.76)	3 (13.04)
		Mild	10 (58.82)	14 (60.87)
		Moderate	5 (29.41)	4 (17.39)
		Severe	0 (0.00)	2 (8.70)
		Very severe	0 (0.00)	0 (0.00)
	Week 12	n	15	27
		None	3 (20.00)	4 (14.81)
		Mild	11 (73.33)	16 (59.26)
		Moderate	1 (6.67)	7 (25.93)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 13	n	20	22
		None	4 (20.00)	2 (9.09)
		Mild	15 (75.00)	15 (68.18)
		Moderate	1 (5.00)	4 (18.18)
		Severe	0 (0.00)	1 (4.55)
		Very severe	0 (0.00)	0 (0.00)
	Week 19	n	15	21
		None	2 (13.33)	1 (4.76)
		Mild	12 (80.00)	14 (66.67)
		Moderate	0 (0.00)	5 (23.81)
		Severe	1 (6.67)	1 (4.76)
		Very severe	0 (0.00)	0 (0.00)
	Week 25	n	13	13
		None	1 (7.69)	3 (23.08)
		Mild	11 (84.62)	9 (69.23)
		Moderate	1 (7.69)	0 (0.00)
		Severe	0 (0.00)	1 (7.69)
		Very severe	0 (0.00)	0 (0.00)
	Week 31	n	12	9
		None	1 (8.33)	1 (11.11)
		Mild	9 (75.00)	8 (88.89)
		Moderate	2 (16.67)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 37	n	7	3
		None	0 (0.00)	1 (33.33)
		Mild	3 (42.86)	2 (66.67)
		Moderate	3 (42.86)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	1 (14.29)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Severity Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Chills Severity	Week 43	n	2	3
		None	0 (0.00)	2 (66.67)
		Mild	0 (0.00)	1 (33.33)
		Moderate	1 (50.00)	0 (0.00)
		Severe	1 (50.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 49	n	2	0
		None	0 (0.00)	0 (0.00)
		Mild	2 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 55	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 61	n	1	0
		None	0 (0.00)	0 (0.00)
		Mild	1 (100.0)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 67	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	Week 73	n	0	0
		None	0 (0.00)	0 (0.00)
		Mild	0 (0.00)	0 (0.00)
		Moderate	0 (0.00)	0 (0.00)
		Severe	0 (0.00)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)
	End of IP Administration	n	20	39
		None	5 (25.00)	1 (2.56)
		Mild	10 (50.00)	25 (64.10)
		Moderate	4 (20.00)	11 (28.21)
		Severe	1 (5.00)	1 (2.56)
		Very severe	0 (0.00)	1 (2.56)
	Safety Follow-Up	n	13	17
		None	1 (7.69)	2 (11.76)
		Mild	9 (69.23)	13 (76.47)
		Moderate	1 (7.69)	2 (11.76)
		Severe	2 (15.38)	0 (0.00)
		Very severe	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Decreased Appetite Interference	Baseline	n	96	106
		Not at all	28 (29.17)	29 (27.36)
		A little bit	40 (41.67)	46 (43.40)
		Somewhat	12 (12.50)	17 (16.04)
		Quite a bit	9 (9.38)	11 (10.38)
		Very much	7 (7.29)	3 (2.83)
	Week 2	n	115	86
		Not at all	30 (26.09)	26 (30.23)
		A little bit	44 (38.26)	27 (31.40)
		Somewhat	24 (20.87)	14 (16.28)
		Quite a bit	12 (10.43)	14 (16.28)
		Very much	5 (4.35)	5 (5.81)
	Week 3	n	148	81
		Not at all	35 (23.65)	12 (14.81)
		A little bit	57 (38.51)	33 (40.74)
		Somewhat	28 (18.92)	18 (22.22)
		Quite a bit	15 (10.14)	15 (18.52)
		Very much	13 (8.78)	3 (3.70)
	Week 4	n	110	101
		Not at all	26 (23.64)	24 (23.76)
		A little bit	48 (43.64)	41 (40.59)
		Somewhat	20 (18.18)	22 (21.78)
		Quite a bit	12 (10.91)	10 (9.90)
		Very much	4 (3.64)	4 (3.96)
	Week 5	n	119	92
		Not at all	34 (28.57)	22 (23.91)
		A little bit	50 (42.02)	40 (43.48)
		Somewhat	21 (17.65)	16 (17.39)
		Quite a bit	9 (7.56)	9 (9.78)
		Very much	5 (4.20)	5 (5.43)
	Week 6	n	82	77
		Not at all	21 (25.61)	17 (22.08)
		A little bit	42 (51.22)	39 (50.65)
		Somewhat	8 (9.76)	11 (14.29)
		Quite a bit	8 (9.76)	8 (10.39)
		Very much	3 (3.66)	2 (2.60)
	Week 7	n	105	88
		Not at all	37 (35.24)	21 (23.86)
		A little bit	44 (41.90)	40 (45.45)
		Somewhat	13 (12.38)	13 (14.77)
		Quite a bit	8 (7.62)	12 (13.64)
		Very much	3 (2.86)	2 (2.27)
	Week 8	n	73	69
		Not at all	30 (41.10)	16 (23.19)
		A little bit	25 (34.25)	30 (43.48)
		Somewhat	11 (15.07)	16 (23.19)
		Quite a bit	5 (6.85)	5 (7.25)
		Very much	2 (2.74)	2 (2.90)
	Week 9	n	84	59
		Not at all	27 (32.14)	8 (13.56)
		A little bit	33 (39.29)	25 (42.37)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Decreased Appetite Interference	Week 9	Somewhat	13 (15.48)	19 (32.20)
		Quite a bit	8 (9.52)	5 (8.47)
		Very much	3 (3.57)	2 (3.39)
	Week 10	n	70	63
		Not at all	26 (37.14)	14 (22.22)
		A little bit	23 (32.86)	32 (50.79)
		Somewhat	14 (20.00)	13 (20.63)
		Quite a bit	4 (5.71)	3 (4.76)
		Very much	3 (4.29)	1 (1.59)
	Week 11	n	70	57
		Not at all	19 (27.14)	11 (19.30)
		A little bit	30 (42.86)	29 (50.88)
		Somewhat	15 (21.43)	6 (10.53)
		Quite a bit	5 (7.14)	6 (10.53)
		Very much	1 (1.43)	5 (8.77)
	Week 12	n	58	63
		Not at all	20 (34.48)	14 (22.22)
		A little bit	23 (39.66)	37 (58.73)
		Somewhat	10 (17.24)	9 (14.29)
		Quite a bit	4 (6.90)	3 (4.76)
		Very much	1 (1.72)	0 (0.00)
	Week 13	n	79	64
		Not at all	26 (32.91)	17 (26.56)
		A little bit	31 (39.24)	33 (51.56)
		Somewhat	14 (17.72)	10 (15.63)
		Quite a bit	6 (7.59)	4 (6.25)
		Very much	2 (2.53)	0 (0.00)
	Week 19	n	58	41
		Not at all	24 (41.38)	10 (24.39)
		A little bit	25 (43.10)	21 (51.22)
		Somewhat	9 (15.52)	6 (14.63)
		Quite a bit	0 (0.00)	4 (9.76)
		Very much	0 (0.00)	0 (0.00)
	Week 25	n	50	16
		Not at all	19 (38.00)	6 (37.50)
		A little bit	20 (40.00)	6 (37.50)
		Somewhat	8 (16.00)	4 (25.00)
		Quite a bit	3 (6.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 31	n	44	15
		Not at all	13 (29.55)	4 (26.67)
		A little bit	25 (56.82)	10 (66.67)
		Somewhat	4 (9.09)	1 (6.67)
		Quite a bit	1 (2.27)	0 (0.00)
		Very much	1 (2.27)	0 (0.00)
	Week 37	n	40	9
		Not at all	20 (50.00)	2 (22.22)
		A little bit	15 (37.50)	5 (55.56)
		Somewhat	2 (5.00)	1 (11.11)
		Quite a bit	2 (5.00)	0 (0.00)
		Very much	1 (2.50)	1 (11.11)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Decreased Appetite Interference	Week 43	n	17	5
		Not at all	7 (41.18)	1 (20.00)
		A little bit	9 (52.94)	4 (80.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	1 (5.88)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 49	n	12	0
		Not at all	4 (33.33)	0 (0.00)
		A little bit	5 (41.67)	0 (0.00)
		Somewhat	2 (16.67)	0 (0.00)
		Quite a bit	1 (8.33)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 55	n	7	0
		Not at all	4 (57.14)	0 (0.00)
		A little bit	2 (28.57)	0 (0.00)
		Somewhat	1 (14.29)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 61	n	3	0
		Not at all	2 (66.67)	0 (0.00)
		A little bit	1 (33.33)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 67	n	2	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	1 (50.00)	0 (0.00)
		Somewhat	1 (50.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 73	n	0	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	End of IP Administration	n	75	75
		Not at all	15 (20.00)	15 (20.00)
		A little bit	27 (36.00)	30 (40.00)
		Somewhat	21 (28.00)	13 (17.33)
		Quite a bit	7 (9.33)	12 (16.00)
		Very much	5 (6.67)	5 (6.67)
	Safety Follow-Up	n	44	36
		Not at all	9 (20.45)	8 (22.22)
		A little bit	16 (36.36)	16 (44.44)
		Somewhat	11 (25.00)	9 (25.00)
		Quite a bit	4 (9.09)	1 (2.78)
		Very much	4 (9.09)	2 (5.56)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Swelling Interference	Baseline	n	29	29
		Not at all	13 (44.83)	12 (41.38)
		A little bit	10 (34.48)	15 (51.72)
		Somewhat	4 (13.79)	2 (6.90)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	2 (6.90)	0 (0.00)
	Week 2	n	24	19
		Not at all	14 (58.33)	11 (57.89)
		A little bit	5 (20.83)	6 (31.58)
		Somewhat	2 (8.33)	1 (5.26)
		Quite a bit	2 (8.33)	1 (5.26)
		Very much	1 (4.17)	0 (0.00)
	Week 3	n	24	24
		Not at all	9 (37.50)	10 (41.67)
		A little bit	10 (41.67)	12 (50.00)
		Somewhat	4 (16.67)	0 (0.00)
		Quite a bit	1 (4.17)	0 (0.00)
		Very much	0 (0.00)	2 (8.33)
	Week 4	n	11	33
		Not at all	3 (27.27)	16 (48.48)
		A little bit	4 (36.36)	11 (33.33)
		Somewhat	3 (27.27)	1 (3.03)
		Quite a bit	1 (9.09)	3 (9.09)
		Very much	0 (0.00)	2 (6.06)
	Week 5	n	12	17
		Not at all	5 (41.67)	5 (29.41)
		A little bit	6 (50.00)	8 (47.06)
		Somewhat	1 (8.33)	3 (17.65)
		Quite a bit	0 (0.00)	1 (5.88)
		Very much	0 (0.00)	0 (0.00)
	Week 6	n	10	20
		Not at all	7 (70.00)	9 (45.00)
		A little bit	2 (20.00)	9 (45.00)
		Somewhat	1 (10.00)	1 (5.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	1 (5.00)
	Week 7	n	12	33
		Not at all	5 (41.67)	19 (57.58)
		A little bit	5 (41.67)	11 (33.33)
		Somewhat	2 (16.67)	2 (6.06)
		Quite a bit	0 (0.00)	1 (3.03)
		Very much	0 (0.00)	0 (0.00)
	Week 8	n	5	20
		Not at all	2 (40.00)	8 (40.00)
		A little bit	3 (60.00)	10 (50.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	2 (10.00)
		Very much	0 (0.00)	0 (0.00)
	Week 9	n	9	22
		Not at all	5 (55.56)	10 (45.45)
		A little bit	4 (44.44)	8 (36.36)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Swelling Interference	Week 9	Somewhat	0 (0.00)	4 (18.18)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 10	n	7	27
		Not at all	4 (57.14)	12 (44.44)
		A little bit	2 (28.57)	13 (48.15)
		Somewhat	1 (14.29)	1 (3.70)
		Quite a bit	0 (0.00)	1 (3.70)
		Very much	0 (0.00)	0 (0.00)
	Week 11	n	11	19
		Not at all	7 (63.64)	6 (31.58)
		A little bit	3 (27.27)	9 (47.37)
		Somewhat	1 (9.09)	2 (10.53)
		Quite a bit	0 (0.00)	1 (5.26)
		Very much	0 (0.00)	1 (5.26)
	Week 12	n	7	18
		Not at all	6 (85.71)	7 (38.89)
		A little bit	1 (14.29)	8 (44.44)
		Somewhat	0 (0.00)	2 (11.11)
		Quite a bit	0 (0.00)	1 (5.56)
		Very much	0 (0.00)	0 (0.00)
	Week 13	n	11	23
		Not at all	7 (63.64)	9 (39.13)
		A little bit	3 (27.27)	9 (39.13)
		Somewhat	1 (9.09)	1 (4.35)
		Quite a bit	0 (0.00)	4 (17.39)
		Very much	0 (0.00)	0 (0.00)
	Week 19	n	6	22
		Not at all	4 (66.67)	13 (59.09)
		A little bit	2 (33.33)	8 (36.36)
		Somewhat	0 (0.00)	1 (4.55)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 25	n	11	10
		Not at all	10 (90.91)	6 (60.00)
		A little bit	1 (9.09)	4 (40.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 31	n	7	9
		Not at all	4 (57.14)	3 (33.33)
		A little bit	3 (42.86)	5 (55.56)
		Somewhat	0 (0.00)	1 (11.11)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 37	n	6	8
		Not at all	6 (100.0)	4 (50.00)
		A little bit	0 (0.00)	4 (50.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Swelling Interference	Week 43	n	3	3
		Not at all	3 (100.0)	3 (100.0)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 49	n	1	0
		Not at all	1 (100.0)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 55	n	1	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	1 (100.0)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 61	n	0	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 67	n	0	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 73	n	1	0
		Not at all	1 (100.0)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	End of IP Administration	n	11	33
		Not at all	5 (45.45)	12 (36.36)
		A little bit	4 (36.36)	14 (42.42)
		Somewhat	0 (0.00)	5 (15.15)
		Quite a bit	2 (18.18)	1 (3.03)
		Very much	0 (0.00)	1 (3.03)
	Safety Follow-Up	n	10	11
		Not at all	5 (50.00)	5 (45.45)
		A little bit	4 (40.00)	2 (18.18)
		Somewhat	0 (0.00)	3 (27.27)
		Quite a bit	1 (10.00)	1 (9.09)
		Very much	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Dizziness Interference	Baseline	n	50	67
		Not at all	11 (22.00)	22 (32.84)
		A little bit	31 (62.00)	32 (47.76)
		Somewhat	5 (10.00)	9 (13.43)
		Quite a bit	2 (4.00)	4 (5.97)
		Very much	1 (2.00)	0 (0.00)
	Week 2	n	65	50
		Not at all	16 (24.62)	14 (28.00)
		A little bit	37 (56.92)	21 (42.00)
		Somewhat	7 (10.77)	11 (22.00)
		Quite a bit	4 (6.15)	3 (6.00)
		Very much	1 (1.54)	1 (2.00)
	Week 3	n	74	46
		Not at all	19 (25.68)	14 (30.43)
		A little bit	34 (45.95)	16 (34.78)
		Somewhat	12 (16.22)	13 (28.26)
		Quite a bit	7 (9.46)	1 (2.17)
		Very much	2 (2.70)	2 (4.35)
	Week 4	n	50	57
		Not at all	16 (32.00)	13 (22.81)
		A little bit	24 (48.00)	27 (47.37)
		Somewhat	5 (10.00)	12 (21.05)
		Quite a bit	3 (6.00)	4 (7.02)
		Very much	2 (4.00)	1 (1.75)
	Week 5	n	56	65
		Not at all	16 (28.57)	19 (29.23)
		A little bit	28 (50.00)	31 (47.69)
		Somewhat	9 (16.07)	10 (15.38)
		Quite a bit	2 (3.57)	3 (4.62)
		Very much	1 (1.79)	2 (3.08)
	Week 6	n	32	51
		Not at all	8 (25.00)	13 (25.49)
		A little bit	20 (62.50)	30 (58.82)
		Somewhat	2 (6.25)	7 (13.73)
		Quite a bit	2 (6.25)	1 (1.96)
		Very much	0 (0.00)	0 (0.00)
	Week 7	n	41	59
		Not at all	11 (26.83)	17 (28.81)
		A little bit	25 (60.98)	31 (52.54)
		Somewhat	2 (4.88)	8 (13.56)
		Quite a bit	2 (4.88)	2 (3.39)
		Very much	1 (2.44)	1 (1.69)
	Week 8	n	25	49
		Not at all	9 (36.00)	12 (24.49)
		A little bit	13 (52.00)	24 (48.98)
		Somewhat	2 (8.00)	9 (18.37)
		Quite a bit	0 (0.00)	4 (8.16)
		Very much	1 (4.00)	0 (0.00)
	Week 9	n	32	38
		Not at all	13 (40.63)	6 (15.79)
		A little bit	14 (43.75)	16 (42.11)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Dizziness Interference	Week 9	Somewhat	3 (9.38)	12 (31.58)
		Quite a bit	1 (3.13)	2 (5.26)
		Very much	1 (3.13)	2 (5.26)
	Week 10	n	23	48
		Not at all	6 (26.09)	7 (14.58)
		A little bit	14 (60.87)	29 (60.42)
		Somewhat	1 (4.35)	8 (16.67)
		Quite a bit	2 (8.70)	4 (8.33)
		Very much	0 (0.00)	0 (0.00)
	Week 11	n	28	46
		Not at all	9 (32.14)	7 (15.22)
		A little bit	15 (53.57)	30 (65.22)
		Somewhat	2 (7.14)	4 (8.70)
		Quite a bit	2 (7.14)	4 (8.70)
		Very much	0 (0.00)	1 (2.17)
	Week 12	n	25	39
		Not at all	7 (28.00)	6 (15.38)
		A little bit	15 (60.00)	25 (64.10)
		Somewhat	3 (12.00)	5 (12.82)
		Quite a bit	0 (0.00)	2 (5.13)
		Very much	0 (0.00)	1 (2.56)
	Week 13	n	31	46
		Not at all	14 (45.16)	11 (23.91)
		A little bit	14 (45.16)	24 (52.17)
		Somewhat	3 (9.68)	5 (10.87)
		Quite a bit	0 (0.00)	6 (13.04)
		Very much	0 (0.00)	0 (0.00)
	Week 19	n	21	31
		Not at all	11 (52.38)	4 (12.90)
		A little bit	10 (47.62)	18 (58.06)
		Somewhat	0 (0.00)	4 (12.90)
		Quite a bit	0 (0.00)	5 (16.13)
		Very much	0 (0.00)	0 (0.00)
	Week 25	n	25	18
		Not at all	10 (40.00)	6 (33.33)
		A little bit	14 (56.00)	9 (50.00)
		Somewhat	0 (0.00)	1 (5.56)
		Quite a bit	0 (0.00)	2 (11.11)
		Very much	1 (4.00)	0 (0.00)
	Week 31	n	17	10
		Not at all	3 (17.65)	2 (20.00)
		A little bit	12 (70.59)	4 (40.00)
		Somewhat	1 (5.88)	4 (40.00)
		Quite a bit	1 (5.88)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 37	n	13	11
		Not at all	8 (61.54)	7 (63.64)
		A little bit	4 (30.77)	4 (36.36)
		Somewhat	1 (7.69)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Dizziness Interference	Week 43	n	9	5
		Not at all	1 (11.11)	2 (40.00)
		A little bit	7 (77.78)	3 (60.00)
		Somewhat	1 (11.11)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 49	n	3	2
		Not at all	2 (66.67)	1 (50.00)
		A little bit	1 (33.33)	1 (50.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 55	n	1	1
		Not at all	0 (0.00)	1 (100.0)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	1 (100.0)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 61	n	2	1
		Not at all	0 (0.00)	0 (0.00)
		A little bit	1 (50.00)	0 (0.00)
		Somewhat	1 (50.00)	1 (100.0)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 67	n	1	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	1 (100.0)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 73	n	0	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	End of IP Administration	n	33	55
		Not at all	8 (24.24)	8 (14.55)
		A little bit	16 (48.48)	36 (65.45)
		Somewhat	7 (21.21)	7 (12.73)
		Quite a bit	2 (6.06)	2 (3.64)
		Very much	0 (0.00)	2 (3.64)
	Safety Follow-Up	n	21	28
		Not at all	5 (23.81)	8 (28.57)
		A little bit	9 (42.86)	19 (67.86)
		Somewhat	6 (28.57)	0 (0.00)
		Quite a bit	0 (0.00)	1 (3.57)
		Very much	1 (4.76)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Concentration Problems Interference	Baseline	n	62	73
		Not at all	21 (33.87)	16 (21.92)
		A little bit	29 (46.77)	44 (60.27)
		Somewhat	8 (12.90)	9 (12.33)
		Quite a bit	3 (4.84)	4 (5.48)
		Very much	1 (1.61)	0 (0.00)
	Week 2	n	68	50
		Not at all	16 (23.53)	9 (18.00)
		A little bit	37 (54.41)	26 (52.00)
		Somewhat	11 (16.18)	11 (22.00)
		Quite a bit	3 (4.41)	4 (8.00)
		Very much	1 (1.47)	0 (0.00)
	Week 3	n	72	60
		Not at all	11 (15.28)	7 (11.67)
		A little bit	47 (65.28)	34 (56.67)
		Somewhat	8 (11.11)	13 (21.67)
		Quite a bit	4 (5.56)	3 (5.00)
		Very much	2 (2.78)	3 (5.00)
	Week 4	n	51	63
		Not at all	6 (11.76)	8 (12.70)
		A little bit	38 (74.51)	44 (69.84)
		Somewhat	2 (3.92)	6 (9.52)
		Quite a bit	4 (7.84)	4 (6.35)
		Very much	1 (1.96)	1 (1.59)
	Week 5	n	54	60
		Not at all	12 (22.22)	13 (21.67)
		A little bit	33 (61.11)	34 (56.67)
		Somewhat	3 (5.56)	8 (13.33)
		Quite a bit	6 (11.11)	4 (6.67)
		Very much	0 (0.00)	1 (1.67)
	Week 6	n	40	50
		Not at all	7 (17.50)	7 (14.00)
		A little bit	25 (62.50)	33 (66.00)
		Somewhat	6 (15.00)	8 (16.00)
		Quite a bit	1 (2.50)	2 (4.00)
		Very much	1 (2.50)	0 (0.00)
	Week 7	n	43	58
		Not at all	3 (6.98)	7 (12.07)
		A little bit	31 (72.09)	39 (67.24)
		Somewhat	7 (16.28)	10 (17.24)
		Quite a bit	2 (4.65)	1 (1.72)
		Very much	0 (0.00)	1 (1.72)
	Week 8	n	28	50
		Not at all	3 (10.71)	6 (12.00)
		A little bit	17 (60.71)	31 (62.00)
		Somewhat	7 (25.00)	10 (20.00)
		Quite a bit	0 (0.00)	2 (4.00)
		Very much	1 (3.57)	1 (2.00)
	Week 9	n	43	42
		Not at all	12 (27.91)	3 (7.14)
		A little bit	22 (51.16)	23 (54.76)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Concentration Problems Interference	Week 9	Somewhat	5 (11.63)	12 (28.57)
		Quite a bit	3 (6.98)	2 (4.76)
		Very much	1 (2.33)	2 (4.76)
	Week 10	n	30	46
		Not at all	6 (20.00)	4 (8.70)
		A little bit	18 (60.00)	31 (67.39)
		Somewhat	4 (13.33)	7 (15.22)
		Quite a bit	1 (3.33)	4 (8.70)
		Very much	1 (3.33)	0 (0.00)
	Week 11	n	47	46
		Not at all	16 (34.04)	7 (15.22)
		A little bit	28 (59.57)	26 (56.52)
		Somewhat	1 (2.13)	9 (19.57)
		Quite a bit	2 (4.26)	3 (6.52)
		Very much	0 (0.00)	1 (2.17)
	Week 12	n	39	37
		Not at all	9 (23.08)	6 (16.22)
		A little bit	26 (66.67)	21 (56.76)
		Somewhat	3 (7.69)	6 (16.22)
		Quite a bit	0 (0.00)	3 (8.11)
		Very much	1 (2.56)	1 (2.70)
	Week 13	n	43	40
		Not at all	14 (32.56)	5 (12.50)
		A little bit	24 (55.81)	23 (57.50)
		Somewhat	5 (11.63)	8 (20.00)
		Quite a bit	0 (0.00)	4 (10.00)
		Very much	0 (0.00)	0 (0.00)
	Week 19	n	27	27
		Not at all	7 (25.93)	2 (7.41)
		A little bit	19 (70.37)	19 (70.37)
		Somewhat	1 (3.70)	3 (11.11)
		Quite a bit	0 (0.00)	3 (11.11)
		Very much	0 (0.00)	0 (0.00)
	Week 25	n	33	13
		Not at all	11 (33.33)	3 (23.08)
		A little bit	22 (66.67)	8 (61.54)
		Somewhat	0 (0.00)	1 (7.69)
		Quite a bit	0 (0.00)	1 (7.69)
		Very much	0 (0.00)	0 (0.00)
	Week 31	n	21	16
		Not at all	9 (42.86)	2 (12.50)
		A little bit	9 (42.86)	11 (68.75)
		Somewhat	3 (14.29)	3 (18.75)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 37	n	17	9
		Not at all	7 (41.18)	1 (11.11)
		A little bit	6 (35.29)	6 (66.67)
		Somewhat	2 (11.76)	1 (11.11)
		Quite a bit	2 (11.76)	0 (0.00)
		Very much	0 (0.00)	1 (11.11)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Concentration Problems Interference	Week 43	n	10	4
		Not at all	7 (70.00)	1 (25.00)
		A little bit	1 (10.00)	3 (75.00)
		Somewhat	2 (20.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 49	n	7	0
		Not at all	2 (28.57)	0 (0.00)
		A little bit	5 (71.43)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 55	n	1	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	1 (100.0)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 61	n	2	1
		Not at all	1 (50.00)	0 (0.00)
		A little bit	1 (50.00)	1 (100.0)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 67	n	1	0
		Not at all	1 (100.0)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 73	n	0	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	End of IP Administration	n	38	60
		Not at all	4 (10.53)	7 (11.67)
		A little bit	25 (65.79)	38 (63.33)
		Somewhat	5 (13.16)	10 (16.67)
		Quite a bit	2 (5.26)	2 (3.33)
		Very much	2 (5.26)	3 (5.00)
	Safety Follow-Up	n	23	30
		Not at all	6 (26.09)	5 (16.67)
		A little bit	11 (47.83)	20 (66.67)
		Somewhat	4 (17.39)	3 (10.00)
		Quite a bit	1 (4.35)	1 (3.33)
		Very much	1 (4.35)	1 (3.33)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Headache Interference	Baseline	n	60	63
		Not at all	33 (55.00)	30 (47.62)
		A little bit	22 (36.67)	22 (34.92)
		Somewhat	3 (5.00)	7 (11.11)
		Quite a bit	2 (3.33)	1 (1.59)
		Very much	0 (0.00)	3 (4.76)
	Week 2	n	73	47
		Not at all	24 (32.88)	17 (36.17)
		A little bit	41 (56.16)	22 (46.81)
		Somewhat	6 (8.22)	7 (14.89)
		Quite a bit	2 (2.74)	1 (2.13)
		Very much	0 (0.00)	0 (0.00)
	Week 3	n	82	39
		Not at all	27 (32.93)	10 (25.64)
		A little bit	32 (39.02)	19 (48.72)
		Somewhat	13 (15.85)	5 (12.82)
		Quite a bit	6 (7.32)	5 (12.82)
		Very much	4 (4.88)	0 (0.00)
	Week 4	n	47	61
		Not at all	15 (31.91)	24 (39.34)
		A little bit	23 (48.94)	27 (44.26)
		Somewhat	7 (14.89)	9 (14.75)
		Quite a bit	1 (2.13)	0 (0.00)
		Very much	1 (2.13)	1 (1.64)
	Week 5	n	46	52
		Not at all	21 (45.65)	18 (34.62)
		A little bit	19 (41.30)	27 (51.92)
		Somewhat	5 (10.87)	5 (9.62)
		Quite a bit	1 (2.17)	1 (1.92)
		Very much	0 (0.00)	1 (1.92)
	Week 6	n	37	43
		Not at all	14 (37.84)	14 (32.56)
		A little bit	19 (51.35)	22 (51.16)
		Somewhat	3 (8.11)	7 (16.28)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	1 (2.70)	0 (0.00)
	Week 7	n	43	39
		Not at all	18 (41.86)	8 (20.51)
		A little bit	20 (46.51)	23 (58.97)
		Somewhat	4 (9.30)	5 (12.82)
		Quite a bit	1 (2.33)	3 (7.69)
		Very much	0 (0.00)	0 (0.00)
	Week 8	n	29	35
		Not at all	14 (48.28)	13 (37.14)
		A little bit	14 (48.28)	18 (51.43)
		Somewhat	0 (0.00)	2 (5.71)
		Quite a bit	1 (3.45)	2 (5.71)
		Very much	0 (0.00)	0 (0.00)
	Week 9	n	38	37
		Not at all	18 (47.37)	15 (40.54)
		A little bit	16 (42.11)	14 (37.84)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Headache Interference	Week 9	Somewhat	3 (7.89)	5 (13.51)
		Quite a bit	0 (0.00)	2 (5.41)
		Very much	1 (2.63)	1 (2.70)
	Week 10	n	28	45
		Not at all	9 (32.14)	20 (44.44)
		A little bit	15 (53.57)	18 (40.00)
		Somewhat	3 (10.71)	6 (13.33)
		Quite a bit	0 (0.00)	1 (2.22)
		Very much	1 (3.57)	0 (0.00)
	Week 11	n	33	40
		Not at all	16 (48.48)	14 (35.00)
		A little bit	13 (39.39)	22 (55.00)
		Somewhat	4 (12.12)	2 (5.00)
		Quite a bit	0 (0.00)	2 (5.00)
		Very much	0 (0.00)	0 (0.00)
	Week 12	n	32	40
		Not at all	13 (40.63)	13 (32.50)
		A little bit	17 (53.13)	23 (57.50)
		Somewhat	1 (3.13)	3 (7.50)
		Quite a bit	1 (3.13)	1 (2.50)
		Very much	0 (0.00)	0 (0.00)
	Week 13	n	29	30
		Not at all	20 (68.97)	5 (16.67)
		A little bit	8 (27.59)	19 (63.33)
		Somewhat	1 (3.45)	5 (16.67)
		Quite a bit	0 (0.00)	1 (3.33)
		Very much	0 (0.00)	0 (0.00)
	Week 19	n	25	24
		Not at all	12 (48.00)	9 (37.50)
		A little bit	11 (44.00)	11 (45.83)
		Somewhat	1 (4.00)	3 (12.50)
		Quite a bit	1 (4.00)	0 (0.00)
		Very much	0 (0.00)	1 (4.17)
	Week 25	n	28	16
		Not at all	16 (57.14)	6 (37.50)
		A little bit	10 (35.71)	10 (62.50)
		Somewhat	2 (7.14)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 31	n	27	11
		Not at all	14 (51.85)	6 (54.55)
		A little bit	9 (33.33)	3 (27.27)
		Somewhat	3 (11.11)	2 (18.18)
		Quite a bit	1 (3.70)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 37	n	23	10
		Not at all	10 (43.48)	4 (40.00)
		A little bit	10 (43.48)	6 (60.00)
		Somewhat	2 (8.70)	0 (0.00)
		Quite a bit	1 (4.35)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Headache Interference	Week 43	n	9	3
		Not at all	3 (33.33)	2 (66.67)
		A little bit	3 (33.33)	1 (33.33)
		Somewhat	3 (33.33)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 49	n	6	0
		Not at all	2 (33.33)	0 (0.00)
		A little bit	3 (50.00)	0 (0.00)
		Somewhat	1 (16.67)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 55	n	2	0
		Not at all	1 (50.00)	0 (0.00)
		A little bit	1 (50.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 61	n	2	0
		Not at all	1 (50.00)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	1 (50.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 67	n	0	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 73	n	0	0
		Not at all	0 (0.00)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	End of IP Administration	n	31	54
		Not at all	9 (29.03)	21 (38.89)
		A little bit	16 (51.61)	23 (42.59)
		Somewhat	4 (12.90)	7 (12.96)
		Quite a bit	2 (6.45)	1 (1.85)
		Very much	0 (0.00)	2 (3.70)
	Safety Follow-Up	n	20	28
		Not at all	12 (60.00)	11 (39.29)
		A little bit	5 (25.00)	15 (53.57)
		Somewhat	2 (10.00)	1 (3.57)
		Quite a bit	0 (0.00)	1 (3.57)
		Very much	1 (5.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Fatigue Interference	Baseline	n	153	159
		Not at all	30 (19.61)	31 (19.50)
		A little bit	79 (51.63)	75 (47.17)
		Somewhat	28 (18.30)	26 (16.35)
		Quite a bit	12 (7.84)	21 (13.21)
		Very much	4 (2.61)	6 (3.77)
	Week 2	n	165	117
		Not at all	31 (18.79)	26 (22.22)
		A little bit	82 (49.70)	49 (41.88)
		Somewhat	27 (16.36)	25 (21.37)
		Quite a bit	17 (10.30)	16 (13.68)
		Very much	8 (4.85)	1 (0.85)
	Week 3	n	165	119
		Not at all	22 (13.33)	18 (15.13)
		A little bit	60 (36.36)	51 (42.86)
		Somewhat	47 (28.48)	30 (25.21)
		Quite a bit	24 (14.55)	14 (11.76)
		Very much	12 (7.27)	6 (5.04)
	Week 4	n	138	137
		Not at all	24 (17.39)	14 (10.22)
		A little bit	66 (47.83)	74 (54.01)
		Somewhat	24 (17.39)	30 (21.90)
		Quite a bit	18 (13.04)	13 (9.49)
		Very much	6 (4.35)	6 (4.38)
	Week 5	n	142	116
		Not at all	22 (15.49)	11 (9.48)
		A little bit	77 (54.23)	57 (49.14)
		Somewhat	21 (14.79)	33 (28.45)
		Quite a bit	16 (11.27)	9 (7.76)
		Very much	6 (4.23)	6 (5.17)
	Week 6	n	99	117
		Not at all	13 (13.13)	18 (15.38)
		A little bit	60 (60.61)	66 (56.41)
		Somewhat	15 (15.15)	20 (17.09)
		Quite a bit	7 (7.07)	8 (6.84)
		Very much	4 (4.04)	5 (4.27)
	Week 7	n	115	117
		Not at all	20 (17.39)	23 (19.66)
		A little bit	60 (52.17)	56 (47.86)
		Somewhat	22 (19.13)	22 (18.80)
		Quite a bit	10 (8.70)	13 (11.11)
		Very much	3 (2.61)	3 (2.56)
	Week 8	n	86	97
		Not at all	19 (22.09)	12 (12.37)
		A little bit	45 (52.33)	52 (53.61)
		Somewhat	14 (16.28)	21 (21.65)
		Quite a bit	7 (8.14)	7 (7.22)
		Very much	1 (1.16)	5 (5.15)
	Week 9	n	100	81
		Not at all	23 (23.00)	9 (11.11)
		A little bit	48 (48.00)	39 (48.15)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Fatigue Interference	Week 9	Somewhat	21 (21.00)	18 (22.22)
		Quite a bit	4 (4.00)	10 (12.35)
		Very much	4 (4.00)	5 (6.17)
	Week 10	n	79	92
		Not at all	20 (25.32)	13 (14.13)
		A little bit	35 (44.30)	42 (45.65)
		Somewhat	13 (16.46)	20 (21.74)
		Quite a bit	9 (11.39)	15 (16.30)
		Very much	2 (2.53)	2 (2.17)
	Week 11	n	100	87
		Not at all	17 (17.00)	16 (18.39)
		A little bit	60 (60.00)	44 (50.57)
		Somewhat	14 (14.00)	14 (16.09)
		Quite a bit	8 (8.00)	8 (9.20)
		Very much	1 (1.00)	5 (5.75)
	Week 12	n	82	76
		Not at all	17 (20.73)	13 (17.11)
		A little bit	50 (60.98)	33 (43.42)
		Somewhat	10 (12.20)	18 (23.68)
		Quite a bit	4 (4.88)	6 (7.89)
		Very much	1 (1.22)	6 (7.89)
	Week 13	n	92	86
		Not at all	16 (17.39)	17 (19.77)
		A little bit	50 (54.35)	33 (38.37)
		Somewhat	18 (19.57)	18 (20.93)
		Quite a bit	6 (6.52)	13 (15.12)
		Very much	2 (2.17)	5 (5.81)
	Week 19	n	65	69
		Not at all	18 (27.69)	12 (17.39)
		A little bit	34 (52.31)	31 (44.93)
		Somewhat	11 (16.92)	18 (26.09)
		Quite a bit	2 (3.08)	5 (7.25)
		Very much	0 (0.00)	3 (4.35)
	Week 25	n	57	36
		Not at all	10 (17.54)	7 (19.44)
		A little bit	35 (61.40)	18 (50.00)
		Somewhat	9 (15.79)	9 (25.00)
		Quite a bit	3 (5.26)	2 (5.56)
		Very much	0 (0.00)	0 (0.00)
	Week 31	n	50	25
		Not at all	17 (34.00)	4 (16.00)
		A little bit	24 (48.00)	13 (52.00)
		Somewhat	6 (12.00)	5 (20.00)
		Quite a bit	3 (6.00)	3 (12.00)
		Very much	0 (0.00)	0 (0.00)
	Week 37	n	40	16
		Not at all	9 (22.50)	3 (18.75)
		A little bit	24 (60.00)	6 (37.50)
		Somewhat	4 (10.00)	4 (25.00)
		Quite a bit	1 (2.50)	1 (6.25)
		Very much	2 (5.00)	2 (12.50)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Fatigue Interference	Week 43	n	24	8
		Not at all	5 (20.83)	1 (12.50)
		A little bit	15 (62.50)	5 (62.50)
		Somewhat	3 (12.50)	2 (25.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	1 (4.17)	0 (0.00)
	Week 49	n	17	2
		Not at all	4 (23.53)	0 (0.00)
		A little bit	12 (70.59)	1 (50.00)
		Somewhat	0 (0.00)	1 (50.00)
		Quite a bit	1 (5.88)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 55	n	10	2
		Not at all	4 (40.00)	1 (50.00)
		A little bit	5 (50.00)	1 (50.00)
		Somewhat	1 (10.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 61	n	5	2
		Not at all	2 (40.00)	1 (50.00)
		A little bit	2 (40.00)	1 (50.00)
		Somewhat	1 (20.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 67	n	2	1
		Not at all	1 (50.00)	1 (100.0)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	1 (50.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 73	n	2	0
		Not at all	1 (50.00)	0 (0.00)
		A little bit	1 (50.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	End of IP Administration	n	82	111
		Not at all	12 (14.63)	13 (11.71)
		A little bit	36 (43.90)	49 (44.14)
		Somewhat	18 (21.95)	21 (18.92)
		Quite a bit	12 (14.63)	14 (12.61)
		Very much	4 (4.88)	14 (12.61)
	Safety Follow-Up	n	46	62
		Not at all	7 (15.22)	15 (24.19)
		A little bit	21 (45.65)	29 (46.77)
		Somewhat	11 (23.91)	10 (16.13)
		Quite a bit	4 (8.70)	6 (9.68)
		Very much	3 (6.52)	2 (3.23)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Anxious Interference	Baseline	n	112	117
		Not at all	46 (41.07)	40 (34.19)
		A little bit	52 (46.43)	47 (40.17)
		Somewhat	9 (8.04)	25 (21.37)
		Quite a bit	3 (2.68)	4 (3.42)
		Very much	2 (1.79)	1 (0.85)
	Week 2	n	97	77
		Not at all	28 (28.87)	28 (36.36)
		A little bit	46 (47.42)	30 (38.96)
		Somewhat	16 (16.49)	15 (19.48)
		Quite a bit	5 (5.15)	4 (5.19)
		Very much	2 (2.06)	0 (0.00)
	Week 3	n	85	79
		Not at all	19 (22.35)	21 (26.58)
		A little bit	43 (50.59)	38 (48.10)
		Somewhat	15 (17.65)	11 (13.92)
		Quite a bit	6 (7.06)	7 (8.86)
		Very much	2 (2.35)	2 (2.53)
	Week 4	n	66	71
		Not at all	23 (34.85)	17 (23.94)
		A little bit	27 (40.91)	44 (61.97)
		Somewhat	10 (15.15)	3 (4.23)
		Quite a bit	5 (7.58)	3 (4.23)
		Very much	1 (1.52)	4 (5.63)
	Week 5	n	75	75
		Not at all	24 (32.00)	16 (21.33)
		A little bit	37 (49.33)	40 (53.33)
		Somewhat	11 (14.67)	11 (14.67)
		Quite a bit	2 (2.67)	7 (9.33)
		Very much	1 (1.33)	1 (1.33)
	Week 6	n	67	69
		Not at all	28 (41.79)	16 (23.19)
		A little bit	31 (46.27)	41 (59.42)
		Somewhat	4 (5.97)	7 (10.14)
		Quite a bit	3 (4.48)	4 (5.80)
		Very much	1 (1.49)	1 (1.45)
	Week 7	n	68	76
		Not at all	25 (36.76)	26 (34.21)
		A little bit	35 (51.47)	30 (39.47)
		Somewhat	7 (10.29)	13 (17.11)
		Quite a bit	1 (1.47)	5 (6.58)
		Very much	0 (0.00)	2 (2.63)
	Week 8	n	50	60
		Not at all	20 (40.00)	6 (10.00)
		A little bit	27 (54.00)	35 (58.33)
		Somewhat	1 (2.00)	14 (23.33)
		Quite a bit	1 (2.00)	4 (6.67)
		Very much	1 (2.00)	1 (1.67)
	Week 9	n	55	55
		Not at all	20 (36.36)	7 (12.73)
		A little bit	25 (45.45)	28 (50.91)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Anxious Interference	Week 9	Somewhat	8 (14.55)	15 (27.27)
		Quite a bit	1 (1.82)	4 (7.27)
		Very much	1 (1.82)	1 (1.82)
	Week 10	n	46	58
		Not at all	20 (43.48)	9 (15.52)
		A little bit	18 (39.13)	33 (56.90)
		Somewhat	6 (13.04)	14 (24.14)
		Quite a bit	2 (4.35)	2 (3.45)
		Very much	0 (0.00)	0 (0.00)
	Week 11	n	55	54
		Not at all	20 (36.36)	13 (24.07)
		A little bit	30 (54.55)	26 (48.15)
		Somewhat	4 (7.27)	7 (12.96)
		Quite a bit	1 (1.82)	7 (12.96)
		Very much	0 (0.00)	1 (1.85)
	Week 12	n	45	49
		Not at all	16 (35.56)	13 (26.53)
		A little bit	24 (53.33)	24 (48.98)
		Somewhat	5 (11.11)	9 (18.37)
		Quite a bit	0 (0.00)	2 (4.08)
		Very much	0 (0.00)	1 (2.04)
	Week 13	n	53	51
		Not at all	21 (39.62)	10 (19.61)
		A little bit	26 (49.06)	28 (54.90)
		Somewhat	5 (9.43)	9 (17.65)
		Quite a bit	1 (1.89)	4 (7.84)
		Very much	0 (0.00)	0 (0.00)
	Week 19	n	42	41
		Not at all	18 (42.86)	8 (19.51)
		A little bit	19 (45.24)	25 (60.98)
		Somewhat	5 (11.90)	6 (14.63)
		Quite a bit	0 (0.00)	2 (4.88)
		Very much	0 (0.00)	0 (0.00)
	Week 25	n	44	25
		Not at all	18 (40.91)	8 (32.00)
		A little bit	23 (52.27)	15 (60.00)
		Somewhat	3 (6.82)	2 (8.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 31	n	32	17
		Not at all	15 (46.88)	2 (11.76)
		A little bit	11 (34.38)	11 (64.71)
		Somewhat	5 (15.63)	4 (23.53)
		Quite a bit	1 (3.13)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 37	n	27	12
		Not at all	12 (44.44)	2 (16.67)
		A little bit	11 (40.74)	8 (66.67)
		Somewhat	1 (3.70)	2 (16.67)
		Quite a bit	3 (11.11)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Summary of PRO-CTCAE Interference Over Time by Original Response
Intention-to-Treat Analysis Set

Domain	Timepoint		Tarlatamab (N=254) n (%)	Standard of Care (N=255) n (%)
Anxious Interference	Week 43	n	13	3
		Not at all	8 (61.54)	1 (33.33)
		A little bit	3 (23.08)	2 (66.67)
		Somewhat	2 (15.38)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 49	n	11	1
		Not at all	4 (36.36)	1 (100.0)
		A little bit	6 (54.55)	0 (0.00)
		Somewhat	1 (9.09)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 55	n	6	0
		Not at all	3 (50.00)	0 (0.00)
		A little bit	2 (33.33)	0 (0.00)
		Somewhat	1 (16.67)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 61	n	5	2
		Not at all	3 (60.00)	2 (100.0)
		A little bit	2 (40.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 67	n	1	0
		Not at all	1 (100.0)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	Week 73	n	1	0
		Not at all	1 (100.0)	0 (0.00)
		A little bit	0 (0.00)	0 (0.00)
		Somewhat	0 (0.00)	0 (0.00)
		Quite a bit	0 (0.00)	0 (0.00)
		Very much	0 (0.00)	0 (0.00)
	End of IP Administration	n	59	80
		Not at all	16 (27.12)	21 (26.25)
		A little bit	30 (50.85)	38 (47.50)
		Somewhat	9 (15.25)	10 (12.50)
		Quite a bit	3 (5.08)	6 (7.50)
		Very much	1 (1.69)	5 (6.25)
	Safety Follow-Up	n	25	39
		Not at all	5 (20.00)	8 (20.51)
		A little bit	11 (44.00)	19 (48.72)
		Somewhat	6 (24.00)	9 (23.08)
		Quite a bit	2 (8.00)	2 (5.13)
		Very much	1 (4.00)	1 (2.56)

N = Number of subjects in the analysis set; n = Number of subjects with observed data
The analysis includes baseline and all scheduled on-treatment visits including safety follow-up visit
Proportions are based on the number of subjects in each visit, treatment arm and response category

Anhang 4-G5: Subgruppenanalysen

Anhang 4-G5.1: Endpunkt „Gesamtüberleben“ – RCT

Table 14-4.1.1. Analysis of Overall Survival
(ITT Analysis Set)

Endpoint	Standard of Care (N = 255) Events[a] /Subjects (%)	Standard of Care (N = 255) Median (95% CI)[b] (Months)	Tarlatamab (N = 254) Events[a] /Subjects (%)	Tarlatamab (N = 254) Median (95% CI)[b] (Months)	p-value[c] Interaction With Treatment	Hazard Ratio (Tarlatamab / SOC) (95% CI)	p-value (2-sided)[d]
Overall Survival							
Overall[e]	152/255 (59.6)	8.3 (7.0, 10.2)	111/254 (43.7)	13.6 (11.1, NE)		0.599 (0.468, 0.768)	< 0.001
Age					0.590		
< 65 years	72/115 (62.6)	7.8 (6.6, 10.2)	56/129 (43.4)	13.6 (10.9, NE)			
≥ 65 years	80/140 (57.1)	9.4 (6.7, 10.6)	55/125 (44.0)	13.9 (10.7, NE)			
Sex					0.077		
Male	103/169 (60.9)	8.7 (6.7, 10.2)	90/182 (49.5)	11.2 (10.3, 13.9)			
Female	49/86 (57.0)	8.3 (6.3, NE)	21/72 (29.2)	17.1 (NE, NE)			

CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable; SOC = standard of care.
[a]Events are death.
[b]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate by Brookmeyer and Crowley (1982) method.
[c]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified log-rank test for 'Overall' and unstratified log-rank test for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-os-pfs-itt.sas
Output: t14-04-001-001-eff-os-itt.rtf (Date Generated: 21DEC25:20:37:36) Source: pa_adam.adsl, pa_adam.adtte

Table 14-4.1.1. Analysis of Overall Survival
(ITT Analysis Set)

Endpoint	Standard of Care (N = 255) Events[a] /Subjects (%)	Standard of Care (N = 255) Median (95% CI)[b] (Months)	Tarlatamab (N = 254) Events[a] /Subjects (%)	Tarlatamab (N = 254) Median (95% CI)[b] (Months)	p-value[c] Interaction With Treatment	Hazard Ratio (Tarlatamab / SOC) (95% CI)	p-value (2-sided)[d]
Region					0.295		
North America and Europe	82/128 (64.1)	6.7 (5.4, 8.7)	60/140 (42.9)	14.9 (10.9, NE)			
Rest of world	70/127 (55.1)	9.9 (8.1, 12.5)	51/114 (44.7)	13.9 (11.0, NE)			
Prior anti-PD-(L)1 exposure					0.693		
Yes	108/180 (60.0)	8.3 (6.8, 10.3)	77/180 (42.8)	14.1 (11.1, NE)			
No	44/75 (58.7)	8.3 (6.2, 12.5)	34/74 (45.9)	13.6 (9.7, NE)			

CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable; SOC = standard of care.
[a]Events are death.
[b]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate by Brookmeyer and Crowley (1982) method.
[c]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified log-rank test for 'Overall' and unstratified log-rank test for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-os-pfs-itt.sas
Output: t14-04-001-001-eff-os-itt.rtf (Date Generated: 21DEC25:20:37:36) Source: pa_adam.adsl, pa_adam.adtte

Table 14-4.1.1. Analysis of Overall Survival
(ITT Analysis Set)

Endpoint	Standard of Care (N = 255) Events[a] /Subjects (%)	Standard of Care (N = 255) Median (95% CI)[b] (Months)	Tarlatamab (N = 254) Events[a] /Subjects (%)	Tarlatamab (N = 254) Median (95% CI)[b] (Months)	p-value[c] Interaction With Treatment	Hazard Ratio (Tarlatamab / SOC) (95% CI)	p-value (2-sided)[d]
Chemotherapy-free interval					0.756		
< 90 days	83/114 (72.8)	6.4 (5.0, 7.9)	59/109 (54.1)	10.9 (8.7, 12.3)			
≥ 90 and < 180 days	44/78 (56.4)	10.2 (6.3, 16.1)	37/85 (43.5)	14.1 (9.4, NE)			
≥ 180 days	25/63 (39.7)	NE (9.4, NE)	15/60 (25.0)	17.1 (13.9, NE)			
Presence (previous or current) of brain metastases					0.024		
Yes	78/115 (67.8)	7.5 (5.7, 8.7)	47/113 (41.6)	14.1 (10.9, NE)		0.450 (0.312, 0.649)	< 0.001
No	74/140 (52.9)	10.3 (7.9, NE)	64/141 (45.4)	12.3 (10.4, NE)		0.811 (0.580, 1.133)	0.218

Page 3 of 4

CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable; SOC = standard of care.
[a]Events are death.
[b]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate by Brookmeyer and Crowley (1982) method.
[c]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified log-rank test for 'Overall' and unstratified log-rank test for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-os-pfs-itt.sas
Output: t14-04-001-001-eff-os-itt.rtf (Date Generated: 21DEC25:20:37:36) Source: pa_adam.adsl, pa_adam.adtte

Table 14-4.1.1. Analysis of Overall Survival
(ITT Analysis Set)

Endpoint	Standard of Care (N = 255) Events[a] /Subjects (%)	Standard of Care (N = 255) Median (95% CI)[b] (Months)	Tarlatamab (N = 254) Events[a] /Subjects (%)	Tarlatamab (N = 254) Median (95% CI)[b] (Months)	p-value[c] Interaction With Treatment	Hazard Ratio (Tarlatamab / SOC) (95% CI)	p-value (2-sided)[d]
Standard of care					0.311		
Topotecan/Amrubicin	125/208 (60.1)	7.9 (6.6, 9.4)	90/209 (43.1)	12.8 (11.1, 14.9)			
Lurbinectedin	27/47 (57.4)	10.6 (8.7, NE)	21/45 (46.7)	NE (6.8, NE)			

CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable; SOC = standard of care.
[a]Events are death.
[b]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate by Brookmeyer and Crowley (1982) method.
[c]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified log-rank test for 'Overall' and unstratified log-rank test for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-os-pfs-itt.sas
Output: t14-04-001-001-eff-os-itt.rtf (Date Generated: 21DEC25:20:37:36) Source: pa_adam.adsl, pa_adam.adtte

Anhang 4-G5.2: Endpunkt „Progressionsfreies Überleben (PFS) – RCT

Table 14-4.2.1. Analysis of Progression-Free Survival (ITT Analysis Set)

Endpoint	Standard of Care (N = 255) Events[a] /Subjects (%)	Standard of Care (N = 255) Median (95% CI)[b] (Months)	Tarlatamab (N = 254) Events[a] /Subjects (%)	Tarlatamab (N = 254) Median (95% CI)[b] (Months)	p-value[c] Interaction With Treatment	Hazard Ratio (Tarlatamab / SOC) (95% CI)	p-value (2-sided)[d]
Progression-Free Survival							
Overall[e]	205/255 (80.4)	3.2 (2.9, 4.2)	191/254 (75.2)	4.2 (3.0, 4.4)		0.716 (0.586, 0.875)	< 0.001
Age					0.265		
< 65 years	94/115 (81.7)	3.0 (2.8, 4.2)	106/129 (82.2)	4.0 (2.8, 4.3)			
≥ 65 years	111/140 (79.3)	3.7 (2.9, 4.2)	85/125 (68.0)	4.4 (3.5, 5.6)			
Sex					0.297		
Male	140/169 (82.8)	3.3 (2.8, 4.2)	139/182 (76.4)	4.0 (2.9, 4.2)			
Female	65/86 (75.6)	3.1 (2.8, 4.3)	52/72 (72.2)	5.6 (3.8, 5.8)			

Page 1 of 4

CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a]Events are disease progression and death, whichever occurs first.
[b]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate by Brookmeyer and Crowley (1982) method.
[c]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified log-rank test for 'Overall' and unstratified log-rank test for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-os-pfs-itt.sas
Output: t14-04-002-001-eff-pfs-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adtte

Table 14-4.2.1. Analysis of Progression-Free Survival (ITT Analysis Set)

Endpoint	Standard of Care (N = 255) Events[a] /Subjects (%)	Standard of Care (N = 255) Median (95% CI)[b] (Months)	Tarlatamab (N = 254) Events[a] /Subjects (%)	Tarlatamab (N = 254) Median (95% CI)[b] (Months)	p-value[c] Interaction With Treatment	Hazard Ratio (Tarlatamab / SOC) (95% CI)	p-value (2-sided)[d]
Region					0.231		
North America and Europe	99/128 (77.3)	3.7 (2.9, 4.3)	107/140 (76.4)	4.2 (3.0, 4.5)			
Rest of world	106/127 (83.5)	2.9 (2.7, 4.2)	84/114 (73.7)	4.2 (3.0, 5.4)			
Prior anti-PD-(L)1 exposure					0.182		
Yes	147/180 (81.7)	3.1 (2.8, 4.2)	136/180 (75.6)	4.2 (3.5, 5.4)			
No	58/75 (77.3)	3.4 (2.9, 5.3)	55/74 (74.3)	3.0 (2.2, 4.3)			

Page 2 of 4

CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a]Events are disease progression and death, whichever occurs first.
[b]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate by Brookmeyer and Crowley (1982) method.
[c]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified log-rank test for 'Overall' and unstratified log-rank test for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-os-pfs-itt.sas
Output: t14-04-002-001-eff-pfs-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adtte

Table 14-4.2.1. Analysis of Progression-Free Survival (ITT Analysis Set)

Endpoint	Standard of Care (N = 255) Events[a] /Subjects (%)	Standard of Care (N = 255) Median (95% CI)[b] (Months)	Tarlatamab (N = 254) Events[a] /Subjects (%)	Tarlatamab (N = 254) Median (95% CI)[b] (Months)	p-value[c] Interaction With Treatment	Hazard Ratio (Tarlatamab / SOC) (95% CI)	p-value (2-sided)[d]
Chemotherapy-free interval					0.911		
< 90 days	99/114 (86.8)	2.6 (1.9, 2.9)	90/109 (82.6)	3.0 (2.8, 4.2)			
≥ 90 and < 180 days	61/78 (78.2)	4.0 (3.0, 5.3)	59/85 (69.4)	4.2 (2.8, 5.4)			
≥ 180 days	45/63 (71.4)	5.2 (4.2, 5.7)	42/60 (70.0)	5.6 (4.2, 7.1)			
Presence (previous or current) of brain metastases					0.097		
Yes	95/115 (82.6)	3.1 (2.8, 4.0)	84/113 (74.3)	4.2 (2.9, 5.5)			
No	110/140 (78.6)	3.7 (2.8, 4.6)	107/141 (75.9)	4.2 (3.0, 5.0)			

CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a]Events are disease progression and death, whichever occurs first.
[b]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate by Brookmeyer and Crowley (1982) method.
[c]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified log-rank test for 'Overall' and unstratified log-rank test for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-os-pfs-itt.sas
Output: t14-04-002-001-eff-pfs-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adtte

Table 14-4.2.1. Analysis of Progression-Free Survival (ITT Analysis Set)

Endpoint	Standard of Care (N = 255) Events[a] /Subjects (%)	Standard of Care (N = 255) Median (95% CI)[b] (Months)	Tarlatamab (N = 254) Events[a] /Subjects (%)	Tarlatamab (N = 254) Median (95% CI)[b] (Months)	p-value[c] Interaction With Treatment	Hazard Ratio (Tarlatamab / SOC) (95% CI)	p-value (2-sided)[d]
Standard of care					0.292		
Topotecan/Amrubicin	163/208 (78.4)	3.2 (2.9, 4.2)	160/209 (76.6)	4.2 (3.0, 4.3)			
Lurbinectedin	42/47 (89.4)	4.0 (2.6, 5.6)	31/45 (68.9)	4.3 (1.3, 8.3)			

Page 4 of 4

CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a]Events are disease progression and death, whichever occurs first.
[b]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate by Brookmeyer and Crowley (1982) method.
[c]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified log-rank test for 'Overall' and unstratified log-rank test for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-os-pfs-itt.sas
Output: t14-04-002-001-eff-pfs-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adtte

Anhang 4-G5.3: Endpunkt „Ansprechen“ – RCT

Table 14-4.3.1. Analyses of Objective Response (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Overall[e]	52/255 (20.4) (15.6, 25.9)	89/254 (35.0) (29.2, 41.3)		14.8 (7.1, 22.5)	2.128 (1.425, 3.178)	1.730 (1.287, 2.325)	< 0.001
Age			0.125				
< 65 years	17/115 (14.8) (8.9, 22.6)	45/129 (34.9) (26.7, 43.8)					
≥ 65 years	35/140 (25.0) (18.1, 33.0)	44/125 (35.2) (26.9, 44.2)					

Page 1 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR).
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better objective response rate of tarlatamab arm
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-orr-itt.sas
Output: t14-04-003-001-eff-orr-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.3.1. Analyses of Objective Response (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Sex			0.083				
Male	37/169 (21.9) (15.9, 28.9)	58/182 (31.9) (25.2, 39.2)					
Female	15/86 (17.4) (10.1, 27.1)	31/72 (43.1) (31.4, 55.3)					

Page 2 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR).
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better objective response rate of tarlatamab arm
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-orr-itt.sas
Output: t14-04-003-001-eff-orr-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.3.1. Analyses of Objective Response
(ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Region			0.106				
North America and Europe	30/128 (23.4) (16.4, 31.7)	45/140 (32.1) (24.5, 40.6)					
Rest of world	22/127 (17.3) (11.2, 25.0)	44/114 (38.6) (29.6, 48.2)					

Page 3 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR).
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better objective response rate of tarlatamab arm
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-orr-itt.sas
Output: t14-04-003-001-eff-orr-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.3.1. Analyses of Objective Response (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Prior anti-PD-(L)1 exposure			0.262				
Yes	36/180 (20.0) (14.4, 26.6)	68/180 (37.8) (30.7, 45.3)					
No	16/75 (21.3) (12.7, 32.3)	21/74 (28.4) (18.5, 40.1)					

Page 4 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR).
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better objective response rate of tarlatamab arm
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-orr-itt.sas
Output: t14-04-003-001-eff-orr-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.3.1. Analyses of Objective Response (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Chemotherapy-free interval			0.027				
< 90 days	11/114 (9.6) (4.9, 16.6)	36/109 (33.0) (24.3, 42.7)		23.4 (13.0, 33.7)	4.618 (2.206, 9.667)	3.423 (1.837, 6.376)	< 0.001
≥ 90 and < 180 days	22/78 (28.2) (18.6, 39.5)	31/85 (36.5) (26.3, 47.6)		8.3 (-6.0, 22.6)	1.461 (0.754, 2.833)	1.293 (0.823, 2.031)	0.262
≥ 180 days	19/63 (30.2) (19.2, 43.0)	22/60 (36.7) (24.6, 50.1)		6.5 (-10.1, 23.2)	1.341 (0.632, 2.843)	1.216 (0.736, 2.008)	0.446

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR).
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better objective response rate of tarlatamab arm
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-orr-itt.sas
Output: t14-04-003-001-eff-orr-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.3.1. Analyses of Objective Response (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Presence (previous or current) of brain metastases			0.093				
Yes	21/115 (18.3) (11.7, 26.5)	46/113 (40.7) (31.6, 50.4)					
No	31/140 (22.1) (15.6, 29.9)	43/141 (30.5) (23.0, 38.8)					

Page 6 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR).
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better objective response rate of tarlatamab arm
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-orr-itt.sas
Output: t14-04-003-001-eff-orr-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.3.1. Analyses of Objective Response (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Standard of care			0.589				
Topotecan/Amrubicin	38/208 (18.3) (13.3, 24.2)	70/209 (33.5) (27.1, 40.3)					
Lurbinectedin	14/47 (29.8) (17.3, 44.9)	19/45 (42.2) (27.7, 57.8)					

Page 7 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR).
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better objective response rate of tarlatamab arm
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-orr-itt.sas
Output: t14-04-003-001-eff-orr-itt.rtf (Date Generated: 21DEC25:20:37:34) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.4.1. Analyses of Disease Control Rate (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Overall[e]	164/255 (64.3) (58.1, 70.2)	173/254 (68.1) (62.0, 73.8)		4.1 (-4.1, 12.2)	1.205 (0.830, 1.748)	1.063 (0.940, 1.202)	0.328
Age			0.451				
< 65 years	74/115 (64.3) (54.9, 73.1)	84/129 (65.1) (56.2, 73.3)					
≥ 65 years	90/140 (64.3) (55.8, 72.2)	89/125 (71.2) (62.4, 78.9)					

Page 1 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR) or Stable Disease.
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better disease control rate of tarlatamab arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-dr-itt.sas
Output: t14-04-004-001-eff-dr-itt.rtf (Date Generated: 21DEC25:20:37:28) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.4.1. Analyses of Disease Control Rate (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Sex			0.203				
Male	112/169 (66.3) (58.6, 73.4)	121/182 (66.5) (59.1, 73.3)					
Female	52/86 (60.5) (49.3, 70.8)	52/72 (72.2) (60.4, 82.1)					

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR) or Stable Disease.
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better disease control rate of tarlatamab arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-dr-itt.sas
Output: t14-04-004-001-eff-dr-itt.rtf (Date Generated: 21DEC25:20:37:28) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.4.1. Analyses of Disease Control Rate (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Region			0.848				
North America and Europe	83/128 (64.8) (55.9, 73.1)	95/140 (67.9) (59.4, 75.5)					
Rest of world	81/127 (63.8) (54.8, 72.1)	78/114 (68.4) (59.1, 76.8)					

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR) or Stable Disease.
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better disease control rate of tarlatamab arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-dr-itt.sas
Output: t14-04-004-001-eff-dr-itt.rtf (Date Generated: 21DEC25:20:37:28) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.4.1. Analyses of Disease Control Rate (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Prior anti-PD-(L)1 exposure			0.281				
Yes	115/180 (63.9) (56.4, 70.9)	127/180 (70.6) (63.3, 77.1)					
No	49/75 (65.3) (53.5, 76.0)	46/74 (62.2) (50.1, 73.2)					

Page 4 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR) or Stable Disease.
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better disease control rate of tarlatamab arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-dr-itt.sas
Output: t14-04-004-001-eff-dr-itt.rtf (Date Generated: 21DEC25:20:37:28) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.4.1. Analyses of Disease Control Rate (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Chemotherapy-free interval			0.428				
< 90 days	63/114 (55.3) (45.7, 64.6)	64/109 (58.7) (48.9, 68.1)					
≥ 90 and < 180 days	53/78 (67.9) (56.4, 78.1)	57/85 (67.1) (56.0, 76.9)					
≥ 180 days	48/63 (76.2) (63.8, 86.0)	52/60 (86.7) (75.4, 94.1)					

Page 5 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR) or Stable Disease.
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better disease control rate of tarlatamab arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-dr-itt.sas
Output: t14-04-004-001-eff-dr-itt.rtf (Date Generated: 21DEC25:20:37:28) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.4.1. Analyses of Disease Control Rate (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Presence (previous or current) of brain metastases			0.263				
Yes	70/115 (60.9) (51.3, 69.8)	79/113 (69.9) (60.6, 78.2)					
No	94/140 (67.1) (58.7, 74.8)	94/141 (66.7) (58.2, 74.4)					

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR) or Stable Disease.
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better disease control rate of tarlatamab arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-dr-itt.sas
Output: t14-04-004-001-eff-dr-itt.rtf (Date Generated: 21DEC25:20:37:28) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Table 14-4.4.1. Analyses of Disease Control Rate (ITT Analysis Set)

	Standard of Care (N = 255)	Tarlatamab (N = 254)	p-value[c]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events[a] /Subjects (%) (95% CI)[b]	Events[a] /Subjects (%) (95% CI)[b]	Interaction With Treatment	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	(Tarlatamab/ Standard of Care)	p-value (2-sided)[d]
Standard of care			0.116				
Topotecan/Amrubicin	132/208 (63.5) (56.5, 70.0)	147/209 (70.3) (63.6, 76.4)					
Lurbinectedin	32/47 (68.1) (52.9, 80.9)	26/45 (57.8) (42.2, 72.3)					

Page 7 of 7

CI = Confidence Interval.
[a]Events are Confirmed Responder (PR/CR) or Stable Disease.
[b]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[c]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[d]2-sided p-values were calculated using the stratified Cochran-Mantel-Haenszel test for 'Overall' and unstratified for subgroups.
[e]Randomization stratification factors are CFI (<90 days, ≥ 90 days) and presence of brain metastases (yes or no).
Subject(s) with unknown or missing subgroup value are not included.
Odds ratio with 95% CI and p-value are estimated using the Cochran Mantel Haenszel Chi-square test; an odds ratio > 1.0 indicates a better disease control rate of tarlatamab arm.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-eff-dr-itt.sas
Output: t14-04-004-001-eff-dr-itt.rtf (Date Generated: 21DEC25:20:37:28) Source: pa_adam.adsl, pa_adam.adresp, pa_adam.adevent

Anhang 4-G5.4: Endpunkt „Symptomatik“ – RCT

Anhang 4-G5.4.1: Endpunkt „EORTC QLQ-C30/-LC13“ – RCT

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Appetite Loss - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.434
< 65 years	85/ 129 (65.9)	3.1 (2.3, 8.4)	61/ 115 (53.0)	6.3 (4.6, 12.1)	1.41 (1.01, 1.96)	0.044	
>= 65 years	86/ 125 (68.8)	3.3 (2.4, 4.6)	90/ 140 (64.3)	4.3 (3.3, 5.8)	1.19 (0.89, 1.60)	0.242	
Gender							0.283
female	51/ 72 (70.8)	2.6 (2.3, 3.7)	52/ 86 (60.5)	5.7 (3.8, 9.7)	1.54 (1.04, 2.27)	0.031	
male	120/ 182 (65.9)	4.3 (2.4, 6.1)	99/ 169 (58.6)	5.1 (3.6, 6.5)	1.18 (0.90, 1.54)	0.231	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	14/ 21 (66.7)		12/ 18 (66.7)				
STAGE IV	157/ 233 (67.4)		137/ 235 (58.3)				
Region							0.054
North America and Europe	96/ 140 (68.6)	4.3 (2.6, 5.8)	63/ 128 (49.2)	6.5 (4.1, 18.5)	1.63 (1.19, 2.25)	0.002	
Rest of the World	75/ 114 (65.8)	2.4 (2.3, 4.3)	88/ 127 (69.3)	4.4 (3.3, 5.3)	1.02 (0.75, 1.40)	0.898	
Prior anti-PD-(L)1 exposure							0.433
yes	120/ 180 (66.7)	2.6 (2.4, 4.7)	108/ 180 (60.0)	4.6 (3.4, 5.4)	1.20 (0.92, 1.56)	0.178	
no	51/ 74 (68.9)	4.3 (2.3, 6.3)	43/ 75 (57.3)	7.4 (4.3, 12.7)	1.44 (0.96, 2.16)	0.077	
Chemotherapy-free interval							0.234
< 90 days	69/ 109 (63.3)	4.6 (2.3, 7.5)	69/ 114 (60.5)	4.1 (3.1, 5.4)	0.99 (0.71, 1.39)	0.927	
>= 90 and < 180 days	58/ 85 (68.2)	2.6 (2.3, 4.3)	42/ 78 (53.8)	6.5 (3.6, 18.2)	1.54 (1.03, 2.30)	0.035	
>= 180 days	44/ 60 (73.3)	3.3 (2.3, 5.6)	40/ 63 (63.5)	6.5 (4.3, 12.1)	1.42 (0.93, 2.19)	0.109	
Presence (previous or current) of brain metastases							0.068
yes	75/ 113 (66.4)	4.6 (2.6, 6.7)	68/ 115 (59.1)	4.3 (3.4, 5.7)	1.02 (0.73, 1.41)	0.933	
no	96/ 141 (68.1)	2.4 (2.3, 4.3)	83/ 140 (59.3)	5.4 (4.3, 8.3)	1.51 (1.12, 2.02)	0.006	
Standard of care							0.270
Amrubicin/Topotecan	142/ 209 (67.9)	3.3 (2.6, 4.7)	117/ 208 (56.3)	5.8 (4.6, 9.5)	1.34 (1.05, 1.71)	0.020	
Lurbinectedin	29/ 45 (64.4)	2.6 (2.1, 6.8)	34/ 47 (72.3)	3.4 (3.0, 4.3)	1.04 (0.63, 1.71)	0.875	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Constipation - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.358
< 65 years	73/ 129 (56.6)	10.5 (7.1, 18.2)	62/ 115 (53.9)	8.3 (4.6, 13.1)	0.86 (0.62, 1.22)	0.406	
>= 65 years	75/ 125 (60.0)	5.3 (3.6, 7.4)	79/ 140 (56.4)	6.1 (4.3, 8.5)	1.09 (0.79, 1.49)	0.606	
Gender							0.620
female	44/ 72 (61.1)	6.4 (4.3, 8.7)	49/ 86 (57.0)	7.4 (3.6, 10.5)	1.06 (0.70, 1.59)	0.774	
male	104/ 182 (57.1)	8.1 (5.1, 13.4)	92/ 169 (54.4)	6.3 (4.6, 10.3)	0.93 (0.70, 1.23)	0.595	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	14/ 21 (66.7)		11/ 18 (61.1)				
STAGE IV	134/ 233 (57.5)		128/ 235 (54.5)				
Region							0.004
North America and Europe	84/ 140 (60.0)	6.4 (4.7, 8.7)	59/ 128 (46.1)	10.5 (6.5, 18.5)	1.34 (0.96, 1.87)	0.085	
Rest of the World	64/ 114 (56.1)	8.4 (5.1, 20.1)	82/ 127 (64.6)	4.6 (4.3, 7.1)	0.70 (0.50, 0.97)	0.035	
Prior anti-PD-(L)1 exposure							0.426
yes	102/ 180 (56.7)	7.5 (5.3, 11.4)	98/ 180 (54.4)	6.3 (4.6, 9.1)	0.90 (0.68, 1.19)	0.477	
no	46/ 74 (62.2)	6.4 (3.4, 12.2)	43/ 75 (57.3)	7.4 (4.3, 13.1)	1.10 (0.72, 1.66)	0.662	
Chemotherapy-free interval							0.506
< 90 days	56/ 109 (51.4)	8.1 (5.6, 13.8)	58/ 114 (50.9)	6.3 (4.3, 10.5)	0.88 (0.61, 1.27)	0.494	
>= 90 and < 180 days	54/ 85 (63.5)	5.3 (2.6, 8.7)	43/ 78 (55.1)	8.3 (4.3, 13.1)	1.19 (0.80, 1.79)	0.387	
>= 180 days	38/ 60 (63.3)	8.5 (4.4, 28.2)	40/ 63 (63.5)	6.8 (3.6, 10.4)	0.84 (0.54, 1.31)	0.447	
Presence (previous or current) of brain metastases							0.085
yes	63/ 113 (55.8)	8.5 (5.6, 14.9)	63/ 115 (54.8)	6.3 (4.3, 9.3)	0.76 (0.53, 1.08)	0.124	
no	85/ 141 (60.3)	6.1 (3.6, 9.8)	78/ 140 (55.7)	7.1 (4.6, 10.5)	1.14 (0.84, 1.55)	0.399	
Standard of care							0.555
Amrubicin/Topotecan	123/ 209 (58.9)	7.4 (5.3, 11.7)	115/ 208 (55.3)	7.5 (4.7, 9.3)	0.92 (0.71, 1.19)	0.513	
Lurbinectedin	25/ 45 (55.6)	5.3 (3.4, 10.5)	26/ 47 (55.3)	5.4 (4.1, NE)	1.15 (0.67, 2.00)	0.607	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Diarrhoea - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.156
< 65 years	39/ 129 (30.2)	NE (36.2, NE)	36/ 115 (31.3)	NE (18.1, NE)	0.84 (0.53, 1.33)	0.467	
>= 65 years	31/ 125 (24.8)	61.9 (61.9, NE)	54/ 140 (38.6)	30.3 (10.5, NE)	0.56 (0.36, 0.87)	0.009	
Gender							0.357
female	25/ 72 (34.7)	NE (11.7, NE)	32/ 86 (37.2)	24.2 (10.0, NE)	0.84 (0.49, 1.43)	0.516	
male	45/ 182 (24.7)	61.9 (61.9, NE)	58/ 169 (34.3)	30.5 (18.1, NE)	0.61 (0.41, 0.91)	0.013	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	5/ 21 (23.8)		9/ 18 (50.0)				
STAGE IV	65/ 233 (27.9)		80/ 235 (34.0)				
Region							0.528
North America and Europe	37/ 140 (26.4)	NE (NE , NE)	40/ 128 (31.3)	30.5 (18.1, NE)	0.74 (0.47, 1.17)	0.193	
Rest of the World	33/ 114 (28.9)	NE (61.9, NE)	50/ 127 (39.4)	24.3 (11.1, NE)	0.62 (0.39, 0.96)	0.031	
Prior anti-PD-(L)1 exposure							0.881
yes	52/ 180 (28.9)	61.9 (61.9, NE)	65/ 180 (36.1)	30.3 (13.5, NE)	0.67 (0.46, 0.97)	0.031	
no	18/ 74 (24.3)	NE (NE , NE)	25/ 75 (33.3)	NE (11.1, NE)	0.68 (0.37, 1.25)	0.209	
Chemotherapy-free interval							0.917
< 90 days	26/ 109 (23.9)	61.9 (61.9, NE)	35/ 114 (30.7)	30.5 (11.4, NE)	0.63 (0.37, 1.06)	0.077	
>= 90 and < 180 days	26/ 85 (30.6)	NE (30.2, NE)	28/ 78 (35.9)	30.3 (13.5, NE)	0.72 (0.42, 1.23)	0.228	
>= 180 days	18/ 60 (30.0)	NE (36.2, NE)	27/ 63 (42.9)	NE (9.1, NE)	0.63 (0.35, 1.15)	0.132	
Presence (previous or current) of brain metastases							0.424
yes	29/ 113 (25.7)	61.9 (61.9, NE)	38/ 115 (33.0)	30.3 (18.1, NE)	0.56 (0.34, 0.92)	0.020	
no	41/ 141 (29.1)	NE (NE , NE)	52/ 140 (37.1)	NE (13.5, NE)	0.76 (0.50, 1.15)	0.186	
Standard of care							0.412
Amrubicin/Topotecan	54/ 209 (25.8)	NE (NE , NE)	71/ 208 (34.1)	NE (18.1, NE)	0.63 (0.44, 0.91)	0.012	
Lurbinectedin	16/ 45 (35.6)	61.9 (9.1, NE)	19/ 47 (40.4)	30.3 (7.1, NE)	0.84 (0.42, 1.66)	0.608	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Dyspnea - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.583
< 65 years	59/ 129 (45.7)	30.5 (10.3, NE)	58/ 115 (50.4)	8.3 (5.3, 24.3)	0.73 (0.51, 1.06)	0.097	
>= 65 years	65/ 125 (52.0)	8.5 (4.3, 18.4)	80/ 140 (57.1)	6.3 (3.8, 8.3)	0.87 (0.63, 1.21)	0.404	
Gender							0.843
female	36/ 72 (50.0)	6.8 (4.0, 36.7)	48/ 86 (55.8)	6.5 (3.6, 12.1)	0.84 (0.54, 1.29)	0.423	
male	88/ 182 (48.4)	18.4 (8.5, 34.2)	90/ 169 (53.3)	7.5 (5.3, 12.1)	0.78 (0.58, 1.05)	0.094	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	11/ 21 (52.4)		9/ 18 (50.0)				
STAGE IV	113/ 233 (48.5)		127/ 235 (54.0)				
Region							0.664
North America and Europe	69/ 140 (49.3)	11.4 (5.7, 30.9)	66/ 128 (51.6)	7.3 (5.1, 9.5)	0.82 (0.59, 1.16)	0.264	
Rest of the World	55/ 114 (48.2)	28.6 (6.1, NE)	72/ 127 (56.7)	7.3 (4.0, 17.9)	0.74 (0.52, 1.06)	0.096	
Prior anti-PD-(L)1 exposure							0.398
yes	93/ 180 (51.7)	11.4 (6.1, 30.0)	97/ 180 (53.9)	7.3 (5.1, 9.5)	0.84 (0.63, 1.11)	0.217	
no	31/ 74 (41.9)	36.7 (5.1, NE)	41/ 75 (54.7)	7.3 (3.6, 19.1)	0.67 (0.42, 1.07)	0.094	
Chemotherapy-free interval							0.718
< 90 days	48/ 109 (44.0)	23.8 (5.1, NE)	57/ 114 (50.0)	6.1 (3.4, 8.4)	0.71 (0.48, 1.05)	0.086	
>= 90 and < 180 days	44/ 85 (51.8)	10.7 (4.3, NE)	41/ 78 (52.6)	7.3 (5.1, 18.7)	0.92 (0.60, 1.42)	0.731	
>= 180 days	32/ 60 (53.3)	12.8 (4.4, NE)	40/ 63 (63.5)	7.5 (3.6, 17.9)	0.77 (0.48, 1.23)	0.260	
Presence (previous or current) of brain metastases							0.908
yes	59/ 113 (52.2)	11.4 (5.1, 34.2)	60/ 115 (52.2)	5.7 (3.6, 10.0)	0.81 (0.57, 1.17)	0.262	
no	65/ 141 (46.1)	18.5 (6.1, NE)	78/ 140 (55.7)	7.5 (5.1, 12.5)	0.77 (0.55, 1.07)	0.115	
Standard of care							0.666
Amrubicin/Topotecan	102/ 209 (48.8)	18.4 (7.5, 32.3)	107/ 208 (51.4)	7.5 (5.3, 12.1)	0.81 (0.62, 1.07)	0.132	
Lurbinectedin	22/ 45 (48.9)	6.1 (3.3, NE)	31/ 47 (66.0)	4.6 (3.4, 8.3)	0.73 (0.42, 1.27)	0.274	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Fatigue - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.720
< 65 years	95/ 129 (73.6)	2.3 (1.6, 3.1)	80/ 115 (69.6)	3.1 (2.4, 4.0)	1.17 (0.87, 1.57)	0.332	
>= 65 years	99/ 125 (79.2)	2.3 (1.9, 2.3)	108/ 140 (77.1)	2.4 (1.6, 3.3)	1.27 (0.96, 1.67)	0.084	
Gender							0.340
female	53/ 72 (73.6)	2.0 (1.6, 2.3)	64/ 86 (74.4)	3.3 (2.4, 4.1)	1.36 (0.94, 1.96)	0.110	
male	141/ 182 (77.5)	2.3 (2.1, 2.6)	124/ 169 (73.4)	2.4 (2.3, 3.1)	1.10 (0.86, 1.40)	0.435	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	15/ 21 (71.4)		15/ 18 (83.3)				
STAGE IV	179/ 233 (76.8)		171/ 235 (72.8)				
Region							0.094
North America and Europe	107/ 140 (76.4)	2.1 (1.6, 2.4)	87/ 128 (68.0)	3.1 (2.6, 3.6)	1.40 (1.06, 1.86)	0.019	
Rest of the World	87/ 114 (76.3)	2.3 (2.0, 3.1)	101/ 127 (79.5)	2.3 (2.1, 3.3)	0.98 (0.74, 1.31)	0.887	
Prior anti-PD-(L)1 exposure							0.106
yes	140/ 180 (77.8)	2.1 (1.6, 2.3)	130/ 180 (72.2)	3.1 (2.4, 3.4)	1.31 (1.03, 1.66)	0.028	
no	54/ 74 (73.0)	2.6 (2.3, 3.3)	58/ 75 (77.3)	2.3 (1.6, 3.6)	0.89 (0.61, 1.29)	0.537	
Chemotherapy-free interval							0.439
< 90 days	80/ 109 (73.4)	2.3 (1.6, 3.1)	76/ 114 (66.7)	3.1 (2.3, 3.6)	1.30 (0.95, 1.78)	0.109	
>= 90 and < 180 days	67/ 85 (78.8)	2.3 (1.9, 2.4)	58/ 78 (74.4)	3.1 (2.3, 3.6)	1.24 (0.87, 1.76)	0.240	
>= 180 days	47/ 60 (78.3)	2.1 (1.6, 3.1)	54/ 63 (85.7)	2.3 (1.6, 3.3)	0.93 (0.63, 1.37)	0.694	
Presence (previous or current) of brain metastases							0.937
yes	90/ 113 (79.6)	2.3 (2.1, 2.7)	79/ 115 (68.7)	3.0 (2.4, 3.4)	1.17 (0.87, 1.59)	0.296	
no	104/ 141 (73.8)	2.1 (1.6, 2.3)	109/ 140 (77.9)	2.6 (2.1, 3.4)	1.16 (0.89, 1.52)	0.296	
Standard of care							0.093
Amrubicin/Topotecan	166/ 209 (79.4)	2.3 (1.7, 2.3)	150/ 208 (72.1)	2.6 (2.3, 3.3)	1.26 (1.01, 1.57)	0.040	
Lurbinectedin	28/ 45 (62.2)	2.4 (1.6, 4.7)	38/ 47 (80.9)	3.2 (2.3, 3.4)	0.81 (0.49, 1.33)	0.408	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Nausea and Vomiting - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.843
< 65 years	63/ 129 (48.8)	22.9 (9.1, 47.8)	61/ 115 (53.0)	7.4 (5.1, 14.4)	0.79 (0.55, 1.13)	0.190	
>= 65 years	56/ 125 (44.8)	12.5 (6.3, NE)	76/ 140 (54.3)	6.3 (4.6, 11.5)	0.79 (0.56, 1.11)	0.168	
Gender							0.005
female	41/ 72 (56.9)	4.3 (2.6, 9.0)	42/ 86 (48.8)	7.1 (4.6, NE)	1.37 (0.89, 2.11)	0.151	
male	78/ 182 (42.9)	38.6 (12.8, NE)	95/ 169 (56.2)	7.1 (4.8, 10.3)	0.62 (0.46, 0.84)	0.002	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	10/ 21 (47.6)		11/ 18 (61.1)				
STAGE IV	109/ 233 (46.8)		125/ 235 (53.2)				
Region							0.774
North America and Europe	60/ 140 (42.9)	24.3 (7.8, NE)	59/ 128 (46.1)	9.3 (6.1, 25.2)	0.83 (0.58, 1.19)	0.297	
Rest of the World	59/ 114 (51.8)	12.5 (4.7, 47.8)	78/ 127 (61.4)	5.4 (4.3, 9.1)	0.78 (0.55, 1.10)	0.146	
Prior anti-PD-(L)1 exposure							0.860
yes	85/ 180 (47.2)	18.5 (8.3, NE)	93/ 180 (51.7)	6.7 (5.1, 14.4)	0.81 (0.60, 1.08)	0.147	
no	34/ 74 (45.9)	18.2 (4.1, NE)	44/ 75 (58.7)	7.5 (4.3, 11.2)	0.77 (0.49, 1.20)	0.235	
Chemotherapy-free interval							0.342
< 90 days	55/ 109 (50.5)	12.2 (6.3, 30.6)	58/ 114 (50.9)	6.1 (3.6, 11.0)	0.85 (0.59, 1.24)	0.401	
>= 90 and < 180 days	42/ 85 (49.4)	12.7 (4.7, NE)	42/ 78 (53.8)	9.3 (5.1, 25.2)	0.89 (0.58, 1.37)	0.586	
>= 180 days	22/ 60 (36.7)	NE (9.1, NE)	37/ 63 (58.7)	7.1 (5.1, 18.5)	0.58 (0.34, 0.98)	0.038	
Presence (previous or current) of brain metastases							0.126
yes	48/ 113 (42.5)	38.6 (9.0, NE)	60/ 115 (52.2)	6.7 (4.6, 11.2)	0.64 (0.44, 0.94)	0.021	
no	71/ 141 (50.4)	12.4 (4.7, 30.0)	77/ 140 (55.0)	7.5 (5.1, 14.2)	0.94 (0.68, 1.29)	0.673	
Standard of care							0.257
Amrubicin/Topotecan	100/ 209 (47.8)	18.4 (7.8, NE)	107/ 208 (51.4)	8.3 (6.1, 14.2)	0.85 (0.65, 1.12)	0.233	
Lurbinectedin	19/ 45 (42.2)	22.9 (5.1, NE)	30/ 47 (63.8)	4.1 (3.4, 7.4)	0.57 (0.32, 1.03)	0.062	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Pain - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.486
< 65 years	86/ 129 (66.7)	4.0 (2.6, 8.5)	74/ 115 (64.3)	6.1 (4.3, 7.4)	1.02 (0.74, 1.39)	0.954	
>= 65 years	70/ 125 (56.0)	4.7 (3.1, 9.0)	89/ 140 (63.6)	4.3 (3.6, 7.4)	0.91 (0.66, 1.24)	0.542	
Gender							0.992
female	46/ 72 (63.9)	2.6 (2.1, 5.0)	61/ 86 (70.9)	3.6 (2.6, 6.3)	1.01 (0.68, 1.48)	0.992	
male	110/ 182 (60.4)	6.0 (3.4, 11.2)	102/ 169 (60.4)	6.8 (4.8, 8.3)	0.98 (0.75, 1.29)	0.895	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	15/ 21 (71.4)		14/ 18 (77.8)				
STAGE IV	141/ 233 (60.5)		147/ 235 (62.6)				
Region							0.768
North America and Europe	88/ 140 (62.9)	4.6 (3.0, 8.4)	78/ 128 (60.9)	5.1 (3.6, 6.5)	0.99 (0.73, 1.34)	0.936	
Rest of the World	68/ 114 (59.6)	4.1 (3.1, 9.5)	85/ 127 (66.9)	6.1 (4.3, 10.1)	0.94 (0.68, 1.29)	0.661	
Prior anti-PD-(L)1 exposure							0.078
yes	105/ 180 (58.3)	5.1 (3.1, 9.5)	115/ 180 (63.9)	5.3 (3.8, 6.5)	0.86 (0.66, 1.13)	0.266	
no	51/ 74 (68.9)	4.3 (2.7, 7.3)	48/ 75 (64.0)	7.1 (3.6, 11.2)	1.32 (0.89, 1.96)	0.170	
Chemotherapy-free interval							0.502
< 90 days	63/ 109 (57.8)	5.0 (3.3, 9.5)	68/ 114 (59.6)	6.3 (3.4, 7.5)	0.93 (0.66, 1.31)	0.679	
>= 90 and < 180 days	48/ 85 (56.5)	6.4 (2.4, 16.4)	49/ 78 (62.8)	4.3 (3.3, 9.3)	0.91 (0.61, 1.35)	0.634	
>= 180 days	45/ 60 (75.0)	3.3 (2.1, 6.5)	46/ 63 (73.0)	6.1 (4.1, 10.3)	1.14 (0.75, 1.72)	0.546	
Presence (previous or current) of brain metastases							<.001
yes	63/ 113 (55.8)	9.4 (3.6, 24.2)	77/ 115 (67.0)	4.3 (3.3, 6.3)	0.61 (0.44, 0.86)	0.004	
no	93/ 141 (66.0)	3.4 (2.4, 5.0)	86/ 140 (61.4)	7.1 (4.3, 10.7)	1.37 (1.02, 1.84)	0.037	
Standard of care							0.376
Amrubicin/Topotecan	132/ 209 (63.2)	4.6 (3.1, 7.3)	133/ 208 (63.9)	6.1 (4.3, 7.4)	1.01 (0.79, 1.28)	0.975	
Lurbinectedin	24/ 45 (53.3)	6.0 (2.3, NE)	30/ 47 (63.8)	4.3 (3.4, 6.5)	0.83 (0.48, 1.42)	0.501	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Insomnia - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.230
< 65 years	65/ 129 (50.4)	18.1 (4.7, NE)	65/ 115 (56.5)	9.1 (5.3, 11.0)	0.77 (0.54, 1.09)	0.132	
>= 65 years	62/ 125 (49.6)	18.5 (6.4, 36.0)	67/ 140 (47.9)	10.5 (7.3, 22.2)	0.98 (0.69, 1.38)	0.886	
Gender							0.547
female	41/ 72 (56.9)	6.8 (3.4, 25.6)	49/ 86 (57.0)	7.7 (4.4, 12.5)	0.97 (0.63, 1.48)	0.863	
male	86/ 182 (47.3)	24.2 (9.7, 42.1)	83/ 169 (49.1)	10.5 (8.1, 22.1)	0.84 (0.62, 1.14)	0.265	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	9/ 21 (42.9)		12/ 18 (66.7)				
STAGE IV	118/ 233 (50.6)		120/ 235 (51.1)				
Region							0.813
North America and Europe	70/ 140 (50.0)	18.1 (6.8, 30.3)	67/ 128 (52.3)	9.1 (6.4, 13.1)	0.80 (0.57, 1.13)	0.204	
Rest of the World	57/ 114 (50.0)	18.2 (4.4, NE)	65/ 127 (51.2)	10.7 (6.7, 18.5)	0.94 (0.66, 1.35)	0.727	
Prior anti-PD-(L)1 exposure							0.780
yes	88/ 180 (48.9)	12.8 (7.1, 38.9)	93/ 180 (51.7)	10.0 (7.3, 11.7)	0.87 (0.64, 1.17)	0.332	
no	39/ 74 (52.7)	22.5 (4.4, 36.0)	39/ 75 (52.0)	10.1 (4.0, 30.0)	0.90 (0.57, 1.40)	0.624	
Chemotherapy-free interval							0.722
< 90 days	51/ 109 (46.8)	24.1 (5.0, 42.3)	54/ 114 (47.4)	10.3 (5.3, 18.5)	0.88 (0.60, 1.30)	0.503	
>= 90 and < 180 days	39/ 85 (45.9)	24.3 (4.7, NE)	41/ 78 (52.6)	9.1 (4.3, 22.2)	0.81 (0.52, 1.25)	0.333	
>= 180 days	37/ 60 (61.7)	9.7 (4.4, 30.2)	37/ 63 (58.7)	10.0 (6.7, 22.1)	0.95 (0.59, 1.50)	0.809	
Presence (previous or current) of brain metastases							0.446
yes	56/ 113 (49.6)	24.1 (6.8, 42.3)	57/ 115 (49.6)	9.1 (6.3, 13.1)	0.77 (0.52, 1.12)	0.168	
no	71/ 141 (50.4)	9.1 (4.7, 30.2)	75/ 140 (53.6)	10.3 (7.0, 18.5)	0.95 (0.69, 1.32)	0.755	
Standard of care							0.068
Amrubicin/Topotecan	111/ 209 (53.1)	11.1 (6.7, 30.0)	104/ 208 (50.0)	10.1 (7.7, 13.1)	0.96 (0.73, 1.26)	0.738	
Lurbinectedin	16/ 45 (35.6)	NE (4.7, NE)	28/ 47 (59.6)	6.4 (3.6, 24.2)	0.56 (0.30, 1.04)	0.059	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Appetite Loss - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.994
< 65 years	128	20.57 (30.77)	123	9.39 (1.81)	114	21.64 (28.73)	104	5.67 (2.02)	3.72 (-1.61, 9.05)	0.170	0.18 (-0.08, 0.44)	
>= 65 years	118	20.06 (28.95)	112	12.90 (1.84)	136	18.14 (26.87)	127	9.15 (1.77)	3.75 (-1.28, 8.78)	0.143	0.19 (-0.06, 0.44)	
Gender												0.128
female	66	19.70 (32.01)	62	16.03 (2.32)	84	22.62 (28.88)	78	8.06 (2.21)	7.96 (1.63, 14.30)	0.014	0.42 (0.08, 0.75)	
male	180	20.56 (29.11)	173	9.11 (1.52)	166	18.27 (27.11)	153	7.08 (1.63)	2.03 (-2.36, 6.42)	0.363	0.10 (-0.12, 0.32)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	15.79 (20.39)	19		18	18.52 (28.52)	16					
STAGE IV	227	20.70 (30.52)	216		230	20.00 (27.79)	213					
Region												0.064
North America and Europe	134	21.64 (30.11)	128	11.46 (1.83)	124	22.58 (28.37)	110	4.81 (2.02)	6.65 (1.27, 12.03)	0.016	0.32 (0.06, 0.57)	
Rest of the World	112	18.75 (29.61)	107	9.79 (1.75)	126	16.93 (26.91)	121	9.91 (1.69)	-0.12 (-4.92, 4.67)	0.960	-0.01 (-0.27, 0.25)	
Prior anti-PD-(L)1 exposure												0.777
yes	174	20.11 (29.73)	167	11.39 (1.52)	177	19.02 (26.52)	161	7.58 (1.58)	3.81 (-0.50, 8.13)	0.083	0.19 (-0.03, 0.41)	
no	72	20.83 (30.35)	68	10.09 (2.40)	73	21.46 (30.62)	70	7.43 (2.42)	2.66 (-4.09, 9.41)	0.435	0.13 (-0.20, 0.47)	
Chemotherapy-free interval												0.155
< 90 days	107	23.99 (33.89)	99	10.02 (2.07)	111	19.22 (28.62)	100	10.30 (2.13)	-0.28 (-6.14, 5.58)	0.925	-0.01 (-0.29, 0.26)	
>= 90 and < 180 days	82	18.70 (27.76)	80	11.37 (2.10)	76	22.81 (27.33)	71	3.39 (2.27)	7.98 (1.88, 14.08)	0.011	0.42 (0.10, 0.74)	
>= 180 days	57	15.79 (23.66)	56	11.35 (2.51)	63	16.93 (26.69)	60	8.13 (2.47)	3.23 (-3.78, 10.23)	0.362	0.17 (-0.20, 0.53)	
Presence (previous or current) of brain metastases												0.130
yes	111	22.22 (30.92)	109	9.13 (1.90)	110	21.21 (27.36)	100	8.85 (2.03)	0.28 (-5.21, 5.78)	0.919	0.01 (-0.26, 0.29)	
no	135	18.77 (28.97)	126	12.44 (1.74)	140	18.57 (28.07)	131	6.54 (1.75)	5.90 (1.05, 10.75)	0.017	0.30 (0.05, 0.54)	
Standard of care												0.270
Amrubicin/Topotecan	203	21.02 (31.05)	196	10.94 (1.42)	203	19.21 (27.91)	189	6.60 (1.48)	4.34 (0.32, 8.37)	0.035	0.22 (0.02, 0.42)	
Lurbinectedin	43	17.05 (23.43)	39	10.81 (3.03)	47	21.99 (27.17)	42	11.65 (2.95)	-0.83 (-9.28, 7.61)	0.844	-0.04 (-0.48, 0.39)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Constipation - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.177
< 65 years	128	13.02 (23.00)	123	6.56 (1.37)	114	12.87 (23.68)	104	5.18 (1.54)	1.38 (-2.69, 5.44)	0.505	0.09 (-0.17, 0.35)	
>= 65 years	118	12.71 (19.93)	112	10.10 (1.65)	136	12.01 (22.10)	127	4.58 (1.57)	5.52 (1.04, 10.01)	0.016	0.31 (0.06, 0.57)	
Gender												0.443
female	66	15.15 (24.93)	62	12.21 (2.28)	84	14.68 (23.91)	78	6.70 (2.15)	5.52 (-0.67, 11.70)	0.080	0.30 (-0.04, 0.63)	
male	180	12.04 (20.17)	173	6.67 (1.15)	166	11.24 (22.19)	153	3.88 (1.24)	2.79 (-0.54, 6.12)	0.101	0.18 (-0.04, 0.40)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	3.51 (10.51)	19		18	14.81 (30.73)	16					
STAGE IV	227	13.66 (22.05)	216		230	12.32 (22.20)	213					
Region												0.022
North America and Europe	134	12.94 (22.36)	128	9.56 (1.53)	124	12.37 (23.46)	110	2.71 (1.68)	6.85 (2.37, 11.32)	0.003	0.39 (0.13, 0.65)	
Rest of the World	112	12.80 (20.62)	107	6.66 (1.49)	126	12.43 (22.20)	121	6.88 (1.44)	-0.22 (-4.31, 3.87)	0.916	-0.01 (-0.27, 0.25)	
Prior anti-PD-(L)1 exposure												0.935
yes	174	12.84 (22.27)	167	8.37 (1.26)	177	11.49 (22.19)	161	5.26 (1.31)	3.11 (-0.46, 6.69)	0.088	0.19 (-0.03, 0.41)	
no	72	12.96 (19.82)	68	7.62 (2.06)	73	14.61 (24.21)	70	4.23 (2.08)	3.39 (-2.39, 9.17)	0.248	0.20 (-0.14, 0.53)	
Chemotherapy-free interval												0.119
< 90 days	107	14.33 (22.94)	99	6.33 (1.53)	111	12.61 (23.81)	100	3.29 (1.58)	3.04 (-1.31, 7.39)	0.169	0.20 (-0.08, 0.47)	
>= 90 and < 180 days	82	13.41 (22.14)	80	12.53 (2.13)	76	12.72 (22.42)	71	5.58 (2.28)	6.95 (0.77, 13.12)	0.028	0.36 (0.04, 0.68)	
>= 180 days	57	9.36 (17.54)	56	5.19 (1.80)	63	11.64 (21.72)	60	6.43 (1.79)	-1.24 (-6.28, 3.80)	0.627	-0.09 (-0.45, 0.27)	
Presence (previous or current) of brain metastases												0.632
yes	111	15.62 (23.28)	109	6.26 (1.45)	110	11.21 (22.25)	100	3.68 (1.56)	2.58 (-1.64, 6.80)	0.230	0.17 (-0.10, 0.44)	
no	135	10.62 (19.80)	126	9.91 (1.55)	140	13.33 (23.25)	131	5.86 (1.55)	4.04 (-0.28, 8.36)	0.066	0.23 (-0.02, 0.47)	
Standard of care												0.716
Amrubicin/Topotecan	203	12.64 (22.22)	196	8.16 (1.16)	203	11.66 (22.52)	189	5.02 (1.21)	3.14 (-0.15, 6.43)	0.062	0.19 (-0.01, 0.39)	
Lurbinectedin	43	13.95 (18.16)	39	8.99 (2.91)	47	15.60 (23.93)	42	4.26 (2.82)	4.73 (-3.36, 12.82)	0.247	0.26 (-0.18, 0.69)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Diarrhoea - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							Interaction
	Baseline		Change from BL		Baseline		Change from BL		Difference of			
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.159
< 65 years	128	3.65 (13.38)	123	-0.97 (0.63)	114	7.60 (16.61)	104	0.50 (0.73)	-1.47 (-3.37, 0.44)	0.131	-0.20 (-0.46, 0.06)	
>= 65 years	118	3.95 (12.46)	112	-1.08 (0.78)	136	3.92 (10.78)	127	2.43 (0.75)	-3.51 (-5.65, -1.37)	0.001	-0.42 (-0.67, -0.16)	
Gender												NE
female	66	6.57 (17.75)	62	NE	84	7.54 (16.65)	78	NE	NE		NE	
male	180	2.78 (10.50)	173	-0.43 (0.52)	166	4.62 (12.12)	153	1.71 (0.57)	-2.14 (-3.67, -0.62)	0.006	-0.31 (-0.53, -0.09)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	3.51 (10.51)	19		18	1.85 (7.86)	16					
STAGE IV	227	3.82 (13.12)	216		230	5.94 (14.22)	213					
Region												0.999
North America and Europe	134	5.47 (15.40)	128	-1.13 (0.70)	124	4.57 (13.66)	110	1.21 (0.78)	-2.34 (-4.42, -0.27)	0.027	-0.29 (-0.55, -0.03)	
Rest of the World	112	1.79 (8.77)	107	-0.72 (0.73)	126	6.61 (14.00)	121	1.62 (0.71)	-2.34 (-4.36, -0.32)	0.023	-0.30 (-0.57, -0.04)	
Prior anti-PD-(L)1 exposure												NE
yes	174	3.83 (12.85)	167	-1.38 (0.59)	177	6.40 (14.96)	161	1.72 (0.62)	-3.11 (-4.79, -1.42)	<.001	-0.40 (-0.62, -0.18)	
no	72	3.70 (13.19)	68	NE	73	3.65 (10.48)	70	NE	NE		NE	
Chemotherapy-free interval												0.961
< 90 days	107	3.43 (12.90)	99	-0.60 (0.80)	111	4.50 (11.45)	100	1.85 (0.84)	-2.45 (-4.74, -0.15)	0.037	-0.30 (-0.58, -0.02)	
>= 90 and < 180 days	82	4.47 (13.62)	80	-2.02 (0.79)	76	6.58 (15.41)	71	0.87 (0.86)	-2.89 (-5.21, -0.57)	0.015	-0.40 (-0.72, -0.08)	
>= 180 days	57	3.51 (12.09)	56	-0.26 (1.10)	63	6.35 (15.68)	60	2.25 (1.09)	-2.51 (-5.60, 0.59)	0.110	-0.30 (-0.66, 0.07)	
Presence (previous or current) of brain metastases												0.918
yes	111	5.11 (15.70)	109	-1.30 (0.81)	110	7.27 (14.55)	100	1.13 (0.88)	-2.43 (-4.80, -0.07)	0.044	-0.28 (-0.55, -0.01)	
no	135	2.72 (10.02)	126	-0.70 (0.62)	140	4.29 (13.17)	131	1.88 (0.63)	-2.59 (-4.34, -0.83)	0.004	-0.36 (-0.61, -0.12)	
Standard of care												NE
Amrubicin/Topotecan	203	4.27 (13.81)	196	-1.40 (0.55)	203	5.42 (14.00)	189	1.32 (0.58)	-2.73 (-4.31, -1.14)	<.001	-0.35 (-0.55, -0.14)	
Lurbinectedin	43	1.55 (7.10)	39	NE	47	6.38 (13.26)	42	NE	NE		NE	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Dyspnea - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.266
< 65 years	128	19.79 (24.55)	123	-2.14 (1.36)	114	21.35 (25.52)	104	5.20 (1.52)	-7.34 (-11.34, -3.34)	<.001	-0.48 (-0.74, -0.22)	
>= 65 years	118	18.36 (22.89)	112	2.06 (1.51)	136	18.87 (22.48)	127	6.17 (1.44)	-4.10 (-8.22, 0.01)	0.051	-0.25 (-0.51, 0.00)	
Gender												0.986
female	66	20.71 (24.64)	62	0.74 (1.95)	84	20.24 (25.36)	78	6.52 (1.81)	-5.78 (-11.06, -0.51)	0.032	-0.37 (-0.70, -0.03)	
male	180	18.52 (23.43)	173	-0.45 (1.20)	166	19.88 (23.20)	153	5.39 (1.29)	-5.84 (-9.30, -2.38)	0.001	-0.37 (-0.59, -0.15)	
Disease Stage at Screening												
STAGE II	0	-	0		2	16.67 (23.57)	2					
STAGE III	19	10.53 (15.92)	19		18	27.78 (28.58)	16					
STAGE IV	227	19.82 (24.16)	216		230	19.42 (23.51)	213					
Region												0.395
North America and Europe	134	21.64 (25.61)	128	0.52 (1.38)	124	23.39 (25.50)	110	5.37 (1.53)	-4.84 (-8.89, -0.80)	0.019	-0.31 (-0.56, -0.05)	
Rest of the World	112	16.07 (20.98)	107	-1.23 (1.49)	126	16.67 (21.81)	121	6.09 (1.44)	-7.32 (-11.40, -3.24)	<.001	-0.47 (-0.73, -0.20)	
Prior anti-PD-(L)1 exposure												0.721
yes	174	18.97 (24.40)	167	0.21 (1.12)	177	19.96 (23.64)	161	6.54 (1.17)	-6.33 (-9.52, -3.14)	<.001	-0.43 (-0.65, -0.21)	
no	72	19.44 (22.20)	68	-1.08 (2.13)	73	20.09 (24.68)	70	4.03 (2.14)	-5.11 (-11.08, 0.86)	0.093	-0.29 (-0.62, 0.05)	
Chemotherapy-free interval												0.436
< 90 days	107	22.43 (27.39)	99	-0.78 (1.75)	111	21.32 (24.12)	100	5.12 (1.79)	-5.90 (-10.83, -0.98)	0.019	-0.33 (-0.61, -0.05)	
>= 90 and < 180 days	82	18.29 (20.39)	80	0.53 (1.52)	76	19.30 (24.50)	71	4.61 (1.64)	-4.08 (-8.50, 0.33)	0.070	-0.30 (-0.62, 0.02)	
>= 180 days	57	14.04 (19.87)	56	-0.37 (2.08)	63	18.52 (23.01)	60	8.46 (2.06)	-8.83 (-14.66, -3.00)	0.003	-0.56 (-0.93, -0.18)	
Presence (previous or current) of brain metastases												0.846
yes	111	16.82 (22.42)	109	-0.34 (1.27)	110	19.09 (22.33)	100	5.89 (1.37)	-6.23 (-9.93, -2.53)	0.001	-0.46 (-0.73, -0.18)	
no	135	20.99 (24.68)	126	0.04 (1.53)	140	20.71 (25.12)	131	5.71 (1.53)	-5.67 (-9.93, -1.42)	0.009	-0.33 (-0.57, -0.08)	
Standard of care												0.184
Amrubicin/Topotecan	203	19.05 (22.95)	196	-0.01 (1.12)	203	20.69 (24.35)	189	4.99 (1.17)	-4.99 (-8.17, -1.82)	0.002	-0.31 (-0.52, -0.11)	
Lurbinectedin	43	19.38 (27.44)	39	-1.26 (2.45)	47	17.02 (21.84)	42	8.76 (2.39)	-10.03 (-16.87, -3.18)	0.005	-0.65 (-1.09, -0.20)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Fatigue - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.469
< 65 years	128	27.78 (26.16)	123	5.45 (1.53)	114	29.63 (25.20)	104	9.92 (1.71)	-4.48 (-8.97, 0.02)	0.051	-0.26 (-0.52, 0.00)	
>= 65 years	118	27.31 (21.82)	112	8.46 (1.44)	136	27.78 (23.85)	127	10.75 (1.38)	-2.29 (-6.20, 1.63)	0.251	-0.15 (-0.40, 0.11)	
Gender												0.537
female	66	33.84 (25.59)	62	6.74 (1.96)	84	35.85 (26.74)	78	8.79 (1.84)	-2.05 (-7.35, 3.25)	0.446	-0.13 (-0.46, 0.21)	
male	180	25.25 (23.22)	173	7.02 (1.24)	166	24.97 (22.40)	153	11.06 (1.33)	-4.04 (-7.61, -0.48)	0.026	-0.25 (-0.46, -0.03)	
Disease Stage at Screening												
STAGE II	0	-	0		2	27.78 (7.86)	2					
STAGE III	19	19.88 (19.09)	19		18	28.40 (25.06)	16					
STAGE IV	227	28.19 (24.43)	216		230	28.65 (24.55)	213					
Region												0.243
North America and Europe	134	32.09 (24.32)	128	7.76 (1.51)	124	32.53 (23.97)	110	9.89 (1.66)	-2.13 (-6.52, 2.26)	0.340	-0.12 (-0.38, 0.13)	
Rest of the World	112	22.12 (22.84)	107	5.40 (1.43)	126	24.78 (24.39)	121	11.02 (1.39)	-5.62 (-9.56, -1.69)	0.005	-0.37 (-0.63, -0.11)	
Prior anti-PD-(L)1 exposure												0.598
yes	174	27.78 (24.65)	167	6.58 (1.21)	177	29.06 (23.21)	161	10.72 (1.26)	-4.13 (-7.57, -0.70)	0.018	-0.26 (-0.48, -0.04)	
no	72	27.01 (22.98)	68	7.46 (2.09)	73	27.55 (27.35)	70	9.79 (2.10)	-2.33 (-8.17, 3.52)	0.432	-0.13 (-0.47, 0.20)	
Chemotherapy-free interval												0.241
< 90 days	107	29.91 (28.16)	99	6.00 (1.69)	111	28.33 (25.24)	100	10.17 (1.74)	-4.18 (-8.94, 0.59)	0.086	-0.24 (-0.52, 0.04)	
>= 90 and < 180 days	82	29.54 (19.06)	80	6.78 (1.83)	76	31.29 (26.21)	71	7.13 (1.96)	-0.35 (-5.62, 4.92)	0.896	-0.02 (-0.34, 0.30)	
>= 180 days	57	20.27 (21.22)	56	7.88 (1.92)	63	25.93 (20.55)	60	14.59 (1.92)	-6.70 (-12.10, -1.31)	0.015	-0.46 (-0.82, -0.09)	
Presence (previous or current) of brain metastases												0.295
yes	111	28.43 (24.69)	109	5.67 (1.44)	110	30.00 (23.20)	100	11.10 (1.55)	-5.43 (-9.59, -1.27)	0.011	-0.35 (-0.63, -0.08)	
no	135	26.83 (23.72)	126	7.66 (1.50)	140	27.54 (25.41)	131	9.96 (1.50)	-2.31 (-6.47, 1.85)	0.276	-0.14 (-0.38, 0.11)	
Standard of care												0.292
Amrubicin/Topotecan	203	27.53 (24.51)	196	7.40 (1.19)	203	28.95 (23.80)	189	10.34 (1.24)	-2.93 (-6.29, 0.43)	0.087	-0.17 (-0.37, 0.03)	
Lurbinectedin	43	27.65 (22.53)	39	3.91 (2.09)	47	27.19 (27.30)	42	10.40 (2.02)	-6.49 (-12.31, -0.67)	0.029	-0.49 (-0.93, -0.05)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Nausea and Vomiting - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							Interaction
	Baseline		Change from BL		Baseline		Change from BL		Difference of			
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.772
< 65 years	128	5.73 (15.29)	123	1.47 (0.86)	114	8.48 (18.58)	104	3.08 (0.97)	-1.61 (-4.16, 0.95)	0.217	-0.16 (-0.43, 0.10)	
>= 65 years	118	4.52 (11.87)	112	1.10 (0.76)	136	6.13 (15.82)	127	3.19 (0.73)	-2.09 (-4.17, -0.02)	0.048	-0.26 (-0.51, -0.00)	
Gender												0.399
female	66	6.82 (19.39)	62	2.51 (1.32)	84	12.30 (23.87)	78	2.76 (1.25)	-0.26 (-3.87, 3.35)	0.888	-0.02 (-0.36, 0.31)	
male	180	4.54 (10.98)	173	0.96 (0.57)	166	4.62 (11.70)	153	2.91 (0.61)	-1.95 (-3.59, -0.30)	0.020	-0.26 (-0.48, -0.04)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	3.51 (6.98)	19		18	4.63 (15.97)	16					
STAGE IV	227	5.29 (14.16)	216		230	7.46 (17.30)	213					
Region												0.639
North America and Europe	134	5.47 (12.39)	128	0.71 (0.80)	124	6.45 (14.68)	110	2.68 (0.88)	-1.97 (-4.31, 0.37)	0.099	-0.22 (-0.47, 0.04)	
Rest of the World	112	4.76 (15.24)	107	2.08 (0.82)	126	7.94 (19.29)	121	3.28 (0.80)	-1.20 (-3.45, 1.06)	0.296	-0.14 (-0.40, 0.12)	
Prior anti-PD-(L)1 exposure												NE
yes	174	4.41 (12.79)	167	1.78 (0.65)	177	6.40 (15.79)	161	3.18 (0.67)	-1.41 (-3.24, 0.43)	0.133	-0.17 (-0.38, 0.05)	
no	72	6.94 (15.76)	68	NE	73	9.13 (20.04)	70	NE	NE		NE	
Chemotherapy-free interval												0.731
< 90 days	107	7.17 (17.75)	99	1.04 (1.00)	111	6.46 (16.69)	100	3.23 (1.02)	-2.19 (-5.01, 0.63)	0.127	-0.22 (-0.50, 0.06)	
>= 90 and < 180 days	82	3.86 (10.24)	80	2.27 (1.00)	76	7.24 (15.71)	71	3.25 (1.08)	-0.98 (-3.89, 1.92)	0.504	-0.11 (-0.43, 0.21)	
>= 180 days	57	3.22 (7.99)	56	0.33 (0.91)	63	8.47 (19.60)	60	2.81 (0.91)	-2.47 (-5.03, 0.08)	0.058	-0.36 (-0.72, 0.01)	
Presence (previous or current) of brain metastases												0.357
yes	111	6.31 (15.74)	109	1.13 (1.01)	110	6.97 (17.10)	100	3.87 (1.08)	-2.74 (-5.67, 0.18)	0.066	-0.26 (-0.53, 0.02)	
no	135	4.20 (11.82)	126	1.44 (0.65)	140	7.38 (17.23)	131	2.57 (0.66)	-1.13 (-2.97, 0.71)	0.228	-0.15 (-0.40, 0.09)	
Standard of care												0.053
Amrubicin/Topotecan	203	5.50 (14.02)	196	1.61 (0.63)	203	6.65 (16.36)	189	2.46 (0.65)	-0.85 (-2.63, 0.93)	0.347	-0.10 (-0.30, 0.10)	
Lurbinectedin	43	3.49 (12.36)	39	0.17 (1.34)	47	9.57 (20.19)	42	5.10 (1.33)	-4.93 (-8.73, -1.13)	0.012	-0.57 (-1.02, -0.13)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Pain - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.140
< 65 years	128	22.66 (25.42)	123	0.76 (1.41)	114	23.68 (27.33)	104	5.51 (1.57)	-4.75 (-8.90, -0.59)	0.025	-0.30 (-0.56, -0.04)	
>= 65 years	118	17.94 (21.70)	112	1.33 (1.15)	136	15.81 (21.78)	127	2.19 (1.10)	-0.85 (-4.00, 2.29)	0.593	-0.07 (-0.32, 0.19)	
Gender												0.824
female	66	23.99 (24.13)	62	2.22 (1.72)	84	21.03 (25.63)	78	4.24 (1.61)	-2.02 (-6.68, 2.63)	0.391	-0.14 (-0.48, 0.19)	
male	180	19.07 (23.58)	173	0.59 (1.06)	166	18.57 (24.30)	153	3.24 (1.14)	-2.65 (-5.72, 0.41)	0.090	-0.19 (-0.41, 0.03)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	10.53 (14.92)	19		18	16.67 (24.25)	16					
STAGE IV	227	21.22 (24.21)	216		230	19.78 (24.85)	213					
Region												0.471
North America and Europe	134	23.13 (24.60)	128	1.69 (1.31)	124	20.97 (25.93)	110	3.53 (1.44)	-1.84 (-5.66, 1.98)	0.343	-0.12 (-0.38, 0.13)	
Rest of the World	112	17.11 (22.42)	107	0.13 (1.28)	126	17.86 (23.49)	121	3.86 (1.24)	-3.74 (-7.25, -0.23)	0.037	-0.28 (-0.54, -0.02)	
Prior anti-PD-(L)1 exposure												0.984
yes	174	21.46 (24.95)	167	0.46 (1.07)	177	19.77 (24.39)	161	3.09 (1.11)	-2.63 (-5.67, 0.40)	0.089	-0.19 (-0.40, 0.03)	
no	72	17.82 (20.62)	68	2.55 (1.80)	73	18.49 (25.69)	70	5.24 (1.81)	-2.69 (-7.74, 2.36)	0.293	-0.18 (-0.51, 0.16)	
Chemotherapy-free interval												0.694
< 90 days	107	24.61 (28.07)	99	0.50 (1.46)	111	19.82 (25.48)	100	2.75 (1.49)	-2.25 (-6.36, 1.87)	0.282	-0.15 (-0.43, 0.13)	
>= 90 and < 180 days	82	20.93 (21.08)	80	0.92 (1.61)	76	19.30 (24.50)	71	1.63 (1.72)	-0.71 (-5.37, 3.96)	0.764	-0.05 (-0.37, 0.27)	
>= 180 days	57	11.70 (15.09)	56	2.75 (1.73)	63	18.78 (24.04)	60	6.36 (1.73)	-3.61 (-8.48, 1.26)	0.145	-0.27 (-0.64, 0.09)	
Presence (previous or current) of brain metastases												0.026
yes	111	19.67 (22.04)	109	-0.04 (1.36)	110	17.88 (23.10)	100	6.06 (1.45)	-6.09 (-10.02, -2.17)	0.003	-0.42 (-0.70, -0.15)	
no	135	20.99 (25.18)	126	1.80 (1.24)	140	20.60 (25.96)	131	2.00 (1.24)	-0.21 (-3.66, 3.25)	0.906	-0.01 (-0.26, 0.23)	
Standard of care												0.145
Amrubicin/Topotecan	203	20.53 (24.04)	196	1.31 (1.04)	203	19.62 (25.19)	189	3.19 (1.08)	-1.88 (-4.82, 1.07)	0.210	-0.13 (-0.33, 0.07)	
Lurbinectedin	43	19.77 (22.79)	39	-0.83 (1.80)	47	18.44 (22.85)	42	5.29 (1.75)	-6.13 (-11.14, -1.11)	0.018	-0.54 (-0.98, -0.09)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Insomnia - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.623
< 65 years	128	20.83 (28.68)	123	0.33 (1.38)	114	19.59 (26.16)	104	3.67 (1.55)	-3.34 (-7.44, 0.76)	0.109	-0.21 (-0.48, 0.05)	
>= 65 years	118	18.08 (26.02)	112	-1.50 (1.25)	136	17.89 (22.92)	127	0.51 (1.20)	-2.01 (-5.42, 1.40)	0.247	-0.15 (-0.40, 0.10)	
Gender												0.320
female	66	23.23 (29.22)	62	-1.74 (1.66)	84	21.43 (25.69)	78	2.46 (1.58)	-4.21 (-8.75, 0.33)	0.069	-0.31 (-0.64, 0.03)	
male	180	18.15 (26.68)	173	-0.08 (1.12)	166	17.27 (23.70)	153	1.33 (1.20)	-1.40 (-4.63, 1.82)	0.393	-0.09 (-0.31, 0.12)	
Disease Stage at Screening												
STAGE II	0	-	0		2	16.67 (23.57)	2					
STAGE III	19	14.04 (23.08)	19		18	11.11 (19.80)	16					
STAGE IV	227	19.97 (27.74)	216		230	19.28 (24.73)	213					
Region												0.244
North America and Europe	134	22.39 (30.25)	128	-1.71 (1.37)	124	20.16 (26.48)	110	2.37 (1.51)	-4.09 (-8.10, -0.07)	0.046	-0.26 (-0.52, -0.00)	
Rest of the World	112	16.07 (23.24)	107	0.37 (1.28)	126	17.20 (22.20)	121	1.31 (1.24)	-0.94 (-4.44, 2.55)	0.595	-0.07 (-0.33, 0.19)	
Prior anti-PD-(L)1 exposure												0.534
yes	174	21.26 (28.24)	167	-1.69 (1.08)	177	19.21 (24.00)	161	1.23 (1.13)	-2.92 (-5.99, 0.15)	0.062	-0.21 (-0.42, 0.01)	
no	72	15.28 (24.98)	68	2.18 (1.87)	73	17.35 (25.53)	70	3.18 (1.89)	-1.00 (-6.28, 4.27)	0.707	-0.06 (-0.40, 0.27)	
Chemotherapy-free interval												0.099
< 90 days	107	21.18 (28.74)	99	-2.00 (1.54)	111	18.32 (23.24)	100	3.10 (1.58)	-5.10 (-9.44, -0.76)	0.022	-0.33 (-0.61, -0.05)	
>= 90 and < 180 days	82	21.95 (29.27)	80	-1.20 (1.58)	76	19.30 (25.68)	71	0.66 (1.69)	-1.86 (-6.43, 2.71)	0.423	-0.13 (-0.45, 0.19)	
>= 180 days	57	12.87 (20.66)	56	2.93 (1.71)	63	18.52 (25.24)	60	0.98 (1.71)	1.94 (-2.88, 6.77)	0.426	0.15 (-0.22, 0.51)	
Presence (previous or current) of brain metastases												0.284
yes	111	18.62 (24.90)	109	-1.45 (1.44)	110	21.21 (25.43)	100	2.61 (1.54)	-4.05 (-8.21, 0.10)	0.056	-0.27 (-0.54, 0.01)	
no	135	20.25 (29.39)	126	0.17 (1.25)	140	16.67 (23.49)	131	1.29 (1.25)	-1.12 (-4.59, 2.36)	0.528	-0.08 (-0.32, 0.17)	
Standard of care												0.116
Amrubicin/Topotecan	203	19.05 (27.52)	196	0.06 (1.05)	203	19.38 (25.41)	189	1.62 (1.10)	-1.56 (-4.56, 1.43)	0.306	-0.10 (-0.30, 0.10)	
Lurbinectedin	43	21.71 (27.10)	39	-4.03 (2.07)	47	15.60 (19.48)	42	2.70 (2.01)	-6.73 (-12.53, -0.93)	0.024	-0.51 (-0.96, -0.07)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Alopecia - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.185
< 65 years	25/ 129 (19.4)	NE (46.8, NE)	40/ 115 (34.8)	20.1 (12.5, NE)	0.33 (0.20, 0.55)	<.001	
>= 65 years	25/ 125 (20.0)	NE (48.5, NE)	64/ 140 (45.7)	12.2 (6.8, 17.5)	0.22 (0.13, 0.35)	<.001	
Gender							0.672
female	15/ 72 (20.8)	NE (46.8, NE)	34/ 86 (39.5)	17.5 (12.1, NE)	0.28 (0.15, 0.53)	<.001	
male	35/ 182 (19.2)	NE (48.5, NE)	70/ 169 (41.4)	15.5 (12.1, 20.1)	0.25 (0.17, 0.38)	<.001	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	1/ 21 (4.8)		11/ 18 (61.1)				
STAGE IV	49/ 233 (21.0)		91/ 235 (38.7)				
Region							0.498
North America and Europe	23/ 140 (16.4)	NE (48.5, NE)	47/ 128 (36.7)	15.7 (12.1, 30.0)	0.22 (0.13, 0.37)	<.001	
Rest of the World	27/ 114 (23.7)	NE (46.8, NE)	57/ 127 (44.9)	14.4 (11.0, 31.7)	0.31 (0.20, 0.50)	<.001	
Prior anti-PD-(L)1 exposure							0.127
yes	34/ 180 (18.9)	NE (48.5, NE)	76/ 180 (42.2)	12.4 (10.8, 18.5)	0.23 (0.15, 0.34)	<.001	
no	16/ 74 (21.6)	NE (32.9, NE)	28/ 75 (37.3)	18.7 (12.5, NE)	0.38 (0.20, 0.70)	0.002	
Chemotherapy-free interval							0.356
< 90 days	20/ 109 (18.3)	NE (44.3, NE)	34/ 114 (29.8)	18.5 (12.1, NE)	0.31 (0.17, 0.55)	<.001	
>= 90 and < 180 days	17/ 85 (20.0)	NE (NE , NE)	33/ 78 (42.3)	18.5 (7.3, NE)	0.29 (0.16, 0.52)	<.001	
>= 180 days	13/ 60 (21.7)	NE (38.9, NE)	37/ 63 (58.7)	12.1 (6.5, 15.7)	0.19 (0.10, 0.37)	<.001	
Presence (previous or current) of brain metastases							0.549
yes	25/ 113 (22.1)	NE (48.5, NE)	44/ 115 (38.3)	12.5 (12.1, 31.7)	0.30 (0.18, 0.49)	<.001	
no	25/ 141 (17.7)	NE (44.3, NE)	60/ 140 (42.9)	17.5 (12.1, NE)	0.23 (0.14, 0.37)	<.001	
Standard of care							0.018
Amrubicin/Topotecan	44/ 209 (21.1)	NE (44.3, NE)	98/ 208 (47.1)	12.1 (7.8, 15.5)	0.20 (0.14, 0.29)	<.001	
Lurbinectedin	6/ 45 (13.3)	NE (NE , NE)	6/ 47 (12.8)	NE (31.7, NE)	0.97 (0.31, 3.02)	0.958	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Coughing - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.769
< 65 years	30/ 129 (23.3)	66.1 (48.0, NE)	26/ 115 (22.6)	NE (31.7, NE)	0.71 (0.41, 1.21)	0.203	
>= 65 years	34/ 125 (27.2)	NE (36.7, NE)	38/ 140 (27.1)	36.3 (24.2, NE)	0.79 (0.50, 1.26)	0.328	
Gender							0.053
female	17/ 72 (23.6)	66.1 (48.4, NE)	27/ 86 (31.4)	25.1 (16.5, NE)	0.44 (0.24, 0.83)	0.009	
male	47/ 182 (25.8)	NE (38.2, NE)	37/ 169 (21.9)	48.8 (30.5, NE)	0.94 (0.61, 1.45)	0.775	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	4/ 21 (19.0)		3/ 18 (16.7)				
STAGE IV	60/ 233 (25.8)		59/ 235 (25.1)				
Region							0.986
North America and Europe	35/ 140 (25.0)	NE (36.2, NE)	32/ 128 (25.0)	NE (24.2, NE)	0.75 (0.46, 1.22)	0.241	
Rest of the World	29/ 114 (25.4)	66.1 (48.4, NE)	32/ 127 (25.2)	48.8 (30.3, NE)	0.69 (0.41, 1.15)	0.152	
Prior anti-PD-(L)1 exposure							0.677
yes	46/ 180 (25.6)	66.1 (48.0, NE)	42/ 180 (23.3)	48.8 (30.5, NE)	0.77 (0.50, 1.18)	0.227	
no	18/ 74 (24.3)	NE (26.3, NE)	22/ 75 (29.3)	30.3 (22.4, NE)	0.67 (0.36, 1.27)	0.216	
Chemotherapy-free interval							0.509
< 90 days	25/ 109 (22.9)	NE (34.2, NE)	26/ 114 (22.8)	36.3 (23.5, NE)	0.64 (0.37, 1.12)	0.117	
>= 90 and < 180 days	22/ 85 (25.9)	NE (38.2, NE)	23/ 78 (29.5)	NE (16.5, NE)	0.65 (0.36, 1.19)	0.161	
>= 180 days	17/ 60 (28.3)	66.1 (36.2, NE)	15/ 63 (23.8)	NE (25.1, NE)	0.99 (0.48, 2.02)	0.973	
Presence (previous or current) of brain metastases							0.088
yes	28/ 113 (24.8)	66.1 (36.7, NE)	33/ 115 (28.7)	31.7 (18.1, NE)	0.55 (0.33, 0.92)	0.022	
no	36/ 141 (25.5)	54.5 (38.2, NE)	31/ 140 (22.1)	48.8 (30.3, NE)	0.96 (0.59, 1.55)	0.855	
Standard of care							0.108
Amrubicin/Topotecan	54/ 209 (25.8)	NE (38.2, NE)	47/ 208 (22.6)	48.8 (30.3, NE)	0.84 (0.57, 1.25)	0.396	
Lurbinectedin	10/ 45 (22.2)	66.1 (48.4, NE)	17/ 47 (36.2)	31.7 (14.1, NE)	0.42 (0.18, 0.99)	0.040	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Dysphagia - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.028
< 65 years	24/ 129 (18.6)	NE (NE , NE)	29/ 115 (25.2)	NE (21.1, NE)	0.54 (0.31, 0.93)	0.024	
>= 65 years	34/ 125 (27.2)	NE (48.1, NE)	26/ 140 (18.6)	54.0 (36.4, NE)	1.18 (0.70, 1.98)	0.528	
Gender							0.562
female	21/ 72 (29.2)	NE (26.3, NE)	20/ 86 (23.3)	54.0 (20.4, 54.0)	0.92 (0.49, 1.71)	0.784	
male	37/ 182 (20.3)	NE (54.7, NE)	35/ 169 (20.7)	NE (31.7, NE)	0.76 (0.48, 1.22)	0.255	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	5/ 21 (23.8)		7/ 18 (38.9)				
STAGE IV	53/ 233 (22.7)		48/ 235 (20.4)				
Region							0.708
North America and Europe	33/ 140 (23.6)	NE (36.7, NE)	29/ 128 (22.7)	NE (29.6, NE)	0.87 (0.53, 1.44)	0.585	
Rest of the World	25/ 114 (21.9)	NE (54.7, NE)	26/ 127 (20.5)	54.0 (31.7, NE)	0.73 (0.42, 1.29)	0.288	
Prior anti-PD-(L)1 exposure							0.743
yes	43/ 180 (23.9)	NE (48.1, NE)	42/ 180 (23.3)	54.0 (30.0, NE)	0.77 (0.50, 1.18)	0.232	
no	15/ 74 (20.3)	NE (54.7, NE)	13/ 75 (17.3)	NE (NE , NE)	0.95 (0.45, 2.03)	0.901	
Chemotherapy-free interval							0.584
< 90 days	19/ 109 (17.4)	NE (36.7, NE)	21/ 114 (18.4)	36.4 (31.7, 54.0)	0.62 (0.33, 1.18)	0.145	
>= 90 and < 180 days	22/ 85 (25.9)	NE (26.3, NE)	20/ 78 (25.6)	NE (18.5, NE)	0.87 (0.47, 1.60)	0.654	
>= 180 days	17/ 60 (28.3)	54.7 (36.4, NE)	14/ 63 (22.2)	NE (30.0, NE)	1.05 (0.51, 2.16)	0.888	
Presence (previous or current) of brain metastases							0.531
yes	21/ 113 (18.6)	NE (54.7, NE)	20/ 115 (17.4)	36.4 (35.4, NE)	0.67 (0.36, 1.27)	0.218	
no	37/ 141 (26.2)	NE (36.4, NE)	35/ 140 (25.0)	54.0 (30.0, NE)	0.92 (0.58, 1.46)	0.723	
Standard of care							0.328
Amrubicin/Topotecan	53/ 209 (25.4)	NE (48.1, NE)	46/ 208 (22.1)	54.0 (35.4, NE)	0.84 (0.56, 1.25)	0.400	
Lurbinectedin	5/ 45 (11.1)	NE (NE , NE)	9/ 47 (19.1)	36.4 (30.0, NE)	0.49 (0.16, 1.53)	0.212	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Dyspnoea - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.900
< 65 years	68/ 129 (52.7)	21.8 (17.9, 30.2)	60/ 115 (52.2)	12.2 (7.3, 18.1)	0.66 (0.46, 0.94)	0.020	
>= 65 years	61/ 125 (48.8)	18.4 (12.2, 30.0)	73/ 140 (52.1)	12.5 (12.1, 17.9)	0.73 (0.52, 1.04)	0.083	
Gender							0.866
female	40/ 72 (55.6)	18.4 (12.2, 24.8)	50/ 86 (58.1)	13.4 (9.1, 18.1)	0.65 (0.42, 0.99)	0.044	
male	89/ 182 (48.9)	20.1 (14.1, 30.5)	83/ 169 (49.1)	12.4 (7.3, 16.9)	0.73 (0.54, 0.99)	0.045	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	10/ 21 (47.6)		9/ 18 (50.0)				
STAGE IV	119/ 233 (51.1)		122/ 235 (51.9)				
Region							0.058
North America and Europe	72/ 140 (51.4)	14.9 (12.2, 21.8)	58/ 128 (45.3)	13.1 (7.5, 18.5)	0.87 (0.61, 1.23)	0.420	
Rest of the World	57/ 114 (50.0)	24.2 (18.4, 34.2)	75/ 127 (59.1)	12.4 (9.1, 16.1)	0.56 (0.39, 0.79)	0.001	
Prior anti-PD-(L)1 exposure							0.988
yes	93/ 180 (51.7)	21.2 (12.5, 30.3)	92/ 180 (51.1)	12.5 (12.1, 18.1)	0.70 (0.52, 0.94)	0.018	
no	36/ 74 (48.6)	18.5 (12.4, 24.6)	41/ 75 (54.7)	12.4 (7.1, 17.2)	0.71 (0.45, 1.12)	0.128	
Chemotherapy-free interval							0.079
< 90 days	50/ 109 (45.9)	21.2 (12.4, 30.6)	49/ 114 (43.0)	12.5 (7.0, 18.4)	0.76 (0.51, 1.14)	0.185	
>= 90 and < 180 days	43/ 85 (50.6)	18.5 (12.2, 37.4)	49/ 78 (62.8)	12.2 (6.7, 14.7)	0.49 (0.32, 0.76)	<.001	
>= 180 days	36/ 60 (60.0)	18.1 (12.2, 30.3)	35/ 63 (55.6)	14.4 (12.1, 18.5)	0.99 (0.62, 1.58)	0.962	
Presence (previous or current) of brain metastases							0.679
yes	62/ 113 (54.9)	18.1 (12.4, 24.2)	57/ 115 (49.6)	12.1 (6.5, 18.1)	0.64 (0.44, 0.92)	0.016	
no	67/ 141 (47.5)	24.1 (18.1, 30.9)	76/ 140 (54.3)	12.5 (12.2, 18.1)	0.73 (0.52, 1.02)	0.065	
Standard of care							0.159
Amrubicin/Topotecan	112/ 209 (53.6)	18.5 (12.5, 24.2)	104/ 208 (50.0)	12.2 (8.8, 16.1)	0.75 (0.57, 0.99)	0.041	
Lurbinectedin	17/ 45 (37.8)	30.2 (12.4, NE)	29/ 47 (61.7)	15.1 (7.1, 18.4)	0.46 (0.25, 0.86)	0.013	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Haemoptysis - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.843
< 65 years	7/ 129 (5.4)	NE (NE , NE)	8/ 115 (7.0)	NE (NE , NE)	0.59 (0.21, 1.65)	0.310	
>= 65 years	7/ 125 (5.6)	NE (NE , NE)	9/ 140 (6.4)	NE (NE , NE)	0.66 (0.24, 1.78)	0.406	
Gender							0.481
female	3/ 72 (4.2)	NE (NE , NE)	6/ 86 (7.0)	NE (NE , NE)	0.45 (0.11, 1.80)	0.245	
male	11/ 182 (6.0)	NE (NE , NE)	11/ 169 (6.5)	NE (NE , NE)	0.70 (0.30, 1.64)	0.411	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	1/ 21 (4.8)		1/ 18 (5.6)				
STAGE IV	13/ 233 (5.6)		16/ 235 (6.8)				
Region							0.163
North America and Europe	4/ 140 (2.9)	NE (NE , NE)	8/ 128 (6.3)	NE (NE , NE)	0.33 (0.10, 1.12)	0.063	
Rest of the World	10/ 114 (8.8)	NE (NE , NE)	9/ 127 (7.1)	NE (NE , NE)	0.96 (0.39, 2.40)	0.937	
Prior anti-PD-(L)1 exposure							0.935
yes	12/ 180 (6.7)	NE (NE , NE)	14/ 180 (7.8)	NE (NE , NE)	0.59 (0.27, 1.29)	0.184	
no	2/ 74 (2.7)	NE (NE , NE)	3/ 75 (4.0)	NE (NE , NE)	0.65 (0.11, 3.88)	0.632	
Chemotherapy-free interval							0.927
< 90 days	5/ 109 (4.6)	NE (NE , NE)	5/ 114 (4.4)	NE (NE , NE)	0.78 (0.22, 2.74)	0.698	
>= 90 and < 180 days	8/ 85 (9.4)	NE (NE , NE)	10/ 78 (12.8)	NE (NE , NE)	0.59 (0.23, 1.50)	0.260	
>= 180 days	1/ 60 (1.7)	NE (NE , NE)	2/ 63 (3.2)	NE (NE , NE)	0.41 (0.04, 4.75)	0.466	
Presence (previous or current) of brain metastases							0.168
yes	4/ 113 (3.5)	NE (NE , NE)	8/ 115 (7.0)	NE (NE , NE)	0.32 (0.10, 1.09)	0.057	
no	10/ 141 (7.1)	NE (NE , NE)	9/ 140 (6.4)	NE (NE , NE)	0.95 (0.38, 2.35)	0.910	
Standard of care							0.989
Amrubicin/Topotecan	14/ 209 (6.7)	NE (NE , NE)	14/ 208 (6.7)	NE (NE , NE)	0.74 (0.35, 1.57)	0.434	
Lurbinectedin	0/ 45 (0.0)	NE (NE , NE)	3/ 47 (6.4)	NE (NE , NE)	NE		

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Pain in arm or shoulder - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.490
< 65 years	43/ 129 (33.3)	36.0 (25.6, NE)	31/ 115 (27.0)	NE (21.1, NE)	0.89 (0.56, 1.42)	0.619	
>= 65 years	29/ 125 (23.2)	NE (36.4, NE)	22/ 140 (15.7)	NE (NE , NE)	1.10 (0.63, 1.92)	0.745	
Gender							0.106
female	21/ 72 (29.2)	NE (29.6, NE)	23/ 86 (26.7)	24.5 (19.8, NE)	0.66 (0.36, 1.21)	0.172	
male	51/ 182 (28.0)	60.9 (36.3, NE)	30/ 169 (17.8)	NE (NE , NE)	1.26 (0.80, 1.98)	0.325	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	4/ 21 (19.0)		5/ 18 (27.8)				
STAGE IV	68/ 233 (29.2)		47/ 235 (20.0)				
Region							0.888
North America and Europe	39/ 140 (27.9)	NE (30.5, NE)	26/ 128 (20.3)	NE (24.5, NE)	1.04 (0.63, 1.71)	0.878	
Rest of the World	33/ 114 (28.9)	60.9 (35.7, NE)	27/ 127 (21.3)	NE (30.3, NE)	0.95 (0.57, 1.59)	0.849	
Prior anti-PD-(L)1 exposure							0.584
yes	47/ 180 (26.1)	60.9 (43.6, NE)	35/ 180 (19.4)	NE (31.7, NE)	0.97 (0.62, 1.51)	0.885	
no	25/ 74 (33.8)	30.6 (24.2, NE)	18/ 75 (24.0)	NE (25.2, NE)	1.15 (0.63, 2.12)	0.642	
Chemotherapy-free interval							0.405
< 90 days	33/ 109 (30.3)	36.3 (30.5, NE)	19/ 114 (16.7)	NE (24.3, NE)	1.18 (0.66, 2.10)	0.573	
>= 90 and < 180 days	25/ 85 (29.4)	NE (24.3, NE)	17/ 78 (21.8)	NE (24.5, NE)	1.15 (0.62, 2.13)	0.665	
>= 180 days	14/ 60 (23.3)	NE (43.6, NE)	17/ 63 (27.0)	NE (19.8, NE)	0.66 (0.32, 1.34)	0.243	
Presence (previous or current) of brain metastases							0.161
yes	34/ 113 (30.1)	43.6 (30.5, NE)	27/ 115 (23.5)	31.7 (24.2, NE)	0.74 (0.44, 1.23)	0.241	
no	38/ 141 (27.0)	60.9 (35.7, NE)	26/ 140 (18.6)	NE (NE , NE)	1.28 (0.78, 2.12)	0.333	
Standard of care							0.526
Amrubicin/Topotecan	59/ 209 (28.2)	60.9 (36.3, 60.9)	40/ 208 (19.2)	NE (NE , NE)	1.08 (0.72, 1.62)	0.709	
Lurbinectedin	13/ 45 (28.9)	NE (22.9, NE)	13/ 47 (27.7)	31.7 (21.1, NE)	0.85 (0.39, 1.86)	0.684	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Pain in chest - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.805
< 65 years	37/ 129 (28.7)	55.1 (30.6, NE)	32/ 115 (27.8)	48.3 (18.5, NE)	0.65 (0.40, 1.06)	0.083	
>= 65 years	21/ 125 (16.8)	NE (NE , NE)	27/ 140 (19.3)	NE (30.2, NE)	0.67 (0.38, 1.20)	0.178	
Gender							0.131
female	14/ 72 (19.4)	NE (NE , NE)	24/ 86 (27.9)	48.3 (18.5, NE)	0.46 (0.24, 0.90)	0.021	
male	44/ 182 (24.2)	NE (42.6, NE)	35/ 169 (20.7)	NE (30.2, NE)	0.84 (0.53, 1.32)	0.443	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	3/ 21 (14.3)		6/ 18 (33.3)				
STAGE IV	55/ 233 (23.6)		52/ 235 (22.1)				
Region							0.708
North America and Europe	31/ 140 (22.1)	NE (42.0, NE)	31/ 128 (24.2)	NE (19.8, NE)	0.65 (0.39, 1.08)	0.092	
Rest of the World	27/ 114 (23.7)	NE (48.0, NE)	28/ 127 (22.0)	NE (30.2, NE)	0.74 (0.43, 1.27)	0.270	
Prior anti-PD-(L)1 exposure							0.938
yes	41/ 180 (22.8)	NE (55.1, NE)	40/ 180 (22.2)	48.3 (30.2, NE)	0.70 (0.45, 1.09)	0.112	
no	17/ 74 (23.0)	NE (30.6, NE)	19/ 75 (25.3)	NE (17.5, NE)	0.68 (0.35, 1.34)	0.267	
Chemotherapy-free interval							0.573
< 90 days	22/ 109 (20.2)	55.1 (34.2, NE)	16/ 114 (14.0)	NE (NE , NE)	0.78 (0.40, 1.51)	0.460	
>= 90 and < 180 days	20/ 85 (23.5)	NE (NE , NE)	23/ 78 (29.5)	48.3 (18.5, 48.3)	0.65 (0.35, 1.19)	0.160	
>= 180 days	16/ 60 (26.7)	NE (36.4, NE)	20/ 63 (31.7)	NE (19.8, NE)	0.66 (0.34, 1.28)	0.216	
Presence (previous or current) of brain metastases							0.260
yes	22/ 113 (19.5)	NE (NE , NE)	24/ 115 (20.9)	48.3 (48.3, NE)	0.57 (0.31, 1.03)	0.059	
no	36/ 141 (25.5)	55.1 (42.0, NE)	35/ 140 (25.0)	NE (22.2, NE)	0.82 (0.51, 1.31)	0.401	
Standard of care							0.631
Amrubicin/Topotecan	51/ 209 (24.4)	55.1 (42.6, NE)	49/ 208 (23.6)	48.3 (30.0, NE)	0.70 (0.47, 1.04)	0.076	
Lurbinectedin	7/ 45 (15.6)	NE (NE , NE)	10/ 47 (21.3)	NE (18.7, NE)	0.72 (0.27, 1.89)	0.499	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Peripheral neuropathy - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.900
< 65 years	33/ 129 (25.6)	NE (30.9, NE)	31/ 115 (27.0)	48.3 (19.1, 48.3)	0.66 (0.40, 1.09)	0.100	
>= 65 years	28/ 125 (22.4)	NE (54.7, NE)	37/ 140 (26.4)	36.4 (24.1, NE)	0.65 (0.40, 1.07)	0.089	
Gender							0.703
female	18/ 72 (25.0)	NE (38.7, NE)	25/ 86 (29.1)	36.4 (18.4, 48.3)	0.60 (0.32, 1.12)	0.101	
male	43/ 182 (23.6)	NE (36.3, NE)	43/ 169 (25.4)	41.4 (24.1, NE)	0.69 (0.45, 1.06)	0.092	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	4/ 21 (19.0)		5/ 18 (27.8)				
STAGE IV	57/ 233 (24.5)		61/ 235 (26.0)				
Region							0.201
North America and Europe	30/ 140 (21.4)	NE (NE , NE)	38/ 128 (29.7)	24.2 (18.4, NE)	0.56 (0.35, 0.91)	0.017	
Rest of the World	31/ 114 (27.2)	NE (30.6, NE)	30/ 127 (23.6)	41.4 (29.9, NE)	0.77 (0.46, 1.29)	0.322	
Prior anti-PD-(L)1 exposure							0.337
yes	43/ 180 (23.9)	NE (NE , NE)	42/ 180 (23.3)	41.4 (29.6, NE)	0.75 (0.49, 1.15)	0.182	
no	18/ 74 (24.3)	54.7 (30.6, NE)	26/ 75 (34.7)	30.3 (16.9, NE)	0.52 (0.28, 0.95)	0.032	
Chemotherapy-free interval							0.344
< 90 days	18/ 109 (16.5)	NE (35.7, NE)	24/ 114 (21.1)	29.9 (18.5, NE)	0.44 (0.24, 0.83)	0.009	
>= 90 and < 180 days	26/ 85 (30.6)	NE (24.1, NE)	25/ 78 (32.1)	36.4 (18.2, 48.3)	0.81 (0.46, 1.41)	0.440	
>= 180 days	17/ 60 (28.3)	54.7 (30.9, NE)	19/ 63 (30.2)	41.4 (29.6, NE)	0.79 (0.41, 1.53)	0.479	
Presence (previous or current) of brain metastases							0.835
yes	31/ 113 (27.4)	NE (30.6, NE)	32/ 115 (27.8)	41.4 (19.1, 48.3)	0.61 (0.37, 1.02)	0.054	
no	30/ 141 (21.3)	NE (38.7, NE)	36/ 140 (25.7)	36.4 (29.6, NE)	0.69 (0.42, 1.12)	0.133	
Standard of care							0.577
Amrubicin/Topotecan	52/ 209 (24.9)	NE (38.7, NE)	55/ 208 (26.4)	36.4 (24.3, NE)	0.67 (0.46, 0.99)	0.041	
Lurbinectedin	9/ 45 (20.0)	NE (30.2, NE)	13/ 47 (27.7)	NE (16.5, NE)	0.64 (0.27, 1.50)	0.303	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Pain in other parts - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.125
< 65 years	44/ 129 (34.1)	42.0 (24.1, NE)	50/ 115 (43.5)	18.1 (12.8, 25.3)	0.59 (0.39, 0.90)	0.012	
>= 65 years	46/ 125 (36.8)	30.2 (18.4, NE)	45/ 140 (32.1)	36.0 (18.2, NE)	0.93 (0.62, 1.41)	0.745	
Gender							0.765
female	25/ 72 (34.7)	42.0 (18.7, NE)	31/ 86 (36.0)	18.2 (13.1, NE)	0.71 (0.42, 1.21)	0.207	
male	65/ 182 (35.7)	36.0 (22.9, NE)	64/ 169 (37.9)	24.2 (17.2, 36.0)	0.77 (0.54, 1.09)	0.143	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	8/ 21 (38.1)		8/ 18 (44.4)				
STAGE IV	82/ 233 (35.2)		86/ 235 (36.6)				
Region							0.948
North America and Europe	50/ 140 (35.7)	36.0 (18.4, NE)	48/ 128 (37.5)	18.2 (12.8, 36.0)	0.73 (0.49, 1.09)	0.122	
Rest of the World	40/ 114 (35.1)	42.0 (24.2, NE)	47/ 127 (37.0)	24.6 (18.2, NE)	0.76 (0.50, 1.17)	0.216	
Prior anti-PD-(L)1 exposure							0.837
yes	61/ 180 (33.9)	42.0 (24.2, NE)	61/ 180 (33.9)	24.6 (18.2, NE)	0.75 (0.52, 1.07)	0.111	
no	29/ 74 (39.2)	24.1 (18.1, NE)	34/ 75 (45.3)	17.5 (12.4, 25.9)	0.79 (0.48, 1.30)	0.350	
Chemotherapy-free interval							0.169
< 90 days	37/ 109 (33.9)	36.0 (18.4, NE)	35/ 114 (30.7)	24.6 (13.1, NE)	0.87 (0.54, 1.39)	0.551	
>= 90 and < 180 days	26/ 85 (30.6)	NE (18.7, NE)	35/ 78 (44.9)	18.2 (12.4, 25.3)	0.55 (0.33, 0.91)	0.018	
>= 180 days	27/ 60 (45.0)	24.5 (18.2, NE)	25/ 63 (39.7)	36.0 (12.5, NE)	0.96 (0.55, 1.65)	0.890	
Presence (previous or current) of brain metastases							0.032
yes	35/ 113 (31.0)	NE (25.1, NE)	43/ 115 (37.4)	21.2 (13.1, NE)	0.53 (0.33, 0.83)	0.005	
no	55/ 141 (39.0)	24.2 (18.2, NE)	52/ 140 (37.1)	24.5 (17.2, 42.4)	0.98 (0.67, 1.43)	0.913	
Standard of care							0.110
Amrubicin/Topotecan	83/ 209 (39.7)	30.2 (18.5, 42.1)	78/ 208 (37.5)	21.6 (13.4, 25.3)	0.80 (0.59, 1.09)	0.163	
Lurbinectedin	7/ 45 (15.6)	NE (NE , NE)	17/ 47 (36.2)	31.7 (17.5, NE)	0.41 (0.17, 1.01)	0.045	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of LC13 Sore mouth - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.468
< 65 years	22/ 129 (17.1)	NE (NE , NE)	26/ 115 (22.6)	35.4 (30.0, 53.1)	0.48 (0.27, 0.86)	0.011	
>= 65 years	19/ 125 (15.2)	NE (54.4, NE)	22/ 140 (15.7)	NE (42.1, NE)	0.66 (0.35, 1.24)	0.198	
Gender							0.665
female	19/ 72 (26.4)	NE (30.5, NE)	22/ 86 (25.6)	42.1 (30.0, 53.1)	0.62 (0.33, 1.17)	0.135	
male	22/ 182 (12.1)	NE (NE , NE)	26/ 169 (15.4)	NE (43.0, NE)	0.54 (0.30, 0.97)	0.036	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	3/ 21 (14.3)		5/ 18 (27.8)				
STAGE IV	38/ 233 (16.3)		42/ 235 (17.9)				
Region							0.380
North America and Europe	24/ 140 (17.1)	NE (NE , NE)	23/ 128 (18.0)	43.0 (35.4, NE)	0.69 (0.39, 1.24)	0.212	
Rest of the World	17/ 114 (14.9)	NE (NE , NE)	25/ 127 (19.7)	42.1 (31.7, NE)	0.43 (0.22, 0.82)	0.009	
Prior anti-PD-(L)1 exposure							0.615
yes	28/ 180 (15.6)	NE (NE , NE)	34/ 180 (18.9)	53.1 (35.4, NE)	0.52 (0.31, 0.87)	0.012	
no	13/ 74 (17.6)	NE (NE , NE)	14/ 75 (18.7)	43.0 (33.6, 43.0)	0.68 (0.32, 1.47)	0.330	
Chemotherapy-free interval							0.546
< 90 days	20/ 109 (18.3)	NE (44.1, NE)	18/ 114 (15.8)	42.1 (29.9, 42.1)	0.66 (0.34, 1.29)	0.222	
>= 90 and < 180 days	15/ 85 (17.6)	NE (54.4, NE)	18/ 78 (23.1)	43.0 (33.6, 43.0)	0.51 (0.25, 1.04)	0.060	
>= 180 days	6/ 60 (10.0)	NE (NE , NE)	12/ 63 (19.0)	NE (53.1, NE)	0.40 (0.15, 1.06)	0.058	
Presence (previous or current) of brain metastases							0.665
yes	17/ 113 (15.0)	NE (NE , NE)	19/ 115 (16.5)	53.1 (31.7, 53.1)	0.51 (0.26, 1.01)	0.048	
no	24/ 141 (17.0)	NE (54.4, NE)	29/ 140 (20.7)	43.0 (42.1, NE)	0.62 (0.36, 1.07)	0.084	
Standard of care							0.229
Amrubicin/Topotecan	33/ 209 (15.8)	NE (NE , NE)	42/ 208 (20.2)	42.1 (35.4, NE)	0.51 (0.32, 0.81)	0.004	
Lurbinectedin	8/ 45 (17.8)	NE (54.4, NE)	6/ 47 (12.8)	53.1 (31.7, NE)	0.89 (0.29, 2.73)	0.836	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Alopecia - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.090
< 65 years	128	14.32 (28.89)	114	-2.02 (1.92)	114	17.25 (29.82)	98	8.57 (2.28)	-10.59 (-16.46, -4.72)	<.001	-0.49 (-0.77, -0.22)	
>= 65 years	119	14.85 (30.90)	99	-5.45 (2.15)	136	12.75 (28.42)	112	12.33 (2.10)	-17.78 (-23.71, -11.85)	<.001	-0.81 (-1.09, -0.53)	
Gender												0.611
female	67	19.40 (36.77)	60	-3.18 (3.23)	84	21.83 (35.66)	69	9.75 (3.31)	-12.92 (-22.12, -3.73)	0.006	-0.49 (-0.84, -0.14)	
male	180	12.78 (26.67)	153	-4.30 (1.49)	166	11.24 (24.50)	141	11.24 (1.64)	-15.53 (-19.90, -11.16)	<.001	-0.82 (-1.05, -0.58)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	7.02 (17.84)	19		18	14.81 (28.52)	14					
STAGE IV	228	15.20 (30.54)	194		230	14.93 (29.29)	194					
Region												0.357
North America and Europe	135	18.27 (31.99)	112	-5.75 (2.14)	124	15.59 (28.96)	98	11.50 (2.48)	-17.25 (-23.73, -10.78)	<.001	-0.73 (-1.01, -0.45)	
Rest of the World	112	10.12 (26.41)	101	-3.08 (1.80)	126	14.02 (29.32)	112	10.34 (1.80)	-13.42 (-18.46, -8.39)	<.001	-0.72 (-1.00, -0.44)	
Prior anti-PD-(L)1 exposure												0.206
yes	175	13.71 (29.07)	150	-4.19 (1.63)	177	13.37 (27.35)	146	12.20 (1.74)	-16.39 (-21.09, -11.69)	<.001	-0.80 (-1.03, -0.56)	
no	72	16.67 (31.65)	63	-3.37 (2.81)	73	18.26 (32.89)	64	7.02 (3.01)	-10.39 (-18.57, -2.20)	0.014	-0.45 (-0.80, -0.09)	
Chemotherapy-free interval												0.056
< 90 days	108	17.90 (33.62)	89	-6.21 (1.84)	111	20.72 (33.05)	88	3.49 (2.07)	-9.70 (-15.20, -4.20)	<.001	-0.52 (-0.82, -0.23)	
>= 90 and < 180 days	82	13.01 (28.57)	71	-4.26 (2.69)	76	12.72 (27.74)	65	11.45 (2.98)	-15.71 (-23.70, -7.72)	<.001	-0.67 (-1.01, -0.32)	
>= 180 days	57	10.53 (22.85)	53	-1.72 (3.01)	63	6.88 (20.00)	57	19.92 (3.03)	-21.64 (-30.13, -13.16)	<.001	-0.96 (-1.35, -0.56)	
Presence (previous or current) of brain metastases												0.520
yes	111	20.72 (33.95)	94	-6.85 (2.20)	110	19.09 (32.70)	88	6.44 (2.57)	-13.29 (-20.00, -6.59)	<.001	-0.58 (-0.88, -0.29)	
no	136	9.56 (24.98)	119	-1.92 (1.84)	140	11.43 (25.53)	122	14.14 (1.89)	-16.05 (-21.27, -10.84)	<.001	-0.78 (-1.04, -0.52)	
Standard of care												<.001
Amrubicin/Topotecan	204	15.52 (30.57)	181	-4.25 (1.51)	203	13.79 (27.27)	170	14.61 (1.70)	-18.86 (-23.33, -14.39)	<.001	-0.89 (-1.11, -0.67)	
Lurbinectedin	43	10.08 (25.75)	32	-3.93 (2.75)	47	19.15 (35.94)	40	-5.55 (2.56)	1.62 (-5.93, 9.17)	0.669	0.10 (-0.36, 0.57)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Coughing - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.158
< 65 years	128	29.69 (24.11)	114	-8.91 (1.31)	114	29.24 (27.74)	98	-3.99 (1.59)	-4.92 (-8.98, -0.85)	0.018	-0.33 (-0.60, -0.06)	
>= 65 years	119	27.45 (22.82)	99	-4.79 (1.55)	136	26.47 (21.51)	112	-4.16 (1.61)	-0.63 (-5.05, 3.78)	0.778	-0.04 (-0.31, 0.23)	
Gender												0.320
female	67	33.33 (23.21)	60	-10.12 (1.97)	84	26.98 (23.98)	69	-4.55 (2.05)	-5.58 (-11.25, 0.09)	0.054	-0.34 (-0.69, 0.01)	
male	180	26.85 (23.40)	153	-5.83 (1.17)	166	28.11 (24.88)	141	-3.60 (1.34)	-2.23 (-5.74, 1.28)	0.213	-0.15 (-0.38, 0.08)	
Disease Stage at Screening												
STAGE II	0	-	0		2	16.67 (23.57)	2					
STAGE III	19	33.33 (24.85)	19		18	38.89 (23.57)	14					
STAGE IV	228	28.22 (23.37)	194		230	26.96 (24.49)	194					
Region												0.804
North America and Europe	135	31.11 (25.17)	112	-7.77 (1.47)	124	30.91 (25.92)	98	-5.05 (1.72)	-2.72 (-7.18, 1.73)	0.229	-0.17 (-0.44, 0.10)	
Rest of the World	112	25.60 (20.98)	101	-6.29 (1.42)	126	24.60 (22.78)	112	-2.80 (1.51)	-3.49 (-7.59, 0.62)	0.095	-0.23 (-0.50, 0.04)	
Prior anti-PD-(L)1 exposure												0.935
yes	175	28.00 (23.91)	150	-6.07 (1.21)	177	25.61 (24.03)	146	-2.94 (1.37)	-3.13 (-6.72, 0.47)	0.088	-0.20 (-0.43, 0.03)	
no	72	30.09 (22.49)	63	-9.77 (1.88)	73	32.88 (25.15)	64	-6.91 (2.04)	-2.85 (-8.37, 2.66)	0.307	-0.18 (-0.53, 0.17)	
Chemotherapy-free interval												0.517
< 90 days	108	28.40 (22.70)	89	-6.84 (1.63)	111	28.83 (26.40)	88	-1.74 (1.91)	-5.11 (-10.08, -0.13)	0.044	-0.30 (-0.60, -0.01)	
>= 90 and < 180 days	82	31.71 (26.14)	71	-7.47 (1.85)	76	25.44 (23.64)	65	-6.51 (2.08)	-0.96 (-6.50, 4.58)	0.731	-0.06 (-0.40, 0.28)	
>= 180 days	57	24.56 (20.44)	53	-6.50 (1.82)	63	28.57 (22.29)	57	-4.29 (1.92)	-2.21 (-7.47, 3.05)	0.406	-0.16 (-0.53, 0.22)	
Presence (previous or current) of brain metastases												0.380
yes	111	26.43 (22.97)	94	-6.30 (1.47)	110	22.42 (22.17)	88	-1.74 (1.72)	-4.56 (-9.03, -0.09)	0.046	-0.30 (-0.59, -0.01)	
no	136	30.39 (23.82)	119	-7.65 (1.41)	140	31.90 (25.56)	122	-5.78 (1.52)	-1.86 (-5.96, 2.23)	0.370	-0.12 (-0.37, 0.14)	
Standard of care												0.032
Amrubicin/Topotecan	204	29.25 (23.62)	181	-6.17 (1.10)	203	28.90 (24.76)	170	-4.74 (1.25)	-1.44 (-4.72, 1.84)	0.388	-0.09 (-0.30, 0.12)	
Lurbinectedin	43	25.58 (22.81)	32	-11.53 (2.50)	47	22.70 (23.16)	40	-1.58 (2.58)	-9.95 (-17.16, -2.74)	0.008	-0.64 (-1.12, -0.16)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Dysphagia - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												NE
< 65 years	128	4.69 (13.71)	114	0.38 (0.91)	114	5.26 (12.99)	98	2.81 (1.11)	-2.43 (-5.28, 0.42)	0.094	-0.23 (-0.50, 0.04)	
>= 65 years	119	5.60 (15.23)	99	NE	136	6.86 (15.24)	112	NE	NE		NE	
Gender												NE
female	67	2.49 (8.83)	60	NE	84	7.14 (14.70)	69	NE	NE		NE	
male	180	6.11 (15.94)	153	0.64 (0.87)	166	5.62 (14.04)	141	1.27 (0.99)	-0.63 (-3.23, 1.97)	0.634	-0.06 (-0.28, 0.17)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	8.77 (15.08)	19		18	7.41 (14.26)	14					
STAGE IV	228	4.82 (14.38)	194		230	6.09 (14.33)	194					
Region												0.306
North America and Europe	135	5.43 (16.39)	112	2.15 (1.06)	124	5.91 (13.47)	98	3.66 (1.23)	-1.51 (-4.71, 1.70)	0.355	-0.13 (-0.40, 0.14)	
Rest of the World	112	4.76 (11.72)	101	1.74 (1.06)	126	6.35 (15.03)	112	0.96 (1.11)	0.78 (-2.26, 3.82)	0.612	0.07 (-0.20, 0.34)	
Prior anti-PD-(L)1 exposure												NE
yes	175	5.14 (15.34)	150	2.33 (0.92)	177	5.46 (13.35)	146	3.29 (1.03)	-0.97 (-3.69, 1.76)	0.486	-0.08 (-0.31, 0.15)	
no	72	5.09 (12.08)	63	NE	73	7.76 (16.22)	64	NE	NE		NE	
Chemotherapy-free interval												0.945
< 90 days	108	3.09 (9.71)	89	2.10 (0.97)	111	6.61 (14.78)	88	2.62 (1.14)	-0.52 (-3.51, 2.47)	0.730	-0.05 (-0.35, 0.24)	
>= 90 and < 180 days	82	6.50 (16.92)	71	2.56 (1.46)	76	4.82 (13.00)	65	2.22 (1.64)	0.34 (-4.01, 4.70)	0.876	0.03 (-0.31, 0.36)	
>= 180 days	57	7.02 (17.52)	53	0.24 (1.25)	63	6.88 (14.86)	57	0.67 (1.28)	-0.43 (-4.00, 3.13)	0.809	-0.05 (-0.42, 0.33)	
Presence (previous or current) of brain metastases												NE
yes	111	5.41 (15.92)	94	-0.26 (0.98)	110	6.36 (14.63)	88	1.84 (1.12)	-2.10 (-5.04, 0.84)	0.161	-0.21 (-0.50, 0.08)	
no	136	4.90 (13.17)	119	NE	140	5.95 (14.00)	122	NE	NE		NE	
Standard of care												NE
Amrubicin/Topotecan	204	5.23 (13.84)	181	2.62 (0.82)	203	5.91 (14.00)	170	2.56 (0.93)	0.06 (-2.38, 2.50)	0.963	0.00 (-0.20, 0.21)	
Lurbinectedin	43	4.65 (17.18)	32	NE	47	7.09 (15.44)	40	NE	NE		NE	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Dyspnoea - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.394
< 65 years	128	21.44 (20.64)	114	-0.38 (1.27)	114	22.71 (21.24)	98	7.08 (1.51)	-7.46 (-11.35, -3.56)	<.001	-0.52 (-0.80, -0.25)	
>= 65 years	119	21.20 (19.57)	99	0.36 (1.42)	136	21.98 (18.81)	112	5.41 (1.44)	-5.05 (-9.05, -1.05)	0.014	-0.34 (-0.61, -0.07)	
Gender												0.362
female	67	22.22 (19.73)	60	1.87 (1.89)	84	23.54 (19.08)	69	5.96 (1.94)	-4.09 (-9.48, 1.29)	0.134	-0.26 (-0.61, 0.08)	
male	180	20.99 (20.27)	153	-0.73 (1.11)	166	21.69 (20.35)	141	6.27 (1.25)	-6.99 (-10.29, -3.70)	<.001	-0.49 (-0.72, -0.26)	
Disease Stage at Screening												
STAGE II	0	-	0		2	27.78 (39.28)	2					
STAGE III	19	15.79 (12.46)	19		18	24.07 (20.26)	14					
STAGE IV	228	21.78 (20.55)	194		230	22.13 (19.84)	194					
Region												0.170
North America and Europe	135	21.89 (21.20)	112	1.47 (1.30)	124	25.45 (22.12)	98	5.57 (1.49)	-4.11 (-8.03, -0.19)	0.040	-0.29 (-0.56, -0.01)	
Rest of the World	112	20.63 (18.74)	101	-1.31 (1.46)	126	19.22 (17.01)	112	6.78 (1.54)	-8.09 (-12.30, -3.89)	<.001	-0.52 (-0.79, -0.25)	
Prior anti-PD-(L)1 exposure												0.823
yes	175	21.65 (20.30)	150	-0.09 (1.06)	177	21.66 (19.22)	146	6.55 (1.20)	-6.64 (-9.79, -3.49)	<.001	-0.48 (-0.71, -0.25)	
no	72	20.52 (19.71)	63	-0.19 (2.02)	73	23.90 (21.57)	64	5.70 (2.11)	-5.90 (-11.70, -0.09)	0.046	-0.36 (-0.71, -0.01)	
Chemotherapy-free interval												0.664
< 90 days	108	22.84 (21.95)	89	-1.22 (1.74)	111	22.22 (20.49)	88	4.85 (2.00)	-6.07 (-11.34, -0.81)	0.024	-0.34 (-0.64, -0.05)	
>= 90 and < 180 days	82	23.31 (19.65)	71	-0.08 (1.52)	76	21.49 (18.36)	65	7.28 (1.70)	-7.36 (-11.87, -2.84)	0.002	-0.55 (-0.90, -0.21)	
>= 180 days	57	15.59 (15.83)	53	1.62 (1.58)	63	23.46 (20.94)	57	6.03 (1.66)	-4.41 (-9.04, 0.22)	0.062	-0.36 (-0.74, 0.01)	
Presence (previous or current) of brain metastases												0.601
yes	111	18.52 (18.61)	94	-1.54 (1.22)	110	21.52 (18.99)	88	5.39 (1.44)	-6.93 (-10.66, -3.20)	<.001	-0.55 (-0.84, -0.25)	
no	136	23.61 (21.01)	119	1.01 (1.39)	140	22.94 (20.66)	122	6.50 (1.45)	-5.49 (-9.46, -1.52)	0.007	-0.35 (-0.61, -0.10)	
Standard of care												0.097
Amrubicin/Topotecan	204	20.32 (19.62)	181	1.08 (1.02)	203	22.61 (20.58)	170	6.15 (1.13)	-5.08 (-8.08, -2.08)	<.001	-0.36 (-0.57, -0.14)	
Lurbinectedin	43	26.10 (21.81)	32	-5.66 (2.71)	47	21.04 (16.90)	40	6.41 (2.84)	-12.06 (-20.03, -4.10)	0.004	-0.71 (-1.19, -0.23)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Haemoptysis - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							Interaction
	Baseline		Change from BL		Baseline		Change from BL		Difference of			
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												NE
< 65 years	128	1.04 (5.82)	114	NE	114	3.22 (9.89)	98	NE	NE		NE	
>= 65 years	119	0.84 (5.25)	99	-0.06 (0.28)	136	1.72 (7.39)	112	-0.41 (0.30)	0.36 (-0.46, 1.17)	0.394	0.12 (-0.15, 0.39)	
Gender												0.912
female	67	1.00 (5.72)	60	-0.22 (0.70)	84	1.59 (7.14)	69	-0.46 (0.78)	0.24 (-1.94, 2.42)	0.822	0.04 (-0.31, 0.39)	
male	180	0.93 (5.49)	153	-0.29 (0.21)	166	2.81 (9.29)	141	-0.41 (0.26)	0.12 (-0.54, 0.78)	0.729	0.04 (-0.19, 0.27)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	0.00 (0.00)	19		18	1.85 (7.86)	14					
STAGE IV	228	1.02 (5.76)	194		230	2.46 (8.74)	194					
Region												NE
North America and Europe	135	0.99 (5.67)	112	-0.83 (0.31)	124	2.42 (8.68)	98	-0.48 (0.38)	-0.35 (-1.33, 0.63)	0.481	-0.10 (-0.37, 0.17)	
Rest of the World	112	0.89 (5.41)	101	NE	126	2.38 (8.62)	112	NE	NE		NE	
Prior anti-PD-(L)1 exposure												NE
yes	175	1.14 (6.08)	150	-0.08 (0.28)	177	1.51 (6.94)	146	0.16 (0.34)	-0.23 (-1.12, 0.65)	0.601	-0.06 (-0.29, 0.17)	
no	72	0.46 (3.93)	63	NE	73	4.57 (11.54)	64	NE	NE		NE	
Chemotherapy-free interval												NE
< 90 days	108	0.93 (5.50)	89	NE	111	1.80 (7.57)	88	NE	NE		NE	
>= 90 and < 180 days	82	1.63 (7.22)	71	0.14 (0.37)	76	1.75 (7.49)	65	0.52 (0.44)	-0.38 (-1.52, 0.75)	0.504	-0.12 (-0.45, 0.22)	
>= 180 days	57	0.00 (0.00)	53	NE	63	4.23 (11.19)	57	NE	NE		NE	
Presence (previous or current) of brain metastases												NE
yes	111	0.90 (5.43)	94	NE	110	2.42 (8.70)	88	NE	NE		NE	
no	136	0.98 (5.65)	119	-0.52 (0.26)	140	2.38 (8.62)	122	-0.94 (0.29)	0.42 (-0.36, 1.20)	0.292	0.14 (-0.12, 0.39)	
Standard of care												NE
Amrubicin/Topotecan	204	0.98 (5.65)	181	-0.12 (0.22)	203	2.46 (8.74)	170	-0.35 (0.27)	0.23 (-0.45, 0.92)	0.506	0.07 (-0.14, 0.28)	
Lurbinectedin	43	0.78 (5.08)	32	NE	47	2.13 (8.24)	40	NE	NE		NE	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Pain in arm or shoulder - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.764
< 65 years	128	12.50 (22.13)	114	0.78 (1.27)	114	15.50 (21.81)	98	0.82 (1.55)	-0.04 (-4.01, 3.92)	0.982	-0.00 (-0.27, 0.27)	
>= 65 years	119	10.92 (20.86)	99	-2.65 (1.04)	136	10.78 (18.09)	112	-3.35 (1.07)	0.71 (-2.24, 3.66)	0.636	0.06 (-0.21, 0.34)	
Gender												0.832
female	67	13.93 (23.32)	60	-0.64 (1.86)	84	13.89 (19.50)	69	-1.03 (2.01)	0.39 (-5.05, 5.84)	0.887	0.02 (-0.32, 0.37)	
male	180	10.93 (20.79)	153	-0.77 (0.92)	166	12.45 (20.24)	141	-1.81 (1.05)	1.04 (-1.70, 3.79)	0.455	0.09 (-0.14, 0.32)	
Disease Stage at Screening												
STAGE II	0	-	0		2	16.67 (23.57)	2					
STAGE III	19	5.26 (12.49)	19		18	9.26 (19.15)	14					
STAGE IV	228	12.28 (22.02)	194		230	13.19 (20.07)	194					
Region												0.864
North America and Europe	135	13.83 (23.88)	112	-1.16 (1.21)	124	13.17 (20.30)	98	-1.67 (1.40)	0.50 (-3.15, 4.16)	0.786	0.04 (-0.23, 0.31)	
Rest of the World	112	9.23 (18.01)	101	-0.36 (1.22)	126	12.70 (19.71)	112	-1.31 (1.31)	0.94 (-2.60, 4.49)	0.599	0.07 (-0.20, 0.34)	
Prior anti-PD-(L)1 exposure												0.184
yes	175	13.52 (23.19)	150	-2.03 (0.96)	177	11.86 (18.56)	146	-1.81 (1.06)	-0.23 (-3.04, 2.59)	0.873	-0.02 (-0.25, 0.21)	
no	72	7.41 (16.04)	63	2.67 (1.77)	73	15.53 (22.96)	64	-1.06 (1.90)	3.73 (-1.49, 8.95)	0.158	0.25 (-0.10, 0.60)	
Chemotherapy-free interval												0.721
< 90 days	108	12.65 (23.56)	89	0.06 (1.74)	111	15.02 (21.90)	88	-0.25 (1.99)	0.31 (-4.92, 5.55)	0.906	0.02 (-0.28, 0.31)	
>= 90 and < 180 days	82	12.20 (21.92)	71	-1.53 (1.20)	76	11.84 (17.81)	65	-3.20 (1.36)	1.68 (-1.91, 5.26)	0.357	0.16 (-0.18, 0.50)	
>= 180 days	57	9.36 (16.37)	53	-0.44 (1.54)	63	10.58 (18.77)	57	0.16 (1.60)	-0.60 (-5.02, 3.81)	0.787	-0.05 (-0.43, 0.32)	
Presence (previous or current) of brain metastases												0.662
yes	111	11.11 (21.24)	94	0.26 (1.26)	110	10.91 (17.55)	88	0.20 (1.50)	0.06 (-3.82, 3.94)	0.975	0.00 (-0.29, 0.30)	
no	136	12.25 (21.78)	119	-1.65 (1.16)	140	14.52 (21.61)	122	-2.84 (1.23)	1.20 (-2.15, 4.54)	0.481	0.09 (-0.16, 0.34)	
Standard of care												0.998
Amrubicin/Topotecan	204	13.40 (22.81)	181	-1.38 (0.93)	203	12.48 (19.56)	170	-2.11 (1.05)	0.73 (-2.04, 3.50)	0.604	0.06 (-0.15, 0.26)	
Lurbinectedin	43	3.88 (10.81)	32	1.24 (2.08)	47	14.89 (21.77)	40	0.50 (2.20)	0.74 (-5.47, 6.95)	0.812	0.06 (-0.41, 0.52)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Pain in chest - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.050
< 65 years	128	13.28 (22.27)	114	-0.66 (1.32)	114	15.50 (21.81)	98	3.00 (1.57)	-3.65 (-7.70, 0.39)	0.076	-0.25 (-0.52, 0.02)	
>= 65 years	119	8.68 (17.06)	99	1.21 (1.28)	136	9.56 (17.64)	112	-0.50 (1.29)	1.71 (-1.88, 5.30)	0.347	0.13 (-0.14, 0.40)	
Gender												NE
female	67	11.44 (20.56)	60	NE	84	9.92 (16.18)	69	NE	NE		NE	
male	180	10.93 (19.88)	153	0.44 (1.09)	166	13.45 (21.39)	141	0.50 (1.23)	-0.07 (-3.29, 3.16)	0.967	-0.00 (-0.23, 0.22)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	10.53 (15.92)	19		18	9.26 (15.36)	14					
STAGE IV	228	11.11 (20.36)	194		230	12.61 (20.20)	194					
Region												0.761
North America and Europe	135	10.62 (21.41)	112	-0.05 (1.26)	124	14.52 (22.19)	98	0.82 (1.46)	-0.87 (-4.68, 2.94)	0.653	-0.06 (-0.33, 0.21)	
Rest of the World	112	11.61 (18.29)	101	1.45 (1.47)	126	10.05 (17.01)	112	1.44 (1.53)	0.01 (-4.20, 4.21)	0.998	0.00 (-0.27, 0.27)	
Prior anti-PD-(L)1 exposure												0.307
yes	175	12.76 (21.35)	150	-1.05 (1.03)	177	12.81 (19.44)	146	0.97 (1.16)	-2.02 (-5.08, 1.04)	0.194	-0.15 (-0.38, 0.08)	
no	72	6.94 (15.76)	63	3.46 (2.00)	73	10.96 (20.83)	64	2.10 (2.12)	1.36 (-4.45, 7.18)	0.642	0.08 (-0.27, 0.43)	
Chemotherapy-free interval												0.673
< 90 days	108	12.96 (21.29)	89	-1.37 (1.36)	111	14.11 (21.34)	88	-0.29 (1.58)	-1.08 (-5.22, 3.06)	0.605	-0.08 (-0.37, 0.22)	
>= 90 and < 180 days	82	10.98 (20.32)	71	1.61 (1.78)	76	10.96 (17.54)	65	1.06 (1.98)	0.56 (-4.75, 5.86)	0.835	0.04 (-0.30, 0.37)	
>= 180 days	57	7.60 (16.69)	53	0.57 (1.83)	63	10.58 (19.70)	57	3.33 (1.85)	-2.77 (-7.95, 2.41)	0.291	-0.20 (-0.58, 0.17)	
Presence (previous or current) of brain metastases												0.337
yes	111	7.51 (16.01)	94	-0.41 (1.19)	110	10.30 (18.48)	88	1.76 (1.37)	-2.16 (-5.74, 1.42)	0.235	-0.18 (-0.47, 0.11)	
no	136	13.97 (22.43)	119	1.15 (1.42)	140	13.81 (20.77)	122	0.67 (1.50)	0.48 (-3.61, 4.57)	0.817	0.03 (-0.22, 0.28)	
Standard of care												0.975
Amrubicin/Topotecan	204	11.60 (20.96)	181	0.59 (1.04)	203	12.64 (20.42)	170	1.33 (1.16)	-0.74 (-3.80, 2.32)	0.633	-0.05 (-0.26, 0.16)	
Lurbinectedin	43	8.53 (14.72)	32	-1.17 (2.12)	47	10.64 (17.18)	40	-0.53 (2.12)	-0.64 (-6.65, 5.38)	0.833	-0.05 (-0.51, 0.42)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Peripheral neuropathy - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												NE
< 65 years	128	8.85 (19.84)	114	-0.46 (1.13)	114	9.06 (17.90)	98	1.46 (1.36)	-1.92 (-5.42, 1.58)	0.281	-0.15 (-0.42, 0.12)	
>= 65 years	119	8.68 (16.50)	99	NE	136	9.07 (17.90)	112	NE	NE		NE	
Gender												NE
female	67	8.96 (19.75)	60	-1.27 (2.25)	84	11.90 (20.47)	69	2.75 (2.29)	-4.02 (-10.41, 2.38)	0.215	-0.22 (-0.57, 0.13)	
male	180	8.70 (17.74)	153	NE	166	7.63 (16.27)	141	NE	NE		NE	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	1.75 (7.65)	19		18	16.67 (23.57)	14					
STAGE IV	228	9.36 (18.78)	194		230	8.55 (17.33)	194					
Region												NE
North America and Europe	135	11.60 (19.66)	112	-1.48 (1.33)	124	10.22 (18.61)	98	3.05 (1.51)	-4.52 (-8.50, -0.55)	0.026	-0.31 (-0.58, -0.04)	
Rest of the World	112	5.36 (15.85)	101	NE	126	7.94 (17.09)	112	NE	NE		NE	
Prior anti-PD-(L)1 exposure												NE
yes	175	7.81 (16.65)	150	NE	177	7.72 (16.95)	146	NE	NE		NE	
no	72	11.11 (21.67)	63	NE	73	12.33 (19.65)	64	NE	NE		NE	
Chemotherapy-free interval												0.250
< 90 days	108	8.64 (17.87)	89	-1.74 (1.37)	111	8.71 (18.92)	88	1.52 (1.54)	-3.27 (-7.36, 0.83)	0.117	-0.24 (-0.53, 0.06)	
>= 90 and < 180 days	82	11.79 (21.19)	71	NE	76	9.21 (17.72)	65	NE	NE		NE	
>= 180 days	57	4.68 (13.27)	53	2.06 (1.49)	63	9.52 (16.32)	57	1.89 (1.54)	0.17 (-4.12, 4.45)	0.938	0.01 (-0.36, 0.39)	
Presence (previous or current) of brain metastases												NE
yes	111	8.41 (17.68)	94	NE	110	8.18 (16.40)	88	NE	NE		NE	
no	136	9.07 (18.80)	119	-0.21 (1.13)	140	9.76 (18.96)	122	-0.08 (1.19)	-0.12 (-3.37, 3.12)	0.940	-0.01 (-0.26, 0.24)	
Standard of care												NE
Amrubicin/Topotecan	204	9.80 (19.34)	181	-0.70 (0.93)	203	8.05 (16.45)	170	1.19 (1.04)	-1.89 (-4.64, 0.86)	0.178	-0.14 (-0.35, 0.07)	
Lurbinectedin	43	3.88 (10.81)	32	NE	47	13.48 (22.69)	40	NE	NE		NE	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Pain in other parts - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.014
< 65 years	128	17.97 (24.71)	114	0.74 (1.61)	114	20.76 (28.53)	98	8.13 (1.94)	-7.40 (-12.38, -2.42)	0.004	-0.41 (-0.68, -0.13)	
>= 65 years	119	13.73 (22.72)	99	1.73 (1.44)	136	14.95 (23.24)	112	1.11 (1.48)	0.62 (-3.44, 4.69)	0.762	0.04 (-0.23, 0.31)	
Gender												0.858
female	67	20.40 (26.56)	60	0.49 (2.18)	84	20.24 (26.39)	69	3.80 (2.28)	-3.31 (-9.56, 2.93)	0.295	-0.18 (-0.53, 0.16)	
male	180	14.26 (22.57)	153	1.65 (1.25)	166	16.27 (25.62)	141	4.31 (1.43)	-2.66 (-6.40, 1.08)	0.163	-0.16 (-0.39, 0.07)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	7.02 (13.96)	19		18	20.37 (30.55)	14					
STAGE IV	228	16.67 (24.34)	194		230	17.54 (25.63)	194					
Region												0.951
North America and Europe	135	18.52 (24.66)	112	2.30 (1.59)	124	18.01 (26.34)	98	5.27 (1.86)	-2.97 (-7.80, 1.85)	0.226	-0.17 (-0.44, 0.10)	
Rest of the World	112	12.80 (22.48)	101	-0.14 (1.42)	126	17.20 (25.55)	112	3.03 (1.50)	-3.17 (-7.26, 0.92)	0.128	-0.21 (-0.48, 0.06)	
Prior anti-PD-(L)1 exposure												0.788
yes	175	16.19 (23.67)	150	1.50 (1.33)	177	17.89 (26.11)	146	4.07 (1.49)	-2.57 (-6.51, 1.38)	0.201	-0.15 (-0.38, 0.08)	
no	72	15.28 (24.35)	63	0.16 (1.71)	73	16.89 (25.53)	64	3.59 (1.84)	-3.43 (-8.41, 1.54)	0.174	-0.24 (-0.59, 0.11)	
Chemotherapy-free interval												0.606
< 90 days	108	17.28 (26.37)	89	2.62 (1.69)	111	15.62 (23.71)	88	4.42 (1.98)	-1.80 (-6.96, 3.36)	0.491	-0.10 (-0.40, 0.19)	
>= 90 and < 180 days	82	19.11 (24.02)	71	-0.74 (1.91)	76	17.54 (25.80)	65	4.71 (2.13)	-5.45 (-11.12, 0.22)	0.060	-0.33 (-0.66, 0.01)	
>= 180 days	57	8.77 (16.09)	53	1.24 (2.20)	63	21.16 (29.51)	57	3.43 (2.33)	-2.18 (-8.66, 4.29)	0.504	-0.13 (-0.50, 0.25)	
Presence (previous or current) of brain metastases												0.078
yes	111	17.42 (24.14)	94	1.94 (1.74)	110	15.15 (22.41)	88	8.48 (1.99)	-6.54 (-11.78, -1.29)	0.015	-0.37 (-0.66, -0.07)	
no	136	14.71 (23.58)	119	0.60 (1.40)	140	19.52 (28.27)	122	1.19 (1.51)	-0.60 (-4.69, 3.49)	0.774	-0.04 (-0.29, 0.22)	
Standard of care												0.353
Amrubicin/Topotecan	204	15.36 (23.71)	181	1.86 (1.21)	203	16.91 (26.19)	170	4.39 (1.36)	-2.53 (-6.11, 1.05)	0.165	-0.15 (-0.36, 0.06)	
Lurbinectedin	43	18.60 (24.45)	32	-2.38 (2.44)	47	20.57 (24.63)	40	3.85 (2.57)	-6.23 (-13.34, 0.88)	0.084	-0.41 (-0.87, 0.06)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of LC13 Sore mouth - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							Interaction
	Baseline		Change from BL		Baseline		Change from BL		Difference of			
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.216
< 65 years	128	3.12 (14.15)	114	0.53 (0.55)	114	4.09 (12.65)	98	2.79 (0.73)	-2.26 (-4.07, -0.44)	0.015	-0.34 (-0.62, -0.07)	
>= 65 years	119	4.20 (14.10)	99	-0.60 (0.95)	136	4.90 (13.78)	112	-0.41 (1.03)	-0.19 (-2.97, 2.60)	0.894	-0.02 (-0.29, 0.25)	
Gender												0.246
female	67	1.49 (6.95)	60	2.58 (1.16)	84	6.75 (16.18)	69	1.95 (1.33)	0.63 (-2.95, 4.20)	0.726	0.06 (-0.28, 0.41)	
male	180	4.44 (15.91)	153	-1.07 (0.59)	166	3.41 (11.39)	141	0.63 (0.71)	-1.70 (-3.53, 0.14)	0.069	-0.21 (-0.44, 0.01)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	1.75 (7.65)	19		18	7.41 (18.28)	14					
STAGE IV	228	3.80 (14.51)	194		230	4.35 (12.86)	194					
Region												NE
North America and Europe	135	4.20 (15.47)	112	NE	124	4.84 (13.90)	98	NE	NE		NE	
Rest of the World	112	2.98 (12.30)	101	0.28 (0.97)	126	4.23 (12.64)	112	1.09 (1.07)	-0.81 (-3.69, 2.07)	0.578	-0.08 (-0.34, 0.19)	
Prior anti-PD-(L)1 exposure												0.039
yes	175	4.38 (15.98)	150	-0.39 (0.62)	177	4.71 (14.09)	146	1.78 (0.75)	-2.17 (-4.09, -0.26)	0.026	-0.26 (-0.49, -0.03)	
no	72	1.85 (7.69)	63	2.51 (1.57)	73	4.11 (11.03)	64	-0.53 (1.71)	3.04 (-1.82, 7.89)	0.206	0.23 (-0.12, 0.58)	
Chemotherapy-free interval												0.862
< 90 days	108	0.93 (5.50)	89	NE	111	3.60 (11.33)	88	NE	NE		NE	
>= 90 and < 180 days	82	4.88 (15.82)	71	0.07 (1.09)	76	3.95 (13.30)	65	1.66 (1.27)	-1.59 (-4.93, 1.74)	0.345	-0.16 (-0.50, 0.17)	
>= 180 days	57	7.02 (20.64)	53	-2.72 (0.89)	63	6.88 (16.02)	57	-0.75 (0.99)	-1.97 (-4.64, 0.71)	0.147	-0.28 (-0.65, 0.10)	
Presence (previous or current) of brain metastases												0.229
yes	111	3.90 (17.26)	94	0.46 (0.72)	110	4.55 (13.15)	88	2.68 (0.91)	-2.22 (-4.52, 0.08)	0.059	-0.28 (-0.58, 0.01)	
no	136	3.43 (10.95)	119	-0.32 (0.78)	140	4.52 (13.39)	122	-0.09 (0.88)	-0.23 (-2.58, 2.12)	0.846	-0.03 (-0.28, 0.23)	
Standard of care												0.412
Amrubicin/Topotecan	204	2.94 (11.56)	181	0.47 (0.63)	203	3.45 (11.69)	170	1.77 (0.75)	-1.30 (-3.24, 0.63)	0.186	-0.14 (-0.35, 0.07)	
Lurbinectedin	43	6.98 (22.49)	32	-1.70 (1.03)	47	9.22 (17.99)	40	-1.91 (1.18)	0.21 (-2.96, 3.38)	0.894	0.03 (-0.43, 0.50)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Anhang 4-G5.4.2: Endpunkt „EQ-5D VAS“ – RCT

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of Visual Analog Score - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.077
< 65 years	45/ 129 (34.9)	38.6 (30.2, NE)	49/ 115 (42.6)	21.2 (18.1, 30.0)	0.61 (0.41, 0.93)	0.020	
>= 65 years	52/ 125 (41.6)	30.0 (18.5, 36.0)	43/ 140 (30.7)	33.6 (22.1, NE)	1.06 (0.70, 1.59)	0.761	
Gender							0.546
female	32/ 72 (44.4)	30.3 (18.2, NE)	32/ 86 (37.2)	24.6 (18.1, 39.2)	0.91 (0.55, 1.48)	0.693	
male	65/ 182 (35.7)	36.0 (26.2, NE)	60/ 169 (35.5)	24.6 (18.9, 36.0)	0.78 (0.55, 1.12)	0.188	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	7/ 21 (33.3)		9/ 18 (50.0)				
STAGE IV	90/ 233 (38.6)		82/ 235 (34.9)				
Region							0.127
North America and Europe	55/ 140 (39.3)	30.5 (25.3, 36.4)	40/ 128 (31.3)	30.0 (22.1, NE)	1.00 (0.66, 1.51)	0.999	
Rest of the World	42/ 114 (36.8)	NE (24.2, NE)	52/ 127 (40.9)	24.3 (17.9, 33.6)	0.68 (0.45, 1.03)	0.073	
Prior anti-PD-(L)1 exposure							0.095
yes	67/ 180 (37.2)	35.3 (30.2, NE)	68/ 180 (37.8)	24.1 (18.1, 36.2)	0.70 (0.49, 0.98)	0.039	
no	30/ 74 (40.5)	30.0 (18.2, NE)	24/ 75 (32.0)	33.6 (19.5, NE)	1.20 (0.70, 2.06)	0.507	
Chemotherapy-free interval							0.885
< 90 days	39/ 109 (35.8)	35.3 (18.5, NE)	35/ 114 (30.7)	24.3 (16.1, 36.3)	0.83 (0.52, 1.32)	0.436	
>= 90 and < 180 days	32/ 85 (37.6)	31.3 (24.2, NE)	30/ 78 (38.5)	24.1 (18.1, NE)	0.75 (0.46, 1.25)	0.267	
>= 180 days	26/ 60 (43.3)	30.9 (17.9, NE)	27/ 63 (42.9)	24.6 (17.9, NE)	0.93 (0.54, 1.60)	0.805	
Presence (previous or current) of brain metastases							0.069
yes	40/ 113 (35.4)	36.0 (24.2, NE)	44/ 115 (38.3)	22.1 (12.5, 31.7)	0.59 (0.38, 0.92)	0.018	
no	57/ 141 (40.4)	30.2 (20.6, NE)	48/ 140 (34.3)	33.6 (24.1, NE)	1.04 (0.70, 1.53)	0.839	
Standard of care							0.820
Amrubicin/Topotecan	85/ 209 (40.7)	30.5 (25.3, 36.4)	78/ 208 (37.5)	24.1 (16.1, 33.6)	0.79 (0.58, 1.07)	0.135	
Lurbinectedin	12/ 45 (26.7)	NE (12.4, NE)	14/ 47 (29.8)	31.7 (24.3, NE)	0.86 (0.39, 1.89)	0.701	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of Visual Analog Score - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.508
< 65 years	128	74.27 (16.82)	114	-3.31 (1.08)	114	74.37 (18.69)	98	-7.14 (1.29)	3.83 (0.50, 7.17)	0.025	0.31 (0.04, 0.59)	
>= 65 years	119	73.58 (17.69)	99	-3.74 (1.18)	136	73.23 (17.68)	112	-6.00 (1.20)	2.26 (-1.06, 5.57)	0.181	0.18 (-0.09, 0.45)	
Gender												0.192
female	67	74.42 (19.08)	60	-3.50 (1.70)	84	71.17 (18.51)	69	-9.15 (1.72)	5.65 (0.83, 10.47)	0.022	0.41 (0.06, 0.76)	
male	180	73.76 (16.52)	153	-3.47 (0.90)	166	75.05 (17.83)	141	-5.50 (1.02)	2.04 (-0.63, 4.71)	0.134	0.18 (-0.05, 0.41)	
Disease Stage at Screening												
STAGE II	0	-	0		2	75.00 (7.07)	2					
STAGE III	19	80.37 (14.73)	19		18	76.28 (15.55)	14					
STAGE IV	228	73.40 (17.33)	194		230	73.54 (18.39)	194					
Region												0.414
North America and Europe	135	70.84 (18.42)	112	-3.07 (1.06)	124	70.79 (18.12)	98	-5.24 (1.23)	2.18 (-1.02, 5.38)	0.181	0.19 (-0.09, 0.46)	
Rest of the World	112	77.67 (14.88)	101	-3.59 (1.18)	126	76.66 (17.71)	112	-7.69 (1.24)	4.10 (0.72, 7.48)	0.018	0.33 (0.06, 0.60)	
Prior anti-PD-(L)1 exposure												0.112
yes	175	73.61 (17.57)	150	-2.27 (0.90)	177	73.67 (18.49)	146	-6.91 (1.00)	4.64 (1.99, 7.29)	<.001	0.40 (0.17, 0.63)	
no	72	74.74 (16.42)	63	-6.62 (1.79)	73	73.95 (17.30)	64	-6.59 (1.90)	-0.03 (-5.26, 5.20)	0.990	-0.00 (-0.35, 0.35)	
Chemotherapy-free interval												0.889
< 90 days	108	72.91 (17.40)	89	-3.09 (1.29)	111	74.95 (19.35)	88	-5.63 (1.47)	2.54 (-1.33, 6.41)	0.197	0.19 (-0.10, 0.49)	
>= 90 and < 180 days	82	70.96 (16.83)	71	-2.99 (1.38)	76	72.93 (17.42)	65	-4.92 (1.53)	1.93 (-2.14, 6.01)	0.349	0.16 (-0.18, 0.50)	
>= 180 days	57	80.18 (16.10)	53	-4.88 (1.54)	63	72.62 (16.79)	57	-8.30 (1.66)	3.42 (-1.11, 7.95)	0.137	0.29 (-0.09, 0.66)	
Presence (previous or current) of brain metastases												0.079
yes	111	71.76 (17.66)	94	-2.04 (1.19)	110	75.55 (15.32)	88	-7.20 (1.37)	5.15 (1.54, 8.77)	0.006	0.42 (0.13, 0.71)	
no	136	75.72 (16.70)	119	-4.96 (1.09)	140	72.34 (19.99)	122	-5.85 (1.16)	0.89 (-2.26, 4.04)	0.578	0.07 (-0.18, 0.32)	
Standard of care												0.810
Amrubicin/Topotecan	204	73.85 (17.34)	181	-4.00 (0.91)	203	73.93 (17.94)	170	-7.32 (1.01)	3.32 (0.64, 6.00)	0.015	0.26 (0.05, 0.47)	
Lurbinectedin	43	74.37 (16.80)	32	-0.36 (1.29)	47	72.96 (19.06)	40	-3.12 (1.41)	2.76 (-1.09, 6.60)	0.156	0.33 (-0.14, 0.80)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Anhang 4-G5.4.3: Endpunkt „PGI-C/PGI-S“ – RCT

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of Cough Now - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.867
< 65 years	18/ 129 (14.0)	NE (NE , NE)	19/ 115 (16.5)	NE (NE , NE)	0.61 (0.31, 1.17)	0.132	
>= 65 years	14/ 125 (11.2)	NE (NE , NE)	20/ 140 (14.3)	NE (48.8, NE)	0.54 (0.27, 1.09)	0.080	
Gender							0.461
female	11/ 72 (15.3)	NE (NE , NE)	11/ 86 (12.8)	NE (NE , NE)	0.83 (0.35, 1.94)	0.668	
male	21/ 182 (11.5)	NE (NE , NE)	28/ 169 (16.6)	48.8 (48.8, NE)	0.50 (0.28, 0.89)	0.016	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	4/ 21 (19.0)		3/ 18 (16.7)				
STAGE IV	28/ 233 (12.0)		36/ 235 (15.3)				
Region							0.900
North America and Europe	16/ 140 (11.4)	NE (NE , NE)	18/ 128 (14.1)	NE (NE , NE)	0.56 (0.29, 1.12)	0.097	
Rest of the World	16/ 114 (14.0)	NE (NE , NE)	21/ 127 (16.5)	NE (36.3, NE)	0.60 (0.31, 1.16)	0.124	
Prior anti-PD-(L)1 exposure							0.274
yes	23/ 180 (12.8)	NE (NE , NE)	23/ 180 (12.8)	NE (48.8, NE)	0.69 (0.38, 1.24)	0.209	
no	9/ 74 (12.2)	NE (NE , NE)	16/ 75 (21.3)	NE (24.6, NE)	0.45 (0.20, 1.01)	0.048	
Chemotherapy-free interval							0.040
< 90 days	14/ 109 (12.8)	NE (42.6, NE)	21/ 114 (18.4)	48.8 (30.2, NE)	0.44 (0.22, 0.89)	0.019	
>= 90 and < 180 days	14/ 85 (16.5)	NE (NE , NE)	7/ 78 (9.0)	NE (NE , NE)	1.57 (0.63, 3.90)	0.330	
>= 180 days	4/ 60 (6.7)	NE (NE , NE)	11/ 63 (17.5)	NE (NE , NE)	0.27 (0.08, 0.85)	0.016	
Presence (previous or current) of brain metastases							0.835
yes	13/ 113 (11.5)	NE (NE , NE)	15/ 115 (13.0)	NE (36.3, NE)	0.56 (0.26, 1.20)	0.132	
no	19/ 141 (13.5)	NE (NE , NE)	24/ 140 (17.1)	NE (48.8, NE)	0.62 (0.34, 1.13)	0.117	
Standard of care							0.266
Amrubicin/Topotecan	28/ 209 (13.4)	NE (NE , NE)	29/ 208 (13.9)	48.8 (48.8, NE)	0.65 (0.39, 1.10)	0.109	
Lurbinectedin	4/ 45 (8.9)	NE (NE , NE)	10/ 47 (21.3)	NE (36.3, NE)	0.37 (0.11, 1.20)	0.085	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of Chest Pain Now - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.978
< 65 years	20/ 129 (15.5)	NE (60.9, NE)	13/ 115 (11.3)	NE (NE , NE)	1.07 (0.52, 2.17)	0.861	
>= 65 years	6/ 125 (4.8)	NE (NE , NE)	5/ 140 (3.6)	NE (NE , NE)	0.93 (0.28, 3.09)	0.910	
Gender							0.417
female	8/ 72 (11.1)	NE (NE , NE)	8/ 86 (9.3)	NE (NE , NE)	0.77 (0.28, 2.09)	0.600	
male	18/ 182 (9.9)	NE (60.9, NE)	10/ 169 (5.9)	NE (NE , NE)	1.37 (0.63, 3.00)	0.425	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	2/ 21 (9.5)		3/ 18 (16.7)				
STAGE IV	24/ 233 (10.3)		15/ 235 (6.4)				
Region							0.983
North America and Europe	14/ 140 (10.0)	NE (NE , NE)	9/ 128 (7.0)	NE (NE , NE)	1.08 (0.47, 2.52)	0.857	
Rest of the World	12/ 114 (10.5)	NE (60.9, NE)	9/ 127 (7.1)	NE (NE , NE)	1.11 (0.46, 2.68)	0.814	
Prior anti-PD-(L)1 exposure							0.322
yes	19/ 180 (10.6)	NE (60.9, NE)	10/ 180 (5.6)	NE (NE , NE)	1.35 (0.62, 2.94)	0.448	
no	7/ 74 (9.5)	NE (NE , NE)	8/ 75 (10.7)	NE (NE , NE)	0.80 (0.29, 2.21)	0.667	
Chemotherapy-free interval							0.163
< 90 days	9/ 109 (8.3)	NE (60.9, NE)	7/ 114 (6.1)	NE (NE , NE)	0.83 (0.29, 2.35)	0.731	
>= 90 and < 180 days	11/ 85 (12.9)	NE (NE , NE)	3/ 78 (3.8)	NE (NE , NE)	3.14 (0.87, 11.27)	0.065	
>= 180 days	6/ 60 (10.0)	NE (NE , NE)	8/ 63 (12.7)	NE (NE , NE)	0.64 (0.22, 1.86)	0.411	
Presence (previous or current) of brain metastases							0.663
yes	10/ 113 (8.8)	NE (NE , NE)	5/ 115 (4.3)	NE (NE , NE)	1.41 (0.47, 4.18)	0.538	
no	16/ 141 (11.3)	NE (60.9, NE)	13/ 140 (9.3)	NE (NE , NE)	1.03 (0.49, 2.16)	0.932	
Standard of care							0.737
Amrubicin/Topotecan	23/ 209 (11.0)	NE (60.9, NE)	15/ 208 (7.2)	NE (NE , NE)	1.14 (0.59, 2.19)	0.698	
Lurbinectedin	3/ 45 (6.7)	NE (NE , NE)	3/ 47 (6.4)	NE (NE , NE)	1.06 (0.21, 5.27)	0.944	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of Breath Shortness Now - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.990
< 65 years	17/ 129 (13.2)	NE (NE , NE)	21/ 115 (18.3)	NE (NE , NE)	0.51 (0.26, 0.98)	0.039	
>= 65 years	17/ 125 (13.6)	NE (NE , NE)	26/ 140 (18.6)	NE (39.4, NE)	0.56 (0.30, 1.04)	0.064	
Gender							0.229
female	13/ 72 (18.1)	NE (NE , NE)	14/ 86 (16.3)	NE (33.0, NE)	0.75 (0.35, 1.63)	0.471	
male	21/ 182 (11.5)	NE (NE , NE)	33/ 169 (19.5)	NE (NE , NE)	0.45 (0.26, 0.78)	0.004	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	3/ 21 (14.3)		3/ 18 (16.7)				
STAGE IV	31/ 233 (13.3)		43/ 235 (18.3)				
Region							0.101
North America and Europe	21/ 140 (15.0)	NE (NE , NE)	19/ 128 (14.8)	NE (39.4, NE)	0.77 (0.41, 1.44)	0.409	
Rest of the World	13/ 114 (11.4)	NE (NE , NE)	28/ 127 (22.0)	NE (33.0, NE)	0.37 (0.19, 0.72)	0.002	
Prior anti-PD-(L)1 exposure							0.383
yes	28/ 180 (15.6)	NE (NE , NE)	34/ 180 (18.9)	NE (39.4, NE)	0.59 (0.35, 0.97)	0.037	
no	6/ 74 (8.1)	NE (NE , NE)	13/ 75 (17.3)	NE (NE , NE)	0.40 (0.15, 1.06)	0.058	
Chemotherapy-free interval							0.266
< 90 days	14/ 109 (12.8)	NE (47.8, NE)	20/ 114 (17.5)	NE (33.0, NE)	0.50 (0.25, 1.00)	0.047	
>= 90 and < 180 days	15/ 85 (17.6)	NE (NE , NE)	14/ 78 (17.9)	39.4 (39.4, NE)	0.84 (0.40, 1.76)	0.647	
>= 180 days	5/ 60 (8.3)	NE (NE , NE)	13/ 63 (20.6)	NE (NE , NE)	0.29 (0.10, 0.81)	0.012	
Presence (previous or current) of brain metastases							0.576
yes	14/ 113 (12.4)	NE (NE , NE)	20/ 115 (17.4)	NE (33.0, NE)	0.46 (0.23, 0.92)	0.025	
no	20/ 141 (14.2)	NE (NE , NE)	27/ 140 (19.3)	NE (39.4, NE)	0.60 (0.34, 1.08)	0.088	
Standard of care							0.934
Amrubicin/Topotecan	29/ 209 (13.9)	NE (NE , NE)	38/ 208 (18.3)	NE (39.4, NE)	0.53 (0.33, 0.87)	0.010	
Lurbinectedin	5/ 45 (11.1)	NE (NE , NE)	9/ 47 (19.1)	NE (NE , NE)	0.52 (0.17, 1.63)	0.256	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of Cough Now - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							Interaction
	Baseline		Change from BL		Baseline		Change from BL		Difference of			
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.305
< 65 years	0	-	114	-0.97 (0.07)	0	-	98	-0.72 (0.09)	-0.26 (-0.48, -0.04)	0.023	-0.32 (-0.59, -0.05)	
>= 65 years	0	-	103	-0.89 (0.07)	0	-	115	-0.79 (0.07)	-0.10 (-0.31, 0.10)	0.324	-0.13 (-0.40, 0.13)	
Gender												0.817
female	0	-	63	-0.93 (0.10)	0	-	69	-0.78 (0.10)	-0.15 (-0.43, 0.12)	0.270	-0.19 (-0.53, 0.15)	
male	0	-	154	-0.94 (0.06)	0	-	144	-0.75 (0.07)	-0.19 (-0.37, -0.01)	0.035	-0.25 (-0.47, -0.02)	
Disease Stage at Screening												
STAGE II	0	-	0		0	-	2					
STAGE III	0	-	20		0	-	14					
STAGE IV	0	-	197		0	-	197					
Region												0.169
North America and Europe	0	-	115	-0.87 (0.07)	0	-	101	-0.79 (0.08)	-0.08 (-0.29, 0.13)	0.464	-0.10 (-0.37, 0.17)	
Rest of the World	0	-	102	-1.01 (0.07)	0	-	112	-0.73 (0.08)	-0.29 (-0.50, -0.07)	0.008	-0.36 (-0.63, -0.09)	
Prior anti-PD-(L)1 exposure												0.609
yes	0	-	152	-0.90 (0.06)	0	-	149	-0.75 (0.07)	-0.16 (-0.34, 0.03)	0.095	-0.19 (-0.42, 0.03)	
no	0	-	65	-1.01 (0.09)	0	-	64	-0.77 (0.09)	-0.24 (-0.49, 0.01)	0.065	-0.33 (-0.68, 0.02)	
Chemotherapy-free interval												0.795
< 90 days	0	-	89	-0.94 (0.09)	0	-	90	-0.71 (0.10)	-0.23 (-0.48, 0.02)	0.074	-0.27 (-0.56, 0.03)	
>= 90 and < 180 days	0	-	72	-0.95 (0.08)	0	-	66	-0.84 (0.09)	-0.11 (-0.35, 0.12)	0.343	-0.16 (-0.50, 0.17)	
>= 180 days	0	-	56	-0.90 (0.10)	0	-	57	-0.71 (0.10)	-0.19 (-0.48, 0.09)	0.180	-0.25 (-0.62, 0.12)	
Presence (previous or current) of brain metastases												0.881
yes	0	-	95	-0.96 (0.08)	0	-	91	-0.80 (0.09)	-0.16 (-0.39, 0.06)	0.160	-0.21 (-0.50, 0.08)	
no	0	-	122	-0.92 (0.07)	0	-	122	-0.74 (0.07)	-0.18 (-0.39, 0.02)	0.073	-0.23 (-0.48, 0.02)	
Standard of care												0.219
Amrubicin/Topotecan	0	-	185	-0.89 (0.05)	0	-	173	-0.75 (0.06)	-0.14 (-0.30, 0.02)	0.092	-0.18 (-0.39, 0.03)	
Lurbinectedin	0	-	32	-1.22 (0.12)	0	-	40	-0.84 (0.12)	-0.38 (-0.73, -0.03)	0.034	-0.50 (-0.97, -0.03)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of Chest Pain Now - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.956
< 65 years	0	-	114	-0.83 (0.07)	0	-	98	-0.77 (0.08)	-0.06 (-0.27, 0.16)	0.603	-0.07 (-0.34, 0.20)	
>= 65 years	0	-	103	-0.85 (0.07)	0	-	115	-0.78 (0.08)	-0.07 (-0.27, 0.14)	0.538	-0.08 (-0.35, 0.18)	
Gender												0.477
female	0	-	63	-0.77 (0.09)	0	-	69	-0.78 (0.10)	0.01 (-0.26, 0.28)	0.933	0.01 (-0.33, 0.36)	
male	0	-	154	-0.87 (0.06)	0	-	144	-0.77 (0.07)	-0.10 (-0.28, 0.08)	0.255	-0.13 (-0.36, 0.10)	
Disease Stage at Screening												
STAGE II	0	-	0		0	-	2					
STAGE III	0	-	20		0	-	14					
STAGE IV	0	-	197		0	-	197					
Region												0.109
North America and Europe	0	-	115	-0.82 (0.07)	0	-	101	-0.88 (0.08)	0.06 (-0.16, 0.27)	0.610	0.07 (-0.20, 0.34)	
Rest of the World	0	-	102	-0.86 (0.07)	0	-	112	-0.67 (0.07)	-0.19 (-0.39, 0.02)	0.073	-0.24 (-0.51, 0.02)	
Prior anti-PD-(L)1 exposure												0.458
yes	0	-	152	-0.81 (0.06)	0	-	149	-0.78 (0.07)	-0.03 (-0.21, 0.15)	0.720	-0.04 (-0.27, 0.18)	
no	0	-	65	-0.90 (0.09)	0	-	64	-0.75 (0.10)	-0.15 (-0.42, 0.11)	0.258	-0.20 (-0.55, 0.15)	
Chemotherapy-free interval												0.709
< 90 days	0	-	89	-0.87 (0.08)	0	-	90	-0.89 (0.09)	0.02 (-0.23, 0.26)	0.881	0.02 (-0.27, 0.32)	
>= 90 and < 180 days	0	-	72	-0.85 (0.08)	0	-	66	-0.74 (0.09)	-0.11 (-0.35, 0.14)	0.396	-0.14 (-0.48, 0.19)	
>= 180 days	0	-	56	-0.78 (0.10)	0	-	57	-0.66 (0.11)	-0.12 (-0.41, 0.18)	0.428	-0.15 (-0.52, 0.22)	
Presence (previous or current) of brain metastases												0.422
yes	0	-	95	-0.84 (0.08)	0	-	91	-0.85 (0.09)	0.01 (-0.23, 0.25)	0.956	0.01 (-0.28, 0.30)	
no	0	-	122	-0.83 (0.06)	0	-	122	-0.72 (0.07)	-0.12 (-0.30, 0.07)	0.217	-0.16 (-0.41, 0.09)	
Standard of care												0.853
Amrubicin/Topotecan	0	-	185	-0.81 (0.06)	0	-	173	-0.73 (0.06)	-0.08 (-0.25, 0.08)	0.324	-0.10 (-0.31, 0.10)	
Lurbinectedin	0	-	32	-0.99 (0.13)	0	-	40	-0.94 (0.13)	-0.05 (-0.40, 0.31)	0.799	-0.06 (-0.52, 0.41)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of Breath Shortness Now - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.486
< 65 years	0	-	114	-0.85 (0.07)	0	-	98	-0.55 (0.09)	-0.30 (-0.52, -0.08)	0.007	-0.38 (-0.65, -0.10)	
>= 65 years	0	-	103	-0.74 (0.08)	0	-	115	-0.55 (0.08)	-0.19 (-0.41, 0.02)	0.082	-0.24 (-0.50, 0.03)	
Gender												0.180
female	0	-	63	-0.70 (0.10)	0	-	69	-0.60 (0.10)	-0.09 (-0.38, 0.19)	0.516	-0.11 (-0.45, 0.23)	
male	0	-	154	-0.84 (0.06)	0	-	144	-0.52 (0.07)	-0.32 (-0.51, -0.14)	<.001	-0.40 (-0.63, -0.17)	
Disease Stage at Screening												
STAGE II	0	-	0		0	-	2					
STAGE III	0	-	20		0	-	14					
STAGE IV	0	-	197		0	-	197					
Region												0.024
North America and Europe	0	-	115	-0.75 (0.07)	0	-	101	-0.67 (0.08)	-0.08 (-0.30, 0.14)	0.497	-0.09 (-0.36, 0.17)	
Rest of the World	0	-	102	-0.86 (0.07)	0	-	112	-0.44 (0.08)	-0.43 (-0.64, -0.21)	<.001	-0.54 (-0.81, -0.27)	
Prior anti-PD-(L)1 exposure												0.773
yes	0	-	152	-0.76 (0.06)	0	-	149	-0.51 (0.07)	-0.25 (-0.44, -0.06)	0.010	-0.30 (-0.52, -0.07)	
no	0	-	65	-0.91 (0.09)	0	-	64	-0.62 (0.10)	-0.29 (-0.56, -0.03)	0.029	-0.39 (-0.74, -0.04)	
Chemotherapy-free interval												0.252
< 90 days	0	-	89	-0.84 (0.08)	0	-	90	-0.62 (0.09)	-0.22 (-0.47, 0.02)	0.078	-0.26 (-0.56, 0.03)	
>= 90 and < 180 days	0	-	72	-0.76 (0.09)	0	-	66	-0.64 (0.10)	-0.12 (-0.40, 0.15)	0.376	-0.15 (-0.49, 0.18)	
>= 180 days	0	-	56	-0.81 (0.10)	0	-	57	-0.36 (0.10)	-0.45 (-0.73, -0.16)	0.002	-0.58 (-0.96, -0.20)	
Presence (previous or current) of brain metastases												0.850
yes	0	-	95	-0.84 (0.08)	0	-	91	-0.61 (0.09)	-0.23 (-0.48, 0.01)	0.060	-0.28 (-0.57, 0.01)	
no	0	-	122	-0.78 (0.07)	0	-	122	-0.51 (0.07)	-0.26 (-0.46, -0.06)	0.010	-0.33 (-0.59, -0.08)	
Standard of care												0.823
Amrubicin/Topotecan	0	-	185	-0.76 (0.06)	0	-	173	-0.51 (0.06)	-0.25 (-0.42, -0.08)	0.004	-0.31 (-0.52, -0.10)	
Lurbinectedin	0	-	32	-1.01 (0.13)	0	-	40	-0.72 (0.13)	-0.30 (-0.68, 0.08)	0.125	-0.36 (-0.83, 0.11)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of Cough - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.030
< 65 years	32/ 129 (24.8)	66.1 (38.6, NE)	38/ 115 (33.0)	31.7 (18.2, NE)	0.48 (0.29, 0.78)	0.002	
>= 65 years	43/ 125 (34.4)	38.2 (24.3, NE)	40/ 140 (28.6)	36.3 (24.3, NE)	1.01 (0.65, 1.56)	0.981	
Gender							0.293
female	18/ 72 (25.0)	66.1 (48.4, NE)	26/ 86 (30.2)	NE (18.1, NE)	0.54 (0.29, 1.01)	0.052	
male	57/ 182 (31.3)	38.9 (30.2, NE)	52/ 169 (30.8)	30.5 (23.9, 48.8)	0.77 (0.53, 1.14)	0.185	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	6/ 21 (28.6)		4/ 18 (22.2)				
STAGE IV	69/ 233 (29.6)		73/ 235 (31.1)				
Region							0.318
North America and Europe	40/ 140 (28.6)	38.6 (30.3, NE)	33/ 128 (25.8)	NE (18.7, NE)	0.86 (0.54, 1.37)	0.544	
Rest of the World	35/ 114 (30.7)	66.1 (36.7, NE)	45/ 127 (35.4)	30.3 (18.7, 48.8)	0.58 (0.36, 0.92)	0.018	
Prior anti-PD-(L)1 exposure							0.837
yes	54/ 180 (30.0)	54.5 (36.7, NE)	53/ 180 (29.4)	31.7 (23.9, NE)	0.68 (0.46, 1.00)	0.050	
no	21/ 74 (28.4)	48.4 (25.2, NE)	25/ 75 (33.3)	30.3 (18.7, NE)	0.75 (0.42, 1.35)	0.336	
Chemotherapy-free interval							0.976
< 90 days	30/ 109 (27.5)	36.7 (30.2, NE)	31/ 114 (27.2)	31.7 (18.5, NE)	0.66 (0.40, 1.10)	0.109	
>= 90 and < 180 days	26/ 85 (30.6)	54.5 (28.6, NE)	25/ 78 (32.1)	NE (18.2, NE)	0.77 (0.44, 1.35)	0.356	
>= 180 days	19/ 60 (31.7)	66.1 (30.0, NE)	22/ 63 (34.9)	30.3 (18.7, NE)	0.68 (0.36, 1.29)	0.233	
Presence (previous or current) of brain metastases							0.227
yes	33/ 113 (29.2)	66.1 (36.2, NE)	37/ 115 (32.2)	23.9 (18.4, NE)	0.59 (0.36, 0.96)	0.031	
no	42/ 141 (29.8)	48.4 (30.2, NE)	41/ 140 (29.3)	48.8 (28.2, NE)	0.82 (0.53, 1.27)	0.376	
Standard of care							0.004
Amrubicin/Topotecan	67/ 209 (32.1)	38.6 (30.3, NE)	57/ 208 (27.4)	48.8 (28.2, NE)	0.89 (0.62, 1.27)	0.520	
Lurbinectedin	8/ 45 (17.8)	NE (54.5, NE)	21/ 47 (44.7)	22.4 (13.5, 36.3)	0.19 (0.07, 0.51)	<.001	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of Chest Pain - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.943
< 65 years	40/ 129 (31.0)	54.0 (30.6, NE)	38/ 115 (33.0)	37.6 (18.2, 48.3)	0.62 (0.39, 0.98)	0.039	
>= 65 years	25/ 125 (20.0)	NE (42.6, NE)	30/ 140 (21.4)	NE (30.2, NE)	0.68 (0.40, 1.17)	0.160	
Gender							0.993
female	17/ 72 (23.6)	NE (54.0, NE)	22/ 86 (25.6)	48.3 (18.7, NE)	0.66 (0.34, 1.25)	0.194	
male	48/ 182 (26.4)	NE (38.6, NE)	46/ 169 (27.2)	37.6 (30.2, NE)	0.67 (0.45, 1.02)	0.061	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	5/ 21 (23.8)		5/ 18 (27.8)				
STAGE IV	60/ 233 (25.8)		62/ 235 (26.4)				
Region							0.347
North America and Europe	31/ 140 (22.1)	NE (42.0, NE)	35/ 128 (27.3)	37.6 (18.7, NE)	0.56 (0.34, 0.92)	0.019	
Rest of the World	34/ 114 (29.8)	55.1 (30.9, NE)	33/ 127 (26.0)	48.3 (30.2, NE)	0.82 (0.50, 1.34)	0.430	
Prior anti-PD-(L)1 exposure							0.582
yes	49/ 180 (27.2)	55.1 (42.0, NE)	46/ 180 (25.6)	42.1 (24.5, NE)	0.70 (0.47, 1.06)	0.091	
no	16/ 74 (21.6)	NE (30.6, NE)	22/ 75 (29.3)	37.6 (18.7, NE)	0.62 (0.32, 1.18)	0.145	
Chemotherapy-free interval							0.925
< 90 days	24/ 109 (22.0)	55.1 (30.6, NE)	23/ 114 (20.2)	42.1 (18.7, NE)	0.67 (0.38, 1.21)	0.184	
>= 90 and < 180 days	23/ 85 (27.1)	NE (30.2, NE)	23/ 78 (29.5)	37.6 (18.5, 48.3)	0.71 (0.39, 1.28)	0.249	
>= 180 days	18/ 60 (30.0)	NE (30.9, NE)	22/ 63 (34.9)	31.2 (18.1, NE)	0.64 (0.34, 1.21)	0.168	
Presence (previous or current) of brain metastases							0.763
yes	26/ 113 (23.0)	NE (42.6, NE)	25/ 115 (21.7)	42.1 (24.3, NE)	0.66 (0.37, 1.16)	0.145	
no	39/ 141 (27.7)	54.0 (30.5, NE)	43/ 140 (30.7)	37.6 (18.7, NE)	0.70 (0.45, 1.09)	0.114	
Standard of care							0.610
Amrubicin/Topotecan	55/ 209 (26.3)	55.1 (38.6, NE)	54/ 208 (26.0)	42.1 (30.2, NE)	0.70 (0.48, 1.02)	0.063	
Lurbinectedin	10/ 45 (22.2)	NE (42.6, NE)	14/ 47 (29.8)	NE (18.1, NE)	0.58 (0.24, 1.36)	0.204	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of Breath Shortness - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.367
< 65 years	42/ 129 (32.6)	NE (25.6, NE)	44/ 115 (38.3)	19.8 (18.1, NE)	0.64 (0.42, 0.98)	0.039	
>= 65 years	39/ 125 (31.2)	43.6 (26.1, NE)	43/ 140 (30.7)	36.3 (18.5, NE)	0.80 (0.52, 1.25)	0.334	
Gender							0.136
female	28/ 72 (38.9)	36.0 (18.2, NE)	27/ 86 (31.4)	42.1 (18.4, 42.1)	0.98 (0.57, 1.69)	0.954	
male	53/ 182 (29.1)	NE (35.7, NE)	60/ 169 (35.5)	25.9 (15.2, NE)	0.62 (0.43, 0.90)	0.013	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	8/ 21 (38.1)		6/ 18 (33.3)				
STAGE IV	73/ 233 (31.3)		81/ 235 (34.5)				
Region							0.428
North America and Europe	45/ 140 (32.1)	42.0 (18.8, NE)	39/ 128 (30.5)	NE (18.4, NE)	0.81 (0.52, 1.24)	0.332	
Rest of the World	36/ 114 (31.6)	NE (34.2, NE)	48/ 127 (37.8)	25.9 (18.1, 42.1)	0.63 (0.40, 0.97)	0.035	
Prior anti-PD-(L)1 exposure							0.484
yes	61/ 180 (33.9)	47.8 (28.6, NE)	59/ 180 (32.8)	31.7 (19.1, NE)	0.76 (0.53, 1.09)	0.137	
no	20/ 74 (27.0)	NE (26.1, NE)	28/ 75 (37.3)	18.7 (12.4, NE)	0.63 (0.36, 1.13)	0.115	
Chemotherapy-free interval							0.610
< 90 days	33/ 109 (30.3)	42.0 (25.6, NE)	31/ 114 (27.2)	36.3 (18.4, NE)	0.81 (0.49, 1.34)	0.412	
>= 90 and < 180 days	29/ 85 (34.1)	NE (18.4, NE)	33/ 78 (42.3)	18.5 (12.1, NE)	0.62 (0.37, 1.02)	0.058	
>= 180 days	19/ 60 (31.7)	NE (26.1, NE)	23/ 63 (36.5)	NE (18.4, NE)	0.73 (0.39, 1.34)	0.304	
Presence (previous or current) of brain metastases							0.555
yes	37/ 113 (32.7)	NE (19.8, NE)	37/ 115 (32.2)	24.3 (18.1, NE)	0.64 (0.40, 1.02)	0.057	
no	44/ 141 (31.2)	47.8 (30.5, NE)	50/ 140 (35.7)	42.1 (18.4, NE)	0.78 (0.52, 1.18)	0.237	
Standard of care							0.251
Amrubicin/Topotecan	71/ 209 (34.0)	42.0 (28.6, NE)	69/ 208 (33.2)	42.1 (18.5, NE)	0.78 (0.56, 1.09)	0.150	
Lurbinectedin	10/ 45 (22.2)	NE (25.6, NE)	18/ 47 (38.3)	24.3 (17.9, NE)	0.43 (0.19, 0.95)	0.034	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of Cough - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.023
< 65 years	128	1.90 (0.80)	114	-0.24 (0.05)	114	1.80 (0.85)	98	-0.03 (0.06)	-0.21 (-0.36, -0.07)	0.005	-0.40 (-0.67, -0.12)	
>= 65 years	119	1.76 (0.72)	99	-0.07 (0.05)	136	1.74 (0.64)	112	-0.09 (0.05)	0.02 (-0.12, 0.16)	0.756	0.04 (-0.23, 0.31)	
Gender												0.757
female	67	1.97 (0.72)	60	-0.24 (0.07)	84	1.81 (0.78)	69	-0.12 (0.07)	-0.12 (-0.32, 0.07)	0.222	-0.22 (-0.56, 0.13)	
male	180	1.78 (0.78)	153	-0.12 (0.04)	166	1.75 (0.73)	141	-0.04 (0.04)	-0.09 (-0.20, 0.03)	0.147	-0.17 (-0.40, 0.06)	
Disease Stage at Screening												
STAGE II	0	-	0		2	2.00 (0.00)	2					
STAGE III	19	1.95 (0.71)	19		18	2.11 (0.58)	14					
STAGE IV	228	1.82 (0.77)	194		230	1.74 (0.75)	194					
Region												0.224
North America and Europe	135	1.87 (0.81)	112	-0.17 (0.05)	124	1.87 (0.81)	98	-0.14 (0.05)	-0.03 (-0.18, 0.11)	0.649	-0.06 (-0.33, 0.21)	
Rest of the World	112	1.79 (0.70)	101	-0.15 (0.05)	126	1.67 (0.67)	112	0.01 (0.05)	-0.16 (-0.31, -0.01)	0.034	-0.29 (-0.56, -0.02)	
Prior anti-PD-(L)1 exposure												0.886
yes	175	1.84 (0.78)	150	-0.14 (0.04)	177	1.70 (0.74)	146	-0.05 (0.05)	-0.09 (-0.21, 0.03)	0.162	-0.16 (-0.39, 0.07)	
no	72	1.82 (0.74)	63	-0.20 (0.06)	73	1.93 (0.75)	64	-0.10 (0.07)	-0.10 (-0.29, 0.09)	0.287	-0.19 (-0.54, 0.16)	
Chemotherapy-free interval												0.334
< 90 days	108	1.87 (0.81)	89	-0.18 (0.05)	111	1.77 (0.82)	88	0.00 (0.06)	-0.18 (-0.35, -0.01)	0.033	-0.32 (-0.62, -0.03)	
>= 90 and < 180 days	82	1.89 (0.77)	71	-0.14 (0.06)	76	1.72 (0.70)	65	-0.14 (0.07)	0.01 (-0.18, 0.19)	0.957	0.01 (-0.33, 0.35)	
>= 180 days	57	1.68 (0.66)	53	-0.16 (0.06)	63	1.81 (0.67)	57	-0.04 (0.06)	-0.12 (-0.30, 0.06)	0.183	-0.25 (-0.63, 0.12)	
Presence (previous or current) of brain metastases												0.844
yes	111	1.80 (0.80)	94	-0.18 (0.05)	110	1.70 (0.75)	88	-0.08 (0.06)	-0.09 (-0.25, 0.06)	0.224	-0.18 (-0.47, 0.11)	
no	136	1.86 (0.74)	119	-0.14 (0.05)	140	1.82 (0.74)	122	-0.06 (0.05)	-0.07 (-0.21, 0.06)	0.273	-0.14 (-0.39, 0.11)	
Standard of care												0.002
Amrubicin/Topotecan	204	1.83 (0.76)	181	-0.12 (0.04)	203	1.79 (0.74)	170	-0.10 (0.04)	-0.01 (-0.12, 0.10)	0.807	-0.03 (-0.24, 0.18)	
Lurbinectedin	43	1.84 (0.78)	32	-0.37 (0.09)	47	1.66 (0.79)	40	0.08 (0.09)	-0.45 (-0.71, -0.19)	<.001	-0.81 (-1.30, -0.33)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of Chest Pain - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) Baseline N	Baseline Mean (SD)	Change from BL N*	Change from BL LSMean (SE)	Standard of Care (N=255) Baseline N	Baseline Mean (SD)	Change from BL N*	Change from BL LSMean (SE)	Difference of LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	Interaction p-Value
Age												0.074
< 65 years	128	1.51 (0.85)	114	-0.02 (0.05)	114	1.42 (0.69)	98	0.12 (0.05)	-0.13 (-0.27, 0.01)	0.066	-0.26 (-0.53, 0.02)	
>= 65 years	119	1.31 (0.61)	99	0.01 (0.04)	136	1.29 (0.57)	112	-0.02 (0.04)	0.03 (-0.08, 0.13)	0.619	0.07 (-0.20, 0.34)	
Gender												0.502
female	67	1.45 (0.84)	60	-0.07 (0.06)	84	1.38 (0.60)	69	0.02 (0.06)	-0.09 (-0.26, 0.08)	0.282	-0.19 (-0.54, 0.16)	
male	180	1.40 (0.71)	153	0.03 (0.03)	166	1.34 (0.65)	141	0.05 (0.04)	-0.03 (-0.13, 0.08)	0.624	-0.06 (-0.29, 0.17)	
Disease Stage at Screening												
STAGE II	0	-	0		2	1.00 (0.00)	2					
STAGE III	19	1.32 (0.58)	19		18	1.44 (0.78)	14					
STAGE IV	228	1.42 (0.76)	194		230	1.35 (0.62)	194					
Region												0.406
North America and Europe	135	1.44 (0.83)	112	-0.03 (0.04)	124	1.37 (0.64)	98	0.05 (0.05)	-0.07 (-0.20, 0.05)	0.236	-0.16 (-0.44, 0.11)	
Rest of the World	112	1.38 (0.63)	101	0.03 (0.04)	126	1.33 (0.62)	112	0.03 (0.04)	-0.00 (-0.12, 0.12)	0.977	-0.00 (-0.27, 0.27)	
Prior anti-PD-(L)1 exposure												0.682
yes	175	1.46 (0.79)	150	-0.02 (0.03)	177	1.39 (0.65)	146	0.01 (0.04)	-0.04 (-0.13, 0.06)	0.475	-0.08 (-0.31, 0.14)	
no	72	1.29 (0.62)	63	0.05 (0.06)	73	1.26 (0.58)	64	0.13 (0.06)	-0.08 (-0.25, 0.10)	0.381	-0.16 (-0.50, 0.19)	
Chemotherapy-free interval												0.286
< 90 days	108	1.46 (0.83)	89	-0.05 (0.04)	111	1.38 (0.66)	88	0.05 (0.05)	-0.10 (-0.22, 0.02)	0.105	-0.25 (-0.54, 0.05)	
>= 90 and < 180 days	82	1.50 (0.77)	71	-0.01 (0.06)	76	1.36 (0.63)	65	-0.08 (0.06)	0.07 (-0.11, 0.24)	0.452	0.13 (-0.21, 0.47)	
>= 180 days	57	1.19 (0.48)	53	0.06 (0.06)	63	1.30 (0.59)	57	0.13 (0.06)	-0.07 (-0.24, 0.09)	0.394	-0.16 (-0.54, 0.21)	
Presence (previous or current) of brain metastases												0.637
yes	111	1.32 (0.62)	94	-0.05 (0.04)	110	1.37 (0.65)	88	0.01 (0.05)	-0.06 (-0.18, 0.06)	0.309	-0.15 (-0.44, 0.14)	
no	136	1.49 (0.83)	119	0.04 (0.04)	140	1.34 (0.62)	122	0.06 (0.04)	-0.02 (-0.14, 0.10)	0.713	-0.05 (-0.30, 0.21)	
Standard of care												0.918
Amrubicin/Topotecan	204	1.44 (0.78)	181	-0.00 (0.03)	203	1.36 (0.62)	170	0.04 (0.04)	-0.04 (-0.13, 0.06)	0.425	-0.09 (-0.29, 0.12)	
Lurbinectedin	43	1.30 (0.56)	32	-0.02 (0.07)	47	1.32 (0.66)	40	0.03 (0.07)	-0.05 (-0.25, 0.15)	0.623	-0.11 (-0.58, 0.35)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of Breath Shortness - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.829
< 65 years	128	1.66 (0.78)	114	-0.04 (0.05)	114	1.63 (0.72)	98	0.12 (0.05)	-0.16 (-0.30, -0.02)	0.026	-0.31 (-0.58, -0.04)	
>= 65 years	119	1.57 (0.73)	99	-0.06 (0.05)	136	1.67 (0.77)	112	0.08 (0.05)	-0.14 (-0.27, -0.00)	0.046	-0.28 (-0.55, -0.00)	
Gender												0.197
female	67	1.72 (0.73)	60	-0.01 (0.07)	84	1.75 (0.77)	69	0.04 (0.07)	-0.05 (-0.25, 0.16)	0.652	-0.08 (-0.43, 0.27)	
male	180	1.58 (0.76)	153	-0.06 (0.04)	166	1.60 (0.73)	141	0.13 (0.04)	-0.20 (-0.30, -0.09)	<.001	-0.42 (-0.65, -0.19)	
Disease Stage at Screening												
STAGE II	0	-	0		2	2.00 (1.41)	2					
STAGE III	19	1.47 (0.70)	19		18	2.00 (0.91)	14					
STAGE IV	228	1.63 (0.76)	194		230	1.62 (0.72)	194					
Region												0.197
North America and Europe	135	1.67 (0.82)	112	0.00 (0.05)	124	1.75 (0.78)	98	0.09 (0.05)	-0.09 (-0.23, 0.05)	0.228	-0.17 (-0.44, 0.10)	
Rest of the World	112	1.56 (0.67)	101	-0.11 (0.05)	126	1.56 (0.70)	112	0.11 (0.05)	-0.21 (-0.34, -0.08)	0.002	-0.43 (-0.71, -0.16)	
Prior anti-PD-(L)1 exposure												0.589
yes	175	1.65 (0.80)	150	-0.03 (0.04)	177	1.66 (0.75)	146	0.11 (0.04)	-0.14 (-0.25, -0.03)	0.016	-0.28 (-0.51, -0.05)	
no	72	1.54 (0.63)	63	-0.11 (0.06)	73	1.64 (0.73)	64	0.08 (0.06)	-0.20 (-0.37, -0.02)	0.029	-0.39 (-0.74, -0.04)	
Chemotherapy-free interval												0.204
< 90 days	108	1.65 (0.80)	89	-0.09 (0.06)	111	1.70 (0.78)	88	0.07 (0.06)	-0.16 (-0.33, 0.01)	0.067	-0.28 (-0.57, 0.02)	
>= 90 and < 180 days	82	1.66 (0.74)	71	-0.00 (0.05)	76	1.59 (0.73)	65	0.06 (0.06)	-0.06 (-0.22, 0.10)	0.438	-0.13 (-0.47, 0.20)	
>= 180 days	57	1.51 (0.68)	53	-0.07 (0.06)	63	1.63 (0.70)	57	0.21 (0.06)	-0.28 (-0.45, -0.10)	0.002	-0.59 (-0.97, -0.21)	
Presence (previous or current) of brain metastases												0.834
yes	111	1.52 (0.67)	94	-0.07 (0.05)	110	1.61 (0.72)	88	0.06 (0.05)	-0.14 (-0.28, 0.00)	0.058	-0.28 (-0.58, 0.01)	
no	136	1.70 (0.81)	119	-0.04 (0.05)	140	1.69 (0.77)	122	0.12 (0.05)	-0.16 (-0.29, -0.02)	0.020	-0.30 (-0.56, -0.05)	
Standard of care												0.097
Amrubicin/Topotecan	204	1.58 (0.74)	181	-0.01 (0.04)	203	1.66 (0.76)	170	0.10 (0.04)	-0.11 (-0.22, -0.01)	0.035	-0.23 (-0.44, -0.02)	
Lurbinectedin	43	1.79 (0.80)	32	-0.21 (0.08)	47	1.64 (0.70)	40	0.12 (0.09)	-0.33 (-0.57, -0.09)	0.008	-0.64 (-1.12, -0.16)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Anhang 4-G5.4.4: Endpunkt „BPI-SF“ – RCT

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain at its Worst in Last 24 Hours - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.132
< 65 years	48/ 129 (37.2)	30.9 (22.5, NE)	47/ 115 (40.9)	24.3 (16.5, 30.0)	0.72 (0.48, 1.08)	0.110	
>= 65 years	47/ 125 (37.6)	25.1 (14.5, NE)	42/ 140 (30.0)	30.3 (18.5, NE)	1.16 (0.76, 1.76)	0.493	
Gender							0.957
female	29/ 72 (40.3)	29.9 (14.5, NE)	31/ 86 (36.0)	18.5 (16.5, NE)	0.91 (0.55, 1.52)	0.713	
male	66/ 182 (36.3)	30.0 (22.9, NE)	58/ 169 (34.3)	25.3 (18.5, NE)	0.92 (0.65, 1.31)	0.651	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	9/ 21 (42.9)		7/ 18 (38.9)				
STAGE IV	86/ 233 (36.9)		82/ 235 (34.9)				
Region							0.450
North America and Europe	53/ 140 (37.9)	24.1 (18.1, 43.6)	41/ 128 (32.0)	24.6 (17.2, NE)	1.00 (0.67, 1.51)	0.997	
Rest of the World	42/ 114 (36.8)	34.2 (22.5, NE)	48/ 127 (37.8)	24.5 (18.2, NE)	0.81 (0.54, 1.24)	0.339	
Prior anti-PD-(L)1 exposure							0.491
yes	66/ 180 (36.7)	30.9 (19.2, NE)	62/ 180 (34.4)	24.5 (18.1, 31.7)	0.84 (0.59, 1.20)	0.341	
no	29/ 74 (39.2)	22.9 (14.1, NE)	27/ 75 (36.0)	25.3 (12.4, NE)	1.09 (0.64, 1.84)	0.751	
Chemotherapy-free interval							0.634
< 90 days	40/ 109 (36.7)	29.9 (18.2, NE)	31/ 114 (27.2)	30.0 (18.5, NE)	1.06 (0.66, 1.69)	0.812	
>= 90 and < 180 days	29/ 85 (34.1)	30.3 (16.4, NE)	32/ 78 (41.0)	18.5 (12.5, 30.3)	0.77 (0.47, 1.28)	0.308	
>= 180 days	26/ 60 (43.3)	25.2 (18.1, NE)	26/ 63 (41.3)	24.6 (16.5, NE)	0.93 (0.54, 1.60)	0.779	
Presence (previous or current) of brain metastases							0.014
yes	36/ 113 (31.9)	43.6 (24.1, NE)	41/ 115 (35.7)	24.2 (13.0, 30.3)	0.59 (0.37, 0.93)	0.021	
no	59/ 141 (41.8)	23.9 (16.4, 30.9)	48/ 140 (34.3)	25.9 (18.5, NE)	1.25 (0.85, 1.83)	0.247	
Standard of care							0.192
Amrubicin/Topotecan	83/ 209 (39.7)	25.2 (18.7, 36.4)	69/ 208 (33.2)	24.6 (18.5, NE)	0.98 (0.71, 1.36)	0.917	
Lurbinectedin	12/ 45 (26.7)	NE (18.2, NE)	20/ 47 (42.6)	24.3 (12.5, NE)	0.62 (0.30, 1.27)	0.185	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain at its Least in Last 24 Hours - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.090
< 65 years	40/ 129 (31.0)	NE (30.0, NE)	40/ 115 (34.8)	25.3 (17.2, 36.0)	0.67 (0.43, 1.04)	0.072	
>= 65 years	40/ 125 (32.0)	43.6 (24.5, NE)	35/ 140 (25.0)	NE (24.2, NE)	1.10 (0.70, 1.74)	0.673	
Gender							0.228
female	25/ 72 (34.7)	48.4 (17.9, NE)	33/ 86 (38.4)	18.5 (15.4, 31.2)	0.67 (0.40, 1.14)	0.141	
male	55/ 182 (30.2)	51.3 (30.5, NE)	42/ 169 (24.9)	37.0 (25.3, NE)	1.00 (0.67, 1.50)	0.993	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	9/ 21 (42.9)		7/ 18 (38.9)				
STAGE IV	71/ 233 (30.5)		68/ 235 (28.9)				
Region							0.575
North America and Europe	49/ 140 (35.0)	32.9 (18.1, 51.3)	41/ 128 (32.0)	24.6 (18.4, 37.0)	0.89 (0.59, 1.36)	0.579	
Rest of the World	31/ 114 (27.2)	NE (36.7, NE)	34/ 127 (26.8)	NE (24.2, NE)	0.78 (0.47, 1.27)	0.318	
Prior anti-PD-(L)1 exposure							0.607
yes	59/ 180 (32.8)	48.4 (30.5, NE)	49/ 180 (27.2)	31.7 (24.1, NE)	0.90 (0.61, 1.32)	0.589	
no	21/ 74 (28.4)	NE (22.9, NE)	26/ 75 (34.7)	36.0 (18.4, NE)	0.78 (0.44, 1.38)	0.382	
Chemotherapy-free interval							0.497
< 90 days	33/ 109 (30.3)	NE (24.1, NE)	27/ 114 (23.7)	36.0 (18.5, NE)	1.03 (0.61, 1.72)	0.924	
>= 90 and < 180 days	24/ 85 (28.2)	51.3 (28.6, NE)	27/ 78 (34.6)	24.5 (18.5, NE)	0.61 (0.34, 1.07)	0.085	
>= 180 days	23/ 60 (38.3)	36.4 (22.5, NE)	21/ 63 (33.3)	31.2 (18.1, NE)	0.94 (0.52, 1.71)	0.854	
Presence (previous or current) of brain metastases							0.328
yes	33/ 113 (29.2)	NE (32.9, NE)	30/ 115 (26.1)	31.7 (18.5, NE)	0.71 (0.43, 1.18)	0.185	
no	47/ 141 (33.3)	36.4 (24.5, NE)	45/ 140 (32.1)	31.2 (18.5, NE)	0.98 (0.65, 1.48)	0.921	
Standard of care							0.649
Amrubicin/Topotecan	69/ 209 (33.0)	43.6 (29.6, NE)	62/ 208 (29.8)	25.3 (18.5, NE)	0.87 (0.61, 1.23)	0.420	
Lurbinectedin	11/ 45 (24.4)	NE (24.5, NE)	13/ 47 (27.7)	NE (18.4, NE)	0.71 (0.31, 1.64)	0.422	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain on the Average - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.128
< 65 years	42/ 129 (32.6)	40.1 (24.2, NE)	41/ 115 (35.7)	24.6 (18.1, NE)	0.65 (0.42, 1.00)	0.051	
>= 65 years	39/ 125 (31.2)	43.6 (23.9, NE)	36/ 140 (25.7)	NE (24.2, NE)	1.11 (0.71, 1.75)	0.647	
Gender							0.909
female	24/ 72 (33.3)	40.1 (18.1, NE)	26/ 86 (30.2)	NE (18.1, NE)	0.91 (0.52, 1.59)	0.735	
male	57/ 182 (31.3)	43.6 (26.6, NE)	51/ 169 (30.2)	31.7 (23.3, NE)	0.85 (0.58, 1.24)	0.397	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	7/ 21 (33.3)		7/ 18 (38.9)				
STAGE IV	74/ 233 (31.8)		70/ 235 (29.8)				
Region							0.786
North America and Europe	45/ 140 (32.1)	36.4 (24.1, 51.3)	40/ 128 (31.3)	24.6 (18.1, NE)	0.79 (0.51, 1.21)	0.279	
Rest of the World	36/ 114 (31.6)	NE (30.9, NE)	37/ 127 (29.1)	NE (30.0, NE)	0.93 (0.59, 1.48)	0.777	
Prior anti-PD-(L)1 exposure							0.731
yes	59/ 180 (32.8)	42.1 (30.9, NE)	50/ 180 (27.8)	NE (19.1, NE)	0.89 (0.61, 1.30)	0.562	
no	22/ 74 (29.7)	NE (19.8, NE)	27/ 75 (36.0)	25.3 (17.2, NE)	0.83 (0.47, 1.45)	0.500	
Chemotherapy-free interval							0.283
< 90 days	32/ 109 (29.4)	42.1 (24.2, NE)	31/ 114 (27.2)	31.7 (18.2, NE)	0.83 (0.50, 1.37)	0.466	
>= 90 and < 180 days	24/ 85 (28.2)	51.3 (24.2, NE)	27/ 78 (34.6)	25.3 (18.1, NE)	0.66 (0.38, 1.16)	0.148	
>= 180 days	25/ 60 (41.7)	30.9 (18.4, NE)	19/ 63 (30.2)	NE (18.4, NE)	1.24 (0.68, 2.25)	0.483	
Presence (previous or current) of brain metastases							0.056
yes	35/ 113 (31.0)	51.3 (26.6, NE)	37/ 115 (32.2)	24.6 (16.5, NE)	0.59 (0.36, 0.95)	0.027	
no	46/ 141 (32.6)	42.1 (24.1, NE)	40/ 140 (28.6)	NE (23.3, NE)	1.13 (0.74, 1.72)	0.567	
Standard of care							0.669
Amrubicin/Topotecan	70/ 209 (33.5)	40.1 (24.2, NE)	66/ 208 (31.7)	25.3 (18.5, NE)	0.82 (0.58, 1.15)	0.249	
Lurbinectedin	11/ 45 (24.4)	NE (22.5, NE)	11/ 47 (23.4)	NE (30.3, NE)	1.02 (0.43, 2.40)	0.966	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Right Now - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.105
< 65 years	43/ 129 (33.3)	42.1 (24.1, NE)	41/ 115 (35.7)	25.3 (18.2, 31.7)	0.66 (0.43, 1.02)	0.060	
>= 65 years	42/ 125 (33.6)	42.6 (18.4, NE)	37/ 140 (26.4)	NE (22.2, NE)	1.14 (0.73, 1.78)	0.552	
Gender							0.310
female	24/ 72 (33.3)	36.4 (18.5, NE)	30/ 86 (34.9)	18.5 (18.1, NE)	0.71 (0.41, 1.21)	0.211	
male	61/ 182 (33.5)	43.6 (24.1, NE)	48/ 169 (28.4)	30.3 (24.3, NE)	0.98 (0.67, 1.44)	0.933	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	9/ 21 (42.9)		9/ 18 (50.0)				
STAGE IV	76/ 233 (32.6)		69/ 235 (29.4)				
Region							0.271
North America and Europe	50/ 140 (35.7)	30.0 (19.2, NE)	37/ 128 (28.9)	25.3 (21.2, NE)	0.99 (0.64, 1.52)	0.954	
Rest of the World	35/ 114 (30.7)	NE (30.2, NE)	41/ 127 (32.3)	30.0 (18.5, NE)	0.75 (0.48, 1.19)	0.228	
Prior anti-PD-(L)1 exposure							0.435
yes	59/ 180 (32.8)	43.6 (30.0, NE)	54/ 180 (30.0)	24.6 (18.5, NE)	0.80 (0.55, 1.16)	0.247	
no	26/ 74 (35.1)	24.5 (19.8, NE)	24/ 75 (32.0)	30.0 (18.5, NE)	1.07 (0.62, 1.87)	0.802	
Chemotherapy-free interval							0.776
< 90 days	33/ 109 (30.3)	42.6 (19.8, NE)	28/ 114 (24.6)	31.7 (18.5, NE)	0.97 (0.58, 1.62)	0.914	
>= 90 and < 180 days	25/ 85 (29.4)	NE (24.1, NE)	25/ 78 (32.1)	25.3 (18.5, NE)	0.74 (0.43, 1.30)	0.303	
>= 180 days	27/ 60 (45.0)	30.0 (18.1, NE)	25/ 63 (39.7)	24.6 (16.5, NE)	0.92 (0.53, 1.60)	0.784	
Presence (previous or current) of brain metastases							0.288
yes	34/ 113 (30.1)	NE (30.0, NE)	32/ 115 (27.8)	30.0 (21.2, NE)	0.68 (0.41, 1.11)	0.119	
no	51/ 141 (36.2)	36.4 (18.5, NE)	46/ 140 (32.9)	30.0 (18.5, NE)	1.03 (0.69, 1.54)	0.867	
Standard of care							0.990
Amrubicin/Topotecan	74/ 209 (35.4)	42.1 (24.5, NE)	65/ 208 (31.3)	24.6 (18.5, NE)	0.85 (0.61, 1.19)	0.345	
Lurbinectedin	11/ 45 (24.4)	NE (18.4, NE)	13/ 47 (27.7)	31.7 (24.3, NE)	0.94 (0.42, 2.11)	0.879	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Interfered General Activity - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.019
< 65 years	44/ 129 (34.1)	36.4 (24.5, NE)	48/ 115 (41.7)	18.5 (13.5, 24.6)	0.57 (0.37, 0.86)	0.007	
>= 65 years	49/ 125 (39.2)	30.3 (14.1, 51.3)	42/ 140 (30.0)	30.3 (18.5, NE)	1.17 (0.77, 1.77)	0.445	
Gender							0.420
female	27/ 72 (37.5)	36.3 (18.5, NE)	33/ 86 (38.4)	18.5 (14.4, 24.2)	0.68 (0.40, 1.14)	0.141	
male	66/ 182 (36.3)	35.7 (24.1, NE)	57/ 169 (33.7)	24.6 (18.7, 37.0)	0.89 (0.63, 1.28)	0.544	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	10/ 21 (47.6)		9/ 18 (50.0)				
STAGE IV	83/ 233 (35.6)		81/ 235 (34.5)				
Region							0.567
North America and Europe	56/ 140 (40.0)	24.5 (18.2, 37.4)	46/ 128 (35.9)	19.1 (18.1, 24.6)	0.83 (0.56, 1.24)	0.361	
Rest of the World	37/ 114 (32.5)	NE (34.2, NE)	44/ 127 (34.6)	30.0 (18.2, NE)	0.76 (0.49, 1.19)	0.230	
Prior anti-PD-(L)1 exposure							0.357
yes	66/ 180 (36.7)	36.3 (25.2, NE)	64/ 180 (35.6)	19.1 (18.2, 31.7)	0.73 (0.52, 1.04)	0.080	
no	27/ 74 (36.5)	24.5 (14.1, NE)	26/ 75 (34.7)	24.2 (18.1, NE)	1.05 (0.61, 1.80)	0.872	
Chemotherapy-free interval							0.301
< 90 days	32/ 109 (29.4)	NE (24.8, NE)	32/ 114 (28.1)	31.7 (14.7, NE)	0.82 (0.50, 1.34)	0.426	
>= 90 and < 180 days	32/ 85 (37.6)	36.3 (22.9, NE)	34/ 78 (43.6)	18.5 (13.0, 25.3)	0.65 (0.40, 1.07)	0.090	
>= 180 days	29/ 60 (48.3)	25.2 (14.5, 43.6)	24/ 63 (38.1)	24.6 (18.1, NE)	1.13 (0.66, 1.95)	0.651	
Presence (previous or current) of brain metastases							0.013
yes	37/ 113 (32.7)	43.6 (26.1, NE)	44/ 115 (38.3)	18.2 (13.0, 25.3)	0.51 (0.32, 0.80)	0.003	
no	56/ 141 (39.7)	26.3 (23.9, NE)	46/ 140 (32.9)	24.5 (18.5, NE)	1.15 (0.77, 1.70)	0.487	
Standard of care							0.274
Amrubicin/Topotecan	83/ 209 (39.7)	26.6 (23.9, 43.6)	74/ 208 (35.6)	19.1 (18.2, 25.3)	0.86 (0.62, 1.18)	0.341	
Lurbinectedin	10/ 45 (22.2)	NE (36.3, NE)	16/ 47 (34.0)	31.7 (16.5, NE)	0.52 (0.23, 1.19)	0.116	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Interfered with Mood - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.072
< 65 years	43/ 129 (33.3)	NE (24.8, NE)	48/ 115 (41.7)	19.1 (18.1, 24.6)	0.58 (0.38, 0.88)	0.010	
>= 65 years	42/ 125 (33.6)	43.6 (14.1, NE)	41/ 140 (29.3)	37.0 (18.5, NE)	1.06 (0.69, 1.63)	0.790	
Gender							0.516
female	24/ 72 (33.3)	NE (17.9, NE)	33/ 86 (38.4)	18.5 (16.5, NE)	0.70 (0.41, 1.19)	0.179	
male	61/ 182 (33.5)	43.6 (24.8, NE)	56/ 169 (33.1)	25.3 (18.7, NE)	0.83 (0.58, 1.20)	0.339	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	8/ 21 (38.1)		7/ 18 (38.9)				
STAGE IV	77/ 233 (33.0)		82/ 235 (34.9)				
Region							0.745
North America and Europe	48/ 140 (34.3)	26.6 (18.5, NE)	47/ 128 (36.7)	21.2 (17.5, 25.3)	0.72 (0.48, 1.08)	0.105	
Rest of the World	37/ 114 (32.5)	NE (28.6, NE)	42/ 127 (33.1)	31.7 (18.5, NE)	0.83 (0.53, 1.30)	0.427	
Prior anti-PD-(L)1 exposure							0.719
yes	59/ 180 (32.8)	NE (26.6, NE)	59/ 180 (32.8)	24.3 (18.5, NE)	0.75 (0.52, 1.08)	0.126	
no	26/ 74 (35.1)	24.5 (14.1, NE)	30/ 75 (40.0)	19.5 (17.5, 37.0)	0.87 (0.51, 1.47)	0.594	
Chemotherapy-free interval							0.139
< 90 days	31/ 109 (28.4)	NE (24.8, NE)	34/ 114 (29.8)	19.1 (14.7, NE)	0.71 (0.43, 1.16)	0.173	
>= 90 and < 180 days	27/ 85 (31.8)	NE (24.5, NE)	34/ 78 (43.6)	23.5 (18.1, 25.3)	0.58 (0.34, 0.96)	0.033	
>= 180 days	27/ 60 (45.0)	25.2 (14.5, NE)	21/ 63 (33.3)	NE (18.1, NE)	1.26 (0.71, 2.23)	0.421	
Presence (previous or current) of brain metastases							0.057
yes	36/ 113 (31.9)	NE (24.2, NE)	44/ 115 (38.3)	19.5 (13.5, 25.3)	0.55 (0.35, 0.86)	0.008	
no	49/ 141 (34.8)	30.9 (23.9, NE)	45/ 140 (32.1)	37.0 (18.5, NE)	1.02 (0.68, 1.53)	0.919	
Standard of care							0.305
Amrubicin/Topotecan	75/ 209 (35.9)	34.2 (24.8, NE)	71/ 208 (34.1)	23.5 (18.5, 37.0)	0.83 (0.60, 1.15)	0.254	
Lurbinectedin	10/ 45 (22.2)	NE (22.9, NE)	18/ 47 (38.3)	30.3 (16.5, NE)	0.55 (0.25, 1.21)	0.129	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Interfered Walking Ability - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.364
< 65 years	38/ 129 (29.5)	NE (30.0, NE)	40/ 115 (34.8)	24.3 (18.2, 31.7)	0.60 (0.38, 0.95)	0.026	
>= 65 years	40/ 125 (32.0)	43.6 (23.9, NE)	46/ 140 (32.9)	24.2 (18.1, NE)	0.84 (0.55, 1.29)	0.440	
Gender							0.936
female	25/ 72 (34.7)	31.3 (18.4, NE)	32/ 86 (37.2)	18.5 (17.5, NE)	0.71 (0.42, 1.21)	0.201	
male	53/ 182 (29.1)	NE (34.2, NE)	54/ 169 (32.0)	25.2 (23.3, NE)	0.74 (0.50, 1.08)	0.117	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	8/ 21 (38.1)		9/ 18 (50.0)				
STAGE IV	70/ 233 (30.0)		77/ 235 (32.8)				
Region							0.605
North America and Europe	45/ 140 (32.1)	42.4 (18.7, NE)	42/ 128 (32.8)	23.5 (18.4, 31.2)	0.76 (0.50, 1.16)	0.199	
Rest of the World	33/ 114 (28.9)	NE (30.2, NE)	44/ 127 (34.6)	24.3 (18.1, NE)	0.66 (0.42, 1.04)	0.076	
Prior anti-PD-(L)1 exposure							0.808
yes	58/ 180 (32.2)	43.6 (30.2, NE)	62/ 180 (34.4)	24.3 (18.2, 31.7)	0.68 (0.47, 0.98)	0.037	
no	20/ 74 (27.0)	NE (18.7, NE)	24/ 75 (32.0)	24.2 (18.4, NE)	0.79 (0.44, 1.44)	0.440	
Chemotherapy-free interval							0.458
< 90 days	31/ 109 (28.4)	NE (24.8, NE)	31/ 114 (27.2)	31.7 (18.5, NE)	0.80 (0.49, 1.33)	0.398	
>= 90 and < 180 days	26/ 85 (30.6)	NE (23.9, NE)	33/ 78 (42.3)	23.3 (13.0, 30.3)	0.54 (0.32, 0.90)	0.018	
>= 180 days	21/ 60 (35.0)	43.6 (18.7, NE)	22/ 63 (34.9)	24.6 (18.1, NE)	0.91 (0.50, 1.66)	0.756	
Presence (previous or current) of brain metastases							0.095
yes	33/ 113 (29.2)	NE (31.3, NE)	41/ 115 (35.7)	20.4 (14.7, 30.3)	0.49 (0.30, 0.79)	0.003	
no	45/ 141 (31.9)	NE (24.5, NE)	45/ 140 (32.1)	31.2 (18.5, NE)	0.93 (0.61, 1.41)	0.741	
Standard of care							0.631
Amrubicin/Topotecan	68/ 209 (32.5)	43.6 (30.2, NE)	70/ 208 (33.7)	24.1 (18.5, NE)	0.74 (0.53, 1.03)	0.075	
Lurbinectedin	10/ 45 (22.2)	NE (18.4, NE)	16/ 47 (34.0)	30.3 (18.1, NE)	0.60 (0.27, 1.34)	0.214	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Interfered with Normal Work - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.162
< 65 years	45/ 129 (34.9)	35.7 (24.5, NE)	46/ 115 (40.0)	20.4 (16.5, 25.3)	0.59 (0.39, 0.90)	0.014	
>= 65 years	44/ 125 (35.2)	43.6 (14.1, NE)	44/ 140 (31.4)	24.3 (18.4, NE)	1.00 (0.66, 1.52)	0.998	
Gender							0.936
female	29/ 72 (40.3)	24.5 (14.5, NE)	34/ 86 (39.5)	18.4 (16.9, 24.2)	0.80 (0.48, 1.31)	0.372	
male	60/ 182 (33.0)	43.6 (25.2, NE)	56/ 169 (33.1)	25.2 (19.1, NE)	0.78 (0.54, 1.12)	0.180	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	9/ 21 (42.9)		7/ 18 (38.9)				
STAGE IV	80/ 233 (34.3)		83/ 235 (35.3)				
Region							0.661
North America and Europe	53/ 140 (37.9)	24.5 (14.5, 43.6)	47/ 128 (36.7)	19.1 (18.1, 25.2)	0.79 (0.53, 1.17)	0.232	
Rest of the World	36/ 114 (31.6)	NE (30.9, NE)	43/ 127 (33.9)	29.9 (18.1, NE)	0.73 (0.46, 1.14)	0.169	
Prior anti-PD-(L)1 exposure							0.574
yes	63/ 180 (35.0)	42.6 (25.2, NE)	64/ 180 (35.6)	24.1 (18.2, 31.2)	0.72 (0.50, 1.02)	0.066	
no	26/ 74 (35.1)	25.2 (17.9, NE)	26/ 75 (34.7)	23.5 (17.5, NE)	0.91 (0.53, 1.58)	0.745	
Chemotherapy-free interval							0.226
< 90 days	34/ 109 (31.2)	42.6 (20.1, NE)	35/ 114 (30.7)	20.4 (16.9, NE)	0.76 (0.47, 1.22)	0.251	
>= 90 and < 180 days	27/ 85 (31.8)	NE (22.9, NE)	32/ 78 (41.0)	23.5 (13.5, 30.3)	0.59 (0.35, 1.00)	0.047	
>= 180 days	28/ 60 (46.7)	25.2 (14.1, NE)	23/ 63 (36.5)	24.3 (17.5, NE)	1.12 (0.65, 1.96)	0.680	
Presence (previous or current) of brain metastases							0.004
yes	35/ 113 (31.0)	NE (24.3, NE)	46/ 115 (40.0)	18.2 (12.5, 24.6)	0.46 (0.29, 0.72)	<.001	
no	54/ 141 (38.3)	30.3 (18.4, NE)	44/ 140 (31.4)	29.9 (18.5, NE)	1.15 (0.77, 1.71)	0.498	
Standard of care							0.144
Amrubicin/Topotecan	79/ 209 (37.8)	31.3 (23.9, NE)	71/ 208 (34.1)	24.1 (18.5, 31.2)	0.84 (0.61, 1.17)	0.301	
Lurbinectedin	10/ 45 (22.2)	NE (22.9, NE)	19/ 47 (40.4)	24.3 (16.5, NE)	0.47 (0.22, 1.03)	0.052	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Interfered with Relations - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.311
< 65 years	40/ 129 (31.0)	NE (26.1, NE)	42/ 115 (36.5)	24.1 (18.2, 31.7)	0.60 (0.38, 0.93)	0.020	
>= 65 years	40/ 125 (32.0)	NE (24.1, NE)	42/ 140 (30.0)	48.8 (18.5, NE)	0.89 (0.57, 1.37)	0.594	
Gender							0.447
female	24/ 72 (33.3)	NE (18.7, NE)	33/ 86 (38.4)	18.4 (13.5, NE)	0.63 (0.37, 1.08)	0.088	
male	56/ 182 (30.8)	NE (26.6, NE)	51/ 169 (30.2)	30.0 (23.5, NE)	0.80 (0.55, 1.18)	0.265	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	8/ 21 (38.1)		6/ 18 (33.3)				
STAGE IV	72/ 233 (30.9)		78/ 235 (33.2)				
Region							0.427
North America and Europe	48/ 140 (34.3)	26.6 (19.9, NE)	42/ 128 (32.8)	24.5 (18.2, NE)	0.81 (0.53, 1.22)	0.310	
Rest of the World	32/ 114 (28.1)	NE (35.7, NE)	42/ 127 (33.1)	31.7 (18.4, NE)	0.64 (0.40, 1.02)	0.062	
Prior anti-PD-(L)1 exposure							0.365
yes	56/ 180 (31.1)	NE (30.2, NE)	60/ 180 (33.3)	24.3 (18.2, 48.8)	0.66 (0.45, 0.95)	0.024	
no	24/ 74 (32.4)	NE (18.5, NE)	24/ 75 (32.0)	30.0 (18.7, NE)	0.93 (0.53, 1.65)	0.814	
Chemotherapy-free interval							0.616
< 90 days	29/ 109 (26.6)	NE (34.2, NE)	32/ 114 (28.1)	30.0 (18.2, NE)	0.65 (0.39, 1.09)	0.101	
>= 90 and < 180 days	27/ 85 (31.8)	NE (18.7, NE)	29/ 78 (37.2)	23.5 (13.5, NE)	0.72 (0.42, 1.22)	0.215	
>= 180 days	24/ 60 (40.0)	36.4 (19.9, NE)	23/ 63 (36.5)	30.0 (16.5, NE)	0.92 (0.52, 1.64)	0.798	
Presence (previous or current) of brain metastases							0.020
yes	32/ 113 (28.3)	NE (26.6, NE)	41/ 115 (35.7)	24.6 (16.5, 30.3)	0.48 (0.30, 0.76)	0.002	
no	48/ 141 (34.0)	42.6 (23.9, NE)	43/ 140 (30.7)	48.8 (18.5, NE)	1.04 (0.68, 1.57)	0.868	
Standard of care							0.109
Amrubicin/Topotecan	71/ 209 (34.0)	42.6 (24.5, NE)	65/ 208 (31.3)	25.3 (18.7, NE)	0.82 (0.58, 1.15)	0.246	
Lurbinectedin	9/ 45 (20.0)	NE (36.4, NE)	19/ 47 (40.4)	24.5 (16.5, NE)	0.39 (0.17, 0.88)	0.019	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Interfered with Sleep - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.836
< 65 years	37/ 129 (28.7)	NE (30.0, NE)	40/ 115 (34.8)	30.0 (18.1, NE)	0.60 (0.38, 0.94)	0.026	
>= 65 years	33/ 125 (26.4)	NE (43.6, NE)	46/ 140 (32.9)	24.5 (18.5, 48.8)	0.64 (0.41, 1.01)	0.051	
Gender							0.141
female	19/ 72 (26.4)	NE (24.5, NE)	36/ 86 (41.9)	18.4 (16.5, 24.2)	0.43 (0.24, 0.75)	0.003	
male	51/ 182 (28.0)	NE (42.4, NE)	50/ 169 (29.6)	31.7 (24.3, NE)	0.74 (0.50, 1.10)	0.142	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	8/ 21 (38.1)		8/ 18 (44.4)				
STAGE IV	62/ 233 (26.6)		78/ 235 (33.2)				
Region							0.878
North America and Europe	39/ 140 (27.9)	43.6 (26.6, NE)	43/ 128 (33.6)	24.2 (18.1, 43.0)	0.62 (0.40, 0.96)	0.030	
Rest of the World	31/ 114 (27.2)	NE (30.3, NE)	43/ 127 (33.9)	31.7 (18.4, NE)	0.59 (0.37, 0.95)	0.029	
Prior anti-PD-(L)1 exposure							0.633
yes	48/ 180 (26.7)	NE (43.6, NE)	58/ 180 (32.2)	30.3 (18.2, NE)	0.59 (0.40, 0.88)	0.008	
no	22/ 74 (29.7)	NE (22.5, NE)	28/ 75 (37.3)	24.2 (18.7, 43.0)	0.69 (0.40, 1.22)	0.202	
Chemotherapy-free interval							0.150
< 90 days	26/ 109 (23.9)	NE (30.3, NE)	36/ 114 (31.6)	31.7 (12.5, 48.8)	0.51 (0.31, 0.86)	0.010	
>= 90 and < 180 days	23/ 85 (27.1)	NE (26.6, NE)	31/ 78 (39.7)	23.5 (13.5, 43.0)	0.52 (0.30, 0.90)	0.016	
>= 180 days	21/ 60 (35.0)	43.6 (24.2, NE)	19/ 63 (30.2)	NE (24.2, NE)	1.04 (0.56, 1.95)	0.897	
Presence (previous or current) of brain metastases							0.054
yes	30/ 113 (26.5)	NE (42.4, NE)	42/ 115 (36.5)	18.7 (13.0, 30.3)	0.42 (0.26, 0.68)	<.001	
no	40/ 141 (28.4)	NE (30.0, NE)	44/ 140 (31.4)	36.4 (23.5, NE)	0.82 (0.53, 1.27)	0.378	
Standard of care							0.219
Amrubicin/Topotecan	61/ 209 (29.2)	NE (30.3, NE)	67/ 208 (32.2)	30.0 (18.5, 48.8)	0.67 (0.47, 0.95)	0.026	
Lurbinectedin	9/ 45 (20.0)	NE (22.9, NE)	19/ 47 (40.4)	24.3 (16.5, NE)	0.43 (0.19, 0.96)	0.035	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Interfered Enjoyment of Life - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.192
< 65 years	38/ 129 (29.5)	NE (30.0, NE)	45/ 115 (39.1)	23.5 (16.5, 31.2)	0.51 (0.33, 0.79)	0.002	
>= 65 years	38/ 125 (30.4)	NE (24.3, NE)	43/ 140 (30.7)	24.5 (18.5, NE)	0.79 (0.51, 1.23)	0.302	
Gender							0.500
female	24/ 72 (33.3)	37.4 (20.8, NE)	35/ 86 (40.7)	18.5 (16.5, 24.5)	0.54 (0.32, 0.92)	0.021	
male	52/ 182 (28.6)	NE (30.9, NE)	53/ 169 (31.4)	30.0 (23.5, NE)	0.69 (0.47, 1.02)	0.065	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	10/ 21 (47.6)		9/ 18 (50.0)				
STAGE IV	66/ 233 (28.3)		79/ 235 (33.6)				
Region							0.604
North America and Europe	47/ 140 (33.6)	30.9 (24.1, NE)	47/ 128 (36.7)	23.5 (18.1, 25.3)	0.66 (0.44, 0.99)	0.041	
Rest of the World	29/ 114 (25.4)	NE (NE , NE)	41/ 127 (32.3)	31.7 (18.5, NE)	0.58 (0.36, 0.94)	0.026	
Prior anti-PD-(L)1 exposure							0.418
yes	54/ 180 (30.0)	NE (30.5, NE)	63/ 180 (35.0)	24.3 (18.2, 31.7)	0.57 (0.40, 0.83)	0.003	
no	22/ 74 (29.7)	NE (22.5, NE)	25/ 75 (33.3)	25.3 (18.7, NE)	0.81 (0.45, 1.43)	0.461	
Chemotherapy-free interval							0.943
< 90 days	30/ 109 (27.5)	NE (25.6, NE)	33/ 114 (28.9)	31.7 (18.2, NE)	0.66 (0.40, 1.08)	0.100	
>= 90 and < 180 days	27/ 85 (31.8)	NE (22.9, NE)	32/ 78 (41.0)	23.5 (18.2, 30.3)	0.61 (0.36, 1.03)	0.059	
>= 180 days	19/ 60 (31.7)	NE (30.2, NE)	23/ 63 (36.5)	30.0 (18.1, NE)	0.66 (0.36, 1.21)	0.176	
Presence (previous or current) of brain metastases							0.061
yes	31/ 113 (27.4)	NE (30.9, NE)	41/ 115 (35.7)	24.2 (13.5, 30.3)	0.42 (0.26, 0.68)	<.001	
no	45/ 141 (31.9)	NE (24.8, NE)	47/ 140 (33.6)	25.9 (18.5, NE)	0.84 (0.56, 1.27)	0.407	
Standard of care							0.328
Amrubicin/Topotecan	66/ 209 (31.6)	43.6 (30.2, NE)	69/ 208 (33.2)	24.5 (18.5, 48.8)	0.68 (0.48, 0.95)	0.025	
Lurbinectedin	10/ 45 (22.2)	NE (22.9, NE)	19/ 47 (40.4)	24.3 (16.5, NE)	0.47 (0.21, 1.01)	0.047	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Interference - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.194
< 65 years	42/ 129 (32.6)	42.4 (24.8, NE)	43/ 115 (37.4)	23.5 (18.1, 31.7)	0.60 (0.39, 0.93)	0.022	
>= 65 years	41/ 125 (32.8)	43.6 (23.9, NE)	41/ 140 (29.3)	30.3 (18.5, NE)	0.97 (0.62, 1.49)	0.887	
Gender							0.371
female	24/ 72 (33.3)	NE (18.5, NE)	33/ 86 (38.4)	18.4 (17.5, 31.2)	0.64 (0.37, 1.08)	0.094	
male	59/ 182 (32.4)	43.6 (25.2, NE)	51/ 169 (30.2)	30.3 (23.5, NE)	0.85 (0.58, 1.25)	0.422	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	9/ 21 (42.9)		9/ 18 (50.0)				
STAGE IV	74/ 233 (31.8)		75/ 235 (31.9)				
Region							0.880
North America and Europe	50/ 140 (35.7)	26.6 (18.7, NE)	45/ 128 (35.2)	21.2 (18.1, 30.3)	0.75 (0.50, 1.13)	0.166	
Rest of the World	33/ 114 (28.9)	NE (30.2, NE)	39/ 127 (30.7)	31.7 (18.5, NE)	0.75 (0.47, 1.21)	0.244	
Prior anti-PD-(L)1 exposure							0.450
yes	56/ 180 (31.1)	NE (30.2, NE)	57/ 180 (31.7)	30.3 (18.5, NE)	0.70 (0.48, 1.01)	0.059	
no	27/ 74 (36.5)	24.5 (17.9, NE)	27/ 75 (36.0)	23.5 (18.1, NE)	0.93 (0.54, 1.58)	0.781	
Chemotherapy-free interval							0.080
< 90 days	29/ 109 (26.6)	NE (25.6, NE)	34/ 114 (29.8)	31.7 (18.2, NE)	0.64 (0.39, 1.06)	0.082	
>= 90 and < 180 days	27/ 85 (31.8)	42.4 (23.9, NE)	31/ 78 (39.7)	23.5 (18.1, 31.2)	0.61 (0.36, 1.04)	0.066	
>= 180 days	27/ 60 (45.0)	28.2 (18.5, NE)	19/ 63 (30.2)	NE (18.1, NE)	1.30 (0.72, 2.35)	0.370	
Presence (previous or current) of brain metastases							0.007
yes	34/ 113 (30.1)	NE (26.6, NE)	44/ 115 (38.3)	18.7 (12.5, 25.3)	0.45 (0.28, 0.72)	<.001	
no	49/ 141 (34.8)	30.5 (24.1, NE)	40/ 140 (28.6)	NE (18.5, NE)	1.13 (0.75, 1.73)	0.542	
Standard of care							0.103
Amrubicin/Topotecan	73/ 209 (34.9)	34.2 (24.8, NE)	64/ 208 (30.8)	25.3 (18.5, NE)	0.86 (0.62, 1.21)	0.403	
Lurbinectedin	10/ 45 (22.2)	NE (22.9, NE)	20/ 47 (42.6)	24.3 (17.5, NE)	0.44 (0.20, 0.96)	0.033	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of BPI2-Pain Severity - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.199
< 65 years	43/ 129 (33.3)	36.4 (24.1, NE)	44/ 115 (38.3)	24.6 (17.2, 31.7)	0.63 (0.41, 0.97)	0.032	
>= 65 years	42/ 125 (33.6)	42.6 (18.4, NE)	42/ 140 (30.0)	30.3 (18.5, NE)	0.98 (0.64, 1.50)	0.920	
Gender							0.172
female	24/ 72 (33.3)	36.4 (18.1, NE)	35/ 86 (40.7)	18.5 (12.5, 31.2)	0.60 (0.36, 1.02)	0.058	
male	61/ 182 (33.5)	34.2 (24.2, NE)	51/ 169 (30.2)	30.3 (24.1, NE)	0.91 (0.63, 1.33)	0.628	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	9/ 21 (42.9)		8/ 18 (44.4)				
STAGE IV	76/ 233 (32.6)		78/ 235 (33.2)				
Region							0.592
North America and Europe	47/ 140 (33.6)	32.9 (22.9, NE)	46/ 128 (35.9)	23.3 (17.2, 31.2)	0.70 (0.47, 1.06)	0.088	
Rest of the World	38/ 114 (33.3)	NE (25.2, NE)	40/ 127 (31.5)	31.7 (18.5, NE)	0.88 (0.56, 1.37)	0.577	
Prior anti-PD-(L)1 exposure							0.703
yes	63/ 180 (35.0)	36.4 (25.1, NE)	58/ 180 (32.2)	24.6 (18.5, NE)	0.80 (0.56, 1.14)	0.221	
no	22/ 74 (29.7)	NE (22.5, NE)	28/ 75 (37.3)	24.2 (12.4, NE)	0.74 (0.42, 1.30)	0.296	
Chemotherapy-free interval							0.070
< 90 days	36/ 109 (33.0)	34.2 (24.1, NE)	30/ 114 (26.3)	31.7 (18.5, NE)	0.95 (0.58, 1.55)	0.848	
>= 90 and < 180 days	23/ 85 (27.1)	NE (24.1, NE)	34/ 78 (43.6)	19.1 (12.4, 30.3)	0.49 (0.29, 0.84)	0.008	
>= 180 days	26/ 60 (43.3)	30.5 (18.7, NE)	22/ 63 (34.9)	31.2 (18.1, NE)	1.07 (0.60, 1.89)	0.818	
Presence (previous or current) of brain metastases							0.051
yes	34/ 113 (30.1)	NE (25.1, NE)	39/ 115 (33.9)	24.2 (16.5, 31.7)	0.54 (0.33, 0.86)	0.009	
no	51/ 141 (36.2)	30.0 (18.5, NE)	47/ 140 (33.6)	31.2 (18.5, NE)	1.02 (0.68, 1.51)	0.921	
Standard of care							0.909
Amrubicin/Topotecan	72/ 209 (34.4)	34.2 (25.1, NE)	70/ 208 (33.7)	24.5 (18.5, 36.0)	0.76 (0.55, 1.06)	0.109	
Lurbinectedin	13/ 45 (28.9)	NE (12.8, NE)	16/ 47 (34.0)	30.3 (18.1, NE)	0.90 (0.43, 1.88)	0.772	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain at its Worst in Last 24 Hours - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.720
< 65 years	128	2.88 (3.01)	113	0.03 (0.18)	114	2.89 (2.98)	98	0.36 (0.21)	-0.33 (-0.87, 0.21)	0.233	-0.17 (-0.44, 0.11)	
>= 65 years	119	2.58 (2.80)	99	-0.07 (0.16)	136	2.10 (2.56)	111	0.13 (0.17)	-0.20 (-0.66, 0.27)	0.402	-0.12 (-0.39, 0.16)	
Gender												0.448
female	67	2.96 (3.03)	59	0.12 (0.23)	84	2.63 (2.78)	68	0.15 (0.25)	-0.03 (-0.71, 0.64)	0.925	-0.02 (-0.37, 0.33)	
male	180	2.65 (2.87)	153	-0.09 (0.14)	166	2.37 (2.79)	141	0.25 (0.16)	-0.33 (-0.75, 0.08)	0.113	-0.19 (-0.42, 0.04)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	1.42 (1.68)	19		18	2.39 (2.89)	14					
STAGE IV	228	2.84 (2.97)	193		230	2.48 (2.78)	193					
Region												0.592
North America and Europe	135	3.22 (3.07)	111	0.04 (0.17)	124	2.80 (2.81)	97	0.23 (0.20)	-0.19 (-0.71, 0.34)	0.482	-0.10 (-0.37, 0.17)	
Rest of the World	112	2.14 (2.60)	101	-0.14 (0.16)	126	2.12 (2.72)	112	0.24 (0.17)	-0.38 (-0.85, 0.09)	0.113	-0.22 (-0.49, 0.05)	
Prior anti-PD-(L)1 exposure												0.851
yes	175	2.87 (2.94)	149	-0.03 (0.14)	177	2.37 (2.76)	145	0.26 (0.16)	-0.30 (-0.71, 0.12)	0.164	-0.16 (-0.39, 0.07)	
no	72	2.39 (2.82)	63	-0.02 (0.23)	73	2.67 (2.85)	64	0.20 (0.25)	-0.22 (-0.89, 0.45)	0.513	-0.12 (-0.46, 0.23)	
Chemotherapy-free interval												0.802
< 90 days	108	3.12 (3.19)	89	0.02 (0.20)	111	2.47 (2.84)	88	0.04 (0.23)	-0.02 (-0.63, 0.59)	0.948	-0.01 (-0.30, 0.28)	
>= 90 and < 180 days	82	3.05 (2.81)	70	-0.20 (0.22)	76	2.37 (2.60)	64	0.08 (0.25)	-0.28 (-0.94, 0.38)	0.407	-0.14 (-0.48, 0.20)	
>= 180 days	57	1.54 (2.11)	53	0.23 (0.21)	63	2.54 (2.93)	57	0.50 (0.22)	-0.27 (-0.87, 0.33)	0.371	-0.17 (-0.55, 0.20)	
Presence (previous or current) of brain metastases												0.276
yes	111	2.74 (2.95)	93	-0.11 (0.18)	110	2.38 (2.74)	87	0.38 (0.21)	-0.49 (-1.03, 0.05)	0.074	-0.27 (-0.56, 0.02)	
no	136	2.73 (2.88)	119	0.03 (0.17)	140	2.51 (2.82)	122	0.12 (0.18)	-0.09 (-0.57, 0.38)	0.700	-0.05 (-0.30, 0.20)	
Standard of care												0.230
Amrubicin/Topotecan	204	2.73 (2.91)	180	-0.03 (0.13)	203	2.45 (2.78)	169	0.11 (0.14)	-0.14 (-0.52, 0.24)	0.471	-0.08 (-0.29, 0.13)	
Lurbinectedin	43	2.74 (2.95)	32	-0.11 (0.35)	47	2.47 (2.80)	40	0.67 (0.35)	-0.78 (-1.78, 0.22)	0.124	-0.36 (-0.83, 0.11)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain at its Least in Last 24 Hours - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.492
< 65 years	128	1.66 (2.33)	113	0.16 (0.15)	113	1.72 (2.24)	98	0.49 (0.18)	-0.33 (-0.79, 0.14)	0.170	-0.19 (-0.46, 0.08)	
>= 65 years	119	1.53 (2.07)	99	-0.07 (0.13)	136	1.43 (1.98)	111	0.05 (0.13)	-0.12 (-0.49, 0.25)	0.528	-0.09 (-0.36, 0.18)	
Gender												0.379
female	67	1.81 (2.36)	59	0.06 (0.20)	84	1.60 (2.11)	68	0.46 (0.21)	-0.40 (-0.98, 0.18)	0.178	-0.24 (-0.59, 0.11)	
male	180	1.52 (2.15)	153	0.06 (0.12)	165	1.54 (2.11)	141	0.15 (0.13)	-0.10 (-0.44, 0.24)	0.572	-0.07 (-0.29, 0.16)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	1.21 (1.65)	19		18	1.72 (1.96)	14					
STAGE IV	228	1.63 (2.25)	193		229	1.56 (2.12)	193					
Region												0.619
North America and Europe	135	1.96 (2.38)	111	0.07 (0.15)	123	1.82 (2.19)	97	0.37 (0.17)	-0.30 (-0.75, 0.14)	0.180	-0.19 (-0.46, 0.09)	
Rest of the World	112	1.16 (1.89)	101	0.05 (0.14)	126	1.30 (1.99)	112	0.20 (0.15)	-0.15 (-0.56, 0.25)	0.457	-0.10 (-0.37, 0.17)	
Prior anti-PD-(L)1 exposure												0.957
yes	175	1.61 (2.13)	149	0.08 (0.11)	176	1.46 (2.08)	145	0.26 (0.13)	-0.18 (-0.51, 0.16)	0.302	-0.12 (-0.35, 0.11)	
no	72	1.58 (2.41)	63	-0.01 (0.21)	73	1.79 (2.15)	64	0.19 (0.22)	-0.19 (-0.80, 0.41)	0.522	-0.11 (-0.46, 0.23)	
Chemotherapy-free interval												0.840
< 90 days	108	1.63 (2.33)	89	0.10 (0.16)	110	1.63 (2.17)	88	0.28 (0.18)	-0.18 (-0.67, 0.30)	0.452	-0.11 (-0.41, 0.18)	
>= 90 and < 180 days	82	2.05 (2.25)	70	-0.10 (0.18)	76	1.29 (1.92)	64	-0.12 (0.20)	0.02 (-0.53, 0.57)	0.952	0.01 (-0.33, 0.35)	
>= 180 days	57	0.89 (1.68)	53	0.36 (0.18)	63	1.76 (2.20)	57	0.38 (0.20)	-0.02 (-0.56, 0.52)	0.943	-0.01 (-0.39, 0.36)	
Presence (previous or current) of brain metastases												0.567
yes	111	1.54 (2.16)	93	0.11 (0.15)	110	1.52 (2.22)	87	0.42 (0.17)	-0.31 (-0.75, 0.13)	0.168	-0.21 (-0.50, 0.09)	
no	136	1.65 (2.25)	119	0.01 (0.14)	139	1.59 (2.01)	122	0.15 (0.15)	-0.14 (-0.54, 0.27)	0.512	-0.08 (-0.34, 0.17)	
Standard of care												0.567
Amrubicin/Topotecan	204	1.67 (2.26)	180	0.04 (0.11)	202	1.50 (2.07)	169	0.23 (0.12)	-0.19 (-0.51, 0.13)	0.239	-0.13 (-0.34, 0.08)	
Lurbinectedin	43	1.28 (1.94)	32	0.18 (0.35)	47	1.81 (2.25)	40	0.67 (0.35)	-0.49 (-1.48, 0.51)	0.330	-0.23 (-0.70, 0.24)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain on the Average - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							Interaction
	Baseline		Change from BL		Baseline		Change from BL		Difference of			
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.287
< 65 years	128	2.34 (2.56)	113	0.07 (0.16)	113	2.23 (2.39)	98	0.56 (0.19)	-0.49 (-0.97, -0.00)	0.048	-0.28 (-0.55, -0.00)	
>= 65 years	119	2.17 (2.35)	99	-0.21 (0.14)	136	1.85 (2.19)	111	-0.06 (0.14)	-0.15 (-0.54, 0.24)	0.442	-0.11 (-0.38, 0.17)	
Gender												0.937
female	67	2.64 (2.67)	59	-0.07 (0.20)	84	2.35 (2.23)	68	0.22 (0.21)	-0.29 (-0.88, 0.29)	0.325	-0.17 (-0.52, 0.18)	
male	180	2.11 (2.36)	153	-0.07 (0.12)	165	1.86 (2.31)	141	0.20 (0.14)	-0.26 (-0.63, 0.10)	0.156	-0.17 (-0.40, 0.06)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.50 (0.71)	2					
STAGE III	19	1.42 (1.71)	19		18	2.11 (2.30)	14					
STAGE IV	228	2.32 (2.50)	193		229	2.03 (2.30)	193					
Region												0.610
North America and Europe	135	2.70 (2.60)	111	-0.09 (0.15)	123	2.33 (2.34)	97	0.32 (0.18)	-0.40 (-0.86, 0.06)	0.088	-0.24 (-0.51, 0.03)	
Rest of the World	112	1.71 (2.15)	101	-0.09 (0.14)	126	1.72 (2.20)	112	0.15 (0.15)	-0.24 (-0.66, 0.17)	0.250	-0.16 (-0.43, 0.11)	
Prior anti-PD-(L)1 exposure												0.910
yes	175	2.30 (2.40)	149	-0.05 (0.12)	176	1.93 (2.25)	145	0.25 (0.13)	-0.30 (-0.66, 0.06)	0.103	-0.19 (-0.42, 0.04)	
no	72	2.15 (2.59)	63	-0.12 (0.21)	73	2.26 (2.39)	64	0.22 (0.22)	-0.34 (-0.94, 0.26)	0.268	-0.20 (-0.54, 0.15)	
Chemotherapy-free interval												0.827
< 90 days	108	2.40 (2.68)	89	-0.05 (0.17)	110	1.92 (2.28)	88	0.30 (0.18)	-0.35 (-0.84, 0.14)	0.157	-0.21 (-0.51, 0.08)	
>= 90 and < 180 days	82	2.73 (2.40)	70	-0.28 (0.20)	76	1.93 (2.04)	64	-0.04 (0.22)	-0.24 (-0.84, 0.36)	0.429	-0.14 (-0.48, 0.20)	
>= 180 days	57	1.30 (1.77)	53	0.22 (0.20)	63	2.32 (2.58)	57	0.33 (0.21)	-0.11 (-0.70, 0.48)	0.704	-0.07 (-0.45, 0.30)	
Presence (previous or current) of brain metastases												0.153
yes	111	2.20 (2.45)	93	0.00 (0.15)	110	1.89 (2.26)	87	0.61 (0.18)	-0.61 (-1.07, -0.14)	0.011	-0.39 (-0.68, -0.09)	
no	136	2.30 (2.47)	119	-0.17 (0.15)	139	2.13 (2.31)	122	-0.02 (0.15)	-0.15 (-0.57, 0.27)	0.470	-0.09 (-0.35, 0.16)	
Standard of care												0.453
Amrubicin/Topotecan	204	2.27 (2.51)	180	-0.07 (0.11)	202	1.99 (2.28)	169	0.18 (0.12)	-0.25 (-0.58, 0.08)	0.136	-0.16 (-0.37, 0.05)	
Lurbinectedin	43	2.16 (2.22)	32	-0.07 (0.38)	47	2.17 (2.34)	40	0.59 (0.38)	-0.67 (-1.75, 0.41)	0.218	-0.29 (-0.76, 0.18)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Right Now - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.509
< 65 years	128	1.80 (2.42)	113	0.13 (0.17)	113	1.70 (2.31)	98	0.62 (0.20)	-0.50 (-1.02, 0.02)	0.060	-0.26 (-0.53, 0.01)	
>= 65 years	119	1.75 (2.31)	99	-0.17 (0.14)	136	1.21 (1.85)	111	0.11 (0.14)	-0.28 (-0.68, 0.12)	0.166	-0.19 (-0.46, 0.08)	
Gender												0.470
female	67	1.90 (2.35)	59	-0.06 (0.20)	84	1.58 (2.15)	68	0.47 (0.21)	-0.53 (-1.11, 0.04)	0.070	-0.32 (-0.67, 0.03)	
male	180	1.73 (2.37)	153	-0.01 (0.13)	165	1.35 (2.04)	141	0.27 (0.15)	-0.28 (-0.67, 0.11)	0.164	-0.16 (-0.39, 0.07)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	1.16 (1.54)	19		18	1.06 (1.63)	14					
STAGE IV	228	1.83 (2.41)	193		229	1.47 (2.11)	193					
Region												0.790
North America and Europe	135	2.14 (2.47)	111	0.00 (0.16)	123	1.82 (2.32)	97	0.35 (0.19)	-0.35 (-0.85, 0.14)	0.161	-0.20 (-0.47, 0.08)	
Rest of the World	112	1.34 (2.16)	101	-0.08 (0.15)	126	1.05 (1.74)	112	0.36 (0.15)	-0.44 (-0.86, -0.02)	0.040	-0.28 (-0.55, -0.01)	
Prior anti-PD-(L)1 exposure												0.954
yes	175	1.83 (2.36)	149	-0.07 (0.12)	176	1.41 (2.10)	145	0.32 (0.14)	-0.39 (-0.76, -0.03)	0.033	-0.25 (-0.48, -0.02)	
no	72	1.64 (2.38)	63	0.10 (0.24)	73	1.48 (2.05)	64	0.48 (0.25)	-0.37 (-1.06, 0.31)	0.284	-0.19 (-0.54, 0.16)	
Chemotherapy-free interval												0.753
< 90 days	108	1.91 (2.56)	89	-0.08 (0.17)	110	1.46 (2.03)	88	0.30 (0.19)	-0.38 (-0.88, 0.12)	0.132	-0.23 (-0.52, 0.07)	
>= 90 and < 180 days	82	2.28 (2.47)	70	-0.18 (0.21)	76	1.29 (2.01)	64	-0.10 (0.23)	-0.08 (-0.72, 0.55)	0.796	-0.05 (-0.38, 0.29)	
>= 180 days	57	0.81 (1.37)	53	0.37 (0.21)	63	1.54 (2.26)	57	0.70 (0.22)	-0.33 (-0.94, 0.28)	0.285	-0.20 (-0.58, 0.17)	
Presence (previous or current) of brain metastases												0.188
yes	111	1.69 (2.26)	93	-0.11 (0.16)	110	1.42 (2.09)	87	0.52 (0.19)	-0.64 (-1.13, -0.15)	0.011	-0.38 (-0.68, -0.09)	
no	136	1.85 (2.45)	119	0.04 (0.15)	139	1.44 (2.08)	122	0.24 (0.16)	-0.20 (-0.64, 0.24)	0.371	-0.12 (-0.37, 0.14)	
Standard of care												NE
Amrubicin/Topotecan	204	1.91 (2.43)	180	-0.12 (0.12)	202	1.47 (2.10)	169	0.22 (0.13)	-0.33 (-0.68, 0.02)	0.063	-0.20 (-0.41, 0.01)	
Lurbinectedin	43	1.14 (1.88)	32	NE	47	1.28 (2.02)	40	NE	NE		NE	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Interfered General Activity - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.103
< 65 years	128	2.03 (2.76)	113	0.21 (0.17)	112	1.89 (2.47)	97	0.94 (0.20)	-0.73 (-1.25, -0.20)	0.007	-0.38 (-0.65, -0.11)	
>= 65 years	119	1.66 (2.26)	99	0.05 (0.14)	136	1.71 (2.59)	111	0.23 (0.14)	-0.18 (-0.58, 0.22)	0.365	-0.12 (-0.40, 0.15)	
Gender												0.344
female	67	2.19 (2.74)	59	0.05 (0.22)	83	1.86 (2.43)	67	0.70 (0.23)	-0.64 (-1.28, -0.00)	0.049	-0.35 (-0.70, 0.00)	
male	180	1.72 (2.45)	153	0.17 (0.13)	165	1.76 (2.59)	141	0.45 (0.15)	-0.29 (-0.67, 0.10)	0.140	-0.17 (-0.40, 0.06)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	1.00 (1.53)	19		18	1.89 (2.91)	14					
STAGE IV	228	1.92 (2.59)	193		228	1.80 (2.51)	192					
Region												0.580
North America and Europe	135	2.33 (2.73)	111	0.15 (0.17)	122	2.15 (2.65)	96	0.66 (0.20)	-0.51 (-1.04, 0.02)	0.057	-0.27 (-0.54, 0.01)	
Rest of the World	112	1.28 (2.16)	101	0.12 (0.14)	126	1.44 (2.37)	112	0.44 (0.14)	-0.33 (-0.72, 0.06)	0.101	-0.22 (-0.49, 0.05)	
Prior anti-PD-(L)1 exposure												0.520
yes	175	2.01 (2.62)	149	0.12 (0.13)	176	1.73 (2.50)	145	0.60 (0.15)	-0.49 (-0.88, -0.09)	0.016	-0.28 (-0.51, -0.05)	
no	72	1.47 (2.28)	63	0.15 (0.19)	72	1.93 (2.62)	63	0.42 (0.20)	-0.27 (-0.82, 0.28)	0.334	-0.17 (-0.52, 0.18)	
Chemotherapy-free interval												0.531
< 90 days	108	2.19 (2.98)	89	-0.09 (0.17)	110	1.87 (2.65)	88	0.33 (0.19)	-0.42 (-0.92, 0.08)	0.096	-0.25 (-0.55, 0.04)	
>= 90 and < 180 days	82	2.10 (2.32)	70	0.18 (0.23)	75	1.56 (2.30)	63	0.74 (0.26)	-0.57 (-1.26, 0.13)	0.109	-0.28 (-0.62, 0.06)	
>= 180 days	57	0.84 (1.47)	53	0.50 (0.20)	63	1.92 (2.59)	57	0.58 (0.22)	-0.08 (-0.68, 0.52)	0.787	-0.05 (-0.43, 0.32)	
Presence (previous or current) of brain metastases												0.003
yes	111	1.76 (2.29)	93	0.03 (0.17)	110	1.69 (2.39)	87	1.07 (0.20)	-1.04 (-1.57, -0.52)	<.001	-0.58 (-0.88, -0.29)	
no	136	1.93 (2.73)	119	0.20 (0.15)	138	1.87 (2.64)	121	0.22 (0.16)	-0.02 (-0.45, 0.40)	0.916	-0.01 (-0.27, 0.24)	
Standard of care												0.282
Amrubicin/Topotecan	204	1.91 (2.61)	180	0.16 (0.12)	202	1.84 (2.58)	169	0.50 (0.13)	-0.33 (-0.68, 0.02)	0.061	-0.20 (-0.41, 0.01)	
Lurbinectedin	43	1.56 (2.17)	32	0.14 (0.42)	46	1.57 (2.33)	39	1.14 (0.42)	-1.00 (-2.20, 0.21)	0.101	-0.39 (-0.87, 0.08)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Interfered with Mood - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.281
< 65 years	128	1.98 (2.79)	113	0.28 (0.18)	112	2.06 (2.75)	97	0.83 (0.21)	-0.56 (-1.10, -0.01)	0.044	-0.28 (-0.55, -0.01)	
>= 65 years	119	1.55 (2.22)	99	0.08 (0.14)	136	1.71 (2.47)	111	0.27 (0.14)	-0.19 (-0.58, 0.19)	0.325	-0.14 (-0.41, 0.14)	
Gender												0.493
female	67	1.93 (2.68)	59	0.20 (0.22)	83	2.19 (2.69)	67	0.71 (0.24)	-0.51 (-1.16, 0.14)	0.122	-0.27 (-0.63, 0.08)	
male	180	1.72 (2.49)	153	0.19 (0.13)	165	1.71 (2.54)	141	0.44 (0.15)	-0.25 (-0.63, 0.14)	0.203	-0.15 (-0.38, 0.08)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	0.89 (1.45)	19		18	1.94 (2.80)	14					
STAGE IV	228	1.85 (2.60)	193		228	1.88 (2.60)	192					
Region												0.402
North America and Europe	135	2.19 (2.75)	111	0.14 (0.17)	122	2.17 (2.68)	96	0.66 (0.19)	-0.52 (-1.02, -0.02)	0.043	-0.28 (-0.56, -0.01)	
Rest of the World	112	1.28 (2.17)	101	0.20 (0.15)	126	1.58 (2.50)	112	0.43 (0.16)	-0.23 (-0.67, 0.20)	0.291	-0.14 (-0.41, 0.13)	
Prior anti-PD-(L)1 exposure												0.948
yes	175	1.90 (2.62)	149	0.17 (0.14)	176	1.86 (2.60)	145	0.51 (0.15)	-0.34 (-0.74, 0.06)	0.097	-0.19 (-0.42, 0.03)	
no	72	1.49 (2.32)	63	0.25 (0.19)	72	1.90 (2.62)	63	0.61 (0.21)	-0.36 (-0.92, 0.20)	0.199	-0.23 (-0.58, 0.12)	
Chemotherapy-free interval												0.773
< 90 days	108	2.15 (2.98)	89	-0.07 (0.17)	110	1.96 (2.69)	88	0.38 (0.20)	-0.45 (-0.97, 0.07)	0.087	-0.26 (-0.55, 0.04)	
>= 90 and < 180 days	82	1.85 (2.32)	70	0.28 (0.22)	75	1.69 (2.32)	63	0.55 (0.24)	-0.27 (-0.93, 0.38)	0.408	-0.14 (-0.48, 0.20)	
>= 180 days	57	0.96 (1.60)	53	0.50 (0.21)	63	1.92 (2.78)	57	0.67 (0.23)	-0.17 (-0.79, 0.46)	0.598	-0.10 (-0.47, 0.27)	
Presence (previous or current) of brain metastases												0.002
yes	111	1.65 (2.36)	93	0.08 (0.17)	110	1.81 (2.48)	87	1.06 (0.20)	-0.98 (-1.50, -0.46)	<.001	-0.56 (-0.85, -0.26)	
no	136	1.88 (2.68)	119	0.26 (0.15)	138	1.92 (2.70)	121	0.19 (0.16)	0.06 (-0.37, 0.50)	0.774	0.04 (-0.22, 0.29)	
Standard of care												0.184
Amrubicin/Topotecan	204	1.88 (2.59)	180	0.20 (0.12)	202	1.94 (2.66)	169	0.43 (0.13)	-0.24 (-0.59, 0.12)	0.190	-0.14 (-0.35, 0.07)	
Lurbinectedin	43	1.28 (2.25)	32	0.16 (0.35)	46	1.59 (2.33)	39	1.11 (0.36)	-0.95 (-1.96, 0.07)	0.068	-0.44 (-0.91, 0.03)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Interfered Walking Ability - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.258
< 65 years	128	1.70 (2.68)	113	0.26 (0.18)	112	1.73 (2.71)	97	1.01 (0.21)	-0.76 (-1.30, -0.21)	0.007	-0.38 (-0.65, -0.11)	
>= 65 years	119	1.60 (2.38)	99	0.05 (0.15)	136	1.68 (2.74)	111	0.40 (0.16)	-0.36 (-0.79, 0.08)	0.109	-0.22 (-0.49, 0.05)	
Gender												0.283
female	67	1.82 (2.75)	59	0.19 (0.24)	83	1.78 (2.74)	67	1.02 (0.25)	-0.83 (-1.52, -0.14)	0.019	-0.42 (-0.77, -0.07)	
male	180	1.58 (2.45)	153	0.13 (0.13)	165	1.66 (2.72)	141	0.52 (0.15)	-0.40 (-0.80, 0.00)	0.053	-0.23 (-0.46, 0.00)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	0.95 (1.87)	19		18	1.72 (2.89)	14					
STAGE IV	228	1.71 (2.57)	193		228	1.71 (2.72)	192					
Region												0.483
North America and Europe	135	2.00 (2.65)	111	0.04 (0.17)	122	2.24 (2.97)	96	0.76 (0.20)	-0.72 (-1.24, -0.19)	0.008	-0.38 (-0.65, -0.10)	
Rest of the World	112	1.22 (2.32)	101	0.18 (0.16)	126	1.18 (2.36)	112	0.66 (0.17)	-0.47 (-0.93, -0.02)	0.041	-0.28 (-0.55, -0.01)	
Prior anti-PD-(L)1 exposure												0.439
yes	175	1.83 (2.62)	149	0.07 (0.14)	176	1.64 (2.71)	145	0.74 (0.16)	-0.67 (-1.08, -0.25)	0.002	-0.37 (-0.60, -0.14)	
no	72	1.21 (2.25)	63	0.29 (0.22)	72	1.86 (2.76)	63	0.66 (0.23)	-0.37 (-1.00, 0.25)	0.240	-0.21 (-0.56, 0.14)	
Chemotherapy-free interval												0.544
< 90 days	108	1.84 (2.89)	89	-0.03 (0.18)	110	1.79 (2.78)	88	0.55 (0.20)	-0.58 (-1.12, -0.05)	0.033	-0.32 (-0.62, -0.03)	
>= 90 and < 180 days	82	1.99 (2.49)	70	0.14 (0.24)	75	1.40 (2.40)	63	0.82 (0.26)	-0.68 (-1.39, 0.03)	0.061	-0.33 (-0.67, 0.01)	
>= 180 days	57	0.79 (1.47)	53	0.44 (0.20)	63	1.90 (2.98)	57	0.66 (0.22)	-0.22 (-0.81, 0.37)	0.459	-0.14 (-0.52, 0.23)	
Presence (previous or current) of brain metastases												<.001
yes	111	1.60 (2.36)	93	-0.07 (0.17)	110	1.70 (2.72)	87	1.18 (0.20)	-1.25 (-1.77, -0.72)	<.001	-0.71 (-1.01, -0.40)	
no	136	1.68 (2.67)	119	0.31 (0.16)	138	1.70 (2.73)	121	0.36 (0.17)	-0.04 (-0.51, 0.42)	0.852	-0.02 (-0.28, 0.23)	
Standard of care												0.273
Amrubicin/Topotecan	204	1.68 (2.56)	180	0.14 (0.13)	202	1.79 (2.78)	169	0.61 (0.15)	-0.47 (-0.85, -0.09)	0.016	-0.26 (-0.47, -0.05)	
Lurbinectedin	43	1.51 (2.39)	32	0.04 (0.29)	46	1.33 (2.46)	39	1.01 (0.30)	-0.98 (-1.83, -0.12)	0.026	-0.55 (-1.02, -0.07)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Interfered with Normal Work - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												NE
< 65 years	128	1.77 (2.70)	113	0.53 (0.19)	112	1.94 (2.77)	97	0.92 (0.22)	-0.39 (-0.97, 0.19)	0.185	-0.19 (-0.46, 0.09)	
>= 65 years	119	1.58 (2.39)	99	NE	136	1.59 (2.53)	111	NE	NE		NE	
Gender												0.568
female	67	1.85 (2.95)	59	0.50 (0.26)	83	1.99 (2.76)	67	0.97 (0.26)	-0.47 (-1.20, 0.26)	0.203	-0.23 (-0.58, 0.13)	
male	180	1.61 (2.40)	153	0.32 (0.14)	165	1.62 (2.58)	141	0.54 (0.16)	-0.23 (-0.64, 0.18)	0.270	-0.13 (-0.36, 0.10)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	1.21 (1.93)	19		18	1.78 (2.73)	14					
STAGE IV	228	1.71 (2.60)	193		228	1.76 (2.65)	192					
Region												0.657
North America and Europe	135	2.14 (2.76)	111	0.32 (0.18)	122	2.20 (2.79)	96	0.75 (0.21)	-0.43 (-0.97, 0.10)	0.114	-0.22 (-0.50, 0.05)	
Rest of the World	112	1.12 (2.16)	101	0.35 (0.17)	126	1.31 (2.42)	112	0.62 (0.17)	-0.27 (-0.75, 0.21)	0.262	-0.15 (-0.42, 0.12)	
Prior anti-PD-(L)1 exposure												0.336
yes	175	1.83 (2.65)	149	0.30 (0.15)	176	1.76 (2.71)	145	0.75 (0.17)	-0.45 (-0.89, -0.01)	0.047	-0.23 (-0.46, -0.00)	
no	72	1.29 (2.28)	63	0.47 (0.21)	72	1.72 (2.48)	63	0.55 (0.22)	-0.09 (-0.69, 0.52)	0.779	-0.05 (-0.40, 0.30)	
Chemotherapy-free interval												0.496
< 90 days	108	1.97 (2.97)	89	0.24 (0.19)	110	1.87 (2.76)	88	0.64 (0.22)	-0.40 (-0.98, 0.19)	0.181	-0.20 (-0.50, 0.09)	
>= 90 and < 180 days	82	1.94 (2.47)	70	0.31 (0.25)	75	1.48 (2.41)	63	0.69 (0.27)	-0.38 (-1.11, 0.35)	0.302	-0.18 (-0.52, 0.16)	
>= 180 days	57	0.74 (1.38)	53	0.69 (0.20)	63	1.84 (2.71)	57	0.63 (0.22)	0.06 (-0.54, 0.66)	0.849	0.04 (-0.34, 0.41)	
Presence (previous or current) of brain metastases												<.001
yes	111	1.68 (2.46)	93	0.07 (0.18)	110	1.77 (2.62)	87	1.17 (0.21)	-1.10 (-1.64, -0.56)	<.001	-0.60 (-0.90, -0.30)	
no	136	1.67 (2.64)	119	0.61 (0.17)	138	1.72 (2.67)	121	0.36 (0.18)	0.25 (-0.23, 0.73)	0.306	0.13 (-0.12, 0.39)	
Standard of care												0.231
Amrubicin/Topotecan	204	1.72 (2.60)	180	0.41 (0.14)	202	1.83 (2.72)	169	0.65 (0.15)	-0.24 (-0.64, 0.16)	0.243	-0.13 (-0.34, 0.08)	
Lurbinectedin	43	1.49 (2.32)	32	0.09 (0.32)	46	1.39 (2.28)	39	0.92 (0.32)	-0.83 (-1.74, 0.07)	0.071	-0.43 (-0.90, 0.04)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Interfered with Relations - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.399
< 65 years	128	1.68 (2.64)	113	0.13 (0.16)	112	1.56 (2.46)	97	0.70 (0.20)	-0.57 (-1.08, -0.07)	0.025	-0.31 (-0.59, -0.04)	
>= 65 years	119	1.23 (2.23)	99	0.08 (0.14)	136	1.16 (2.12)	111	0.38 (0.14)	-0.31 (-0.69, 0.07)	0.114	-0.22 (-0.49, 0.05)	
Gender												0.438
female	67	1.63 (2.73)	59	0.09 (0.21)	83	1.54 (2.39)	67	0.69 (0.22)	-0.60 (-1.20, -0.00)	0.050	-0.35 (-0.70, 0.00)	
male	180	1.40 (2.35)	153	0.13 (0.12)	165	1.24 (2.23)	141	0.45 (0.14)	-0.32 (-0.70, 0.05)	0.087	-0.20 (-0.43, 0.03)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	0.74 (1.59)	19		18	1.28 (2.65)	14					
STAGE IV	228	1.52 (2.51)	193		228	1.36 (2.26)	192					
Region												0.660
North America and Europe	135	1.84 (2.65)	111	0.04 (0.15)	122	1.66 (2.48)	96	0.55 (0.18)	-0.51 (-0.97, -0.05)	0.031	-0.30 (-0.58, -0.03)	
Rest of the World	112	1.01 (2.12)	101	0.14 (0.15)	126	1.03 (2.04)	112	0.51 (0.15)	-0.37 (-0.79, 0.05)	0.085	-0.24 (-0.51, 0.03)	
Prior anti-PD-(L)1 exposure												0.463
yes	175	1.61 (2.54)	149	0.06 (0.13)	176	1.37 (2.38)	145	0.56 (0.14)	-0.49 (-0.87, -0.12)	0.010	-0.30 (-0.53, -0.07)	
no	72	1.11 (2.22)	63	0.21 (0.18)	72	1.28 (2.04)	63	0.46 (0.19)	-0.25 (-0.78, 0.28)	0.346	-0.17 (-0.52, 0.18)	
Chemotherapy-free interval												0.455
< 90 days	108	1.93 (2.89)	89	-0.16 (0.16)	110	1.52 (2.52)	88	0.44 (0.19)	-0.60 (-1.10, -0.10)	0.019	-0.36 (-0.65, -0.06)	
>= 90 and < 180 days	82	1.50 (2.36)	70	0.13 (0.20)	75	0.99 (1.70)	63	0.44 (0.22)	-0.31 (-0.90, 0.28)	0.295	-0.18 (-0.52, 0.16)	
>= 180 days	57	0.53 (1.09)	53	NE	63	1.46 (2.44)	57	NE	NE		NE	
Presence (previous or current) of brain metastases												<.001
yes	111	1.41 (2.33)	93	-0.10 (0.16)	110	1.30 (2.12)	87	0.97 (0.19)	-1.07 (-1.56, -0.57)	<.001	-0.64 (-0.94, -0.34)	
no	136	1.50 (2.57)	119	0.28 (0.14)	138	1.38 (2.41)	121	0.22 (0.15)	0.06 (-0.34, 0.47)	0.762	0.04 (-0.21, 0.29)	
Standard of care												0.165
Amrubicin/Topotecan	204	1.56 (2.54)	180	0.16 (0.12)	202	1.42 (2.37)	169	0.49 (0.13)	-0.33 (-0.68, 0.01)	0.060	-0.20 (-0.41, 0.01)	
Lurbinectedin	43	0.98 (1.98)	32	-0.20 (0.26)	46	1.02 (1.86)	39	0.70 (0.26)	-0.90 (-1.65, -0.15)	0.019	-0.57 (-1.04, -0.09)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Interfered with Sleep - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.871
< 65 years	128	2.16 (3.07)	113	0.09 (0.18)	112	1.98 (2.68)	97	0.57 (0.21)	-0.48 (-1.03, 0.07)	0.087	-0.24 (-0.51, 0.03)	
>= 65 years	119	1.74 (2.53)	99	-0.28 (0.15)	136	1.32 (2.24)	111	0.26 (0.15)	-0.54 (-0.96, -0.12)	0.013	-0.35 (-0.62, -0.07)	
Gender												0.067
female	67	2.30 (3.09)	59	-0.10 (0.26)	83	1.60 (2.49)	67	0.96 (0.26)	-1.06 (-1.79, -0.33)	0.005	-0.51 (-0.87, -0.16)	
male	180	1.83 (2.72)	153	-0.13 (0.13)	165	1.63 (2.46)	141	0.18 (0.14)	-0.30 (-0.68, 0.08)	0.120	-0.18 (-0.41, 0.05)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	0.84 (1.77)	19		18	1.50 (2.71)	14					
STAGE IV	228	2.05 (2.88)	193		228	1.64 (2.46)	192					
Region												0.981
North America and Europe	135	2.36 (2.96)	111	-0.14 (0.17)	122	2.00 (2.68)	96	0.37 (0.19)	-0.51 (-1.02, -0.01)	0.046	-0.28 (-0.56, -0.01)	
Rest of the World	112	1.46 (2.57)	101	-0.05 (0.17)	126	1.25 (2.19)	112	0.47 (0.17)	-0.52 (-1.00, -0.05)	0.032	-0.29 (-0.57, -0.02)	
Prior anti-PD-(L)1 exposure												0.405
yes	175	2.18 (2.93)	149	-0.23 (0.14)	176	1.64 (2.48)	145	0.38 (0.16)	-0.61 (-1.02, -0.19)	0.004	-0.34 (-0.57, -0.11)	
no	72	1.40 (2.48)	63	0.19 (0.20)	72	1.57 (2.44)	63	0.49 (0.21)	-0.31 (-0.89, 0.27)	0.296	-0.19 (-0.54, 0.16)	
Chemotherapy-free interval												0.202
< 90 days	108	2.20 (3.03)	89	-0.26 (0.18)	110	1.63 (2.61)	88	0.45 (0.21)	-0.71 (-1.26, -0.16)	0.012	-0.38 (-0.68, -0.08)	
>= 90 and < 180 days	82	2.16 (2.95)	70	-0.24 (0.22)	75	1.48 (2.24)	63	0.35 (0.24)	-0.58 (-1.24, 0.07)	0.080	-0.31 (-0.65, 0.03)	
>= 180 days	57	1.19 (2.02)	53	0.36 (0.22)	63	1.78 (2.49)	57	0.35 (0.23)	0.02 (-0.61, 0.64)	0.961	0.01 (-0.36, 0.38)	
Presence (previous or current) of brain metastases												0.004
yes	111	1.88 (2.60)	93	-0.23 (0.18)	110	1.57 (2.51)	87	0.89 (0.21)	-1.12 (-1.67, -0.57)	<.001	-0.61 (-0.91, -0.31)	
no	136	2.01 (3.00)	119	-0.03 (0.15)	138	1.66 (2.45)	121	0.08 (0.16)	-0.11 (-0.55, 0.32)	0.608	-0.07 (-0.32, 0.19)	
Standard of care												0.369
Amrubicin/Topotecan	204	2.02 (2.88)	180	-0.09 (0.12)	202	1.72 (2.53)	169	0.34 (0.14)	-0.43 (-0.79, -0.07)	0.021	-0.25 (-0.46, -0.04)	
Lurbinectedin	43	1.65 (2.56)	32	-0.07 (0.40)	46	1.20 (2.13)	39	0.89 (0.40)	-0.96 (-2.10, 0.18)	0.096	-0.40 (-0.87, 0.07)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Interfered Enjoyment of Life - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.363
< 65 years	128	2.03 (3.01)	113	0.16 (0.18)	112	2.07 (2.86)	97	0.83 (0.21)	-0.66 (-1.21, -0.12)	0.017	-0.33 (-0.61, -0.06)	
>= 65 years	119	1.61 (2.48)	99	0.01 (0.16)	136	1.64 (2.56)	111	0.35 (0.16)	-0.34 (-0.78, 0.09)	0.122	-0.21 (-0.49, 0.06)	
Gender												0.251
female	67	1.96 (3.08)	59	0.10 (0.24)	83	1.95 (2.83)	67	0.90 (0.24)	-0.80 (-1.47, -0.12)	0.021	-0.42 (-0.77, -0.06)	
male	180	1.78 (2.65)	153	0.07 (0.14)	165	1.78 (2.64)	141	0.41 (0.15)	-0.34 (-0.75, 0.06)	0.096	-0.20 (-0.42, 0.03)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	0.74 (1.76)	19		18	1.72 (2.80)	14					
STAGE IV	228	1.92 (2.82)	193		228	1.86 (2.71)	192					
Region												0.437
North America and Europe	135	2.34 (2.98)	111	-0.00 (0.17)	122	2.21 (2.82)	96	0.64 (0.19)	-0.64 (-1.14, -0.13)	0.014	-0.35 (-0.62, -0.07)	
Rest of the World	112	1.21 (2.37)	101	0.14 (0.17)	126	1.47 (2.54)	112	0.50 (0.17)	-0.37 (-0.84, 0.11)	0.132	-0.21 (-0.48, 0.06)	
Prior anti-PD-(L)1 exposure												0.455
yes	175	2.05 (2.88)	149	-0.01 (0.14)	176	1.82 (2.72)	145	0.57 (0.16)	-0.58 (-1.00, -0.17)	0.006	-0.32 (-0.56, -0.09)	
no	72	1.29 (2.41)	63	0.29 (0.21)	72	1.88 (2.69)	63	0.59 (0.23)	-0.30 (-0.92, 0.31)	0.328	-0.17 (-0.52, 0.18)	
Chemotherapy-free interval												0.923
< 90 days	108	2.03 (3.09)	89	-0.01 (0.18)	110	2.02 (2.87)	88	0.48 (0.21)	-0.50 (-1.05, 0.05)	0.077	-0.27 (-0.56, 0.03)	
>= 90 and < 180 days	82	2.05 (2.70)	70	0.03 (0.22)	75	1.53 (2.35)	63	0.41 (0.24)	-0.38 (-1.03, 0.27)	0.247	-0.20 (-0.54, 0.14)	
>= 180 days	57	1.14 (2.08)	53	0.34 (0.22)	63	1.87 (2.80)	57	0.67 (0.23)	-0.33 (-0.97, 0.30)	0.300	-0.20 (-0.57, 0.18)	
Presence (previous or current) of brain metastases												<.001
yes	111	1.84 (2.58)	93	-0.19 (0.18)	110	1.97 (2.83)	87	1.00 (0.20)	-1.18 (-1.72, -0.65)	<.001	-0.66 (-0.96, -0.36)	
no	136	1.82 (2.93)	119	0.30 (0.16)	138	1.72 (2.60)	121	0.29 (0.17)	0.01 (-0.44, 0.46)	0.958	0.01 (-0.25, 0.26)	
Standard of care												0.289
Amrubicin/Topotecan	204	1.95 (2.89)	180	0.08 (0.12)	202	1.91 (2.75)	169	0.47 (0.14)	-0.39 (-0.76, -0.03)	0.035	-0.23 (-0.44, -0.02)	
Lurbinectedin	43	1.28 (2.09)	32	0.14 (0.40)	46	1.50 (2.50)	39	1.16 (0.40)	-1.02 (-2.17, 0.12)	0.078	-0.42 (-0.90, 0.05)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Interference - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.415
< 65 years	128	1.91 (2.59)	113	0.25 (0.16)	112	1.89 (2.47)	97	0.83 (0.19)	-0.58 (-1.08, -0.09)	0.021	-0.32 (-0.60, -0.05)	
>= 65 years	119	1.57 (2.17)	99	0.02 (0.13)	136	1.54 (2.30)	111	0.34 (0.14)	-0.33 (-0.71, 0.05)	0.088	-0.24 (-0.51, 0.04)	
Gender												0.247
female	67	1.95 (2.66)	59	0.14 (0.21)	83	1.85 (2.37)	67	0.86 (0.22)	-0.73 (-1.34, -0.11)	0.021	-0.41 (-0.77, -0.06)	
male	180	1.66 (2.29)	153	0.13 (0.12)	165	1.63 (2.39)	141	0.44 (0.14)	-0.31 (-0.67, 0.05)	0.092	-0.20 (-0.43, 0.03)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.00 (0.00)	2					
STAGE III	19	0.91 (1.60)	19		18	1.69 (2.71)	14					
STAGE IV	228	1.81 (2.44)	193		228	1.72 (2.37)	192					
Region												0.555
North America and Europe	135	2.17 (2.60)	111	0.08 (0.15)	122	2.09 (2.52)	96	0.65 (0.18)	-0.56 (-1.03, -0.10)	0.019	-0.33 (-0.61, -0.06)	
Rest of the World	112	1.23 (2.01)	101	0.16 (0.14)	126	1.32 (2.18)	112	0.54 (0.15)	-0.38 (-0.79, 0.03)	0.070	-0.25 (-0.52, 0.02)	
Prior anti-PD-(L)1 exposure												0.428
yes	175	1.92 (2.52)	149	0.07 (0.13)	176	1.69 (2.41)	145	0.61 (0.14)	-0.54 (-0.91, -0.16)	0.006	-0.33 (-0.56, -0.10)	
no	72	1.32 (2.02)	63	0.27 (0.18)	72	1.73 (2.32)	63	0.54 (0.19)	-0.28 (-0.80, 0.25)	0.296	-0.19 (-0.54, 0.16)	
Chemotherapy-free interval												0.420
< 90 days	108	2.04 (2.80)	89	-0.05 (0.16)	110	1.81 (2.53)	88	0.48 (0.18)	-0.53 (-1.02, -0.05)	0.031	-0.33 (-0.62, -0.03)	
>= 90 and < 180 days	82	1.94 (2.25)	70	0.12 (0.21)	75	1.45 (2.02)	63	0.62 (0.23)	-0.51 (-1.13, 0.12)	0.112	-0.28 (-0.62, 0.06)	
>= 180 days	57	0.88 (1.40)	53	0.51 (0.19)	63	1.81 (2.51)	57	0.58 (0.20)	-0.07 (-0.63, 0.49)	0.795	-0.05 (-0.42, 0.32)	
Presence (previous or current) of brain metastases												<.001
yes	111	1.69 (2.18)	93	-0.07 (0.16)	110	1.69 (2.30)	87	1.07 (0.18)	-1.14 (-1.62, -0.66)	<.001	-0.70 (-1.00, -0.40)	
no	136	1.79 (2.57)	119	0.29 (0.14)	138	1.71 (2.45)	121	0.26 (0.15)	0.03 (-0.38, 0.44)	0.896	0.02 (-0.24, 0.27)	
Standard of care												0.217
Amrubicin/Topotecan	204	1.82 (2.46)	180	0.15 (0.11)	202	1.78 (2.45)	169	0.51 (0.13)	-0.36 (-0.69, -0.02)	0.036	-0.23 (-0.44, -0.02)	
Lurbinectedin	43	1.39 (2.08)	32	0.07 (0.34)	46	1.37 (2.06)	39	1.06 (0.34)	-0.99 (-1.97, -0.01)	0.048	-0.48 (-0.95, -0.00)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of BPI2-Pain Severity - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							Interaction
	Baseline		Change from BL		Baseline		Change from BL		Difference of			
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.509
< 65 years	128	2.17 (2.41)	113	0.10 (0.15)	113	2.12 (2.24)	98	0.50 (0.18)	-0.41 (-0.86, 0.05)	0.082	-0.24 (-0.51, 0.03)	
>= 65 years	119	2.01 (2.20)	99	-0.15 (0.13)	136	1.65 (2.03)	111	0.06 (0.13)	-0.21 (-0.58, 0.17)	0.275	-0.15 (-0.42, 0.12)	
Gender												0.829
female	67	2.32 (2.37)	59	-0.00 (0.19)	84	2.04 (2.12)	68	0.33 (0.20)	-0.33 (-0.89, 0.23)	0.243	-0.21 (-0.56, 0.14)	
male	180	2.00 (2.28)	153	-0.04 (0.12)	165	1.77 (2.14)	141	0.22 (0.13)	-0.26 (-0.61, 0.09)	0.144	-0.17 (-0.40, 0.06)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.13 (0.18)	2					
STAGE III	19	1.30 (1.60)	19		18	1.82 (2.07)	14					
STAGE IV	228	2.16 (2.35)	193		229	1.88 (2.15)	193					
Region												0.947
North America and Europe	135	2.51 (2.43)	111	-0.01 (0.15)	123	2.18 (2.21)	97	0.32 (0.17)	-0.33 (-0.77, 0.12)	0.148	-0.20 (-0.48, 0.07)	
Rest of the World	112	1.59 (2.04)	101	-0.07 (0.14)	126	1.55 (2.02)	112	0.24 (0.14)	-0.31 (-0.70, 0.09)	0.128	-0.21 (-0.48, 0.06)	
Prior anti-PD-(L)1 exposure												0.932
yes	175	2.15 (2.27)	149	-0.03 (0.12)	176	1.78 (2.11)	145	0.28 (0.13)	-0.31 (-0.65, 0.03)	0.072	-0.21 (-0.44, 0.02)	
no	72	1.94 (2.39)	63	-0.02 (0.21)	73	2.05 (2.20)	64	0.26 (0.22)	-0.28 (-0.88, 0.32)	0.354	-0.16 (-0.51, 0.18)	
Chemotherapy-free interval												0.919
< 90 days	108	2.26 (2.52)	89	-0.01 (0.16)	110	1.86 (2.19)	88	0.26 (0.18)	-0.27 (-0.75, 0.21)	0.275	-0.16 (-0.46, 0.13)	
>= 90 and < 180 days	82	2.53 (2.29)	70	-0.21 (0.19)	76	1.72 (1.89)	64	-0.01 (0.21)	-0.20 (-0.78, 0.38)	0.493	-0.12 (-0.46, 0.22)	
>= 180 days	57	1.14 (1.55)	53	0.32 (0.18)	63	2.04 (2.32)	57	0.43 (0.20)	-0.12 (-0.66, 0.42)	0.667	-0.08 (-0.46, 0.29)	
Presence (previous or current) of brain metastases												0.211
yes	111	2.04 (2.24)	93	-0.04 (0.15)	110	1.80 (2.14)	87	0.49 (0.17)	-0.54 (-0.99, -0.08)	0.021	-0.35 (-0.64, -0.06)	
no	136	2.13 (2.37)	119	-0.03 (0.14)	139	1.91 (2.14)	122	0.13 (0.15)	-0.15 (-0.56, 0.25)	0.456	-0.10 (-0.35, 0.16)	
Standard of care												0.573
Amrubicin/Topotecan	204	2.15 (2.36)	180	-0.05 (0.11)	202	1.85 (2.12)	169	0.19 (0.12)	-0.24 (-0.56, 0.07)	0.129	-0.16 (-0.37, 0.05)	
Lurbinectedin	43	1.83 (2.05)	32	0.12 (0.33)	47	1.93 (2.22)	40	0.65 (0.34)	-0.53 (-1.48, 0.43)	0.273	-0.26 (-0.72, 0.21)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Anhang 4-G5.4.5: Endpunkt „FACT-G GP5“ – RCT

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=15% of Treatment Side Effects - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.829
< 65 years	92/ 129 (71.3)	2.6 (2.1, 3.6)	85/ 115 (73.9)	3.3 (3.1, 4.3)	0.99 (0.73, 1.33)	0.905	
>= 65 years	92/ 125 (73.6)	2.4 (2.3, 3.0)	106/ 140 (75.7)	3.1 (2.3, 3.6)	1.03 (0.78, 1.37)	0.840	
Gender							0.020
female	55/ 72 (76.4)	2.3 (1.6, 2.4)	61/ 86 (70.9)	3.3 (2.4, 4.4)	1.44 (1.00, 2.08)	0.055	
male	129/ 182 (70.9)	2.6 (2.3, 3.4)	130/ 169 (76.9)	3.3 (2.6, 3.6)	0.86 (0.67, 1.10)	0.219	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	15/ 21 (71.4)		15/ 18 (83.3)				
STAGE IV	169/ 233 (72.5)		175/ 235 (74.5)				
Region							0.017
North America and Europe	108/ 140 (77.1)	2.4 (2.3, 2.6)	87/ 128 (68.0)	3.3 (3.0, 4.1)	1.28 (0.97, 1.70)	0.085	
Rest of the World	76/ 114 (66.7)	2.4 (2.1, 4.7)	104/ 127 (81.9)	3.3 (2.3, 3.7)	0.77 (0.57, 1.04)	0.080	
Prior anti-PD-(L)1 exposure							0.407
yes	132/ 180 (73.3)	2.4 (2.1, 3.0)	137/ 180 (76.1)	3.3 (2.6, 3.6)	0.94 (0.74, 1.19)	0.577	
no	52/ 74 (70.3)	2.6 (2.3, 3.6)	54/ 75 (72.0)	3.7 (2.4, 7.1)	1.14 (0.78, 1.66)	0.533	
Chemotherapy-free interval							0.435
< 90 days	75/ 109 (68.8)	2.7 (2.3, 3.7)	83/ 114 (72.8)	3.1 (2.4, 3.7)	0.86 (0.63, 1.18)	0.333	
>= 90 and < 180 days	61/ 85 (71.8)	2.3 (1.6, 2.4)	56/ 78 (71.8)	3.4 (2.4, 4.6)	1.19 (0.83, 1.71)	0.383	
>= 180 days	48/ 60 (80.0)	2.7 (2.3, 3.6)	52/ 63 (82.5)	3.3 (2.3, 4.3)	1.03 (0.70, 1.53)	0.876	
Presence (previous or current) of brain metastases							0.719
yes	88/ 113 (77.9)	2.6 (2.1, 3.0)	81/ 115 (70.4)	3.3 (2.4, 3.6)	1.04 (0.76, 1.40)	0.829	
no	96/ 141 (68.1)	2.4 (2.3, 3.3)	110/ 140 (78.6)	3.3 (2.6, 4.1)	0.95 (0.73, 1.26)	0.703	
Standard of care							0.356
Amrubicin/Topotecan	157/ 209 (75.1)	2.3 (2.3, 2.7)	155/ 208 (74.5)	3.3 (2.6, 3.6)	1.03 (0.83, 1.29)	0.807	
Lurbinectedin	27/ 45 (60.0)	3.3 (2.3, 10.7)	36/ 47 (76.6)	3.6 (2.4, 4.4)	0.84 (0.51, 1.39)	0.498	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of Treatment Side Effects - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.895
< 65 years	128	0.32 (0.69)	122	0.47 (0.07)	114	0.35 (0.72)	104	0.66 (0.08)	-0.19 (-0.39, 0.01)	0.063	-0.25 (-0.51, 0.01)	
>= 65 years	119	0.28 (0.62)	113	0.57 (0.07)	136	0.44 (0.78)	127	0.78 (0.07)	-0.21 (-0.41, -0.01)	0.039	-0.27 (-0.52, -0.01)	
Gender												0.110
female	67	0.33 (0.75)	63	0.67 (0.11)	84	0.49 (0.88)	78	0.68 (0.10)	-0.01 (-0.29, 0.27)	0.945	-0.01 (-0.34, 0.32)	
male	180	0.29 (0.62)	172	0.46 (0.06)	166	0.36 (0.67)	153	0.73 (0.06)	-0.27 (-0.43, -0.11)	<.001	-0.38 (-0.59, -0.16)	
Disease Stage at Screening												
STAGE II	0	-	0		2	0.50 (0.71)	2					
STAGE III	19	0.05 (0.23)	19		18	0.39 (0.61)	16					
STAGE IV	228	0.32 (0.68)	216		230	0.40 (0.76)	213					
Region												0.152
North America and Europe	135	0.30 (0.66)	128	0.63 (0.07)	124	0.32 (0.70)	110	0.74 (0.08)	-0.11 (-0.32, 0.10)	0.316	-0.13 (-0.39, 0.12)	
Rest of the World	112	0.30 (0.66)	107	0.39 (0.07)	126	0.48 (0.79)	121	0.71 (0.07)	-0.31 (-0.50, -0.13)	0.001	-0.44 (-0.70, -0.18)	
Prior anti-PD-(L)1 exposure												0.833
yes	175	0.32 (0.70)	167	0.51 (0.06)	177	0.40 (0.72)	161	0.72 (0.06)	-0.22 (-0.38, -0.05)	0.011	-0.28 (-0.50, -0.07)	
no	72	0.25 (0.55)	68	0.54 (0.10)	73	0.41 (0.83)	70	0.72 (0.10)	-0.18 (-0.45, 0.08)	0.178	-0.23 (-0.56, 0.10)	
Chemotherapy-free interval												0.331
< 90 days	108	0.35 (0.74)	100	0.44 (0.08)	111	0.45 (0.85)	100	0.66 (0.08)	-0.22 (-0.43, -0.00)	0.047	-0.28 (-0.56, -0.00)	
>= 90 and < 180 days	82	0.30 (0.66)	80	0.57 (0.08)	76	0.45 (0.79)	71	0.64 (0.09)	-0.07 (-0.31, 0.17)	0.554	-0.10 (-0.42, 0.22)	
>= 180 days	57	0.19 (0.44)	55	0.55 (0.11)	63	0.25 (0.44)	60	0.91 (0.10)	-0.36 (-0.65, -0.06)	0.020	-0.44 (-0.81, -0.07)	
Presence (previous or current) of brain metastases												0.776
yes	111	0.29 (0.62)	108	0.52 (0.07)	110	0.37 (0.78)	100	0.70 (0.08)	-0.18 (-0.39, 0.03)	0.094	-0.23 (-0.51, 0.04)	
no	136	0.31 (0.68)	127	0.51 (0.07)	140	0.42 (0.73)	131	0.73 (0.07)	-0.22 (-0.41, -0.03)	0.022	-0.29 (-0.53, -0.04)	
Standard of care												0.160
Amrubicin/Topotecan	204	0.29 (0.66)	196	0.55 (0.06)	203	0.38 (0.73)	189	0.72 (0.06)	-0.16 (-0.32, -0.00)	0.043	-0.21 (-0.41, -0.01)	
Lurbinectedin	43	0.33 (0.64)	39	0.31 (0.11)	47	0.49 (0.83)	42	0.71 (0.11)	-0.40 (-0.70, -0.10)	0.010	-0.58 (-1.03, -0.14)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Anhang 4-G5.5: Endpunkt „Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ-C30“ – RCT

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Cognitive Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.655
< 65 years	72/ 129 (55.8)	8.3 (4.0, 30.6)	62/ 115 (53.9)	7.5 (5.3, 18.2)	1.00 (0.71, 1.41)	0.976	
>= 65 years	67/ 125 (53.6)	6.8 (3.3, 18.4)	79/ 140 (56.4)	6.3 (4.3, 9.8)	0.91 (0.66, 1.27)	0.580	
Gender							0.026
female	48/ 72 (66.7)	3.7 (2.6, 7.5)	47/ 86 (54.7)	7.7 (4.6, 18.2)	1.39 (0.93, 2.09)	0.108	
male	91/ 182 (50.0)	12.2 (6.0, 42.3)	94/ 169 (55.6)	6.4 (4.3, 9.7)	0.81 (0.61, 1.09)	0.148	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	12/ 21 (57.1)		11/ 18 (61.1)				
STAGE IV	127/ 233 (54.5)		128/ 235 (54.5)				
Region							0.948
North America and Europe	77/ 140 (55.0)	8.3 (4.0, 18.5)	70/ 128 (54.7)	6.3 (5.1, 10.4)	0.90 (0.65, 1.26)	0.531	
Rest of the World	62/ 114 (54.4)	6.3 (3.3, 19.8)	71/ 127 (55.9)	7.7 (4.3, 10.4)	1.00 (0.71, 1.41)	0.970	
Prior anti-PD-(L)1 exposure							0.546
yes	99/ 180 (55.0)	8.0 (3.6, 18.4)	101/ 180 (56.1)	6.1 (4.6, 9.3)	0.91 (0.69, 1.20)	0.481	
no	40/ 74 (54.1)	7.7 (3.1, 42.3)	40/ 75 (53.3)	10.0 (4.3, 25.2)	1.05 (0.68, 1.64)	0.832	
Chemotherapy-free interval							0.920
< 90 days	62/ 109 (56.9)	6.1 (3.0, 8.4)	62/ 114 (54.4)	5.7 (4.1, 7.7)	1.01 (0.71, 1.44)	0.981	
>= 90 and < 180 days	41/ 85 (48.2)	10.5 (4.8, NE)	38/ 78 (48.7)	19.5 (5.6, 25.2)	0.95 (0.61, 1.48)	0.812	
>= 180 days	36/ 60 (60.0)	9.5 (3.1, 35.6)	41/ 63 (65.1)	5.8 (4.1, 10.4)	0.87 (0.55, 1.37)	0.539	
Presence (previous or current) of brain metastases							0.316
yes	60/ 113 (53.1)	9.7 (6.3, 34.9)	61/ 115 (53.0)	6.1 (4.1, 9.5)	0.83 (0.58, 1.19)	0.298	
no	79/ 141 (56.0)	6.0 (3.1, 10.5)	80/ 140 (57.1)	8.1 (5.1, 12.1)	1.06 (0.77, 1.45)	0.763	
Standard of care							0.378
Amrubicin/Topotecan	119/ 209 (56.9)	7.5 (4.8, 12.2)	121/ 208 (58.2)	6.0 (4.6, 9.1)	0.87 (0.68, 1.13)	0.292	
Lurbinectedin	20/ 45 (44.4)	10.7 (2.3, NE)	20/ 47 (42.6)	NE (5.4, NE)	1.32 (0.71, 2.46)	0.391	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Emotional Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.417
< 65 years	56/ 129 (43.4)	30.6 (14.2, NE)	59/ 115 (51.3)	7.8 (5.3, 30.0)	0.68 (0.47, 0.99)	0.043	
>= 65 years	56/ 125 (44.8)	12.1 (8.7, NE)	66/ 140 (47.1)	9.1 (6.1, 24.5)	0.89 (0.62, 1.27)	0.522	
Gender							0.127
female	39/ 72 (54.2)	11.4 (6.8, 28.2)	42/ 86 (48.8)	8.5 (4.3, 33.0)	1.01 (0.65, 1.57)	0.968	
male	73/ 182 (40.1)	NE (12.8, NE)	83/ 169 (49.1)	9.1 (6.1, 24.3)	0.70 (0.51, 0.96)	0.026	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	7/ 21 (33.3)		11/ 18 (61.1)				
STAGE IV	105/ 233 (45.1)		112/ 235 (47.7)				
Region							0.885
North America and Europe	64/ 140 (45.7)	18.1 (7.5, 36.4)	65/ 128 (50.8)	7.1 (5.1, 9.7)	0.75 (0.53, 1.06)	0.105	
Rest of the World	48/ 114 (42.1)	30.8 (11.4, NE)	60/ 127 (47.2)	23.1 (7.3, 30.2)	0.77 (0.53, 1.14)	0.188	
Prior anti-PD-(L)1 exposure							0.789
yes	80/ 180 (44.4)	19.8 (9.8, NE)	86/ 180 (47.8)	9.1 (5.4, 28.5)	0.80 (0.59, 1.09)	0.164	
no	32/ 74 (43.2)	28.2 (9.3, NE)	39/ 75 (52.0)	8.5 (5.3, 30.0)	0.72 (0.45, 1.15)	0.161	
Chemotherapy-free interval							0.913
< 90 days	42/ 109 (38.5)	30.6 (9.3, NE)	44/ 114 (38.6)	23.1 (5.7, NE)	0.85 (0.56, 1.31)	0.467	
>= 90 and < 180 days	37/ 85 (43.5)	18.5 (7.1, NE)	39/ 78 (50.0)	9.7 (5.1, NE)	0.79 (0.50, 1.24)	0.308	
>= 180 days	33/ 60 (55.0)	12.8 (7.1, 36.4)	42/ 63 (66.7)	7.4 (4.4, 9.5)	0.69 (0.43, 1.09)	0.112	
Presence (previous or current) of brain metastases							0.876
yes	53/ 113 (46.9)	18.5 (9.3, NE)	53/ 115 (46.1)	9.5 (5.3, 30.2)	0.79 (0.54, 1.17)	0.235	
no	59/ 141 (41.8)	30.8 (10.5, NE)	72/ 140 (51.4)	9.1 (5.3, 24.3)	0.76 (0.54, 1.08)	0.121	
Standard of care							0.243
Amrubicin/Topotecan	99/ 209 (47.4)	18.1 (9.7, 36.4)	103/ 208 (49.5)	7.8 (6.1, 23.1)	0.83 (0.63, 1.09)	0.180	
Lurbinectedin	13/ 45 (28.9)	NE (19.8, NE)	22/ 47 (46.8)	24.3 (4.1, NE)	0.51 (0.25, 1.03)	0.057	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Physical Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.450
< 65 years	79/ 129 (61.2)	4.3 (2.7, 8.4)	67/ 115 (58.3)	6.8 (4.3, 8.4)	1.10 (0.79, 1.53)	0.572	
>= 65 years	75/ 125 (60.0)	4.7 (3.1, 8.3)	92/ 140 (65.7)	4.3 (3.1, 7.3)	0.92 (0.68, 1.25)	0.594	
Gender							0.259
female	43/ 72 (59.7)	3.6 (2.3, 6.4)	62/ 86 (72.1)	4.4 (2.6, 7.4)	0.83 (0.56, 1.23)	0.330	
male	111/ 182 (61.0)	4.4 (3.6, 8.4)	97/ 169 (57.4)	6.3 (4.3, 8.3)	1.09 (0.83, 1.43)	0.547	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	15/ 21 (71.4)		13/ 18 (72.2)				
STAGE IV	139/ 233 (59.7)		145/ 235 (61.7)				
Region							0.345
North America and Europe	89/ 140 (63.6)	4.1 (2.6, 5.3)	76/ 128 (59.4)	5.1 (3.1, 7.4)	1.10 (0.81, 1.49)	0.553	
Rest of the World	65/ 114 (57.0)	8.0 (3.3, 12.1)	83/ 127 (65.4)	6.3 (4.1, 8.3)	0.87 (0.63, 1.21)	0.403	
Prior anti-PD-(L)1 exposure							0.967
yes	110/ 180 (61.1)	4.3 (3.3, 6.4)	110/ 180 (61.1)	5.3 (4.1, 7.5)	1.00 (0.76, 1.30)	0.964	
no	44/ 74 (59.5)	4.3 (2.6, 11.2)	49/ 75 (65.3)	6.5 (3.3, 7.7)	0.95 (0.63, 1.44)	0.802	
Chemotherapy-free interval							0.560
< 90 days	59/ 109 (54.1)	4.8 (3.1, 18.2)	66/ 114 (57.9)	5.7 (3.1, 7.7)	0.86 (0.60, 1.23)	0.400	
>= 90 and < 180 days	53/ 85 (62.4)	4.3 (2.6, 5.8)	51/ 78 (65.4)	5.3 (4.1, 9.7)	1.08 (0.74, 1.59)	0.702	
>= 180 days	42/ 60 (70.0)	4.3 (2.3, 11.5)	42/ 63 (66.7)	5.1 (3.3, 8.8)	1.12 (0.73, 1.73)	0.600	
Presence (previous or current) of brain metastases							0.819
yes	72/ 113 (63.7)	4.1 (2.6, 6.5)	71/ 115 (61.7)	4.3 (3.1, 7.4)	0.95 (0.69, 1.33)	0.754	
no	82/ 141 (58.2)	4.7 (3.3, 8.4)	88/ 140 (62.9)	6.3 (4.3, 8.3)	1.01 (0.75, 1.37)	0.948	
Standard of care							0.575
Amrubicin/Topotecan	133/ 209 (63.6)	4.3 (3.1, 6.0)	130/ 208 (62.5)	5.1 (4.1, 7.4)	1.00 (0.78, 1.27)	0.981	
Lurbinectedin	21/ 45 (46.7)	4.7 (2.6, NE)	29/ 47 (61.7)	6.5 (3.4, 8.4)	0.89 (0.51, 1.57)	0.681	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Global Health Status/QOL - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.866
< 65 years	86/ 129 (66.7)	2.6 (2.3, 6.0)	76/ 115 (66.1)	4.3 (3.1, 6.3)	1.04 (0.77, 1.42)	0.821	
>= 65 years	86/ 125 (68.8)	3.0 (2.3, 3.7)	96/ 140 (68.6)	3.4 (3.1, 5.1)	1.09 (0.81, 1.46)	0.567	
Gender							0.351
female	51/ 72 (70.8)	2.3 (2.0, 3.3)	61/ 86 (70.9)	3.6 (2.4, 6.3)	1.26 (0.86, 1.83)	0.234	
male	121/ 182 (66.5)	3.3 (2.3, 5.3)	111/ 169 (65.7)	4.3 (3.3, 5.4)	1.01 (0.78, 1.31)	0.960	
Disease Stage at Screening							
STAGE II	0		1/ 2 (50.0)				
STAGE III	13/ 21 (61.9)		13/ 18 (72.2)				
STAGE IV	159/ 233 (68.2)		158/ 235 (67.2)				
Region							0.210
North America and Europe	96/ 140 (68.6)	2.6 (2.3, 4.1)	79/ 128 (61.7)	4.4 (3.3, 7.1)	1.22 (0.90, 1.64)	0.201	
Rest of the World	76/ 114 (66.7)	3.0 (2.1, 4.3)	93/ 127 (73.2)	3.4 (2.6, 5.3)	0.93 (0.69, 1.27)	0.639	
Prior anti-PD-(L)1 exposure							0.219
yes	121/ 180 (67.2)	2.7 (2.3, 4.3)	124/ 180 (68.9)	3.3 (3.0, 4.3)	0.97 (0.75, 1.24)	0.766	
no	51/ 74 (68.9)	2.4 (2.0, 5.3)	48/ 75 (64.0)	5.1 (4.0, 7.7)	1.28 (0.86, 1.90)	0.229	
Chemotherapy-free interval							0.787
< 90 days	72/ 109 (66.1)	2.7 (2.1, 4.8)	73/ 114 (64.0)	3.3 (2.6, 4.3)	1.04 (0.75, 1.44)	0.845	
>= 90 and < 180 days	58/ 85 (68.2)	2.6 (2.3, 4.3)	56/ 78 (71.8)	5.1 (2.4, 7.3)	0.97 (0.67, 1.41)	0.834	
>= 180 days	42/ 60 (70.0)	2.7 (2.0, 6.3)	43/ 63 (68.3)	5.1 (3.1, 8.1)	1.19 (0.78, 1.82)	0.424	
Presence (previous or current) of brain metastases							0.016
yes	70/ 113 (61.9)	3.0 (2.3, 6.4)	75/ 115 (65.2)	3.3 (2.4, 4.8)	0.80 (0.58, 1.11)	0.178	
no	102/ 141 (72.3)	2.6 (2.3, 3.6)	97/ 140 (69.3)	4.4 (3.3, 6.3)	1.33 (1.01, 1.76)	0.044	
Standard of care							0.944
Amrubicin/Topotecan	143/ 209 (68.4)	3.0 (2.3, 4.3)	137/ 208 (65.9)	4.3 (3.3, 5.8)	1.06 (0.84, 1.35)	0.625	
Lurbinectedin	29/ 45 (64.4)	2.3 (1.3, 3.3)	35/ 47 (74.5)	3.3 (2.3, 4.4)	1.04 (0.64, 1.71)	0.870	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Role Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.208
< 65 years	81/ 129 (62.8)	2.7 (2.4, 4.6)	82/ 115 (71.3)	4.3 (3.3, 5.3)	0.89 (0.66, 1.22)	0.457	
>= 65 years	91/ 125 (72.8)	2.6 (2.1, 4.1)	94/ 140 (67.1)	3.3 (2.4, 4.4)	1.17 (0.87, 1.56)	0.290	
Gender							0.808
female	49/ 72 (68.1)	2.3 (2.0, 2.7)	63/ 86 (73.3)	2.8 (2.4, 4.1)	1.02 (0.70, 1.48)	0.929	
male	123/ 182 (67.6)	3.1 (2.4, 4.6)	113/ 169 (66.9)	4.4 (3.4, 5.6)	1.04 (0.81, 1.35)	0.772	
Disease Stage at Screening							
STAGE II	0		2/ 2 (100.0)				
STAGE III	15/ 21 (71.4)		13/ 18 (72.2)				
STAGE IV	157/ 233 (67.4)		161/ 235 (68.5)				
Region							0.181
North America and Europe	101/ 140 (72.1)	2.6 (2.3, 3.6)	86/ 128 (67.2)	4.1 (2.8, 5.1)	1.14 (0.85, 1.52)	0.375	
Rest of the World	71/ 114 (62.3)	3.1 (2.3, 6.4)	90/ 127 (70.9)	4.1 (3.3, 5.3)	0.89 (0.65, 1.22)	0.446	
Prior anti-PD-(L)1 exposure							0.720
yes	123/ 180 (68.3)	2.6 (2.3, 4.1)	120/ 180 (66.7)	4.1 (3.1, 4.6)	1.05 (0.82, 1.36)	0.706	
no	49/ 74 (66.2)	3.1 (2.4, 4.6)	56/ 75 (74.7)	4.1 (2.6, 7.4)	0.92 (0.63, 1.36)	0.670	
Chemotherapy-free interval							0.816
< 90 days	65/ 109 (59.6)	3.1 (2.1, 6.7)	71/ 114 (62.3)	4.1 (3.1, 5.3)	1.04 (0.74, 1.46)	0.845	
>= 90 and < 180 days	62/ 85 (72.9)	2.6 (2.1, 4.0)	58/ 78 (74.4)	4.1 (2.6, 6.3)	1.07 (0.75, 1.54)	0.730	
>= 180 days	45/ 60 (75.0)	3.1 (2.4, 4.6)	47/ 63 (74.6)	3.3 (2.3, 4.4)	0.91 (0.60, 1.38)	0.665	
Presence (previous or current) of brain metastases							0.421
yes	82/ 113 (72.6)	2.6 (2.3, 4.3)	78/ 115 (67.8)	3.3 (2.4, 4.1)	0.93 (0.68, 1.27)	0.647	
no	90/ 141 (63.8)	2.6 (2.3, 4.4)	98/ 140 (70.0)	4.4 (3.3, 6.0)	1.09 (0.82, 1.45)	0.594	
Standard of care							0.993
Amrubicin/Topotecan	147/ 209 (70.3)	2.7 (2.3, 4.3)	146/ 208 (70.2)	4.0 (3.0, 4.4)	0.99 (0.79, 1.25)	0.929	
Lurbinectedin	25/ 45 (55.6)	2.6 (2.3, 8.3)	30/ 47 (63.8)	4.6 (3.3, 9.3)	1.10 (0.65, 1.88)	0.737	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
Time to deterioration of >=10 points of C30 Social Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup Level	Tarlatamab (N=254) n/ N (%)	Tarlatamab (N=254) Median (95%-CI)	Standard of Care (N=255) n/ N (%)	Standard of Care (N=255) Median (95%-CI)	Tarlatamab vs. Standard of Care Hazard Ratio (95% CI)	Tarlatamab vs. Standard of Care p-Value	Interaction p-Value
Age							0.724
< 65 years	77/ 129 (59.7)	4.1 (2.4, 10.5)	69/ 115 (60.0)	5.3 (4.1, 8.0)	1.01 (0.73, 1.40)	0.982	
>= 65 years	70/ 125 (56.0)	3.1 (2.3, 8.7)	90/ 140 (64.3)	4.1 (3.1, 5.4)	0.93 (0.68, 1.28)	0.626	
Gender							0.619
female	42/ 72 (58.3)	2.6 (2.1, 5.4)	56/ 86 (65.1)	4.3 (3.1, 7.3)	1.09 (0.73, 1.62)	0.719	
male	105/ 182 (57.7)	4.6 (2.6, 10.5)	103/ 169 (60.9)	5.1 (3.6, 6.7)	0.93 (0.71, 1.22)	0.584	
Disease Stage at Screening							
STAGE II	0		0/ 2 (0.0)				
STAGE III	14/ 21 (66.7)		15/ 18 (83.3)				
STAGE IV	133/ 233 (57.1)		144/ 235 (61.3)				
Region							0.110
North America and Europe	85/ 140 (60.7)	2.6 (2.3, 4.7)	76/ 128 (59.4)	5.1 (3.6, 8.3)	1.13 (0.83, 1.55)	0.459	
Rest of the World	62/ 114 (54.4)	6.3 (2.4, 22.9)	83/ 127 (65.4)	4.3 (3.3, 5.6)	0.80 (0.58, 1.12)	0.188	
Prior anti-PD-(L)1 exposure							0.296
yes	106/ 180 (58.9)	3.3 (2.4, 8.4)	116/ 180 (64.4)	3.6 (3.1, 5.1)	0.89 (0.68, 1.16)	0.377	
no	41/ 74 (55.4)	4.4 (2.3, 19.2)	43/ 75 (57.3)	7.7 (5.1, 14.2)	1.12 (0.73, 1.72)	0.624	
Chemotherapy-free interval							0.515
< 90 days	58/ 109 (53.2)	4.6 (2.4, 22.9)	68/ 114 (59.6)	4.6 (3.3, 7.1)	0.87 (0.61, 1.24)	0.424	
>= 90 and < 180 days	51/ 85 (60.0)	2.6 (2.3, 10.5)	53/ 78 (67.9)	4.1 (2.6, 7.3)	0.91 (0.62, 1.34)	0.621	
>= 180 days	38/ 60 (63.3)	2.9 (2.1, 12.8)	38/ 63 (60.3)	4.6 (3.6, 8.5)	1.18 (0.75, 1.85)	0.494	
Presence (previous or current) of brain metastases							0.251
yes	67/ 113 (59.3)	4.7 (2.6, 10.5)	71/ 115 (61.7)	4.1 (3.1, 6.5)	0.81 (0.58, 1.14)	0.217	
no	80/ 141 (56.7)	3.1 (2.3, 8.7)	88/ 140 (62.9)	5.1 (3.6, 8.3)	1.09 (0.80, 1.47)	0.614	
Standard of care							0.511
Amrubicin/Topotecan	124/ 209 (59.3)	3.3 (2.4, 6.5)	132/ 208 (63.5)	4.3 (3.3, 5.3)	0.92 (0.72, 1.17)	0.465	
Lurbinectedin	23/ 45 (51.1)	4.7 (2.3, NE)	27/ 47 (57.4)	8.0 (3.6, 18.4)	1.20 (0.68, 2.09)	0.539	

Effect measures are calculated if each subgroup level comprises at least 10 patients and at least 10 events occurred in one of the subgroup levels.
Median was estimated using the Kaplan-Meier method, and the 95% CI was estimated using log-log transformation of the KM survival estimate as described by Brookmeyer and Crowley (1982). Median is presented in weeks.
Hazard ratios and 95% CIs are estimated using a Cox proportional hazards model
p-value for hazard ratio is calculated using a log-rank test.
p-Value for interaction is calculated from Cox Proportional Hazard Model with additional factors for subgroup and treatment-by-subgroup interaction.
n=Number of subjects with event; N=Number of patients included in the analysis; CI=Confidence Interval; HR=Hazard Ratio; NE=Not estimable

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Cognitive Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.965
< 65 years	128	91.28 (14.64)	123	-3.29 (1.31)	114	86.55 (18.67)	104	-5.34 (1.47)	2.06 (-1.84, 5.96)	0.299	0.14 (-0.12, 0.40)	
>= 65 years	118	86.02 (17.97)	112	-1.58 (1.23)	136	88.48 (16.04)	127	-3.53 (1.17)	1.94 (-1.40, 5.29)	0.253	0.15 (-0.11, 0.40)	
Gender												0.988
female	66	89.39 (14.21)	62	-3.13 (1.93)	84	81.75 (22.35)	78	-4.94 (1.80)	1.81 (-3.44, 7.06)	0.495	0.12 (-0.22, 0.45)	
male	180	88.52 (17.29)	173	-2.21 (0.99)	166	90.56 (13.15)	153	-4.07 (1.06)	1.86 (-0.99, 4.71)	0.200	0.14 (-0.08, 0.36)	
Disease Stage at Screening												
STAGE II	0	-	0		2	83.33 (23.57)	2					
STAGE III	19	95.61 (9.37)	19		18	89.81 (12.96)	16					
STAGE IV	227	88.18 (16.84)	216		230	87.46 (17.58)	213					
Region												0.377
North America and Europe	134	88.68 (17.53)	128	-2.41 (1.26)	124	88.17 (16.57)	110	-5.51 (1.38)	3.10 (-0.58, 6.78)	0.098	0.22 (-0.04, 0.47)	
Rest of the World	112	88.84 (15.24)	107	-2.56 (1.27)	126	87.04 (18.00)	121	-3.39 (1.23)	0.83 (-2.65, 4.32)	0.639	0.06 (-0.20, 0.32)	
Prior anti-PD-(L)1 exposure												0.968
yes	174	88.60 (16.79)	167	-2.31 (1.01)	177	87.66 (17.50)	161	-4.25 (1.05)	1.94 (-0.92, 4.80)	0.183	0.15 (-0.07, 0.36)	
no	72	89.12 (15.86)	68	-2.59 (1.79)	73	87.44 (16.85)	70	-4.41 (1.80)	1.82 (-3.21, 6.85)	0.475	0.12 (-0.21, 0.46)	
Chemotherapy-free interval												0.725
< 90 days	107	88.94 (16.18)	99	-3.63 (1.38)	111	88.29 (18.06)	100	-5.28 (1.41)	1.65 (-2.24, 5.55)	0.403	0.12 (-0.16, 0.40)	
>= 90 and < 180 days	82	87.80 (18.15)	80	-1.55 (1.41)	76	86.62 (17.00)	71	-2.68 (1.51)	1.12 (-2.97, 5.22)	0.588	0.09 (-0.23, 0.41)	
>= 180 days	57	89.77 (14.69)	56	-1.39 (1.97)	63	87.57 (16.39)	60	-5.21 (1.93)	3.82 (-1.66, 9.30)	0.169	0.26 (-0.11, 0.62)	
Presence (previous or current) of brain metastases												0.022
yes	111	87.24 (17.11)	109	-1.07 (1.37)	110	85.91 (19.71)	100	-6.46 (1.47)	5.38 (1.41, 9.36)	0.008	0.37 (0.10, 0.64)	
no	135	90.00 (15.93)	126	-3.50 (1.16)	140	88.93 (15.04)	131	-2.95 (1.16)	-0.55 (-3.78, 2.69)	0.740	-0.04 (-0.29, 0.20)	
Standard of care												0.656
Amrubicin/Topotecan	203	88.67 (16.51)	196	-2.95 (0.98)	203	88.01 (16.04)	189	-4.65 (1.02)	1.70 (-1.08, 4.48)	0.229	0.12 (-0.08, 0.32)	
Lurbinectedin	43	89.15 (16.62)	39	0.43 (1.95)	47	85.82 (21.97)	42	-2.63 (1.88)	3.06 (-2.38, 8.50)	0.264	0.25 (-0.19, 0.69)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Emotional Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)							
	Baseline		Change from BL		Baseline		Change from BL		Difference of			Interaction
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.267
< 65 years	128	80.73 (21.78)	123	0.95 (1.26)	114	81.07 (20.39)	104	-3.19 (1.40)	4.14 (0.43, 7.84)	0.029	0.29 (0.03, 0.55)	
>= 65 years	118	84.32 (17.09)	112	-0.84 (1.15)	136	84.87 (18.32)	127	-2.25 (1.09)	1.41 (-1.70, 4.53)	0.372	0.12 (-0.14, 0.37)	
Gender												0.315
female	66	79.04 (20.79)	62	1.87 (1.55)	84	78.67 (20.05)	78	-2.54 (1.45)	4.41 (0.22, 8.60)	0.039	0.35 (0.01, 0.69)	
male	180	83.70 (19.21)	173	-0.66 (1.01)	166	85.39 (18.63)	153	-2.47 (1.08)	1.81 (-1.10, 4.72)	0.222	0.14 (-0.08, 0.35)	
Disease Stage at Screening												
STAGE II	0	-	0		2	83.33 (11.79)	2					
STAGE III	19	86.84 (16.03)	19		18	85.19 (17.75)	16					
STAGE IV	227	82.09 (19.98)	216		230	82.97 (19.56)	213					
Region												0.549
North America and Europe	134	79.98 (19.82)	128	0.84 (1.21)	124	81.45 (21.22)	110	-2.69 (1.32)	3.52 (0.01, 7.04)	0.050	0.26 (0.00, 0.51)	
Rest of the World	112	85.42 (19.26)	107	-0.59 (1.20)	126	84.79 (17.23)	121	-2.66 (1.15)	2.06 (-1.21, 5.33)	0.215	0.16 (-0.10, 0.42)	
Prior anti-PD-(L)1 exposure												0.895
yes	174	82.28 (19.50)	167	0.18 (0.92)	177	82.77 (19.25)	161	-2.68 (0.96)	2.86 (0.24, 5.48)	0.033	0.24 (0.02, 0.45)	
no	72	82.87 (20.36)	68	-0.25 (1.86)	73	84.02 (19.68)	70	-2.72 (1.85)	2.47 (-2.72, 7.66)	0.347	0.16 (-0.17, 0.49)	
Chemotherapy-free interval												0.067
< 90 days	107	84.11 (21.19)	99	-0.63 (1.38)	111	83.78 (19.94)	100	-2.76 (1.41)	2.13 (-1.76, 6.03)	0.281	0.15 (-0.13, 0.43)	
>= 90 and < 180 days	82	80.08 (18.51)	80	0.37 (1.32)	76	83.44 (19.65)	71	0.12 (1.40)	0.25 (-3.58, 4.08)	0.898	0.02 (-0.30, 0.34)	
>= 180 days	57	82.75 (18.49)	56	1.11 (1.69)	63	81.61 (18.09)	60	-6.16 (1.66)	7.26 (2.57, 11.96)	0.003	0.57 (0.19, 0.94)	
Presence (previous or current) of brain metastases												0.209
yes	111	82.81 (20.14)	109	0.67 (1.17)	110	82.42 (18.73)	100	-3.76 (1.25)	4.44 (1.08, 7.80)	0.010	0.36 (0.09, 0.63)	
no	135	82.16 (19.43)	126	-0.37 (1.21)	140	83.69 (19.86)	131	-1.78 (1.20)	1.41 (-1.96, 4.77)	0.410	0.10 (-0.14, 0.35)	
Standard of care												0.197
Amrubicin/Topotecan	203	81.44 (20.34)	196	-0.51 (0.95)	203	83.13 (18.86)	189	-2.64 (0.98)	2.13 (-0.54, 4.81)	0.118	0.16 (-0.04, 0.36)	
Lurbinectedin	43	87.21 (15.79)	39	3.32 (1.89)	47	83.16 (21.53)	42	-2.64 (1.83)	5.95 (0.70, 11.21)	0.027	0.50 (0.06, 0.94)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Physical Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of		Hedges'g (95% CI)	Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value		p-Value
Age												0.381
< 65 years	128	81.25 (21.42)	123	-3.34 (1.33)	114	78.95 (20.39)	104	-8.46 (1.49)	5.12 (1.20, 9.04)	0.011	0.34 (0.08, 0.60)	
>= 65 years	119	78.04 (19.14)	113	-5.17 (1.39)	136	79.95 (19.16)	127	-7.86 (1.32)	2.70 (-1.08, 6.47)	0.160	0.18 (-0.07, 0.44)	
Gender												0.964
female	67	76.82 (20.71)	63	-5.99 (1.79)	84	75.71 (19.30)	78	-9.68 (1.69)	3.69 (-1.18, 8.56)	0.136	0.25 (-0.08, 0.58)	
male	180	80.78 (20.21)	173	-3.62 (1.12)	166	81.41 (19.68)	153	-7.44 (1.20)	3.82 (0.60, 7.05)	0.020	0.26 (0.04, 0.48)	
Disease Stage at Screening												
STAGE II	0	-	0		2	83.33 (23.57)	2					
STAGE III	19	89.47 (11.18)	19		18	79.26 (18.84)	16					
STAGE IV	228	78.89 (20.77)	217		230	79.48 (19.82)	213					
Region												0.308
North America and Europe	135	76.05 (21.75)	129	-4.83 (1.40)	124	75.16 (21.51)	110	-7.64 (1.55)	2.81 (-1.29, 6.91)	0.178	0.17 (-0.08, 0.43)	
Rest of the World	112	84.11 (17.70)	107	-3.13 (1.30)	126	83.76 (16.75)	121	-8.75 (1.26)	5.61 (2.05, 9.18)	0.002	0.41 (0.15, 0.67)	
Prior anti-PD-(L)1 exposure												0.695
yes	175	79.16 (20.97)	168	-3.78 (1.09)	177	80.00 (19.21)	161	-8.31 (1.14)	4.53 (1.44, 7.63)	0.004	0.32 (0.10, 0.53)	
no	72	81.02 (18.94)	68	-5.11 (2.02)	73	78.26 (20.91)	70	-8.37 (2.03)	3.26 (-2.37, 8.89)	0.254	0.19 (-0.14, 0.53)	
Chemotherapy-free interval												0.722
< 90 days	108	76.23 (23.91)	100	-3.17 (1.65)	111	78.86 (21.18)	100	-8.33 (1.69)	5.16 (0.51, 9.81)	0.030	0.31 (0.03, 0.59)	
>= 90 and < 180 days	82	78.94 (17.00)	80	-4.57 (1.52)	76	79.65 (18.08)	71	-7.12 (1.62)	2.55 (-1.83, 6.93)	0.251	0.19 (-0.13, 0.51)	
>= 180 days	57	87.37 (15.15)	56	-5.16 (1.78)	63	80.42 (19.12)	60	-8.96 (1.80)	3.80 (-1.24, 8.84)	0.138	0.28 (-0.09, 0.64)	
Presence (previous or current) of brain metastases												0.120
yes	111	78.62 (19.35)	109	-3.02 (1.43)	110	78.12 (19.99)	100	-9.61 (1.52)	6.60 (2.51, 10.68)	0.002	0.44 (0.16, 0.71)	
no	136	80.59 (21.21)	127	-5.03 (1.32)	140	80.57 (19.47)	131	-7.30 (1.32)	2.27 (-1.40, 5.94)	0.225	0.15 (-0.09, 0.40)	
Standard of care												0.278
Amrubicin/Topotecan	204	79.71 (20.92)	197	-4.98 (1.09)	203	79.41 (20.28)	189	-8.55 (1.14)	3.56 (0.47, 6.66)	0.024	0.23 (0.03, 0.43)	
Lurbinectedin	43	79.69 (17.81)	39	0.03 (2.07)	47	79.86 (17.17)	42	-7.09 (1.99)	7.12 (1.37, 12.87)	0.016	0.55 (0.10, 0.99)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Global Health Status/QOL - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of		Hedges'g (95% CI)	Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value		p-Value
Age												0.816
< 65 years	128	68.75 (19.37)	123	-5.53 (1.15)	114	65.64 (20.72)	104	-8.85 (1.29)	3.32 (-0.08, 6.73)	0.056	0.26 (-0.01, 0.52)	
>= 65 years	118	67.44 (19.28)	112	-5.82 (1.26)	136	65.99 (20.01)	127	-9.72 (1.21)	3.90 (0.47, 7.32)	0.026	0.29 (0.03, 0.54)	
Gender												0.985
female	66	68.81 (19.68)	62	-7.13 (1.56)	84	64.19 (20.24)	78	-10.66 (1.48)	3.53 (-0.72, 7.78)	0.103	0.28 (-0.06, 0.61)	
male	180	67.87 (19.20)	173	-5.06 (1.01)	166	66.67 (20.33)	153	-8.63 (1.09)	3.58 (0.65, 6.50)	0.017	0.27 (0.05, 0.48)	
Disease Stage at Screening												
STAGE II	0	-	0		2	62.50 (17.68)	2					
STAGE III	19	74.56 (15.83)	19		18	66.20 (16.29)	16					
STAGE IV	227	67.58 (19.49)	216		230	65.83 (20.65)	213					
Region												0.131
North America and Europe	134	66.73 (19.10)	128	-5.94 (1.06)	124	63.51 (20.35)	110	-7.88 (1.18)	1.93 (-1.20, 5.07)	0.225	0.16 (-0.10, 0.41)	
Rest of the World	112	69.79 (19.48)	107	-4.91 (1.33)	126	68.12 (20.06)	121	-10.53 (1.29)	5.62 (1.97, 9.27)	0.003	0.40 (0.14, 0.66)	
Prior anti-PD-(L)1 exposure												0.035
yes	174	67.48 (19.42)	167	-5.33 (1.00)	177	66.53 (19.99)	161	-10.76 (1.04)	5.42 (2.59, 8.26)	<.001	0.41 (0.20, 0.63)	
no	72	69.68 (19.04)	68	-6.20 (1.59)	73	64.16 (21.05)	70	-5.92 (1.63)	-0.28 (-4.80, 4.24)	0.903	-0.02 (-0.35, 0.31)	
Chemotherapy-free interval												0.915
< 90 days	107	66.28 (21.64)	99	-5.69 (1.36)	111	67.42 (21.13)	100	-9.28 (1.39)	3.58 (-0.25, 7.41)	0.066	0.26 (-0.02, 0.54)	
>= 90 and < 180 days	82	65.55 (18.55)	80	-4.07 (1.47)	76	63.38 (20.19)	71	-7.34 (1.59)	3.26 (-1.01, 7.53)	0.133	0.25 (-0.08, 0.57)	
>= 180 days	57	75.29 (13.27)	56	-7.20 (1.66)	63	66.01 (18.89)	60	-11.78 (1.68)	4.58 (-0.17, 9.32)	0.058	0.36 (-0.01, 0.72)	
Presence (previous or current) of brain metastases												0.726
yes	111	67.04 (18.17)	109	-5.61 (1.29)	110	66.97 (18.78)	100	-9.81 (1.38)	4.20 (0.47, 7.93)	0.028	0.31 (0.03, 0.58)	
no	135	69.01 (20.20)	126	-5.56 (1.13)	140	64.94 (21.43)	131	-8.89 (1.14)	3.33 (0.16, 6.49)	0.039	0.26 (0.01, 0.50)	
Standard of care												0.189
Amrubicin/Topotecan	203	69.17 (18.90)	196	-5.70 (0.92)	203	65.64 (20.28)	189	-8.46 (0.97)	2.76 (0.13, 5.38)	0.039	0.21 (0.01, 0.41)	
Lurbinectedin	43	63.18 (20.59)	39	-5.31 (2.12)	47	66.67 (20.56)	42	-12.32 (2.05)	7.01 (1.12, 12.91)	0.020	0.52 (0.08, 0.97)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Role Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of			Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value	Hedges'g (95% CI)	p-Value
Age												0.283
< 65 years	128	80.99 (25.42)	123	-6.26 (1.58)	114	82.31 (21.98)	104	-11.62 (1.76)	5.36 (0.72, 10.00)	0.024	0.30 (0.04, 0.56)	
>= 65 years	119	82.49 (22.22)	113	-8.89 (1.65)	136	83.09 (22.77)	127	-10.74 (1.58)	1.84 (-2.66, 6.34)	0.420	0.10 (-0.15, 0.36)	
Gender												0.577
female	67	79.85 (25.71)	63	-10.19 (2.36)	84	78.57 (24.62)	78	-12.24 (2.22)	2.05 (-4.36, 8.45)	0.528	0.11 (-0.23, 0.44)	
male	180	82.41 (23.22)	173	-6.61 (1.29)	166	84.84 (20.91)	153	-10.74 (1.38)	4.13 (0.42, 7.85)	0.029	0.24 (0.02, 0.46)	
Disease Stage at Screening												
STAGE II	0	-	0		2	91.67 (11.79)	2					
STAGE III	19	92.11 (12.87)	19		18	84.26 (20.98)	16					
STAGE IV	228	80.85 (24.41)	217		230	82.54 (22.58)	213					
Region												0.716
North America and Europe	135	79.38 (24.87)	129	-9.28 (1.66)	124	79.70 (23.04)	110	-12.77 (1.83)	3.49 (-1.36, 8.34)	0.157	0.18 (-0.07, 0.44)	
Rest of the World	112	84.52 (22.45)	107	-5.26 (1.54)	126	85.71 (21.37)	121	-9.93 (1.48)	4.67 (0.46, 8.89)	0.030	0.29 (0.03, 0.55)	
Prior anti-PD-(L)1 exposure												0.505
yes	175	80.48 (24.07)	168	-7.42 (1.39)	177	82.30 (22.62)	161	-11.94 (1.45)	4.52 (0.57, 8.47)	0.025	0.25 (0.03, 0.46)	
no	72	84.72 (23.36)	68	-7.88 (2.04)	73	83.79 (21.87)	70	-10.07 (2.06)	2.18 (-3.53, 7.90)	0.451	0.13 (-0.21, 0.46)	
Chemotherapy-free interval												0.263
< 90 days	108	78.24 (28.04)	100	-5.87 (1.86)	111	82.58 (20.77)	100	-11.41 (1.91)	5.54 (0.29, 10.79)	0.039	0.29 (0.01, 0.57)	
>= 90 and < 180 days	82	81.71 (21.21)	80	-9.51 (1.97)	76	80.92 (24.75)	71	-9.56 (2.11)	0.04 (-5.66, 5.74)	0.988	0.00 (-0.32, 0.32)	
>= 180 days	57	88.30 (16.95)	56	-7.15 (2.10)	63	85.19 (22.22)	60	-13.14 (2.08)	5.99 (0.13, 11.84)	0.045	0.37 (0.01, 0.74)	
Presence (previous or current) of brain metastases												0.077
yes	111	80.33 (23.48)	109	-6.54 (1.79)	110	81.97 (22.25)	100	-13.76 (1.90)	7.22 (2.09, 12.36)	0.006	0.38 (0.11, 0.66)	
no	136	82.84 (24.25)	127	-8.19 (1.48)	140	83.33 (22.53)	131	-9.50 (1.49)	1.31 (-2.82, 5.45)	0.532	0.08 (-0.17, 0.32)	
Standard of care												0.672
Amrubicin/Topotecan	204	82.35 (23.90)	197	-8.45 (1.29)	203	83.33 (22.25)	189	-11.95 (1.34)	3.50 (-0.15, 7.14)	0.060	0.19 (-0.01, 0.39)	
Lurbinectedin	43	78.68 (23.94)	39	-2.46 (2.39)	47	80.14 (22.96)	42	-7.57 (2.31)	5.11 (-1.54, 11.76)	0.130	0.34 (-0.10, 0.78)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Amgen Inc.
Tarlatamab (AMG 757) - Study DeLLphi-304 - data cutoff date: 29 Jan 2025
Study population
MMRM Analysis of change from baseline of C30 Social Functioning - Subgroup analysis
Intention-to-Treat Analysis Set

Subgroup	Tarlatamab (N=254)				Standard of Care (N=255)				Difference of		Hedges'g (95% CI)	Interaction
	Baseline		Change from BL		Baseline		Change from BL					
Level	N	Mean (SD)	N*	LSMean (SE)	N	Mean (SD)	N*	LSMean (SE)	LSMeans (95% CI)	p-Value		p-Value
Age												0.322
< 65 years	128	81.25 (22.91)	123	-3.74 (1.50)	114	81.29 (22.41)	104	-10.30 (1.66)	6.56 (2.15, 10.97)	0.004	0.39 (0.13, 0.65)	
>= 65 years	118	83.19 (22.80)	112	-6.47 (1.61)	136	86.52 (19.72)	127	-9.91 (1.52)	3.44 (-0.93, 7.82)	0.122	0.20 (-0.05, 0.46)	
Gender												0.266
female	66	81.06 (25.13)	62	-5.99 (2.38)	84	83.33 (22.70)	78	-13.70 (2.19)	7.71 (1.31, 14.11)	0.019	0.40 (0.06, 0.74)	
male	180	82.59 (21.99)	173	-4.74 (1.21)	166	84.54 (20.31)	153	-8.35 (1.29)	3.61 (0.13, 7.09)	0.042	0.23 (0.01, 0.44)	
Disease Stage at Screening												
STAGE II	0	-	0		2	83.33 (23.57)	2					
STAGE III	19	89.47 (13.84)	19		18	86.11 (17.39)	16					
STAGE IV	227	81.57 (23.35)	216		230	83.99 (21.43)	213					
Region												0.875
North America and Europe	134	81.97 (23.40)	128	-5.67 (1.57)	124	83.74 (22.24)	110	-11.06 (1.71)	5.39 (0.82, 9.97)	0.021	0.30 (0.04, 0.56)	
Rest of the World	112	82.44 (22.24)	107	-4.56 (1.51)	126	84.52 (20.02)	121	-9.46 (1.46)	4.90 (0.76, 9.04)	0.021	0.31 (0.05, 0.57)	
Prior anti-PD-(L)1 exposure												0.136
yes	174	80.94 (24.02)	167	-4.72 (1.27)	177	85.22 (20.63)	161	-11.53 (1.31)	6.82 (3.21, 10.42)	<.001	0.41 (0.19, 0.63)	
no	72	85.19 (19.49)	68	-5.92 (2.19)	73	81.51 (22.15)	70	-7.36 (2.21)	1.45 (-4.70, 7.59)	0.642	0.08 (-0.26, 0.41)	
Chemotherapy-free interval												0.556
< 90 days	107	79.13 (24.98)	99	-3.48 (1.65)	111	84.53 (21.99)	100	-8.73 (1.68)	5.25 (0.59, 9.91)	0.028	0.31 (0.03, 0.59)	
>= 90 and < 180 days	82	81.30 (23.19)	80	-5.75 (1.93)	76	83.33 (22.11)	71	-8.64 (2.05)	2.89 (-2.69, 8.48)	0.307	0.17 (-0.15, 0.49)	
>= 180 days	57	89.18 (15.90)	56	-6.48 (2.28)	63	84.39 (18.42)	60	-13.97 (2.25)	7.50 (1.13, 13.86)	0.021	0.43 (0.06, 0.80)	
Presence (previous or current) of brain metastases												0.045
yes	111	81.53 (23.18)	109	-3.85 (1.61)	110	83.64 (20.32)	100	-12.43 (1.71)	8.58 (3.94, 13.21)	<.001	0.50 (0.23, 0.78)	
no	135	82.72 (22.62)	126	-6.18 (1.49)	140	84.52 (21.78)	131	-8.43 (1.48)	2.25 (-1.90, 6.40)	0.286	0.13 (-0.11, 0.38)	
Standard of care												0.505
Amrubicin/Topotecan	203	82.59 (23.18)	196	-6.06 (1.23)	203	84.40 (20.32)	189	-10.60 (1.27)	4.54 (1.07, 8.00)	0.010	0.26 (0.06, 0.46)	
Lurbinectedin	43	80.23 (21.29)	39	-0.32 (2.41)	47	82.98 (24.45)	42	-7.38 (2.32)	7.07 (0.36, 13.77)	0.039	0.47 (0.02, 0.91)	

Effect measures are calculated if each subgroup level comprises at least 10 patients.
Analysis displays overall estimates from MMRM.
MMRM is based on change from baseline as dependent variable, intercept, time, baseline score, treatment arms, interaction term between treatment arm and time as fixed effects, and subject intercept and slope of time for the change from baseline as random effects.
N* describes number of patients included in the MMRM, e.g. all patients with non-missing values at baseline and at least one post-baseline visit.
p-Value for interaction from test for heterogeneity of the mean differences in the subgroups using Cochrane`s Q statistic.
BL: Baseline, N: Number of subjects included in the analysis, SD: Standard Deviation; LSMean: Least Square Mean, SE: Standard Error; CI=Confidence Interval

Anhang 4-G5.6: Endpunkt „Sicherheit“ – RCT

Anhang 4-G5.6.1: Unerwünschte Ereignisse – Gesamtraten

Table 14-6.1.1. Summary of Time to First Treatment Emergent Adverse Event (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) KM Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) KM Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first TEAE							
Overall	243/244 (99.6)	0.3 (0.2, 0.3)	249/252 (98.8)	0.1 (NE, NE)		1.971 (1.641, 2.367)	< 0.001
Age					0.247		
< 65 years	108/109 (99.1)	0.4 (0.2, 0.5)	126/128 (98.4)	0.1 (0.0, 0.1)			
≥ 65 years	135/135 (100.0)	0.2 (0.2, 0.3)	123/124 (99.2)	0.1 (NE, NE)			
Sex					0.006		
Male	161/161 (100.0)	0.3 (0.2, 0.3)	177/180 (98.3)	0.1 (NE, NE)		1.723 (1.383, 2.146)	< 0.001
Female	82/83 (98.8)	0.3 (0.2, 0.4)	72/72 (100.0)	0.0 (0.0, 0.1)		3.329 (2.343, 4.730)	< 0.001
Region					0.610		
North America and Europe	121/121 (100.0)	0.4 (0.3, 0.5)	138/139 (99.3)	0.1 (0.0, 0.1)			
Rest of world	122/123 (99.2)	0.1 (0.1, 0.2)	111/113 (98.2)	0.1 (NE, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-subgroup.sas
Output: t14-06-001-001-ae-teae.rtf (Date Generated: 21DEC25:20:37:32) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.1. Summary of Time to First Treatment Emergent Adverse Event (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) KM Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) KM Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.312		
Yes	171/172 (99.4)	0.3 (0.2, 0.3)	177/179 (98.9)	0.1 (0.0, 0.1)			
No	72/72 (100.0)	0.3 (0.2, 0.5)	72/73 (98.6)	0.1 (NE, NE)			
Chemotherapy-free interval					0.909		
< 90 days	109/109 (100.0)	0.3 (0.1, 0.3)	106/107 (99.1)	0.1 (0.0, 0.1)			
≥ 90 and < 180 days	73/73 (100.0)	0.3 (0.2, 0.4)	84/85 (98.8)	0.1 (0.0, 0.1)			
≥ 180 days	61/62 (98.4)	0.3 (0.2, 0.6)	59/60 (98.3)	0.1 (0.1, 0.1)			
Presence (previous or current) of brain metastases					0.422		
Yes	108/108 (100.0)	0.3 (0.2, 0.3)	112/113 (99.1)	0.1 (NE, NE)			
No	135/136 (99.3)	0.3 (0.2, 0.3)	137/139 (98.6)	0.1 (0.0, 0.1)			

Page 2 of 3

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-subgroup.sas
Output: t14-06-001-001-ae-teae.rtf (Date Generated: 21DEC25:20:37:32) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.1.1. Summary of Time to First Treatment Emergent Adverse Event (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) KM Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) KM Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.073		
Topotecan/Amrubicin	198/199 (99.5)	0.3 (0.2, 0.3)	205/208 (98.6)	0.1 (NE, NE)			
Lurbinectedin	45/45 (100.0)	0.3 (0.1, 0.4)	44/44 (100.0)	0.1 (0.0, 0.1)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-subgroup.sas
Output: t14-06-001-001-ae-teae.rtf (Date Generated: 21DEC25:20:37:32) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.1. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event (Safety Analysis Set)

	Standard of Care (N = 244)		Tarlatamab (N = 252)		p-value[b]	Hazard Ratio	
Endpoint	Events/Subjects (%)	KM Median (95% CI) (months)[a]	Events/Subjects (%)	KM Median (95% CI) (months)[a]	Interaction with Treatment	(Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first grade ≥ 3 TEAE							
Overall	195/244 (79.9)	1.1 (0.7, 1.5)	136/252 (54.0)	5.0 (3.3, 9.3)		0.462 (0.368, 0.579)	< 0.001
Age					0.789		
< 65 years	87/109 (79.8)	1.2 (0.7, 1.8)	67/128 (52.3)	6.8 (2.4, NE)			
≥ 65 years	108/135 (80.0)	0.9 (0.7, 1.6)	69/124 (55.6)	4.5 (2.8, 9.3)			
Sex					0.995		
Male	127/161 (78.9)	1.1 (0.8, 1.6)	97/180 (53.9)	6.1 (3.3, 10.0)			
Female	68/83 (81.9)	0.9 (0.6, 1.9)	39/72 (54.2)	4.5 (1.7, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
The adverse events graded using CTCAE version 5.0
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-subgroup.sas
Output: t14-06-002-001-ae-teae-grd3.rtf (Date Generated: 21DEC25:20:37:35) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.1. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) KM Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) KM Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Region					0.801		
North America and Europe	97/121 (80.2)	1.4 (0.9, 2.1)	72/139 (51.8)	7.6 (2.8, 10.1)			
Rest of world	98/123 (79.7)	0.7 (0.5, 1.4)	64/113 (56.6)	3.8 (2.1, 8.2)			
Prior anti-PD-(L)1 exposure					0.166		
Yes	130/172 (75.6)	1.2 (0.7, 1.7)	101/179 (56.4)	4.6 (3.0, 9.1)			
No	65/72 (90.3)	0.9 (0.7, 1.5)	35/73 (47.9)	6.1 (1.8, NE)			
Chemotherapy-free interval					0.056		
< 90 days	86/109 (78.9)	1.0 (0.7, 1.4)	69/107 (64.5)	2.4 (1.4, 4.6)			
≥ 90 and < 180 days	54/73 (74.0)	1.1 (0.5, 2.7)	40/85 (47.1)	8.2 (3.7, NE)			
≥ 180 days	55/62 (88.7)	1.4 (0.7, 2.2)	27/60 (45.0)	10.1 (3.7, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
The adverse events graded using CTCAE version 5.0
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-subgroup.sas
Output: t14-06-002-001-ae-teae-grd3.rtf (Date Generated: 21DEC25:20:37:35) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.2.1. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) KM Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) KM Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases					0.281		
Yes	93/108 (86.1)	0.7 (0.6, 1.1)	63/113 (55.8)	4.6 (1.8, 10.1)			
No	102/136 (75.0)	1.4 (0.9, 2.1)	73/139 (52.5)	6.8 (3.3, 11.1)			
Standard of care					< 0.001		
Topotecan/Amrubicin	164/199 (82.4)	0.9 (0.7, 1.4)	104/208 (50.0)	7.6 (4.3, NE)		0.381 (0.295, 0.491)	< 0.001
Lurbinectedin	31/45 (68.9)	3.0 (1.2, 4.7)	32/44 (72.7)	1.4 (0.8, 3.8)		1.076 (0.649, 1.786)	0.793

Page 3 of 3

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
The adverse events graded using CTCAE version 5.0
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-subgroup.sas
Output: t14-06-002-001-ae-teae-grd3.rtf (Date Generated: 21DEC25:20:37:35) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.1. Summary of Time to First Serious Treatment Emergent Adverse Event (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) KM Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) KM Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Time to first serious TEAE							
Overall	125/244 (51.2)	4.6 (3.4, 7.0)	129/252 (51.2)	5.1 (3.6, NE)		1.035 (0.808, 1.327)	0.827
Age					0.265		
< 65 years	53/109 (48.6)	5.2 (4.0, NE)	66/128 (51.6)	4.7 (1.8, NE)			
≥ 65 years	72/135 (53.3)	3.6 (2.6, 7.0)	63/124 (50.8)	5.1 (3.3, NE)			
Sex					0.666		
Male	81/161 (50.3)	5.2 (3.3, 7.0)	93/180 (51.7)	5.0 (3.2, 11.1)			
Female	44/83 (53.0)	4.3 (2.2, NE)	36/72 (50.0)	6.8 (1.8, NE)			
Region					0.398		
North America and Europe	65/121 (53.7)	4.3 (2.7, 7.0)	77/139 (55.4)	3.9 (1.2, 9.3)			
Rest of world	60/123 (48.8)	4.8 (3.4, NE)	52/113 (46.0)	11.1 (3.8, NE)			

Page 1 of 3

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-subgroup.sas
Output: t14-06-003-001-ae-teae-ser.rtf (Date Generated: 21DEC25:20:37:37) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.1. Summary of Time to First Serious Treatment Emergent Adverse Event (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) KM Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) KM Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure					0.033		
Yes	83/172 (48.3)	5.8 (3.4, NE)	99/179 (55.3)	4.5 (2.6, 9.3)		1.216 (0.906, 1.631)	0.207
No	42/72 (58.3)	3.5 (1.5, 6.0)	30/73 (41.1)	NE (3.3, NE)		0.700 (0.437, 1.122)	0.129
Chemotherapy-free interval					0.078		
< 90 days	54/109 (49.5)	4.6 (2.4, NE)	61/107 (57.0)	3.8 (1.2, 10.4)			
≥ 90 and < 180 days	38/73 (52.1)	5.2 (2.6, NE)	47/85 (55.3)	4.5 (0.9, NE)			
≥ 180 days	33/62 (53.2)	4.8 (2.9, NE)	21/60 (35.0)	NE (NE, NE)			
Presence (previous or current) of brain metastases					0.951		
Yes	56/108 (51.9)	4.8 (2.7, 7.0)	59/113 (52.2)	4.6 (1.7, NE)			
No	69/136 (50.7)	4.5 (3.0, NE)	70/139 (50.4)	6.8 (3.3, NE)			

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-subgroup.sas
Output: t14-06-003-001-ae-teae-ser.rtf (Date Generated: 21DEC25:20:37:37) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.3.1. Summary of Time to First Serious Treatment Emergent Adverse Event (Safety Analysis Set)

Endpoint	Standard of Care (N = 244) Events/Subjects (%)	Standard of Care (N = 244) KM Median (95% CI) (months)[a]	Tarlatamab (N = 252) Events/Subjects (%)	Tarlatamab (N = 252) KM Median (95% CI) (months)[a]	p-value[b] Interaction with Treatment	Hazard Ratio (Tarlatamab/SOC) (95% CI)	p-value (2-sided)[c]
Standard of care					0.147		
Topotecan/Amrubicin	104/199 (52.3)	4.5 (2.9, 7.0)	101/208 (48.6)	7.6 (3.6, NE)			
Lurbinectedin	21/45 (46.7)	6.0 (3.0, NE)	28/44 (63.6)	4.5 (0.8, 10.4)			

Page 3 of 3

KM = Kaplan-Meier; CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b]The p-value (2-sided) for interaction was from a Cox regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified log-rank test.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/output/t-teae-sum-subgroup.sas
Output: t14-06-003-001-ae-teae-ser.rtf (Date Generated: 21DEC25:20:37:37) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.4.2. Summary of Treatment Emergent Adverse Event leading to Discontinuation of Treatment (Safety Analysis Set)

	Standard of Care (N = 244)	Tarlatamab (N = 252)	p-value[b]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events/Subjects (%) (95% CI)[a]	Events/Subjects (%) (95% CI)[a]	Interaction with Treatment	(Tarlatamab /SOC)	(Tarlatamab /SOC)	Tarlatamab /SOC)	p-value (2-sided)[c]
Overall	30/244 (12.3) (8.5, 17.1)	13/252 (5.2) (2.8, 8.7)		-7.1 (-12.1, -2.2)	0.388 (0.197, 0.763)	0.420 (0.224, 0.785)	0.005
Age			0.973				
< 65 years	14/109 (12.8) (7.2, 20.6)	7/128 (5.5) (2.2, 10.9)					
≥ 65 years	16/135 (11.9) (6.9, 18.5)	6/124 (4.8) (1.8, 10.2)					

Page 1 of 4

CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[b]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified Cochran-Mantel-Haenszel test for 'Overall' and for subgroups.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-ae-teae-disc.sas
Output: t14-06-004-002-ae-teae-disc.rtf (Date Generated: 21DEC25:20:37:31) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.4.2. Summary of Treatment Emergent Adverse Event leading to Discontinuation of Treatment (Safety Analysis Set)

	Standard of Care (N = 244)	Tarlatamab (N = 252)		Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events/Subjects (%) (95% CI)[a]	Events/Subjects (%) (95% CI)[a]	p-value[b] Interaction with Treatment	(Tarlatamab /SOC)	(Tarlatamab /SOC)	Tarlatamab /SOC)	p-value (2-sided)[c]
Sex			0.278				
Male	16/161 (9.9) (5.8, 15.6)	10/180 (5.6) (2.7, 10.0)					
Female	14/83 (16.9) (9.5, 26.7)	3/72 (4.2) (0.9, 11.7)					
Region			0.209				
North America and Europe	20/121 (16.5) (10.4, 24.4)	12/139 (8.6) (4.5, 14.6)					
Rest of world	10/123 (8.1) (4.0, 14.4)	1/113 (0.9) (0.0, 4.8)					

Page 2 of 4

CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[b]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified Cochran-Mantel-Haenszel test for 'Overall' and for subgroups.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-ae-teae-disc.sas
Output: t14-06-004-002-ae-teae-disc.rtf (Date Generated: 21DEC25:20:37:31) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.4.2. Summary of Treatment Emergent Adverse Event leading to Discontinuation of Treatment (Safety Analysis Set)

	Standard of Care (N = 244)	Tarlatamab (N = 252)	p-value[b]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events/Subjects (%) (95% CI)[a]	Events/Subjects (%) (95% CI)[a]	Interaction with Treatment	(Tarlatamab /SOC)	(Tarlatamab /SOC)	Tarlatamab /SOC)	p-value (2-sided)[c]
Prior anti-PD-(L)1 exposure			0.328				
Yes	23/172 (13.4) (8.7, 19.4)	12/179 (6.7) (3.5, 11.4)					
No	7/72 (9.7) (4.0, 19.0)	1/73 (1.4) (0.0, 7.4)					
Chemotherapy-free interval			0.876				
< 90 days	14/109 (12.8) (7.2, 20.6)	7/107 (6.5) (2.7, 13.0)					
≥ 90 and < 180 days	8/73 (11.0) (4.9, 20.5)	3/85 (3.5) (0.7, 10.0)					
≥ 180 days	8/62 (12.9) (5.7, 23.9)	3/60 (5.0) (1.0, 13.9)					

Page 3 of 4

CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[b]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified Cochran-Mantel-Haenszel test for 'Overall' and for subgroups.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-ae-teae-disc.sas
Output: t14-06-004-002-ae-teae-disc.rtf (Date Generated: 21DEC25:20:37:31) Source: pa_adam.adsl, pa_adam.adae

Table 14-6.4.2. Summary of Treatment Emergent Adverse Event leading to Discontinuation of Treatment (Safety Analysis Set)

	Standard of Care (N = 244)	Tarlatamab (N = 252)	p-value[b]	Risk Difference % (95% CI)	Odds Ratio (95% CI)	Relative Risk (95% CI)	
	Events/Subjects (%) (95% CI)[a]	Events/Subjects (%) (95% CI)[a]	Interaction with Treatment	(Tarlatamab /SOC)	(Tarlatamab /SOC)	Tarlatamab /SOC)	p-value (2-sided)[c]
Presence (previous or current) of brain metastases			0.615				
Yes	18/108 (16.7) (10.2, 25.1)	7/113 (6.2) (2.5, 12.3)					
No	12/136 (8.8) (4.6, 14.9)	6/139 (4.3) (1.6, 9.2)					
Standard of care			0.964				
Topotecan/Amrubicin	27/199 (13.6) (9.1, 19.1)	12/208 (5.8) (3.0, 9.9)					
Lurbinectedin	3/45 (6.7) (1.4, 18.3)	1/44 (2.3) (0.1, 12.0)					

Page 4 of 4

CI = Confidence Interval; TEAE = Treatment Emergent Adverse Event; NE = Not Estimable.
Unstratified analysis was conducted for overall and subgroups.
[a]Exact 95% confidence interval was calculated using the Clopper Pearson method.
[b]The p-value (2-sided) for interaction was from a logistic regression model with baseline characteristic, treatment group and interaction term between baseline characteristic and treatment as covariates.
[c]2-sided p-values were calculated using the unstratified Cochran-Mantel-Haenszel test for 'Overall' and for subgroups.
Data snapshot date: 13MAR2025; Data cutoff date: 29JAN2025

Program: /userdata/stat/amg757/onc/20210004/analysis/gba_amnog_2025/tables/t-ae-teae-disc.sas
Output: t14-06-004-002-ae-teae-disc.rtf (Date Generated: 21DEC25:20:37:31) Source: pa_adam.adsl, pa_adam.adae

Anhang 4-G5.6.2: Unerwünschte Ereignisse nach SOC und PT

Die Ergebnisse zu den Subgruppenanalysen für unerwünschte Ereignisse nach SOC und PT befinden sich in Abschnitt 4-G4.1.